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Summary	
	
Metastatic	 disease	 is	 the	 major	 cause	 of	 death	 in	 advanced	 breast	 cancer	 and	 is	
supposed	 to	 be	 initiated	 by	 a	 sub-population	 of	 cancer	 stem	 cells	 (CSCs)	 that	
disseminate	 from	 the	 primary	 tumour	 at	 an	 early	 stage	 in	 disease	 pathogenesis.	
Detailed	insight	into	the	biology	underpinning	the	emergence	and	survival	of	the	CSC	
population	will	therefore	likely	be	critical	to	the	development	of	therapeutic	strategies	
for	 prevention	 of	 breast	 cancer	 relapse.	 However,	 the	 isolation	 of	 CSCs	 based	 on	
specific	 marker	 signatures	 is	 increasingly	 recognised	 as	 being	 unreliable	 due	 to	
population	plasticity	and	the	ambiguous	functional	significance	of	the	markers	used.	A	
number	 of	 relatively	 recent	 studies	 have	 reported	 pulse-chase	 techniques	 using	
lipophilic	fluorescent	dyes	that	enable	the	prospective	isolation	of	live	CSC	populations	
based	on	their	inherently	quiescent	nature.	
	
The	main	aim	of	this	thesis	was	to	establish	a	lipophilic	dye	retention	method	for	the	
isolation	 of	 mitotically	 quiescent	 human	 breast	 cancer	 cells	 from	 commercially	
available	cell	lines	grown	in	vitro,	and	to	establish	whether	quiescence	was	associated	
with	 characteristics	 of	 the	 purported	 metastasis-initiating	 breast	 CSC	 population.	 A	
latent	quiescent	 sub-population	accounting	 for	<	2%	of	 the	 total	 cell	population	was	
identified	 in	 the	 MCF-7,	 ZR-75-1,	 MDA-MB-468,	 MDA-MB-231	 and	 SK-BR-3	 human	
breast	 cancer	 cell	 lines	 based	on	 their	 ability	 to	 retain	 the	 lipophilic	 fluorescent	 dye	
Vybrant®	DiD.	The	relatively	quiescent	nature	of	dye-retaining	cells	was	confirmed	by	
their	 tendency	 to	 collect	 in	 the	 G2/M-phase	 of	 the	 cell	 cycle	 and	 by	 a	 significant	
enrichment	 with	 cells	 that	 were	 Ki67-	 (G0-phase)	 following	 immunostaining.	 The	
quiescent	sub-population	was	shown	not	to	be	an	intrinsic	feature	of	the	cell	 lines	in	
which	they	were	identified,	but	that	they	could	emerge	spontaneously	within	isolated	
rapidly	 dividing	 cultures.	 Immunoprofiling	 of	 quiescent	 cells	 illustrated	only	 a	 partial	
overlap	with	the	CD44+CD24-/low	signature	commonly	used	to	identify	breast	CSCs	but	
showed	a	significant	enrichment	for	cells	that	were	CD44+CD24+	and	ALDH+.	Quiescent	
cells	 also	 displayed	 an	 enhanced	 ability	 to	 survive	 chemotherapy	 and	 exclusively	
contained	 sub-clones	 capable	 of	 subsequent	 outgrowth.	 Further	 characterisation	 of	
this	 population	 could	 identify	 novel	 therapeutic	 targets	 for	 elimination	 of	 the	 cells	
responsible	for	de	novo	drug	resistance	and	breast	cancer	recurrence.	
	 xvi	
List	of	Abbreviations	
	
2D	 Two-dimensional	
3D	 Three-dimensional	
3H-TdR	 Tritiated	thymidine	
AA11	 Novel	anti-stem	cell	antigen	AA11	
AG10	 Novel	anti-stem	cell	antigen	AG10	
AHRI	 Aplysia	ras	homology	member	1	
ALDH	 Aldehyde	dehydrogenase	
ALDH1	 Aldehyde	dehydrogenase-1	
ANOVA	 Analysis	of	variance	
ATCC	 American	Type	Culture	Collection	
ATF6	 Activating	transcription	factor-6	
ATM	 ATM	serine/threonine	kinase	
AXL	 Tyrosine-protein	kinase	receptor	UFO	
BAAA-DA	 BODIPY-aminoacetaldehydediethylacetate	
BAAA	 BODIPY-aminoacetaldehyde	
BCA	 Bicinchoninic	acid	
BCL-2	 B-cell	lymphoma-2	
BCL-XL	 B-cell	lymphoma-extra	large	
BE12	 Novel	anti-stem	cell	antigen	BE12	
BF4	 Novel	anti-stem	cell	antigen	BF4	
bFGF	 Basic	fibroblast	growth	factor	
BHLHE41	 Basic	helix-loop-helix	family	member	e41	
BM-HMSC	 Bone	marrow-derived	human	mesenchymal	stem	cells	
BMP	 Bone	morphogenetic	protein	
BMP7	 Bone	morphogenetic	protein-7	
BMPR2	 Bone	morphogenetic	protein	receptor	type-2	
BRCA1	 Breast	cancer	1	
BrdU	 5-bromo-2-deoxyuridine	
BSA	 Bovine	serum	albumin	
oC	 Degrees	Celsius	
CC9	 Novel	anti-stem	cell	antigen	CC9	
CD24	 Signal	transducer	CD24	
CD29	 Integrin	β1	
CD34	 Hematopoietic	progenitor	cell	antigen	CD34	
CD38	 Cyclic	ADP	ribose	hydrolase	
CD44	 Hyaluronan	receptor	
CD46	 Complement	regulatory	protein	
CD49f	 Integrin	α6	
CD56	 Neural	cell	adhesion	molecule	
CD57	 Human	natural	killer-1	
CD133	 Prominin-1	
CD147	 Basigin	
CD271	 Low-affinity	nerve	growth	factor	receptor	
CDK	 Cyclin-dependent	kinase	
CDK4	 Cyclin-dependent	kinase-4	
	 xvii	
CE	 Clonal	evolution	
c-FLIP	 FLICE-like	inhibitory	protein	
CFSE	 Carboxyfluorescein	diacetate	succinimidyl	ester	
CH8	 Novel	anti-stem	cell	antigen	CH8	
cm	 Centimetre	
CO2	 Carbon	dioxide	
CSC	 Cancer	stem	cell	
CTC	 Circulating	tumour	cell	
CXCL12	 CXC	motif	chemokine-12	
CXCR4	 CXC	motif	chemokine	receptor-4	
DA9	 Novel	anti-stem	cell	antigen	DA9	
DAPI	 4ʹ,6-diamidino-2-phenylindole	
DCIS	 Ductal	carcinoma	in	situ	
DEAB	 Diethylaminobenzaldehyde	
DEC2	 See	BHLHE41	
dH2O	 Distilled	water	
DMSO	 Dimethylsulphoxide	
DNA	 Deoxyribonucleic	acid	
DTC	 Disseminated	tumour	cell	
EC0	 No	effective	concentration	
EC25	 25%	maximal	effective	concentration	
EC50	 50%	maximal	effective	concentration	
EC100	 Maximal	effective	concentration	
ECM	 Extracellular	matrix	
EDTA	 Ethylenediaminetetraacetic	acid	
EF12	 Novel	anti-stem	cell	antigen	EF12	
EMT	 Epithelial-to-mesenchymal	transition	
EpCAM	 Epithelial	cell	adhesion	molecule	
ER	 Oestrogen	receptor	
ERK	 Extracellular	regulated	kinase	
ERR-α	 Oestrogen-related	receptor-α	
FACS	 Fluorescence	activated	cell	sorting	
F-actin	 Filamentous	actin	
FAK	 Focal	adhesion	kinase	
FBS	 Foetal	bovine	serum	
fM	 Femtomolar	
FMO	 Fluorescence	minus-one	
g	 Gram(s)	
GAS6	 Growth	arrest-specific	6	
GD2	 Ganglioside	GD2	
GD3	 Ganglioside	GD3	
GFP	 Green	fluorescent	protein	
GJIC	 Gap	junctional	intercellular	communication	
GLUT1	 Glucose	transporter-1	
GRAF	 GTPase	regulator	associated	with	focal	adhesion	kinase	
GT3	 Ganglioside	GT3	
GTPase	 Guanosine	triphosphate	hydrolase	
H&L	 Heavy	and	light	chain	
	 xviii	
HCC	 Hepatocellular	carcinoma	cells	
hEC	 Human	embryocarcinoma	stem	cells	
HER2	 Human	epidermal	growth	factor	receptor	type-2	
hES	 Human	embryonic	stem	cells	
HIF-1α	 Hypoxia-inducible	factor-1-α	
HNSCC	 Head	and	neck	squamous	cell	carcinoma	
HRP	 Horseradish	peroxidase	
HSC	 Haematopoietic	stem	cell	
IBC	 Invasive	breast	cancer	
IC50	 50%	maximal	inhibitory	concentration	
IC95	 95%	maximal	inhibitory	concentration	
IgG	 Immunoglobulin	G	
IgG1	 Immunoglobulin	G	subclass-1	
IgG2b	 Immunoglobulin	G	subclass-2b	
IgG3	 Immunoglobulin	G	subclass-3	
IgM	 Immunoglobulin	M	
ISCI	 International	stem	cell	initiative	
M	 Molar	
MAPK	 Mitogen-activated	protein	kinase	
MARCKS	 Myristoylated	alanine-rich	C-kinase	substrate	
MER	 Proto-oncogene	tyrosine-protein	kinase	MER	
MET	 Mesenchymal-to-epithelial	transition	
MFI	 Median	fluorescence	intensity	
mg	 Milligram	
μg	 Microgram	
miRNA	 MicroRNA	
ml	 Millilitre	
μl	 Microlitre	
mm	 Millimetre	
μm	 Micrometre	
mM	 Millimolar	
μM	 Micromolar	
MMC	 Mitomycin	C	
MMP	 Matrix	metalloproteinase	
MSC	 Mesenchymal	stem	cell	
mTOR	 Mammalian	target	of	rapamycin	
MTT	 Methylthiazolyltetrazolium	bromide	
NADH	 Reduced	nicotinamide	adenine	dinucleotide	
NADP+	 Oxidised	nicotinamide	adenine	dinucleotide	phosphate	
NDRG1	 Protein	NDRG1	
NDRG2	 Protein	NDRG2	
NF-κB	 Nuclear	factor	κ-light-chain-enhancer	of	activated	B-cells	
NK1R	 Neurokinin-1	receptor	
NK2R	 Neurokinin-2	receptor	
NK3R	 Neurokinin-3	receptor	
NK1R-Tr	 Truncated	neurokinin-1	receptor	
NK1R-FL	 Full-length	neurokinin-1	receptor	
nm	 Nanometre	
	 xix	
nM	 Nanomolar	
NOTCH	 NOTCH	protein	
NR2F1	 Nuclear	receptor	subfamily	2	group	F	member	1	
p21	 Cyclin-dependent	kinase	inhibitor-1	
p27	 Cyclin-dependent	kinase	inhibitor-1B	
p38	 p38	mitogen-activated	protein	kinase	
p38-α	 p38	mitogen-activated	protein	kinase-14	
p38-β	 p38	mitogen-activated	protein	kinase-11	
PBS	 Phosphate-buffered	saline	
PBST	 PBS	with	Tween®20	
PCC	 Prostate	cancer	cell	
PDX	 Patient-derived	xenograft	
PI3K	 Phosphatidylinositide	3-kinase	
PKB	 Protein	kinase	B	
pM	 Picomolar	
poly-HEMA	 Poly-2-hydroxyethylmethacrylate	
PVDF	 Polyvinylidene	fluoride	
qPCR	 Real-time	quantitative	polymerase	chain	reaction	
Ras	 Ras	protein	
RFU	 Relative	fluorescence	units	
Rheb	 Ras	protein	homolog	enriched	in	brain	
RhoA	 Ras	homolog	gene	family	member	A	
RIPA	 Radioimmunoprecipitation	assay	
RNase	A	 Ribonuclease	A	
SDS	 Sodium	dodecyl	sulphate	
SEM	 Standard	error	of	the	mean	
SHARP1	 See	BHLHE41	
SMAD1	 SMAD	family	member	1	
SMAD5	 SMAD	family	member	5	
shRNA	 Short	hairpin	RNA	
SSEA-1	 Stage-specific	embryonic	antigen-1	
SSEA-3	 Stage-specific	embryonic	antigen-3	
SSEA-4	 Stage-specific	embryonic	antigen-4	
TBK1	 TANK-binding	kinase-1	
TBST	 Tris-buffered	saline	with	Tween®20	
TGF-β2	 Transforming	growth	factor-β2	
TGF-βRI	 Transforming	growth	factor-β	receptor	type-1	
TGF-βRIII	 Transforming	growth	factor-β	receptor	type-3	
TNBC	 Triple-negative	breast	cancer	
TRA-1-60R	 Neuraminidase-resistant	podocalyxin	isoform	TRA-1-60	
TRA-1-60S	 Neuraminidase-sensitive	podocalyxin	isoform	TRA-1-60	
TRA-1-81	 Podocalyxin	isoform	TRA-1-81	
TRA-2-49	 Tissue	non-specific	alkaline	phosphatase	
TRA-2-54	 Tissue	non-specific	alkaline	phosphatase	
TSP-1	 Thrombospondin-1	
TYRO3	 Tyrosine-protein	kinase	receptor	TYRO3	
uPAR	 Urokinase	receptor	
v/v	 Volume	concentration	
	 xx	
V	 Volts	
VEGF	 Vascular	endothelial	growth	factor	
w/v	 Weight	concentration	
x	g	 Times	gravity	
X-gal	 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside	
ZEB1	 Zinc	finger	E-box-binding	homeobox-1	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 1	
	
	
Chapter	1	
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1.1. Understanding	Cellular	Heterogeneity	in	Breast	Cancer	
	
Breast	 cancer	 is	 characterised	 by	 a	 significant	 degree	 of	 cellular	 and	 molecular	
intertumoural	heterogeneity	which	gives	rise	to	variability	 in	disease	progression	and	
clinical	 outcome	 (Rich,	 2016).	 Considerable	 genetic,	 phenotypic	 and	 functional	
diversity	 has	 also	 been	 documented	 at	 the	 cellular	 level	 within	 individual	 breast	
tumours.	In	fact,	a	vast	body	of	experimental	evidence	reported	across	virtually	every	
documented	major	cancer	type	has	demonstrated	intratumoural	variance	in	terms	of	
cell	 surface	 marker	 expression,	 genetic	 and	 epigenetic	 alterations,	 genetic	 stability,	
mitotic,	invasive,	metastatic,	tumourigenic	and	angiogenic	potential,	and	susceptibility	
to	chemo-	and	radiotherapies	(Burrell	et	al.,	2013;	Kreso	and	Dick,	2014;	McGranahan	
and	Swanton,	2017).	Two	predominant	models	have	historically	been	used	to	account	
for	 such	 intratumoural	 heterogeneity	 and	 explain	 the	 natural	 history	 of	 tumour	
pathogenesis,	 the	 stochastic	 or	 clonal	 evolution	 (CE)	 model	 and	 the	 hierarchy	 or	
cancer	stem	cell	(CSC)	model	(Figure	1.1.).	The	former	postulates	that	malignant	cells	
are	initially	biologically	homogenous	but	are	able	to	accumulate	genetic	and	epigenetic	
aberrations	over	time	due	to	intrinsic	genetic	instability.	The	acquisition	of	numerous	
genetic	and	epigenetic	abnormalities	leads	to	the	development	of	variable	phenotypic	
and	functional	traits	that	then	undergo	microenvironmental	selection	to	drive	tumour	
progression	and	 increased	tumoural	heterogeneity	(Michor	and	Polyak,	2010;	Gerdes	
et	 al.,	 2014).	 In	 contrast,	 the	 long-standing	 observation	 of	 multiple	 similarities	
between	normal	embryonic	developmental	processes	and	abnormal	neoplastic	growth	
led	to	the	development	of	the	CSC	model,	which	proposes	that	tumour	pathogenesis	is	
driven	 by	 a	minority	 sub-population	 of	 transformed	 stem-like	 cancer	 cells	 that,	 like	
their	 non-malignant	 counterparts,	 are	 capable	 of	 self-renewal	 and	 differentiation	 to	
generate	 multiple	 cellular	 phenotypes.	 Accordingly,	 tumours	 are	 supposed	 to	 be	
hierarchically	organised	to	include	highly	tumourigenic	CSCs,	transitory	progenitor	cells	
and	terminally	differentiated	progeny	(Gerdes	et	al.,	2014).	
	
	
	
	
	
	 3	
The	concept	that	cancers	are	propagated	by	a	rare,	biologically	distinct	cellular	sub-set	
was	 first	 suggested	 by	 the	 German	 pathologist	 Rudolf	 Virchow	 over	 150	 years	 ago	
(Nguyen	et	al.,	2012).	However,	it	was	not	until	the	seminal	study	by	Bonnet	and	Dick	
(1997)	 that	 direct	 experimental	 evidence	 to	 support	 this	 proposal	 emerged.	 The	
existence	of	CSCs	has	 since	become	widely	accepted	 following	 the	demonstration	of	
the	 existence	 of	 CSCs	 in	 multiple	 other	 tumour	 types,	 including	 those	 of	 breast,	
prostate,	 pancreas,	 colon,	 liver	 ovaries,	 head	 and	neck,	 and	 the	brain	 (Al-Hajj	 et	 al.,	
2003;	Singh	et	al.,	2004;	Collins	et	al.,	2005;	Li	et	al.,	2007;	Ma	et	al.,	2007;	O'Brien	et	
al.,	 2007;	 Prince	 et	 al.,	 2007;	 Gao	 et	 al.,	 2010).	 However,	 a	myriad	 of	 experimental	
evidence	 that	 demonstrates	 the	 dynamic	 and	 reversible	 induced	 transition	 of	 non-
stem	cancer	 cells	 to	 a	more	 stem-like	phenotype,	 thereby	 supporting	 the	CE	model,	
has	also	been	reported	in	this	time	(Reviewed	by	Plaks	et	al.,	2015).	Consequently,	an	
alternative	 model	 of	 reversible	 cellular	 plasticity	 has	 recently	 been	 proposed	 as	 a	
unifying	framework	that	 incorporates	both	CE	and	CSC	models	(Cabrera	et	al.,	2015).	
This	so-called	plasticity	model	of	intratumoural	heterogeneity	postulates	that	tumour	
cells	 transiently	 interconvert	 between	 stem-like	 and	 differentiated	 states	 under	 the	
influence	of	intrinsic	cellular	processes	and	extrinsic	stimuli	(Figure	1.1.).	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 4	
	
	
Figure	1.1.	Conceptual	Models	of	Intratumoural	Heterogeneity	
In	the	clonal	evolution	(CE)	or	stochastic	model,	the	tumourigenic	potential	of	cells	is	initially	equal	and	
is	acquired	over	time	as	the	cumulative	result	of	mutational	events	that	confer	a	selective	advantage	to	
particular	clones	in	response	to	microenvironmental	selection.	In	the	cancer	stem	cell	(CSC)	or	hierarchic	
model,	only	stem	cells	possess	tumourigenic	potential	while	their	non-stem	progeny	possess	little	or	no	
intrinsic	tumourigenicity.	According	to	the	plasticity	model,	differentiation	can	be	bidirectional	so	that	
initially	non-tumourigenic	cancer	cells	are	capable	of	reversion	to	a	CSC	state	under	microenvironmental	
instruction.	Image	reprinted	from	Rich,	J.	N.	(2016).	Cancer	stem	cells:	understanding	tumour	hierarchy	
and	heterogeneity.	Medicine	(Baltimore),	95,	S2-7	with	permission	from	Wolters	Kluwer	Health,	Inc.	
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1.2. Metastasis:	A	Conceptual	Overview	
	
Metastasis,	 the	 systemic	 spread	 of	 a	 tumour	 to	 secondary	 sites,	 invariably	
foreshadows	 a	 poor	 prognosis	 and	 is	 ultimately	 responsible	 for	 greater	 than	 90%	of	
tumour-related	 patient	 mortality	 (Chaffer	 and	 Weinberg,	 2011).	 From	 a	 clinical	
perspective,	 metastasis	 occurs	 in	 two	 distinct	 phases:	 a	 clinically	 latent	 stage	 of	
systemic	dissemination	that	occurs	early	in	disease	pathogenesis	(during	formation	of	
the	 primary	 tumour	 and	 prior	 to	 clinical	 presentation)	 followed	 by	 the	 formation	 of	
overt	metastatic	 lesions	 (Klein,	 2003;	 Husemann	 et	 al.,	 2008;	 Hosseini	 et	 al.,	 2016).	
Manifest	metastasis	 is	 largely	 incurable;	secondary	foci	 frequently	become	refractory	
to	 chemotherapeutic	 agents,	 seed	 additional	 metastatic	 colonies,	 and	 eventually	
compromise	functionality	of	vital	organs,	ultimately	leading	to	death	(Giancotti,	2013).	
	
From	a	pathophysiological	perspective,	the	conventional	description	of	the	metastatic	
process	 is	 that	 of	 a	 linear	 series	 of	 discrete	 events,	 the	 invasion-metastasis	 cascade	
(Figure	 1.2.),	 that	culminate	 in	 the	eventual	outgrowth	of	disseminated	 tumour	cells	
(DTCs)	in	the	distant	target	organ	(Nguyen	et	al.,	2009).	The	process	commences	when	
tumour	 cells	 at	 the	 primary	 site	 undergo	 a	 partial	 or	 complete	 epithelial-to-
mesenchymal	 transition	 (EMT).	 Having	 shed	 their	 epithelial	 traits,	 cells	 partially	
degrade	 and	 invade	 into	 the	 interstitial	 matrix,	 and	 induce	 the	 development	 of	 a	
supporting	 vasculature	 through	 neoangiogenesis.	 Intravasation	 and	 haematogenous	
dissemination	 subsequently	 occur	 as	 tumour	 cells	 exploit	 either	 local	 lymphatic	
drainage	 or	 discontinuities	 in	 the	 developing	 tumour-associated	 vasculature.	 Upon	
becoming	 arrested	 in	 the	 vascular	 beds	 of	 the	 distant	 target	 organ,	 DTCs	 undergo	
extravasation	 into	 the	 surrounding	 stroma	 and	 adopt	 various	 strategies	 that	 allow	
their	 survival	 and	 eventual	 successful	 colonisation	 of	 the	 non-orthotopic	 tissue	
(Valastyan	and	Weinberg,	2011).	
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Figure	1.2.	The	Invasion-Metastasis	Cascade	
During	metastasis,	metastatic	cancer	cells	reduce	their	adhesion	to	neighbouring	cells	(a)	and	degrade	
the	epithelial	basement	membrane	 in	order	 to	gain	access	 to	 the	 surrounding	 stroma	and	 supporting	
vasculature	(b).	 If	 the	tumoural	vasculature	 is	continuous,	cancer	cells	must	undergo	 intravasation	(c);	
endothelial	cell	retraction	is	induced	by	release	of	molecules	such	as	vascular	endothelial	growth	factor	
(VEGF)	 and	 the	 release	 of	 reactive	 oxygen	 species	 and	 factors	 including	 matrix	 metalloproteinases	
(MMPs)	cause	cell	death,	allowing	access	to	the	bloodstream.	The	distribution	of	circulating	tumour	cells	
(CTCs)	is	determined	by	blood	flow	and	interactions	between	cancer	cells	and	the	secondary	organs	that	
they	colonise;	cells	can	get	trapped	in	narrow	capillary	beds	and	can	also	express	receptors	that	bind	to	
vascular	endothelial	cells	(d)	or	to	platelets	(e),	which	protect	the	cancer	cells	from	the	immune	system	
and	 facilitate	 access	 to	 secondary	 tissues.	Upon	 arrival	 at	 secondary	 sites,	 cancer	 cells	 exit	 the	blood	
stream	by	extravasation	(f),	a	process	that	 is	mechanistically	comparable	to	 intravasation.	Cancer	cells	
then	 proceed	 to	 invade	 into	 and	 take-up	 residence	 in	 secondary	 tissues	 (g).	 Image	 reprinted	 from	
Schroeder,	 A.,	 Heller,	 D.	 A.,	 Winslow,	 M.	 M.,	 Dahlman,	 J.	 E.,	 Pratt,	 G.	 W.,	 Langer,	 R.,	 Jacks,	 T.	 &	
Anderson,	D.	G.	(2011).	Treating	metastatic	cancer	with	nanotechnology.	Nat	Rev	Cancer,	12,	39-50	with	
permission	from	Nature	Publishing	Group.	
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The	colonisation	of	remote	tissues	by	cells	derived	from	particular	primary	tumours	is	
a	type-specific	phenomenon	(Gupta	and	Massague,	2006).	In	breast	cancer,	the	bones,	
liver,	 lungs	 and	 brain	 are	 especially	 susceptible	 to	 the	 development	 of	 metastases,	
although	 the	 temporal	 course	 of	 disease	 within	 these	 target	 organs	 is	 often	 very	
different	 and	 varies	 by	 the	 molecular	 sub-type	 of	 breast	 cancer	 involved.	 In	 bone	
metastasis,	and	in	oestrogen	receptor	positive	(ER+)	breast	cancer	in	particular,	relapse	
often	 occurs	 years	 and	 even	 several	 decades	 after	 initial	 diagnosis	 (Bragado	 et	 al.,	
2012;	 Gomis	 and	 Gawrzak,	 2016).	 These	 observations	 support	 the	 contemporary	
conceptualisation	 of	 the	 well-established	 “seed	 and	 soil’	 theory	 of	 metastasis,	
originally	 proposed	 by	 Stephen	 Paget	 over	 a	 century	 ago	 (reviewed	 by	 Langley	 and	
Fidler,	2011),	which	proposes	 that	 it	 is	 the	compatibility	or	 interactions	between	the	
genetic	 signature	 and	 cellular	 phenotype	of	 the	DTCs	or	 "the	 seeds"	 and	 the	 signals	
encoded	 within	 specific	 niche	 microenvironments	 or	 "the	 soil"	 that	 is	 the	 primary	
determinant	 of	 whether	 DTCs	 are	 able	 to	 proliferate	 and	 produce	 overt	 secondary	
lesions,	or	are	forced	to	enter	a	protracted	state	of	mitotic	arrest	(Sosa	et	al.,	2013).	
	
1.3. Clinical	Implications	of	Breast	Cancer	Metastasis	to	Bone	
	
Skeletal	metastatic	foci	are	a	complication	of	advanced	malignancy	of	the	breast	and	
prostate	in	approximately	80%	of	diagnoses	(Smith	et	al.,	2012;	Coleman	et	al.,	2014a;	
Coleman	 et	 al.,	 2014b).	 The	 development	 of	 secondary	 tumours	 disrupts	 the	 tightly	
controlled	process	of	bone	remodelling,	resulting	in	the	well-established	“vicious	cycle	
of	 bone	 metastasis”	 (Figure	 1.3.)	 that	 leads	 to	 increased	 bone	 resorption	 and,	
ultimately,	 tumour	 progression	 (Mundy,	 1997).	 During	 the	 course	 of	 disease,	 a	
significant	 number	 of	 individuals	 with	 bone	 metastases	 will	 suffer	 frequent	 or	
recurrent	skeletal	related	events,	including;	pathological	fractures,	spinal-compression	
syndromes,	bone	pain	and	hypercalcaemia	(Coleman,	2006).	The	development	of	such	
cancer-related	 skeletal	 morbidity	 causes	 considerable	 personal,	 social	 and	 financial	
burden,	 and	 a	 markedly	 diminished	 quality	 of	 life	 (Kinnane,	 2007).	 Patients	 are	
generally	 considered	 incurable	once	 skeletal	 dissemination	 is	 diagnosed	 (Coleman	 et	
al.,	2014a).	Although	bone-targeting	anti-resorptive	agents	have	been	very	successful	
in	 reducing	 the	 rate	 of	 disease	 progression,	 decreasing	 the	 incidence	 of	 skeletal-
related	 events	 and	 lengthening	 patient	 life	 expectancy,	 the	 median	 survival	 rate	
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remains	 around	 2	 years	 from	 the	 initial	 diagnosis	 of	 bone	metastasis	 (Harries	 et	 al.,	
2014).	
	
Secondary	skeletal	foci	in	breast	and	prostate	cancer	are	invariably	derived	from	DTCs	
that	are	initially	maintained	in	a	protracted	state	of	reversible	mitotic	arrest.	This	non-
proliferative	 state	 confers	 an	 inherent	 resistance	 to	 conventional	 anti-neoplastic	
chemotherapeutics	that	prevents	the	removal	of	DTCs	from	the	bone.	These	cells	may	
emerge	from	quiescence	a	number	of	years	or	decades	following	 initial	 treatment	to	
form	 tumours	 that	 lead	 to	 skeletal	 destruction,	 complications	 and	 eventual	 patient	
mortality	(Sosa	et	al.,	2014).	The	exact	molecular	mechanisms	that	maintain	DTCs	in	a	
state	 of	 mitotic	 arrest	 and	 determine	 their	 reawakening	 to	 form	metastatic	 lesions	
remain	 some	 of	 the	 most	 important	 unanswered	 questions	 in	 cancer	 biology.	
Obtaining	 a	 greater	 understanding	 of	 these	 areas	 will	 likely	 hold	 the	 key	 to	 vastly	
improving	the	prognosis	of	those	patients	that	are	diagnosed	at	an	advanced	stage	of	
disease.	
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Figure	1.3.	The	Vicious	Cycle	of	Bone	Metastasis	
Overtly	 growing	 metastatic	 cancer	 cells	 secrete	 soluble	 factors	 that	 act	 in	 a	 paracrine	 manner	 on	
osteoblasts	 and	 osteoclasts	 and	 ultimately	 stimulate	 bone	 resorption	 resulting	 in	 lytic	 bone	 lesions.	
Osteoclast	activity	acts	to	degrade	the	bone	and	releases	an	array	of	growth	factors	sequestered	within	
bone	tissue	during	osteogenesis.	The	action	of	these	mitogenic	factors	perpetuates	the	cycle	of	tumor	
cell	 growth	 and	 osteolysis.	 Image	 reprinted	 from	 Gomis,	 R.	 R.	 &	 Gawrzak,	 S.	 (2016).	 Tumor	 cell	
dormancy.	Mol	Oncol.	with	permission	from	FEBS	Press	and	John	Wiley	&	Sons	Ltd.	
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1.4. The	Metastasis-Initiating	Breast	Cancer	Cell	Population	
	
Metastasis	 itself	 is	 an	 inefficient	 process;	 despite	 the	 persistent	 shedding	 of	 vast	
numbers	of	cells	 into	the	circulation	by	primary	tumours,	very	few	metastatic	 lesions	
actually	 develop	 (Fidler,	 1970;	 Weilbaecher	 et	 al.,	 2011).	 Metastatic	 inefficiency	
indicates	that	the	majority	of	tumour	cells	fail	to	successfully	execute	one	of	the	steps	
of	 the	 invasion-metastasis	 cascade.	However,	 a	 small	 proportion	of	 cancer	 cells	 that	
arise	 within	 the	 primary	 tumour	 will	 invariably	 complete	 the	 metastatic	 process,	
evidenced	 by	 the	 fact	 that	many	 cancer	 patients	 do	 eventually	 progress	 to	 develop	
secondary	 tumours	 (Chaffer	 and	 Weinberg,	 2011).	 Various	 experimental	 studies	
indicate	 that	 these	metastasis-initiating	 sub-clones	 arise	 within	 the	 primary	 tumour	
from	 progenitors	 that	 are	 initially	 devoid	 of	 significant	 survival	 or	 self-renewal	
capacity,	under	 the	 influence	of	 tumour-derived	microenvironmental	 conditions	 (e.g.	
hypoxia	 and	 nutritional	 stress),	 and	 through	 interactions	 with	 tumour-associated	
stromal	cells	(Joyce	and	Pollard,	2009;	Chaffer	et	al.,	2011;	Scheel	et	al.,	2011;	Fluegen	
et	al.,	2017).	The	phenotypic	adaptations	 that	 these	cells	acquire	presumably	do	not	
confer	a	strong	selective	advantage	at	the	primary	site	and	therefore	are	not	prevalent	
within	 the	primary	 tumour.	 Instead,	 these	changes	 likely	act	 to	 facilitate	 initial	entry	
into,	 and	 transition	 through,	 the	 invasion-metastasis	 cascade	and	only	prove	vital	 to	
cell	survival	and	progression	post-dissemination.	The	identification	of	driver	mutations	
and	 the	 convergent	 adaptation	 of	 metastatic	 clones	 in	 a	 number	 of	 cancer	 types	
indicates	 that	 environmental	 conditions	 encountered	 during	 systemic	 spread	 also	
influences	 acquisition	 of	 genetic	 and	 epigenetic	 alterations	 that	 potentiate	 the	
metastatic	capacity	of	tumour	cells	already	equipped	to	survive	the	preceding	stages	
of	 the	 dissemination	 process	 (Campbell	 et	 al.,	 2010;	 Gerlinger	 et	 al.,	 2012).	 The	
acquisition	 of	 the	 phenotypic	 attributes	 that	 enable	 individual	 tumour	 cells	 to	
successfully	 traverse	 the	 metastatic	 cascade	 can	 therefore	 be	 seen	 as	 a	 dynamic	
adaptation	 akin	 to	 the	 Darwinian	 process	 of	 natural	 selection;	 tumour	 cells	 that	
eventually	 succeed	 in	 colonising	 distant	 tissues	 have	 acquired	 the	 traits	 that	 enable	
emergence	from	each	preceding	stage	of	metastasis.	
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Although	 an	 exact	 definition	 of	 the	 metastasis-initiating	 phenotype	 has	 remained	
largely	elusive,	characteristic	properties	that	recurrently	emerge	are	that	of	multi-drug	
resistance,	 high	 metastatic	 and	 invasive	 capability,	 dormancy	 competence	 and	
features	of	stem	cells,	 including;	self-renewal,	serial	passaging	ability,	enhanced	DNA	
repair,	 impaired	 apoptosis,	 a	 long	 doubling	 time,	 asymmetric	 division	 and	 cycling	
quiescence	(Ginestier	et	al.,	2007;	Singh	and	Settleman,	2010;	Patel	et	al.,	2012;	Kreso	
et	 al.,	 2013).	 Cancer	 stem	 cell	 populations	 have	 primarily	 been	 defined	 by	 their	
increased	 functional	 capacity	 for	 tumour	 initiation	 and	 ability	 to	 subsequently	
recapitulate	tumoural	heterogeneity	(Luo	et	al.,	2015).	 In	breast	cancer,	a	number	of	
marker	 signatures	 have	 been	 used	 to	 identify	 cell	 populations	 possessing	 such	
enhanced	tumourigenicity	(summarised	in	Table	1.1.).	
	
The	most	 prolific	 marker	 signature	 used	 to	 identify	 prospective	 breast	 cancer	 stem	
cells	 is	 the	 CD44+CD24-/low	 phenotype.	 Al-Hajj	 et	 al.	 (2003)	 first	 demonstrated	 that	
breast	 cancer	 cells	 possessing	 the	 CD44+CD24-/low	 signature	 were	 significantly	 more	
tumorigenic	than	the	corresponding	CD44+CD24+	population	when	implanted	into	the	
mammary	fat	pads	of	the	immunodeficient	mice.	While	the	prognostic	significance	of	
the	 CD44+CD24-/low	 phenotype	 remains	 uncertain,	 the	 CD44+CD24-/low	 phenotype	 has	
been	shown	to	correlate	with	enhanced	 invasive	and	metastatic	capability	 (Abraham	
et	al.,	2005;	Sheridan	et	al.,	2006).	 It	has	been	suggested	that	this	could	be	linked	to	
the	 role	of	CD44	as	 the	primary	 receptor	 for	hyaluronan,	a	major	 component	of	 the	
extracellular	 matrix	 (Orian-Rousseau,	 2015).	 However,	 the	 diverse	 and	 complex	
biological	functions	of	both	CD44	and	CD24	have	made	their	exact	roles	in	relation	to	
the	 functional	 properties	of	 the	putative	breast	CSC	population	difficult	 to	delineate	
and	 these	 still	 remain	 unclear	 (Jaggupilli	 and	 Elkord,	 2012).	 Other	 less	 common	
markers	that	have	been	associated	with	enhanced	tumourigenicity	and	have	therefore	
been	 used	 to	 identify	 putative	 breast	 CSC	 populations	 include	 the	 cell	 surface	
glycoprotein	 CD133	 (also	 called	 prominin-1)	 or	 the	 CD29+CD49f+	 phenotype	
(expression	of	α6β1	integrin),	although	the	functionality	of	these	markers	in	relation	to	
stemness,	like	CD44	and	CD24,	also	remain	to	be	elucidated.	
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Due	 to	 a	 number	 of	 progenitor	 functions	 being	 conserved	 in	 CSCs	 across	 multiple	
disease	types,	functional	markers	of	stemness	such	as	aldehyde	dehydrogenase	(ALDH)	
are	 also	 widely	 used	 to	 demark	 CSC	 populations.	 ALDH	 is	 a	 detoxifying	 enzyme	
responsible	 for	 the	 oxidation	 of	 retinol	 to	 retinoic	 acid,	 an	 essential	 process	 in	 the	
early	 differentiation	 of	 stem	 cells	 (Chute	 et	 al.,	 2006).	 Enhanced	 ALDH	 activity	 has	
been	 observed	 in	 both	 normal	 and	malignant	 breast	 stem	 cell,	 and	 can	 serve	 as	 an	
independent	 indicator	for	poor	clinical	outcome	(Ginestier	et	al.,	2007).	 Interestingly,	
relatively	 recent	 studies	 have	 demonstrated	 that	 CD44+CD24-/low	 and	 ALDH+	
phenotypes	 are	 differentially	 expressed	 depending	 on	 the	 sub-type	 of	 breast	 cancer	
involved;	the	CD44+CD24-/low	phenotype	 is	more	commonly	associated	with	basal-like	
breast	cancers,	while	ALDH+	cells	are	more	common	in	HER2-enriched	and	basal	sub-
types	 (Ricardo	 et	 al.,	 2011).	 The	 specific	 biological	 mechanisms	 that	 underpin	 the	
different	 expression	 of	 CD44,	 CD24	 and	 ALDH	 in	 breast	 cancer	 have	 yet	 to	 be	
identified.	
	
Although	the	specific	functionality	of	many	of	the	breast	CSC	markers	remains	unclear,	
the	 correlation	between	 their	 expression	and	 the	 invasive	properties	 and	metastatic	
potential	 of	 tumours	 is	 generally	 well	 accepted.	 For	 example,	 DTCs	 expressing	
CD44+CD24-/low	 and	 ALDH+	 have	 been	 detected	 within	 the	 axillary	 lymph	 node	
metastases	 of	 breast	 cancer	 patients	 (Wei	 et	 al.,	 2012;	Nogami	 et	 al.,	 2014).	 	Given	
that	CSCs	are	supposed	to	transit	through	the	bloodstream	from	the	primary	tumour	
to	secondary	sites,	one	might	also	expect	that	stem	marker	expression	would	also	be	
highly	conserved	within	both	CTCs	and	DTCs.	Evidence	to	support	this	hypothesis	has	
recently	been	reported	 in	a	number	of	studies	that	show	the	expression	of	stem	cell	
marker	 by	 cancer	 cells	 isolated	 from	 the	 peripheral	 blood	 and	 the	 bone	marrow	 of	
breast	cancer	patients	(Balic	et	al.,	2006;	Theodoropoulos	et	al.,	2010;	Giordano	et	al.,	
2013).	 However,	 whether	 stem	 cell	 marker	 expression	 is	 stable	 during	 systemic	
dissemination	or	how	their	expression	changes	 throughout	 the	metastatic	cascade	 is	
still	unknown.	
	
	
	
	
	 13	
Table	1.1.	Marker	Profiles	Routinely	Used	to	Identify	Breast	Cancer	Stem	Cells	
	
Marker	Profile	
	
Clinical-Pathological	
Features	
	
Clinical	
Observations	 References	
CD44+	CD24-/Low	
Enriched	in	claudin-low	
and	basal	sub-types	
	
Associated	with	BRCA1	
mutational	status	
	
Poor	prognosis	
Tumour	recurrence	
	
Resistance	to	radiotherapy	
and	standard	chemotherapy	
	
High	metastatic	propensity	
(Abraham	et	al.,	2005)	
(Li	et	al.,	2008)	
(Lagadec	et	al.,	2010)	
(Bernardi	et	al.,	2012)	
(Bane	et	al.,	2013)	
ALDH1+	
Associated	with	ER	
negativity,	HER2	
amplification	and	basal-
like	sub-type	
	
Poor	prognosis	
Tumour	recurrence	
	
Enhanced	capacity	for	
metastatic	behaviour	
	
Resistance	to	standard	
chemotherapy	
(Ginestier	et	al.,	2007)	
(Morimoto	et	al.,	2009)	
(Tanei	et	al.,	2009)	
(Park	et	al.,	2010)	
CD44+	ALDH1+/High	
Enriched	in	high-grade	
DCIS	
	
Indicative	of	high	risk	
patients	
Predicts	distant	metastasis	
and	overall	survival	
	
Resistance	to	standard	
chemotherapy	
	
High	metastatic	propensity	
(Croker	and	Allan,	2012)	
(Da	Cruz	et	al.,	2014)	
(Da	Cruz	et	al.,	2016)	
CD133+	
Enriched	in	IBC	
	
Highly	enriched	in	
TNBC	
Tumour	recurrence	
	
Resistance	to	standard	
chemotherapy	
(Meyer	et	al.,	2010)	
(Aomatsu	et	al.,	2012)	
(Liu	et	al.,	2013)	
CD29+	CD49f+	
CD29	is	associate	with	
shorter	disease-free	
survival	and	overall	
survival	
	
CD49f	is	a	prognostic	
indicator	and	is	
associated	with	poorer	
clinical	outcome	
Tumour	relapse	
	
High	metastatic	propensity	
	
Resistance	to	radiotherapy	
and	standard	chemotherapy	
(Narita	et	al.,	1998)	
(Lim	et	al.,	2009)	
(Ahmed	et	al.,	2013)	
(Ye	et	al.,	2015)	
	
ALDH1:	 aldehyde	 dehydrogenase	 1;	 BRCA1:	 breast	 cancer	 1;	 CD24:	 signal	 transducer	 CD24;	 CD29:	
integrin	 β1;	 CD44:	 hyaluronan	 receptor;	 CD49f:	 integrin	 α6;	 DCIS:	 ductal	 carcinoma	 in	 situ;	 ER:	
oestrogen	receptor;	HER2:	human	epidermal	growth	factor	receptor	type-2;	IBC:	invasive	breast	cancer;	
TNBC:	triple-negative	breast	cancer.	
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1.5. Epithelial-to-Mesenchymal	Transition	and	Metastasis	
	
Pathological	 exploitation	 of	 the	 developmental	 EMT	 programme	 in	 cancer	 has	 been	
centrally	 implicated	 in	 cellular	 de-differentiation	 and	 acquisition	 of	 both	 stem	 cell	
traits	 and	 invasive	 capability	 (Figure	 1.4.).	 Enhanced	 expression	 of	 EMT-promoting	
transcriptional	 factors	Snail,	 Slug	and	Twist	 in	breast	carcinoma	have	been	shown	to	
induce	 the	 so-called	 “cadherin	 switch”	 which	 involves	 concomitant	 loss	 of	 tumour-
suppressing	 junctional	 protein	 E-cadherin	 and	 up-regulation	 of	 the	 transendothelial	
migration-enabling	N-cadherin,	 resulting	 in	 increased	 invasive	capability	 (Bolos	et	al.,	
2003;	 Yang	 et	 al.,	 2004;	Moody	 et	 al.,	 2005;	 Thiery	 et	 al.,	 2009).	 In	 addition,	 the	 E-
cadherin-suppressing	 ZEB1	 transcription	 factor	 also	 promotes	 tumour	 cell	 de-
differentiation	by	repressing	the	ability	of	a	myriad	of	master	regulators	of	epithelial	
polarity	and	intercellular	adhesion	to	inhibit	the	development	of	stemness	and	induce	
epithelial	 differentiation	 (Aigner	 et	 al.,	 2007;	 Shimono	 et	 al.,	 2009;	 Wellner	 et	 al.,	
2009;	Korpal	et	al.,	2011).	These	studies	collectively	demonstrate	that	EMT	is	central	
to	 the	 shedding	of	epithelial	 attributes	and	acquisition	of	a	 stem	cell-like	phenotype	
that	in-turn	facilitates	enhanced	invasive	and	metastatic	behaviours.	Interestingly,	the	
CD44+CD24-/low	and	ALDH+	marker	profiles	associated	with	putative	stem	cells	in	breast	
cancer	 have	 been	 shown	 to	 identify	 spatiotemporally	 distinct	 but	 dynamically	
transitioning	 populations	 with	 respect	 to	 genetic	 signatures	 associated	 with	 EMT	
across	different	breast	cancer	sub-types	(Liu	et	al.,	2014).	Relatively	recently,	Ombrato	
and	Malanchi	(2014)	proposed	the	"EMT-gradient	model"	to	explain	how	the	transient	
nature	 of	 the	 EMT	 process	 might	 regulate	 stemness	 and	 epithelial-mesenchymal	
phenotypes	 during	 metastasis.	 According	 to	 this	 model,	 the	 activation	 of	 the	 EMT	
program	presents	different	 threshold	 levels	at	which	EMT	and	stemness	are	coupled	
and	 is	 instructed	 by	microenvironmental	 signals;	 cellular	 phenotypes	 therefore	 exist	
somewhere	along	a	spectrum,	becoming	more	mesenchymal	during	invasion	and	more	
epithelial	 and	 progressively	 more	 stem-like	 during	 later	 stages	 of	 metastatic	
colonisation	(Figure	1.5.).	One	notable	consequence	of	this	EMT	gradient	state	is	the	
differential	expression	of	stem	cell	and	EMT	markers	by	the	CSC	population	depending	
on	 their	epithelial-mesenchymal	phenotypic	 status,	 as	exemplified	by	 the	 findings	of	
Liu	et	al.	(2014).	
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Figure	1.4.	Epithelial-to-Mesenchymal	Transition	
During	 the	 epithelial-to-mesenchymal	 transition,	 epithelial	 traits	 and	 intracellular	 junctional	 complex	
proteins	are	down	regulated	while	mesenchymal	markers	are	increasingly	expressed.	These	changes	are	
accompanied	by	loss	of	apical-basal	polarity	and	a	change	to	lateral	polarisation	that	aids	invasive	and	
migratory	 behaviour.	 Image	 reprinted	 from	 Angadi,	 P.	 &	 Kale,	 A.	 (2015).	 Epithelial-mesenchymal	
transition	 -	 A	 fundamental	 mechanism	 in	 cancer	 progression:	 An	 overview.	 Indian	 Journal	 of	 Health	
Sciences	 and	 Biomedical	 Research	 (KLEU),	 8,	 77-84,	 with	 permission	 from	Wolters	 Kluwer	Medknow	
Publications.	
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Figure	1.5.	The	EMT-Gradient	Model	of	Stemness	and	Phenotypic	Plasticity	
The	activation	of	the	epithelial-to-mesenchymal	transition	(EMT)	program	during	the	metastatic	cascade	
presents	 different	 threshold	 levels	 at	 which	 EMT	 and	 stemness	 are	 coupled.	 Cellular	 phenotypes	
therefore	exist	somewhere	along	a	spectrum	that	is	instructed	by	microenvironmental	signals;	cells	gain	
plasticity	 and	 become	 more	 mesenchymal	 following	 initial	 activation	 of	 EMT	 during	 invasion,	 but	
subsequently	become	more	epithelial	and	progressively	more	stem-like	during	later	stages	of	metastatic	
colonisation	following	phenotypic	reversion	through	mesenchymal-to-epithelial	transition	(MET).	Image	
reprinted	 from	 Fabregat,	 I.,	Malfettone,	 A.	 &	 Soukupova,	 J.	 (2016).	 New	 Insights	 into	 the	 Crossroads	
between	 EMT	 and	 Stemness	 in	 the	 Context	 of	 Cancer.	 J	 Clin	 Med,	 5,	 with	 permission	 from	
Multidisciplinary	Digital	Publishing	Institute	(MDPI).	
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1.6. Quiescence	and	the	Metastasis-Initiating	Cell	Population	
	
Metastatic	 dormancy,	 a	 period	 of	 latency	 between	 systemic	 dissemination	 and	
metastatic	 outgrowth,	 is	 a	well-established	 concept	 in	 a	 number	 of	 cancer	 types.	 In	
breast	cancer	in	particular,	the	detection	of	overt	metastasis	has	been	reported	up	to	
several	decades	post-surgery	(Gomis	and	Gawrzak,	2016).	From	a	cellular	perspective,	
this	 asymptomatic	 period	 that	 precedes	 relapse	 or	 recurrence	 can	 be	 explained	 by	
either	cellular	mitotic	quiescence,	 in	which	cells	exist	 in	a	state	of	reversible	growth-
arrest,	or	micrometastatic	dormancy,	 in	which	sub-clinical	metastatic	 foci	are	unable	
to	progress	to	overt	disease	due	to	insufficient	vascularisation	and	a	rate	of	cell	death	
that	 compensates	 for	 the	 rate	 of	 proliferation	 (Aguirre-Ghiso,	 2007).	 While	 these	
situations	 are	 likely	 non-mutually	 exclusive,	 the	 former	 is	 best	 supported	 by	 clinical	
evidence;	 the	tumour	cells	 isolated	from	bone	marrow	aspirates	taken	from	patients	
with	 various	 bone-tropic	 cancers	 have	 been	 found	 to	 be	 growth	 arrested,	 and	 their	
number	 have	 been	 shown	 to	 directly	 correlate	 with	 reduced	 disease-free	 survival	
(Pantel	 et	 al.,	 2008;	 Hartkopf	 et	 al.,	 2014;	 Hartkopf	 et	 al.,	 2015).	 Indeed,	 cellular	
mitotic	 quiescence	 is	 now	 recognised	 as	 a	 phenomenon	 that	 is	 integral	 to	 the	
pathogenesis	of	metastatic	disease,	enforced	by	the	increasing	ubiquitous	association	
of	 quiescence	 and	 both	 de	 novo	 drug	 resistance	 and	 stemness	 in	 both	 normal	 and	
neoplastic	 cell	 populations	 (Moore	 and	 Lyle,	 2011).	 Consequently,	 a	 number	 of	
mechanisms	leading	to	cellular	quiescence	have	now	been	described.	
	
The	balance	between	activated	extracellular	regulated	kinase	(ERK)	and	activated	p38	
α/β	was	one	of	the	earliest	quiescence	inductive	mechanisms	elucidated.	Early	studies	
in	 a	 transgenic	 mouse	 model	 of	 breast	 cancer	 undertaken	 by	 White	 et	 al.	 (2004)	
reported	that	 the	 loss	of	β1-integrin	 from	tumour	cells	was	 linked	with	resistance	to	
apoptotic	 cell	 death	 and	 entry	 into	 a	 growth-arrested	 quiescent	 state.	 Around	 this	
time,	studies	undertaken	in	human	epidermoid	carcinoma	models	 in	vitro	and	 in	vivo	
demonstrated	 that	 the	 induction	 of	 growth	 arrest	 followed	 abolition	 of	 fibronectin-
dependent	proliferative	signalling	via	the	FAK-Ras-ERK	pathway	in	response	to	reduced	
urokinase	 receptor	 (uPAR)-mediated	 α5β1-integrin	 activation	 (Aguirre	 Ghiso	 et	 al.,	
1999;	Aguirre	Ghiso,	2002;	 Liu	 et	al.,	 2002).	 In	 all	 of	 these	 studies,	disruption	of	β1-
integrin	function	was	seen	to	occur	 in	conjunction	with	the	sustained	over-activation	
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of	 the	 p38	 mitogen-activated	 protein	 kinase	 (MAPK)	 pathway.	 Subsequent	
investigations	have	since	demonstrated	that	deactivated	ERK	signalling	in	conjunction	
with	high	p38	activity	can	initiate	the	unfolded	protein	response	pathway,	promoting	a	
protracted	 state	 of	 cellular	 quiescence	 through	 ATF6	 and	 Rheb-mediated	 mTOR	
signalling	 and	 subsequent	 induction	 of	 quiescence-associated	 transcription	 factors	
BHLHE41	 (DEC2	or	 Sharp1)	 and	NR2F1,	 and	 cyclin-dependent	 kinase	 (CDK)	 inhibitors	
p21	and	p27	(Schewe	and	Aguirre-Ghiso,	2008;	Bragado	et	al.,	2013;	Sosa	et	al.,	2015).	
	
Just	 as	 the	 roles	 of	 uPAR-	 and	 integrin-mediated	 signalling	 identified	 an	 early	 link	
between	mitotic	quiescence	and	the	cellular	microenvironment,	a	 recently	published	
study	by	Fluegen	et	al.	(2017)	has	linked	the	induction	of	quiescence-associated	genes	
within	 primary	 tumour	 microenvironments	 to	 a	 predisposition	 to	 entry	 into	 a	
dormancy	 program	 at	 post-metastatic	 sites.	 In	 this	 study,	 hypoxic	 primary	 breast	 or	
head	 and	 neck	 squamous	 cell	 carcinoma	 (HNSCC)	 tumour	 microenvironments	
displayed	 up-regulation	 of	 quiescence-	 and	 hypoxia-associated	 genes	
(NR2F1/DEC2/p27	 and	 HIF-1α/GLUT1,	 respectively).	 Tracking	 of	 individual	 DTCs	
revealed	 that	 those	 originating	 from	 a	 hypoxic	 microenvironment	 were	 frequently	
quiescent	 and	 displayed	 a	 DEC2hip27hiNR2F1hiTGF-β2hi	 signature.	 These	 post-hypoxic	
DTCs	were	 shown	 to	 evade	 chemotherapy	 and	were	 prone	 to	 enter	 into	 a	 state	 of	
dormancy	 at	 secondary	 sites.	 Interestingly,	 while	 p27	 induction	 was	 shown	 to	 be	
dependent	on	at	 least	HIF-1α	and	NR2F1	at	primary	sites,	post-hypoxic	DTCs	did	not	
appear	 to	maintain	 a	 hypoxic	 gene	 signature,	 being	 negative	 for	 GLUT1	 expression.	
These	 findings	 suggest	 that	 the	 primary	 tumour	 plays	 a	 key	 role	 in	 generation	 of	
quiescent,	 chemoresistant	 and	 metastasis-competent	 cells	 but	 that	 the	 post-
metastatic	microenvironment	plays	a	critical	role	in	regulating	the	switch	between	DTC	
dormancy	and	proliferation.	
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1.7. The	Bone	Microenvironment	and	Post-Metastatic	Regulation	of	Dormancy	
	
A	 myriad	 of	 studies	 have	 provided	 evidence	 supporting	 disseminated	 tumour	 cells	
being	maintained	 in	 a	 state	 of	mitotic	 arrest	 following	 infiltration	 of	 a	 target	 organ	
(reviewed	 extensively	 by	 Sosa	 et	 al.,	 2014).	 The	 collective	 findings	 of	 these	 studies	
indicate	 that	 the	mitotically	 dormant	 state	 is	 largely	 the	 result	 of	 growth-restrictive	
microenvironmental	 conditions	 or	 deprivation	 of	 pro-proliferative	 signalling	
interactions	 within	 the	 post-metastatic	 niche.	 Consequently,	 cellular	 dormancy	 in	
metastasis	 can	be	 seen	as	 the	 result	of	 a	maladaptation	 that	 can	potentially	 resolve	
following	 acquisition	 of	 traits	 that	 facilitate	 cell	 growth	 within	 a	 specific	 tissue	
microenvironment.	 Given	 that	mitotic	 quiescence	 is	 not	 conducive	 to	 acquisition	 of	
genetic	alterations	due	to	a	vastly	decreased	probability	of	mutational	events,	even	in	
genetically	unstable	tumour	cells,	it	is	more	likely	that	adaptations	that	favour	survival	
and	 eventual	 outgrowth	 are	 driven	 by	 reciprocal	 interactions	 with	 the	 tissue	
microenvironment,	 reconfiguration	 of	metastable	 intracellular	 signalling	 networks	 or	
modulated	 epigenetic	 states	 (Michor	 et	 al.,	 2004).	 Gaining	 further	 insight	 into	 the	
quiescent	 cell	 phenotype	 and	 how	 signals	 encoded	within	 the	 post-metastatic	 niche	
microenvironment	 modulate	 the	 signalling	 pathways	 that	 regulate	 this	 state	 to	
maintain	 long-term	dormancy	will	 be	 critical	 to	 identifying	 novel	 therapeutic	 targets	
for	prevention	of	metastatic	disease.	
	
The	bone	marrow	is	characterised	by	high	cellular	heterogeneity,	being	composed	of	
cells	 of	 haematopoietic	 origin	 (osteoclasts,	 macrophages	 and	 lymphocytes),	
mesenchymal	 origin	 (osteoblasts	 and	 adipocytes),	 neurones	 and	 endothelial	 cells	
(Shiozawa	et	al.,	2015).	These	cell	populations	compose	the	niche	microenvironments	
in	which	haematopoietic	stem	cells	(HSCs)	and	mesenchymal	stem	cells	(MSCs)	reside	
(reviewed	by	 Ren	 et	 al.,	 2015).	 A	multitude	 of	 studies	 have	 showed	 that	DTCs	 from	
bone-tropic	 cancers	 appropriate	 these	 microenvironments	 and	 that	 these	 either	
expedite	or	impede	metastatic	progression.	The	following	sections	outline	established	
mechanisms	by	which	the	post-metastatic	niche	in	bone	can	regulate	DTC	dormancy	in	
bone-tropic	cancers;	these	are	summarised	in	Table	1.2.	and	discussed	in	more	detail	
thereafter.	
	
	 20	
Table	1.2.	Molecular	Mechanisms	Implicated	in	Tumour	Cell	Dormancy	in	Bone	
	
Molecule	/	Pathway	 Cancer	Type	
	
Implication	
	
References	
GAS6	-	AXL	 Prostate	
High	AXL:TYRO3	expression	ratio	
on	DTCs	induced	by	osteoblastic	
annexin-II	leads	to	over-
stimulation	by	GAS6	and	
dormancy	
(Shiozawa	et	al.,	2010)	
(Mishra	et	al.,	2012)	
(Taichman	et	al.,	2013)	
TBK1	 Prostate	
Bone	stroma	induces	an	
overexpression	of	TBK1	by	DTCs	
which	induces	dormancy	by	
modulating	mTOR	activity	
(Kim	et	al.,	2013)	
BMP7	-	BMPR2	 Prostate	
Bone	stroma-derived	BMP7	acts	
on	BMPR2	on	DTCs	to	induce	
high	p38:ERK	ratio	leading	to	
dormancy	
(Kobayashi	et	al.,	2011)	
TGF-β2	-	TGF-βRI	 Breast	
Bone	stroma-derived	TGF-β2	
signalling	via	TGF-βRI	on	DTCs	
induces	high	p38:ERK	ratio	
leading	to	dormancy	
(Bragado	et	al.,	2013)	
(Marlow	et	al.,	2013)	
NK1R-Tr	:	NK1R-FL	 Breast	
Bone	stroma-derived	CXCL12	
induces	reduction	of	NK1R-Tr	
expression	by	DTCs	allowing	
over	activation	of	NK1R-FL	by	
tachykinins	leading	to	dormancy	
(Zhou	et	al.,	2014)	
bFGF	 Breast	
Bone	marrow-derived	bFGF	
causes	expression	of	α5β1	
integrin	allowing	ligation	by	
fibronectin	and	signalling	via	
PI3K	to	induce	dormancy	
(Korah	et	al.,	2004)	
(Barrios	and	Wieder,	2009)	
TSP-1	 Breast	
TSP-1	expressed	on	mature	bone	
vascular	endothelium	induces	
DTC	dormancy	
(Ghajar	et	al.,	2013)	
miRNAs	via	GJIC	 Breast	
Multiple	bone-derived	miRNAs	
act	on	DTCs	via	GJIC	induced	
between	bone	stromal	cells	and	
DTCs	by	the	paracrine	action	of	
CXCL12	
(Lim	et	al.,	2011)	
(Ono	et	al.,	2014)	
	
GAS6:	 growth	 arrest-specific	 6;	 AXL:	 AXL	 receptor	 tyrosine	 kinase;	 TYRO3:	 tyrosine-protein	 kinase	
receptor	 TYRO3;	DTCs:	 disseminated	 tumour	 cells;	 TBK1:	 TANK-binding	 kinase-1;	mTOR:	 mammalian	
target	 of	 rapamycin;	 BMP7:	 bone	 morphogenetic	 protein-7;	 BMPR2:	 bone	 morphogenetic	 protein	
receptor	type-2;	ERK:	extracellular	signal-regulated	kinase;	TGF-β2:	transforming	growth	factor-β2;	TGF-
βRI:	transforming	growth	factor-	β	receptor	type-1;	NK1R-Tr:	truncated	neurokinin-1	receptor;	NK1R-FL:	
full-length	 neurokinin-1	 receptor;	 CXCL12:	 CXC	 motif	 chemokine-12;	 bFGF:	 basic	 fibroblast	 growth	
factor;	 PI3K:	 phosphoinositide	 3-kinase;	 TSP-1:	 thrombospondin-1;	 miRNA:	 microRNA;	 GJIC:	 gap	
junctional	intercellular	communication.	
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GAS6	Receptor	Signalling	
	
Studies	undertaken	in	vivo	have	demonstrated	that	disseminated	prostate	cancer	cells	
(PCCs)	 preferentially	 migrate	 to	 osteoblast-rich	 regions	 of	 bone	 and	 are	 shown	 to	
directly	compete	for	occupancy	of	the	HSC	niche	(Shiozawa	et	al.,	2011;	Wang	et	al.,	
2014).	Molecular	pathways	which	are	known	to	be	critical	to	HSC	niche	selection,	such	
as	 the	 annexin-II	 and	 chemokine	 receptor-4	 (CXCR4)/chemokine	 ligand-12	 (CXCL12)	
axes,	have	been	centrally	implicated	in	this	process	(Shiozawa	et	al.,	2008;	Wang	et	al.,	
2014).	 Exploration	 of	 the	 role	 of	 osteoblastic	 annexin-II	 in	 directing	 interactions	
between	disseminated	PCCs	and	the	HSC	niche	showed	that	 it	significantly	enhanced	
expression	of	the	AXL	sub-family	of	receptor-tyrosine	kinases	by	PCCs	(Shiozawa	et	al.,	
2010).	This	group	of	 receptors,	which	 includes	AXL,	TYRO3	and	MER,	selectively	bind	
the	 stromal-derived	 growth	 arrest-specific	 6	 (GAS6)	 growth	 factor	 (Hafizi	 and	
Dahlback,	 2006).	 Enhanced	 expression	 of	 AXL	 receptors	 and	 consequent	 ligation	 by	
GAS6,	 mediated	 by	 annexin-II,	 was	 shown	 to	 increase	 survival,	 confer	 resistance	 to	
chemotherapy	and	reduce	the	mitotic	activity	of	PCCs	by	inducing	G0	arrest	(Shiozawa	
et	al.,	2010).	
	
In	 PC-3	 and	 DU-145	 prostate	 cancer	 subcutaneous	 xenograft	 models,	 DTCs	 isolated	
from	 bone	 marrow	 demonstrated	 markedly	 reduced	 proliferative	 activity	 during	
fluorescence-activated	cell	sorting	(FACS)	analysis	of	Ki67	when	compared	with	cells	of	
the	 primary	 tumour	 (Taichman	 et	 al.,	 2013).	 Primary	 tumour	 cells	 possessed	 a	
significantly	 reduced	 AXL:TYRO3	 expression	 ratio	 compared	 to	 cells	 grown	 in	 vitro,	
whereas	DTCs	isolated	from	tumour-free	marrow	showed	increased	expression	of	AXL	
and	down-regulated	TYRO3	compared	with	cells	taken	from	both	primary	tumours	and	
from	 secondary	metastatic	 foci.	 Evidence	 from	 a	 study	 undertaken	 by	Mishra	 et	 al.	
(2012)	 indicates	 that	 such	alterations	 in	 receptor	 sub-type	profiles	might	be	partially	
dependent	on	stabilisation	of	AXL	expression	regulated	by	hypoxia-inducible	factor-1-
alpha	(HIF-1α).	Irrespective	of	the	mechanism,	the	observations	made	by	Taichman	et	
al.	 (2013)	 appear	 to	 demonstrate	 that	 differential	 expression	 of	 AXL	 receptor	 sub-
types	 is	a	key	determinant	of	 the	tightly	controlled	switch	between	proliferative	and	
dormant	 phenotypes	 in	 prostate	 cancer	 bone	 metastasis.	 More	 specifically,	 a	 low	
AXL:TYRO3	ratio	appears	to	favour	cellular	proliferation	while	a	high	AXL:TYRO3	ratio	is	
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suggested	 to	 be	 conducive	 to	 a	 state	 of	 dormancy.	 Such	 induction	 of	 a	 dormancy-
permissive	 phenotype	 during	 niche	 selection	 closely	 resembles	 the	 situation	 that	 is	
seen	during	HSC	occupancy	of	osteoblastic	niche	within	the	bone	marrow	(Crosier	et	
al.,	 1996;	 Darby	 et	 al.,	 2000).	 Hence,	 it	 may	 be	 that	 other	 microenvironmental	
mechanisms	 known	 to	 instruct	 HSC	 function	 are	 also	 responsible	 for	 regulation	 of	
dormancy	in	DTCs	resident	within	the	bone	marrow.	
	
TBK1	Expression	
	
Evidence	reported	in	a	study	by	Kim	et	al.	(2013)	indicates	that	cell-niche	interactions	
that	 regulate	prostate	 cancer	 cell	 dormancy	within	 the	bone	microenvironment	may	
be	mediated	by	modulation	of	mTOR	signalling.	Kim	et	al.	(2013)	found	that	binding	of	
PCCs	 to	bone	marrow	 stromal	 cells	 (ST2	 lineage)	 during	 in	 vitro	 co-culture	markedly	
increased	 the	 number	 of	 cells	 in	 proliferative	 arrest.	 This	 sub-population	 of	 cells,	
isolated	 based	 on	 Ki67	 expression	 by	 FACS,	 were	 also	 noted	 as	 having	 significant	
chemoresistance	to	the	anti-mitotic	agent	docetaxel.	In	both	PC-3	and	C4-2B	prostate	
cancer	cell	lineages,	real-time	quantitative	polymerase	chain	reaction	(qPCR)	analyses	
revealed	hyper-expression	of	the	serine/threonine-protein	kinase	TBK1	(TANK-binding	
kinase-1)	in	response	to	ST2-cell	binding	interactions.	
	
TBK1	 has	 been	 implicated	 in	 mediating	 a	 number	 of	 functions	 that	 facilitate	 both	
malignant	 transformation	 and	 cell	 survival	 in	 cancer	 (Chien	 et	 al.,	 2006;	 Shen	 and	
Hahn,	 2011;	 Baldwin,	 2012).	 In	 the	 study	 undertaken	 by	 Kim	 et	 al.	 (2013),	
immunofluorescent	 staining	 of	 PCCs	 taken	 from	 their	 in	 vitro	 co-culture	 model	
revealed	co-localisation	of	TBK1	with	mTOR	around	the	nuclear	periphery.	Rapamycin-
induced	 inhibition	 of	 mTOR	 increased	 the	 proportion	 of	 dormant	 PCCs	 (Ki67-)	 and	
enhanced	resistance	to	an	array	of	conventional	chemotherapeutic	agents	in	both	PC-
3	 and	 C4-2B	 cell	 lines.	 Lentiviral	 shRNA	 knockdown	 of	 TBK1	 resulted	 in	 a	 significant	
increase	 in	mTOR	 activity	 and	 loss	 of	 chemoresistance.	 In	 addition,	 in	 stem	 cell-like	
(CD133+CD44+)	 sub-populations	 of	 PC-3	 and	 C4-2B	 cells	 isolated	 from	 mouse	 bone	
marrow,	TBK1	levels	were	significantly	increased.	In	vitro,	shRNA-induced	loss	of	TBK1	
not	 only	 caused	 enhanced	mTOR	 activation	 but	 also	 was	 associated	 with	 a	marked	
decrease	 in	 the	CD133+CD44+	cell	population.	This	effect	was	 significantly	 reduced	 in	
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the	presence	of	rapamycin.	When	taken	together,	these	studies	demonstrate	that	an	
inverse	 regulatory	 relationship	 exists	 between	 TBK1	 and	mTOR,	 and	 it	 appears	 that	
PCC-stromal	interactions	that	increase	TBK1-induced	inhibition	of	mTOR	are	seemingly	
important	 in	 the	 formation	 of	 stem	 cell-like	 sub-populations,	 maintenance	 of	
dormancy,	 and	 chemoresistance	 in	 prostate	 cancer.	 However,	 the	 mechanisms	 by	
which	PCC-niche	 interactions	 induce	enhanced	TBK1	expression,	and	by	which	TBK1-
mediated	inhibition	of	mTOR	leads	to	the	observed	chemoresistance	and	proliferative	
arrest,	remain	to	be	elucidated.	An	earlier	study	in	ovarian	tumours	undertaken	by	Lu	
et	 al.	 (2008)	 showed	 that	 dormancy	 was	 mediated	 by	 autophagic	 induction	 due	 to	
enhanced	expression	of	aplysia	ras	homology	member-I	(AHRI)	and	resultant	inhibition	
of	 the	 PI3K-PKB-mTOR	 pathway.	 The	 dramatic	 reduction	 in	 tumour	 regrowth	 in	 the	
presence	 of	 doxorubicin	 following	 chloroquine-induced	 inhibition	 of	 autophagy	 also	
indicated	 that	 autophagy	 is	 likely	 to	 be	 an	 important	 survival	 mechanism	 enabling	
dormant	tumour	cells	to	survive	chemotherapy.	In	light	of	this,	it	is	possible	that	TBK1-
induced	 mTOR	 inhibition	 results	 in	 autophagy,	 and	 that	 this	 is	 responsible	 for	 the	
dormancy	and	enhanced	chemoresistance	in	prostate	cancer	cells	reported	by	Kim	et	
al.	(2013).	
	
BMPR2	Signalling	
	
While	attempting	to	further	elucidate	bone	stroma-derived	secretory	factors	that	may	
have	modulatory	effects	on	DTC	dormancy	in	bone,	Kobayashi	et	al.	(2011)	noted	that	
the	 conditioned	medium	 from	normal	 bone	marrow	 stromal	 cells	 (HS5	 lineage)	was	
able	 to	 significantly	 reduce	 prostate	 cancer	 cell	 proliferation	 but	 did	 not	 elicit	 any	
cytotoxic	 effects.	On	 further	 investigation,	 reduced	proliferative	 activity	 appeared	 to	
strongly	correlate	with	markedly	enhanced	p38-MAPK	signalling,	loss	of	ERK	signalling,	
and	 simultaneous	 induction	 of	 the	 N-myc	 downstream-regulated	 gene-1	 (NDRG1)	
metastasis	suppressor	protein,	and	the	CDK	inhibitors	p21	and	p27.	Addition	of	small	
molecule	 inhibitors	 that	 block	 the	 action	 of	 secretory	 factors	 produced	 by	 bone	
stromal	 cells	 showed	 that	 inhibition	of	bone	morphogenetic	protein	 (BMP)	 signalling	
re-establish	 the	 dormancy-associated	 signalling	 profile	 observed	 in	 the	 presence	 of	
HS5	 conditioned	medium.	Analysis	 of	 the	 effects	 of	 purified	BMPs	 in	 vitro	 identified	
only	 BMP7	 as	 being	 able	 to	 activate	 p38,	 NDRG1,	 p21	 and	 p27,	 and	 diminish	 ERK	
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signalling,	 eliciting	 a	 state	 of	 dormancy.	 This	 dormant	 state	 was	 reversed	 following	
removal	of	BMP7	or	knockdown	of	its	receptor,	bone	morphogenetic	protein	receptor	
type-II	(BMPR2).	
	
The	 increased	 expression	 of	 NDRG1,	 an	 apparent	 effector	 in	 BMP7-mediated	
dormancy,	has	previously	been	shown	to	inversely	correlate	with	occurrence	of	bone	
metastasis	 in	 prostate	 cancer	 patients	 (Bandyopadhyay	 et	 al.,	 2003).	NDRG1	 activity	
has	 also	 been	 associated	 with	 suppression	 of	 metastatic	 activity	 in	 cancers	 of	 the	
breast	and	colon	(Guan	et	al.,	2000;	Bandyopadhyay	et	al.,	2004).	NDRG1	apparently	
achieves	 these	 effects	 via	 disruptive	 interactions	 with	 low-density	 lipoprotein	
receptor-related	protein	6	 (LRP6),	 the	 specific	 receptor	of	 the	Wnt	 ligand	 (Liu	 et	 al.,	
2012).	When	taken	together,	these	studies	suggest	that	the	BMP7-BMPR2-NDRG1	axis	
plays	 a	 pivotal	 role	 in	 maintaining	 a	 state	 of	 cellular	 dormancy	 that	 is	 likely	 to	
contribute	 to	 the	 suppression	 of	 metastasis	 in	 prostate	 cancer,	 and	 probably	 other	
cancer	 types,	 and	 that	 loss	 of	 BMPR2	 signal	 transduction	 may	 precede	 metastatic	
progression.	
	
TGF-β2	Signalling	
	
Transforming	growth	factor-beta-2	(TGF-β2)	is	a	cytokine	known	to	be	present	within	
the	bone	marrow	where	it	has	been	shown	to	regulate	haematopoietic	progenitor	cell	
development	 (Henckaerts	 et	 al.,	 2004).	 Relatively	 recently,	 Bragado	 et	 al.	 (2013)	
demonstrated	 that	 TGF-β2	 signals	 present	 in	 the	bone	marrow	are	 able	 to	maintain	
HNSCC	DTCs	in	a	dormant	state.	In	this	study,	GFP-tagged	dormant	HEp-3	cells	isolated	
from	 the	 bone	marrow	 of	 mice	 showed	 a	 prolonged	 87%	 reduction	 in	 proliferative	
capacity	 compared	 to	 dormant	 cells	 isolated	 from	 lung.	 The	 bone	 marrow	
microenvironment	 thus	 appeared	 to	 specifically	 instruct	 activation	 of	 persistent	
dormancy-inductive	 signalling	 programmes	 within	 DTCs.	 Expression	 profile	 analyses	
revealed	up-regulation	of	TGF-β2	in	dormant	cells	from	bone	at	greater	than	five-times	
the	level	present	in	either	the	parental	cell	line	or	DTCs	isolated	from	the	lungs.	TGF-β2	
levels	were	also	significantly	elevated	in	bone	marrow	compared	to	lung	tissue	and	the	
basal	culture	medium	used	in	vitro.	
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Within	 dormant	 DTCs,	 p38α/β	 was	 strongly	 activated	 while	 ERK	 signalling	 was	
diminished.	The	resultant	high	p38:ERK	signalling	ratio	 led	to	 induction	of	metastatic	
suppressor	proteins	BHLHE41	and	p27,	and	subsequent	repression	of	CDK4,	leading	to	
a	 state	 of	 cellular	 dormancy.	 This	 dormancy-instructive	 phenotype	 was	 specifically	
restored	 in	 the	 presence	 of	 the	 β2-isoform	of	 TGF	 only.	 However,	 TGF-β2-mediated	
dormancy	was	critically	dependent	on	the	co-expression	of	TGF-β-receptor-I	(TGFβRI)	
and	TGF-β-receptor-III	(TGFβRIII)	for	the	down-stream	activation	of	SMAD1	or	SMAD5	
that	 is	 necessary	 for	 subsequent	 induction	 of	 p27	 and	 mitotic	 arrest.	 Inhibition	 of	
TGFβRI	 or	 p38α/β	 favoured	 escape	 from	dormancy	 and	 increased	overall	metastatic	
burden	(Bragado	et	al.,	2013).	Similar	findings	were	reported	by	Marlow	et	al.	(2013)	
following	 TGFβRI	 or	 p38-MAPK	 inhibition	 in	 growth-arrested	 breast	 cancer	 cell	 lines	
(MCF-7	 and	 SUM159)	 generated	 within	 a	 3D	 in	 vitro	 model	 of	 the	 dormancy-
permissive	bone	marrow	niche.	This	finding,	therefore,	strongly	suggests	that	TGF-β2-
mediated	mechanisms	elucidated	by	Bragado	et	al.	(2013)	may	be	of	equal	importance	
to	dormancy	in	breast	cancer	following	metastasis	to	bone.	
	
NK1R-Tr	Status	
	
Tachykinin	 family	proteins	 are	produced	by	alternate	exon	 splicing	of	 the	Tac1	 gene	
followed	by	post-translational	modification,	and	are	constitutively	expressed	by	breast	
cancer	 and	 bone	marrow	 stromal	 cells	 (Rameshwar	 et	 al.,	 1997;	 Singh	 et	 al.,	 2000).	
These	 molecules	 exert	 their	 biological	 effects	 through	 ligation	 of	 three	 different	 G	
protein-coupled	transmembrane	receptors;	NK1R,	NK2R	and	NK3R	(Singh	et	al.,	2000).	
In	 both	 primary	 and	 metastatic	 breast	 cancer,	 interaction	 of	 tachykinins	 with	 the	
truncated	variant	of	NK1R	(NK1R-Tr)	expressed	by	malignant	cells	has	been	shown	to	
promote	mitogenesis.	 In	addition,	reduced	expression	of	the	full-length	NK1R	variant	
(NK1R-FL)	 and	 overexpression	 of	NK1R-Tr	 has	 been	 associated	with	 a	 propensity	 for	
malignant	 transformation,	 as	 well	 as	 an	 enhanced	 capacity	 for	 invasiveness	 and	
metastatic	activity	(Singh	et	al.,	2000;	Zhou	et	al.,	2013).	In	a	recent	study	conducted	
by	Zhou	et	al.	(2014),	knockdown	of	NK1R-Tr	using	shRNA	in	the	MDA-MB-231	cell	line	
resulted	in	a	markedly	reduced	growth	rate	compared	to	cells	of	the	parental	lineage.	
Co-culture	 of	 MDA-MB-231	 cells	 with	 bone	 marrow-derived	 human	 mesenchymal	
stem	cells	(BM-HMSCs)	resulted	in	reduced	NK1R-Tr	expression	and	concomitant	cell-
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cycle	arrest.	This	observation	was	linked	to	markedly	increased	levels	of	CXCL12	in	the	
conditioned	medium	taken	from	the	co-culture	system	which	were	not	present	in	that	
harvested	 from	MDA-MB-231	 cells	 grown	alone.	When	 taken	 together,	 these	 results	
imply	 that	 reversion	 to	 a	 low	 NK1R-Tr	 phenotype	 in	 metastatic	 breast	 cancer	 is	
involved	 in	 regulation	of	DTC	dormancy	 in	bone,	and	 that	BM-HMSC-derived	CXCL12	
instructing	 reduced	 NK1R-Tr	 expression	 by	 breast	 tumour	 cells	 might	 mediate	 this	
process.	However,	both	a	detailed	mechanism	and	evidence	for	the	relevance	of	this	
purported	dormancy	mechanism	to	breast	cancer	bone	metastasis	in	vivo	remain	to	be	
established.	
	
bFGF	Signalling	
	
In	contrast	to	their	suggested	roles	in	induction	of	breast	cancer	cell	dormancy,	α5β1	
integrin	 expression	 and	 re-acquisition	 of	 an	 activated	 PI3K-PKB	 signalling	 axis	 have	
been	 previously	 implicated	 in	 maintenance	 of	 breast	 cancer	 dormancy	 in	 the	 bone	
marrow.	 Basic	 fibroblast	 growth	 factor	 (bFGF)	 is	 a	 well-known	 mammary	
differentiation	factor	that	is	present	in	the	bone	marrow	and	is	capable	of	modulating	
integrin	expression.	Korah	et	al.	(2004)	first	reported	that	bFGF	was	able	to	induce	the	
reversible	 up-regulation	 of	 α5β1	 integrin	 lost	 during	 malignant	 transformation.	
Reconstitution	of	α5β1	 integrin	 in	 this	 investigation	was	associated	with	 fibronectin-
ligation-dependent	 survival	 through	 inhibition	 of	 apoptosis	 that	 appeared	 to	 be	
mediated	 by	 enhanced	 PI3K-PKB	 signalling.	 In	 a	 subsequent	 investigation	 by	 Barrios	
and	Wieder	(2009),	PI3K	pathway	activation	was	shown	to	occur	in	a	bFGF-dependent	
manner,	independent	of	α5β1	activation.	In	this	case,	the	mitotic	arrest	necessary	for	
maintained	cellular	dormancy	was	shown	to	occur	through	the	stabilisation	of	cortical	
F-actin	fibres	following	inactivation	of	RhoA.	This	loss	of	RhoA	activity	was	preceded	by	
PI3K-dependent	activation	of	GTPase	regulator	associated	with	 focal	adhesion	kinase	
(GRAF),	 a	 RhoA	 GTPase-activating	 protein-like	 complex,	 and	 the	 subsequent	 α5β1	
integrin-dependent	 recruitment	 of	 FAK.	 Hence,	 dormancy	 of	 disseminated	 breast	
cancer	 cells	 within	 fibronectin-rich	 compartments	 of	 the	 bone	 marrow	 may	 be	
initiated	 and	 maintained,	 at	 least	 in	 part,	 through	 simultaneous	 bFGF-dependent	
signalling	via	α5β1	and	PI3K.	
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Thrombospondin-1	
	
The	 multi-functional	 endothelium-derived	 matrix	 glycoprotein	 thrombospondin-1	
(TSP-1)	has	previously	been	implicated	in	regulating	both	micrometastatic	and	cellular	
dormancy,	suggested	to	occur	through	negative	regulation	of	angiogenesis	(Weinstat-
Saslow	et	al.,	1994;	Almog	et	al.,	2009).	Relatively	recently,	Ghajar	et	al.	(2013)	showed	
that	TSP-1	surrounding	the	mature	vascular	endothelium	acts	as	an	angiocrine	tumour	
suppressor	 that	 is	 able	 to	maintain	breast	 tumour	 cells	 (HMT-3522	T4-2,	MCF-7	 and	
MDA-MB-231	lineages)	in	a	protracted	dormant	state	within	the	murine	bone	marrow	
in	 vivo.	 This	 finding	was	 confirmed	 using	 an	 organotypic	model	 of	 the	 human	 bone	
microvascular	niche	 in	vitro.	 In	a	similar	model	of	 the	developing	vasculature,	where	
TSP-1	expression	was	significantly	diminished,	the	dormant	cellular	phenotype	was	not	
recapitulated.	This	study	supports	the	hypothesis	that	endothelial	cells	and	secretory	
factors	 deposited	within	 their	 surrounding	 basal	 lamina	 comprise,	 at	 least	 in	 part,	 a	
dormancy-permissive	 perivascular	 niche.	 It	 also	 appears	 to	 demonstrate	 vascular	
regulation	of	tumour	cell	behaviour,	a	drastic	shift	 from	the	 long-established	existing	
paradigm,	and	also	suggests	the	potential	existence	of	other,	as	yet	uncharacterised,	
vascular	regulators	of	cellular	dormancy.	In	addition,	while	the	anti-angiogenic	activity	
and	 effects	 of	 TSP-1	 on	 endothelial	 cells	 are	well	 characterised	 (reviewed	 by	 Lawler	
and	Lawler,	2012),	the	molecular	mechanism	by	which	it	is	apparently	able	to	regulate	
cellular	dormancy	remains	to	be	elucidated.	
	
Gap	Junctional	Intercellular	Communication	and	microRNAs	
	
Park	 et	 al.	 (2013)	 reported	 that	 low	 levels	 of	 CXCL12	 were	 able	 to	 enhance	 gap	
junctional	 intercellular	 communication	 (GJIC)	 between	 confluent	 breast	 cancer	 cells	
(MDA-MB-231)	by	increasing	the	translation	and	protein	kinase-C-mediated	activation	
of	 the	 connexin	 protein	 Cx43.	 In	 a	 previous	 study,	 gap	 junctional	 transmission	 of	
dormancy-inducing	microRNA	(miRNA)	molecules	miR-127,	-197,	-222,	and	-223	from	
primary	 bone	 marrow-derived	 stromal	 cells	 to	 cells	 of	 the	 MDA-MB-231	 and	 T47D	
breast	cancer	 lineages	was	 linked	to	 induction	of	dormancy	during	co-culture	(Lim	et	
al.,	2011).	Transmission	of	these	miRNAs	resulted	in	a	marked	decrease	in	cyclins	D1,	
D3,	C	and	CDK4,	and	a	concomitant	 increase	 in	p21,	 leading	to	proliferative	arrest	 in	
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the	 G0	 phase	 of	 the	 cell	 cycle.	 Lim	 et	 al.	 (2011)	 also	 noted	 that	miRNA	 transfer	 via	
stromal-derived	exosomes	was	 linked	 to	 tumour	 cell	 dormancy,	 although	 to	 a	 lesser	
degree	than	that	occurring	via	GJIC.	However,	the	exosomal	transfer	of	miRNA	leading	
to	dormancy	is	concurrent	with	a	more	recent	investigation	undertaken	by	Ono	et	al.	
(2014),	 in	 which	 bone	 marrow-metastatic	 MDA-MB-231	 variant	 cells	 underwent	
growth	arrest	 in	co-culture	with	BM-HMSCs,	 in	 the	presence	of	conditioned	medium	
from	BM-HMSCs,	or	 following	uptake	of	exosomes	derived	 from	the	BM-HMSC	cells.	
Amongst	44	miRNAs	that	were	found	to	be	present	in	BM-HSMC-derived	exosomes	at	
an	 elevated	 level,	miR-23b	was	 identified	 as	 being	 able	 to	 reconstitute	 the	dormant	
phenotype	observed	 in	earlier	experiments.	Analysis	of	 several	putative	 target	genes	
identified	 the	MARCKS	 gene	as	 the	 target	of	miR-23b	action.	 Examination	of	patient	
bone	 marrow	 aspirates	 demonstrated	 the	 coexistence	 of	 BM-HMSCs	 amongst	
disseminated	breast	tumour	cells,	and	that	these	DTCs	had	elevated	levels	of	miR-23b	
and	 diminished	MARCKS	 expression	 compared	 to	 primary	 breast	 tumour	 tissue.	 The	
combined	 findings	 of	 these	 studies	 not	 only	 identify	 two	 means	 by	 which	 bone	
marrow-derived	miRNAs	reach	DTCs	resident	within	the	bone	microenvironment,	but	
also	 demonstrate	 that	 these	miRNAs	 appear	 to	 play	 a	 role	 in	 the	 promotion	of	DTC	
dormancy	 within	 the	 metastatic	 niche.	 This	 finding	 also	 suggests	 that	 there	 are	
potentially	several	other	miRNAs	that	might	play	important	roles	in	the	induction	and	
maintenance	of	DTC	dormancy	following	metastasis	to	bone.	
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1.8. The	Challenge	of	Targeting	Mitotically	Inactive	Cell	Populations	
	
The	fact	that	quiescent	or	dormant	cells	are,	by	their	very	nature,	mitotically	inactive	
confers	 an	 inherent	 resistance	 to	 chemotherapy	 because	 the	 majority	 of	
chemotherapeutic	 agents	 are	 reliant	 on	 active	 cell	 division	 for	 their	 efficacy.	 This	
challenge	 is	 further	 confounded	 by	 a	 number	 of	 other	 drug-resistance	 mechanisms	
that	have	been	shown	to	be	enriched	within	quiescent	cell	populations	(reviewed	by	
Cree	and	Charlton,	2017).	Such	resistance	to	chemotherapy	enables	dormant	DTCs	to	
evade	drug-induced	 cell	 death	 and	 therefore	 to	 persist	 at	 post-metastatic	 sites	 until	
they	commence	overt	outgrowth.	 In	a	relatively	recent	position	paper,	Weber	(2013)	
described	 two	 potential	 alternative	 strategies	 for	 effective	 treatment	 of	 metastatic	
disease:	either	prevent	dissemination	of	cancer	cells	by	developing	drugs	 that	would	
be	administered	in	the	neoadjuvant	setting	to	remove	this	population,	or	to	target	pre-
existing	metastatic	tumours.	Unfortunately,	both	of	these	suggestions	are	likely	to	be	
of	limited	utility.	Firstly,	dissemination	has	been	shown	to	be	an	early	event	in	disease	
pathogenesis	and	 likely	occurs	before	 the	 initial	diagnosis	 (Klein,	2003;	Husemann	et	
al.,	2008;	Hosseini	et	al.,	2016);	being	able	to	prevent	dissemination	therefore	seems	
implausible.	Secondly,	overtly	growing	secondary	 lesions	are	composed	of	millions	of	
tumour	 cells.	 Given	 that	 intratumoural	 heterogeneity	 has	 been	 one	 of	 the	 major	
barriers	 to	 the	 successful	 treatment	 of	 cancers,	 targeting	 a	 large,	 growing,	
heterogeneous	 post-metastatic	 cell	 mass	 also	 seems	 unlikely	 to	 yield	 any	 potential	
success.	 Ironically,	 targeting	 the	 dormant	 disseminated	 tumour	 cell	 population	
therefore	 appears	 the	 strategy	 most	 likely	 to	 offer	 any	 significant	 potential	 clinical	
utility.	 This	might	be	 achieved	either	by	 the	potentially	 risky	 strategy	of	maintaining	
dormancy	 indefinitely,	 either	 by	 modulating	 cell-intrinsic	 processes	 or	 targeting	 the	
cellular	 microenvironment,	 or	 by	 specifically	 targeting	 differentially	 regulated	
metabolic	pathways	that	enable	dormant	cell	survival,	thereby	killing	dormant	cells	in	
situ	and	removing	any	risk	of	their	eventual	overt	outgrowth.	Unfortunately	however,	
the	 current	 lack	 of	 mechanistic	 understanding	 of	 tumour	 cell	 quiescence	 and	 post-
metastatic	dormancy	has	severely	 limited	 the	development	of	drugs	 that	are	able	 to	
target	this	cell	population	and	affect	either	of	these	strategies.	
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1.9. Modelling	Tumour	Cell	Dormancy:	Current	Models	and	Future	Prospects	
	
One	of	the	predominant	challenges	in	studying	tumour	cell	dormancy	is	that	it	remains	
virtually	 impossible	 to	 isolate	 DTCs	 from	 clinical	 samples	 in	 the	 earliest	 stages	 of	
metastasis.	 This	 is	 primarily	 because,	 by	 definition,	 minimal	 residual	 disease	 is	 not	
detectable	by	conventional	whole-body	 imaging,	and	because	the	systemic	spread	of	
tumour	 cells	 to	 the	bone	occurs	 as	 early	 as	 the	pre-invasive	 stages	of	 disease	when	
tumours	are	either	asymptomatic	or	clinically	undetectable	(Klein,	2003;	Husemann	et	
al.,	 2008;	 Hosseini	 et	 al.,	 2016).	 In	 addition,	 the	 isolation	 of	 patient-derived	DTCs	 is	
technically	difficult	in	itself	and	the	bone	marrow	biopsy	procedure	is	associated	with	
some	risk	of	procedural	complications,	meaning	that	both	patients	and	their	clinicians	
are	frequently	unwilling	to	participate	in	their	acquisition	(Balic	et	al.,	2005).	Given	the	
restrictions	 surrounding	 the	 use	 of	 patient-derived	 DTCs,	 further	 advances	 in	 the	
knowledge	 of	 tumour	 cell	 dormancy	 in	 bone	 is	 likely	 to	 rely	 predominantly	 on	 the	
continued	development	and	usage	of	reliable	pre-clinical	model	systems	in	which	the	
molecular	mechanisms	 that	 cause	 cellular	 dormancy	 can	 be	 successfully	 unravelled.	
However,	 a	 number	 of	 reports	 by	 non-clinical	 researchers	 have	 stated	 that	 one	 of	
primary	obstacles	 in	the	study	of	 tumour	cell	dormancy	 is	 the	 lack	of	model	systems	
(Yumoto	et	al.,	2014;	Linde	et	al.,	2016).	Although	most	metastasis	research	relies	on	
the	use	of	aggressively	growing	cancer	models,	 in	which	metastases	develop	without	
latency,	 and	 often	 employ	 unsuitable	 endpoints,	 thereby	 completely	 missing	 the	
opportunity	 to	 study	 solitary	 DTCs,	 the	 notion	 that	 there	 are	 insufficient	models	 to	
study	 dormancy	 is	 simply	 not	 correct.	 Table	 1.3.	 outlines	 model	 systems	 presently	
available	for	the	study	of	cellular	dormancy.	
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Table	1.3.	Models	Available	for	Studying	Human	Tumour	Cell	Dormancy	
	
Model	Type	 Cancer	Type	
	
Application	
	
References	
In	vitro	
2D	culture	 Multiple	cancer	types	
Isolation	of	quiescent	
cell	sub-population	
(Dembinski	and	Krauss,	2009)	
(Moore	et	al.,	2012)	
(Yumoto	et	al.,	2014)	
(Wang	et	al.,	2015a)	
In	vitro	
2D	culture	 Dormant	breast	cancer	
Role	of	ECM	in	
dormancy	 (Guiro	et	al.,	2015)	
In	vitro	
2D	culture	
Breast	cancer	
bone	metastasis	
Role	of	ECM	in	
dormancy	 (Tivari	et	al.,	2015)	
In	vitro	
3D	culture	 Dormant	breast	cancer	
Role	of	ECM	in	
dormancy	 (Barkan	and	Green,	2011)	
In	vitro	
3D	co-culture	
Breast	cancer	
bone	metastasis	
Role	of	ECM	and	
stroma	in	dormancy	 (Marlow	et	al.,	2013)	
In	vitro	
3D	co-culture	
Breast	cancer	
liver	metastasis	
Role	of	ECM	and	
stroma	in	dormancy	 (Wheeler	et	al.,	2014)	
In	vitro	
3D	co-culture	 Ovarian	cancer	
Role	of	ECM	and	
stroma	in	dormancy	 (Kenny	et	al.,	2015)	
In	vitro	
organotypic	
co-culture	
Pulmonary	metastasis	
(multiple	types)	
Role	of	lung	
microenvironment	in	
dormancy	
(Mendoza	et	al.,	2010)	
In	vitro	
organotypic	
co-culture	
Breast	cancer	
metastasis	
Role	of	microvascular	
niche	in	dormancy	 (Ghajar	et	al.,	2013)	
In	vitro	
organotypic	
co-culture	
Prostate	cancer	
bone	metastasis	
Role	of	microvascular	
niche	in	dormancy	 (Chong	et	al.,	2014)	
In	vivo	murine	
xenograft	
Breast	cancer	
bone	metastasis	
Complex	model	of	
tumour	cell	dormancy	 (Lu	et	al.,	2011)	
In	vivo	murine	
xenograft	
Breast	cancer	
bone	metastasis	
Complex	model	of	
tumour	cell	dormancy	 (Ottewell	et	al.,	2014a)	
In	vivo	murine	
xenograft	
Prostate	cancer	
bone	metastasis	
Complex	model	of	
tumour	cell	dormancy	 (Ottewell	et	al.,	2014b)	
In	vivo	murine	
xenograft	 Lung	cancer	metastasis	
Complex	model	of	
tumour	cell	dormancy	 (Sakamoto	et	al.,	2015)	
In	vivo	murine	
PDX	 HNSCC	metastasis	 Isolation	of	DTCs	 (Aguirre-Ghiso	et	al.,	2001)	
In	vivo	murine	
PDX	
Breast	cancer	
metastasis	
Complex	model	of	
tumour	cell	dormancy	 (Marsden	et	al.,	2012)	
In	vivo	murine	
PDX	
Breast	cancer	
metastasis	 Isolation	of	DTCs	 (Lawson	et	al.,	2015)	
	
ECM:	extracellular	matrix;	2D:	two-dimensional;	3D:	three-dimensional;	PDX:	patient-derived	xenograft;	
HNSCC:	head	and	neck	squamous	cell	carcinoma;	DTCs:	disseminated	tumour	cells.	
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One	notable	feature	of	the	model	systems	described	in	Table	1.3.	is	that	they	primarily	
focus	 on	 the	 post-metastatic	 microenvironmental	 regulation	 of	 the	 dormant	 state.	
Indeed,	 there	 appears	 to	 be	 a	 somewhat	 dogmatic	 opinion	 at	 present	 that	
understanding	 signals	 encoded	 by	 the	 post-metastatic	 niche	 is	 the	 most	 important	
element	in	understanding	tumour	cell	dormancy.	This	is	reflected	in	the	sheer	volume	
of	 research	 publications	 available	 regarding	 the	microenvironment	 in	 cancer	 (Holen,	
2016).	 While	 this	 is	 clearly	 an	 essential	 component	 of	 understanding	 metastatic	
biology,	 the	 conceptual	 framework	 on	 which	 much	 of	 metastasis	 research	 is	 based	
states	that	it	is	the	reciprocal	crosstalk	between	seeds	(DTCs)	and	the	soil	(metastatic	
niche)	that	 is	 involved	in	regulating	the	dormant	state.	The	benefit	of	a	more	holistic	
approach	that	incorporates	understanding	the	phenotype	of	the	cells	that	are	able	to	
successfully	 traverse	 the	entire	metastatic	 cascade,	as	well	 as	how	 the	underpinning	
mechanisms	 regulating	 this	 phenotype	 are	 modulated	 by	 the	 post-metastatic	
microenvironment	 to	 maintain	 prolonged	 dormancy	 is	 perhaps	 most	 clearly	
exemplified	by	the	recent	work	of	Fluegen	et	al.	(2017).	The	previous	elucidation	of	a	
dormancy-associated	 gene	 signature	 by	 this	 group	 allowed	 a	 more	 comprehensive	
understanding	 of	 how	 the	 dormant	 phenotype	 arises	 within	 the	 pre-metastatic	
microenvironment	and	is	then	modulated	in	different	cancers	and	molecular	sub-types	
to	maintain	dormancy	at	post-metastatic	sites.	Understanding	the	intrinsic	biology	and	
phenotype	 of	 the	 metastasis-initiating	 population	 and	 developing	 suitable	 model	
systems	in	which	to	do	so	will	therefore	be	equally	critical	as	an	understanding	of	the	
post-metastatic	microenvironment	 in	ultimately	unravelling	the	mechanisms	involved	
in	 sub-clinical	 disease	 and	 therefore	 the	 development	 of	 therapies	 for	 successfully	
treating	patients	diagnosed	in	the	advanced	stages	of	cancer.	
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1.10. Thesis	Aims	
	
The	primary	aims	of	the	work	presented	in	this	thesis	were	as	follows:	
	
1. Develop	a	robust	and	reproducible	in	vitro	model	system	enabling	the	isolation	
of	mitotically	quiescent	human	breast	cancer	cells.	
	
2. Explore	 how	 modulating	 cellular	 environmental	 conditions	 affects	 the	
mitotically	quiescent	breast	cancer	cell	population.	
	
3. Establish	 the	 sensitivity	 of	 mitotically	 quiescent	 breast	 cancer	 cells	 to	 anti-
cancer	agents.	
	
4. Characterise	mitotically	quiescent	breast	cancer	cells	and	determine	whether	
they	 share	 characteristics	 with	 the	 purported	 metastasis-initiating	 breast	
cancer	stem	cell	population.	
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Chapter	2	
	
	
General	Materials	and	Methods	
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2.1. Cell	Lines	
	
A	human	breast	cancer	cell	line	panel	was	composed	for	initial	investigations	designed	
to	determine	the	presence	or	absence	of	mitotically	quiescent	sub-populations	using	
lipophilic	dye	 retention	 (Table	 2.1.).	 Cell	 lines	were	 chosen	 to	 represent	each	of	 the	
main	sub-types	into	which	breast	cancer	can	be	divided	based	on	molecular	profiling.	
All	cell	lines	listed	in	Table	2.1.	were	sourced	directly	from	the	American	Type	Culture	
Collection	 (ATCC)	 (Manassas,	 Virginia,	 U.S.A.)	 as	 fully	 authenticated	 cryogenically	
frozen	 cultures.	 Two	 further	 cell	 lines	 were	 sourced	 specifically	 for	 use	 as	 positive	
controls	 in	 particular	 experiments	 described	 herein;	 a	 bone	 homing	 variant	 of	 the	
MDA-MB-231	 lineage	 engineered	 to	 stably	 express	 β-galactosidase	 (denoted	 as	 the	
BO2-β-gal	 lineage)	 was	 provided	 by	 Prof.	 P.	 Clezardin	 (INSERM,	 Lyon,	 France)	 while	
human	cervical	cancer	cells	of	the	HeLa	lineage	were	sourced	directly	from	the	ATCC	as	
a	fully	authenticated	cryogenically	frozen	culture.	
	
Table	2.1.	Human	Breast	Cancer	Cell	Line	Panel	
Cell	Line	 Classification	 Immunoprofile	 References	
MCF-7	 Luminal	A	
ER	Positive	
ER+	PR+/-	HER2-	 (Soule	et	al.,	1973)	
ZR-75-1	 Luminal	B	 ER+	PR+/-	HER2+	 (Engel	et	al.,	1978)	
MDA-MB-468	 Basal	
Triple	Negative	
ER-	PR-	HER2-	 (Cailleau	et	al.,	1978)	
MDA-MB-231	 Claudin-Low	 ER-	PR-	HER2-	 (Cailleau	et	al.,	1974)	
SK-BR-3	 HER2	 HER2	 ER-	PR-	HER2+	 (Trempe,	1976)	
	
Cell	 lines	are	classified	according	to	both	the	clinically	 relevant	Perou	classification	 (left	column	under	
"classification"	 heading)	 and	 the	 traditional	 classification	 system	based	 on	 receptor	 expression	 status	
(right	column	under	"classification"	heading).	ER:	oestrogen	receptor,	PR:	progesterone	receptor,	HER2:	
human	epidermal	growth	factor	receptor	2.	
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2.2. Cell	Culture	Procedures	
	
All	 procedures	 involving	 the	 handling	 of	 human	 breast	 cancer	 cell	 lines,	 unless	
otherwise	 stated,	were	 carried	out	 under	 laboratory	 containment	 level	 2	 inside	of	 a	
class-2	microbiological	safety	cabinet	using	standard	aseptic	technique	 in	accordance	
with	 the	 biosafety	 level	 requirements	 identified	 by	 the	 ATCC.	 All	 culture	media	 and	
solutions	 to	which	 cells	 were	 exposed	were	 pre-sterilised	 and	warmed	 to	 37oC	 in	 a	
water	 bath	 maintained	 at	 this	 temperature	 prior	 to	 their	 described	 usage	 unless	
otherwise	stated.	
	
2.2.1. Adherent	Monolayer	Cell	Cultures	
	
2.2.1.1. Maintenance	of	Adherent	Monolayer	Cell	Cultures	
	
All	 cell	 lines,	 with	 the	 exception	 of	 HeLa,	 were	 routinely	 maintained	 in	 vitro	 as	
adherent	cultures	grown	 in	complete	growth	medium	composed	of	RPMI-1640	basal	
medium	 (11mM	 glucose,	 2mM	 L-glutamine)	 (Life	 Technologies	 Ltd.,	 Paisley,	 U.K.)	
supplemented	 with	 10%	 (v/v)	 dialysed	 foetal	 bovine	 serum	 (FBS)	 (Life	 Technologies	
Ltd.).	 HeLa	 cells	 were	 maintained	 as	 adherent	 cultures	 grown	 in	 complete	 growth	
medium	 composed	 of	 DMEM	 basal	 medium	 (25mM	 glucose,	 3.97mM	 L-glutamine,	
1mM	sodium	pyruvate)	(Life	Technologies	Ltd.)	supplemented	with	10%	(v/v)	dialysed	
FBS.	All	cultures	were	routinely	grown	inside	of	sterile	75cm2	high-quality	polystyrene	
tissue	 culture	 flasks	 (T75)	 (Scientific	 Laboratory	 Supplies	 Ltd.,	 Hessle,	 U.K.).	 All	 cells	
were	seeded	at	an	initial	optimal	density	as	recommended	by	the	respective	supplier	
(Table	2.2.)	supplemented	with	0.2ml	of	complete	culture	medium	per	cm2	of	culture	
vessel	 surface	 area.	 Culture	 medium	 was	 maintained	 at	 physiological	 pH	 and	
temperature	by	equilibration	with	a	mixture	of	5%	CO2	 and	95%	air	at	37oC	 inside	a	
humidified	 (100%	 relative	 humidity)	 water-jacketed	 incubator.	 Nutrient-depleted	
medium	was	 removed	 from	growing	cultures	and	exchanged	 for	an	equal	volume	of	
fresh	 medium	 at	 intervals	 of	 approximately	 48	 hours.	 The	 degree	 of	 confluency	
(surface	 coverage)	 of	 growing	 cells	 was	monitored	 daily	 by	 inverted	 phase-contrast	
microscopy.	 Sub-culture	 was	 undertaken	 at	 a	 time	 point	 corresponding	 with	
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approximately	 80%	 of	 the	 duration	 of	 the	 logarithmic	 phase	 of	 culture	 growth	 as	
determined	from	the	growth	profile	established	for	each	cell	line	(Section	3.4.1.).	
	
Table	2.2.	Optimal	Seeding	Densities	and	Culture	Media	Used	for	Cell	Lines	
Cell	Line	 Seeding	Density	(cells	per	cm2)	 Complete	Culture	Medium	
MCF-7	 2.0	x	104	 RPMI-1640	+	10%	FBS	
ZR-75-1	 3.0	x	104	 RPMI-1640	+	10%	FBS	
MDA-MB-468	 2.0	x	104	 RPMI-1640	+	10%	FBS	
MDA-MB-231	 1.0	x	104	 RPMI-1640	+	10%	FBS	
SK-BR-3	 3.0	x	104	 RPMI-1640	+	10%	FBS	
BO2-β-gal	 1.0	x	104	 RPMI-1640	+	10%	FBS	
HeLa	 1.3	x	104	 DMEM	+	10%	FBS	
	
All	initial	seeding	densities	and	the	composition	of	complete	culture	media	stated	are	as	recommended	
by	 the	 ATCC	 (Manassas,	 Virginia,	 U.S.A.).	 Information	 stated	 for	 the	 BO2-β-gal	 MDA-MB-231	 variant	
lineage	is	according	to	the	information	for	the	parental	cell	line.	
	
2.2.1.2. Retrieval	of	Adherent	Monolayer	Cell	Cultures	
	
Spent	growth	medium	was	removed	from	the	adherent	cell	monolayer	and	two	repeat	
washes	 undertaken	 using	 70μl	 phosphate-buffered	 saline	 (PBS)	 (pH	 7.4	 at	 37oC)	 per	
cm2.	The	monolayer	was	detached	from	the	tissue	culture	flask	surface	by	incubation	
in	 the	 presence	 of	 70μl	 per	 cm2	 of	 trypsin-ethylenediaminetetraacetic	 acid	 (EDTA)	
solution	 (0.25%	 (w/v)	 porcine	 pancreatic	 trypsin	 with	 0.002%	 (w/v)	 EDTA	 in	 Hank’s	
Balanced	 Salt	 Solution)	 (Sigma-Aldrich	 Company	 Ltd.,	 Dorset,	 U.K.)	 for	 a	 period	 of	 5	
minutes.	An	equivalent	volume	of	complete	growth	medium	was	then	added	in	order	
to	neutralise	the	proteolytic	action	of	trypsin,	and	the	total	volume	of	each	trypsinised	
cell	 suspension	 subsequently	 transferred	 to	 an	 appropriately	 sized	 centrifuge	 tube.	
Culture	vessels	were	rinsed	once	more	with	complete	growth	medium	and	this	volume	
subsequently	transferred	to	the	corresponding	centrifuge	tube.	Cells	were	pelleted	by	
centrifugation	 of	 the	 retrieved	 suspension	 at	 150	 x	 g	 for	 5	 minutes	 at	 25oC.	 The	
resultant	supernatant	was	discarded	and	the	cell	pellet	re-suspended	in	an	appropriate	
volume	of	complete	growth	medium	prior	to	haemocytometric	counting.	
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2.2.2. Three-Dimensional	Spheroid	Cultures	
	
2.2.2.1. Production	of	Ultra-Low	Attachment	96-Well	Plates	
	
Poly-2-hydroxyethylmethacrylate	 (poly-HEMA)	 (Sigma-Aldrich	 Company	 Ltd.)	 was	
prepared	as	a	12%	(w/v)	stock	solution	in	95%	(v/v)	ethanol.	Dissolution	was	achieved	
by	 continuous	mixing	with	a	magnetic	 stirrer	bar	at	ambient	 temperature	overnight.	
This	 stock	 solution	 was	 stored	 at	 ambient	 temperature	 until	 required.	 Poly-HEMA	
stock	 solution	was	 diluted	 1:24	 in	 95%	 (v/v)	 ethanol	 in	 order	 to	 produce	 a	working	
solution	 with	 a	 final	 concentration	 of	 0.5%	 (w/v).	 This	 working	 solution	 was	 gently	
vortexed	before	being	sterile	filtered	through	a	0.2μm	polycarbonate	syringe	filter.	A	
60μl	 volume	 of	 the	 sterilised	 poly-HEMA	 solution	 was	 pipetted	 into	 each	 well	 of	 a	
Corning®	Costar®	96-well	round-bottomed	cluster	plate	(Scientific	Laboratory	Supplies	
Ltd.).	Plates	then	had	their	lid	fitted	and	were	removed	to	a	non-humidified	incubator	
maintained	at	37oC	for	minimum	period	of	72	hours	in	order	to	completely	evaporate	
the	 ethanol	 within	 each	 well.	 After	 plates	 were	 completely	 dried,	 their	 edges	 were	
sealed	with	plastic	paraffin	film	before	being	stored	in	a	refrigerator	maintained	at	4oC	
until	required.	
	
2.2.2.2. Generation	and	Maintenance	of	Three-Dimensional	Spheroid	Cultures	
	
Cells	were	seeded	 into	poly-HEMA-coated	ultra-low	attachment	96-well	plates	at	the	
optimal	 density	 assuming	 0.32	 cm2	 of	 surface	 area	 for	 cell	 growth;	 the	 equivalent	
surface	area	of	flat-bottomed	96-well	cluster	plates.	Cells	were	seeded	in	a	volume	of	
200μl	 complete	 growth	 medium	 supplemented	 with	 2.5%	 (v/v)	 Corning®	 Matrigel®	
basement	membrane	matrix	 (Scientific	Laboratory	Supplies	Ltd.)	 that	was	pre-cooled	
to	 4oC.	 Plates	 were	 immediately	 centrifuged	 at	 1000	 x	 g	 for	 10	 minutes	 at	 4oC	
following	seeding	of	cells,	before	being	placed	into	incubation	under	standard	growth	
conditions.	At	48-hour	 intervals,	100μl	of	 spent	medium	was	 removed	 from	all	wells	
and	replaced	with	an	equal	volume	of	fresh	complete	growth	medium.	
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2.2.2.3. Dispersal	of	Three-Dimensional	Spheroid	Cultures	
	
In	order	to	achieve	a	single	cell	suspension	for	subsequent	analyses,	three-dimensional	
spheroid	 cultures	 were	 dispersed	 using	 mechanical	 homogenisation	 and	 enzymatic	
digestion	 in	 combination.	 Non-adherent	 spheroidal	 cell	 cultures	 were	 first	 removed	
from	the	wells	of	96-well	culture	plates	using	a	sterile	plastic	Pasteur	pipette	and	then	
decanted	 into	an	appropriately	sized	centrifuge	 tube.	Centrifugation	was	undertaken	
for	5	minutes	at	150	x	g	 and	25oC	 in	order	 to	 loosely	pellet	 the	spheroids	and	allow	
removal	 of	 the	 spent	 culture	 medium.	 Spheroids	 were	 washed	 twice	 by	 careful	
resuspension	 in	 a	 5ml	 volume	 of	 PBS	 and	 repeating	 centrifugation	 as	 previously	
described.	 Dispersal	 of	 spheroids	 was	 achieved	 by	 incubation	 in	 a	 1ml	 volume	 of	
collagenase-dispase®	 solution	 (≥	 0.1U/ml	 collagenase	 and	 ≥	 0.8U/ml	 dispase	 in	 PBS)	
(Sigma-Aldrich	Company	Ltd.)	with	gentle	 repeat	aspiration	being	undertaken	until	 a	
homogenous	 suspension	 was	 visibly	 evident.	 An	 equal	 volume	 of	 complete	 growth	
medium	 was	 then	 added	 before	 each	 suspension	 was	 passed	 through	 a	 40μm	 cell	
strainer.	The	resultant	suspension	was	immediately	centrifuged	at	150	x	g	and	25oC	for	
5	minutes.	 The	 supernatant	was	 discarded	 and	 the	 cell	 pellet	 resuspended	 in	 a	 1ml	
volume	of	serum	free-culture	medium	prior	to	haemocytometric	counting.	
	
2.2.3. Haemocytometric	Counting	of	Cells	in	Suspension	
	
The	 cellular	 concentration	 of	 each	 retrieved	 cell	 suspension	 was	 determined	 by	
haemocytometric	counting	using	the	trypan	blue	dye	exclusion	method.	Briefly,	each	
retrieved	 cell	 suspension	 was	 mixed	 thoroughly	 by	 repeat	 aspiration	 followed	 by	
gentle	 vortexing	 to	ensure	 complete	homogeneity.	A	50μl	 volume	of	 cell	 suspension	
was	 then	 decanted	 into	 a	 0.5ml	microcentrifuge	 tube	 to	which	 an	 equal	 volume	 of	
filtered	0.4%	(w/v)	trypan	blue	solution	(Sigma-Aldrich	Company	Ltd.)	was	added.	The	
suspension	was	gently	mixed	by	repeat	aspiration	and	allowed	to	incubate	at	ambient	
temperature	 for	 5	 minutes.	 During	 this	 period,	 a	 Bright-Line™	 haemocytometer	
(Sigma-Aldrich	 Company	 Ltd.)	 was	 cleaned	 thoroughly	 with	 70%	 (v/v)	 ethanol	 in	
distilled	water,	dried	with	lens	tissue,	and	then	fitted	with	0.5mm	thick	glass	coverslip.	
A	10μl	volume	of	the	trypan	blue-cell	suspension	mixture	was	loaded	into	one	of	the	
haemocytometer	chambers	 (Figure	 2.1.).	The	number	of	viable	 (unstained)	and	non-
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viable	 (blue-stained)	 cells	 present	within	 each	 of	 the	 four	 corner	 4	 x	 4	 square	 grids	
were	 counted	under	 inverted	phase	 contrast	microscopy	 at	 100X	magnification.	 The	
mean	average	viable	cell	count	within	the	chamber	was	calculated	and	corrected	for	
the	dilution	factor	with	trypan	blue.	Each	haemocytometer	counting	grid	has	a	volume	
of	0.1mm3	and	1ml	has	an	equivalent	volume	of	1000mm3;	the	dilution	factor-adjusted	
average	viable	cell	count	was	therefore	multiplied	by	104	 in	order	to	express	the	cell	
count	 achieved	 as	 the	 number	 of	 cells	 per	 millilitre	 of	 suspension.	 The	 requisite	
volume	of	suspension	to	seed	cells	at	the	desired	density	was	then	determined	from	
the	viable	cell	concentration.	
	
	
	
Figure	2.1.	Schematic	Representation	of	a	Haemocytometer	
The	left	diagram	illustrates	the	main	features	of	the	haemocytometer.	The	right	diagram	represents	one	
of	 the	 four	 1mm2	 laser-etched	 counting	 grids	 at	 each	 corner	 of	 a	 haemocytometer	 chamber	 as	
highlighted	 in	 blue	 on	 the	 left	 diagram.	 The	 convention	 for	 determining	 the	 number	 of	 viable	
(unstained)	 and	 non-viable	 (trypan	 blue-stained)	 cells	 within	 each	 of	 the	 four	 corner	 grids	 is	 also	
depicted	by	the	diagram	on	the	right;	only	those	cells	in	contact	with	the	outer	two	lines	of	the	bottom	
and	right	margins	were	excluded	from	the	count.	
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2.2.4. Cryogenic	Storage	and	Revival	of	Cells	
	
Cells	 were	 stored	 cryogenically	 frozen	 at	 a	 density	 of	 1.0	 x	 106	 cells	 per	 sterile	
cryogenic	 storage	 ampoule	 suspended	 in	 a	 1ml	 volume	of	 cryopreservation	medium	
composed	 of	 complete	 growth	 medium	 supplemented	 with	 10%	 (v/v)	
dimethylsulphoxide	 (DMSO).	 Cryogenic	 ampoules	 of	 cell	 suspension	 designated	 for	
long-term	storage	were	initially	preserved	by	controlled	rate	freezing	(-1oC	per	minute)	
over	a	24-hour	period	inside	of	an	isopropyl	alcohol-jacketed	freezing	chamber	placed	
into	 a	 freezer	 maintained	 at	 -80oC.	 Frozen	 ampoules	 were	 stored	 long-term	 at	 a	
temperature	 below	 -135oC	 in	 the	 vapour	 phase	 of	 nitrogen.	 Frozen	 cultures	 of	 cells	
required	 for	 thawing	were	 removed	 from	 storage	 and	 immediately	 transferred	 to	 a	
water	 bath	 maintained	 at	 37oC.	 Thawing	 ampoules	 were	 gently	 agitated	 for	
approximately	 three	minutes	 until	 the	 contents	were	 completely	 thawed.	 Defrosted	
vials	 were	 wiped	 dry	 and	 decontaminated	 by	 spraying	 with	 70%	 (v/v)	 ethanol	 in	
distilled	water	 prior	 to	 being	 transferred	 to	 a	 class-2	microbiological	 safety	 cabinet.	
Vial	 contents	 were	 mixed	 gently	 by	 repeat	 aspiration	 before	 subsequently	 being	
transferred	to	a	sterile	15ml	centrifuge	tube.	A	9ml	volume	of	pre-warmed	complete	
growth	 medium	 was	 slowly	 added	 to	 the	 cell	 suspension	 and	 centrifugation	
subsequently	 undertaken	 (5	 minutes	 at	 150	 x	 g	 and	 25oC).	 The	 cryoprotectant-
containing	 supernatant	was	discarded	 from	 the	 resultant	 cell	 pellet,	which	was	 then	
resuspended	in	an	appropriate	volume	of	complete	growth	medium	and	subsequently	
used	to	seed	tissue	culture	vessels	with	cells	at	the	required	density.	
	
2.2.5. Generation	of	Cell	Proliferation	Curves	
	
Cells	 were	 seeded	 in	 triplicate	 wells	 of	 24-well	 cluster	 plates	 (Scientific	 Laboratory	
Supplies	Ltd.)	at	the	stipulated	optimal	density	(Table	2.2.)	supplemented	with	0.2ml	
of	 complete	 growth	 medium	 per	 cm2	 growth	 area.	 Cluster	 plates	 were	 place	 into	
incubation	 under	 standard	 growth	 conditions	 (37oC	with	 95%	 air,	 5%	CO2	 and	 100%	
relative	humidity).	At	each	subsequent	24-hour	 interval,	 the	cells	within	each	row	of	
three	wells	were	retrieved	by	trypsinisation	and	the	viable	cell	number	determined	by	
haemocytometric	 counting	 using	 trypan	 blue	 dye	 exclusion.	 The	 mean	 average	 cell	
count	across	all	three	replicate	samples	recorded	at	each	time	interval	was	calculated	
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and	 used	 to	 construct	 a	 growth	 profile	 by	 plotting	 viable	 cell	 count	 against	 time	 in	
culture	graphically.	Growth	profiles	were	then	used	to	identify	each	of	the	main	phases	
of	the	growth	cycle	(Figure	2.2.).	The	doubling	time	of	cultures	during	the	logarithmic	
growth	phase	was	calculated	as	the	product	of	the	incubation	period	and	the	natural	
logarithm	of	2,	divided	by	 the	natural	 logarithm	of	 the	ratio	of	 the	number	of	viable	
cells	at	the	beginning	and	end	of	the	incubation	period.	
	
	
	
Figure	2.2.	Culture	Growth	Profile	and	Phases	of	Population	Growth	
The	lag-phase	is	defined	as	the	period	between	initial	seeding	of	cells	and	the	point	at	which	they	enter	
the	 logarithmic	 growth	 phase.	 The	 logarithmic	 phase	 of	 growth	 (log-phase)	 is	 characterised	 by	 a	
constant	 rate	 of	 population	 growth	 per	 unit	 time.	 Once	 growth-limiting	 factors	 (e.g.	 depletion	 of	
essential	 nutrients	 and	 accumulation	 of	 inhibitory	 metabolic	 products)	 are	 encountered	 the	 rate	 of	
population	growth	is	gradually	reduced	until	a	plateau	phase	occurs	during	which	the	rates	of	new	cell	
formation	and	cell	death	are	equal.	
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2.2.6. Clonogenic	Assays	
	
2.2.6.1. Adherent	Colony	Formation	Assay	
	
Cells	were	seeded	at	a	clonogenic	density	of	20	cells	per	cm2	of	growth	area	in	high-
quality	 polystyrene	 60mm	 tissue	 culture	 dishes	 or	 6-well	 cluster	 plates	 (Scientific	
Laboratory	 Supplies	 Ltd.)	 and	 were	 supplemented	 with	 0.2ml	 of	 complete	 growth	
medium	per	cm2.	Culture	vessels	were	placed	into	incubation	under	standard	growth	
conditions	for	a	time	period	of	at	least	six	log-phase	doubling	times	(determined	from	
the	respective	growth	curve).	Following	incubation	for	the	desired	period,	the	growth	
medium	was	carefully	removed	from	all	dishes	and	adherent	cell	colonies	fixed	in	a	4%	
(v/v)	 solution	of	Pierce™	methanol-free	 formaldehyde	 (Life	Technologies	 Ltd.)	 in	PBS	
(pH	7.4	at	37oC)	for	15	minutes	at	ambient	temperature.	Once	fixation	was	complete,	
the	 fixative	 solution	 was	 removed	 and	 colonies	 immediately	 stained	 with	 an	 equal	
volume	 of	 0.05%	 (w/v)	 aqueous	 crystal	 violet	 solution	 (Merck	 Chemicals	 Ltd.,	
Nottingham,	 U.K.)	 for	 30	 minutes	 at	 ambient	 temperature.	 Subsequently,	 culture	
vessels	were	washed	 by	 two	 repeat	 immersions	 in	 a	 tub	 of	 tap	water	 before	 being	
inverted	 onto	 tissue	 paper	 and	 allowed	 to	 dry	 completely.	 Once	 dried,	 plates	 were	
imaged	using	the	Pixera	Professional	1.2	megapixel	digital	camera	system	(Pixera	U.K.	
Ltd.,	Bourne	End,	U.K.)	and	colonies	counted	by	way	of	semi-automated	image	analysis	
(Figure	 2.3.)	 undertaken	 using	 GeneTools	 software	 (Syngene	 U.K.	 Ltd.,	 Cambridge,	
U.K.).	
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Figure	2.3.	Semi-Automated	Colony	Number	Analysis	in	GeneTools	Software	
The	region	of	interest	(red)	was	set	manually	to	define	the	outer	boundary	of	the	area	for	analysis.	The	
sensitivity	and	 thresholds	of	detection	were	pre-set	and	calibrated	using	manual	 counts,	 allowing	 the	
software	to	automatically	detect	 individual	colonies	 (yellow	circles).	The	 lower	 limit	of	detection	 for	a	
colony	was	 set	 to	 the	 number	 of	 pixels	 approximately	 equivalent	 to	 10	 cells.	Merged	 colonies,	 false-
positives	and	false-negatives	were	manually	resolved	before	the	final	colony	count	was	recorded.	
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2.2.6.2. Mammosphere	Formation	Assay	
	
Mammosphere	assays	were	undertaken	according	to	a	method	described	by	Weiswald	
et	al.	(2015).	Mammosphere	formation	assay	plates	were	made	by	coating	each	well	of	
a	6-well	cluster	plate	with	2ml	of	1.5%	(w/v)	agarose	in	RPMI-1640	+	10%	FBS.	Briefly,	
electrophoresis	grade	agarose	powder	(Thermo	Fisher	Scientific,	Paisley,	U.K.)	was	pre-
weighed	into	50ml	centrifuge	tubes,	to	which	RPMI-1640	+	10%	FBS	was	added	inside	
a	 sterile	 microbiological	 safety	 hood.	 Tubes	 were	 tightly	 sealed	 and	 then	 gently	
inverted	several	times	to	form	a	suspension	before	the	lids	were	loosened	and	tubes	
were	placed	into	a	glass	beaker	placed	inside	of	a	microwave.	Heating	was	undertaken	
in	cycles	of	10	seconds	followed	by	closure	of	the	tube	lid	and	gentle	inversion.	These	
cycles	were	 repeated	until	 the	agarose	had	 completely	dissolved	 to	 form	a	 solution.	
Tubes	of	molten	agarose	were	each	placed	inside	a	glass	beaker	containing	water	pre-
heated	 to	 90oC	 in	 order	 to	 prevent	 solidification.	 The	 molten	 agarose	 solution	 was	
carefully	dispensed	 into	6-well	cluster	plates	 inside	of	a	sterile	microbiological	 safety	
hood	 and	 allowed	 to	 set	 completely	 for	 approximately	 30	minutes	 with	 the	 cluster	
plate	lid	removed.	Once	the	agarose	had	set,	cells	were	seeded	into	these	plates	at	a	
clonogenic	 density	 of	 20	 cells	 per	 cm2	 of	 growth	 area	 and	were	 supplemented	with	
0.2ml	of	complete	growth	medium	per	cm2.	Cluster	plates	were	placed	into	incubation	
under	standard	growth	conditions	for	a	time	period	of	at	least	six	log-phase	doubling	
times	 (determined	 from	 the	 respective	 growth	 curve).	 Following	 incubation	 for	 the	
desired	 period,	 the	 number	 of	 non-adherent	 mammospheres	 was	 quantified	 under	
inverted	phase-contrast	microscopy.	
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2.2.7. Scratch	Closure	Cell	Migration	Assay	
	
Scratch	 closure	 cell	 migration	 assays	 were	 undertaken	 according	 to	 the	 methods	
described	by	Rodriguez	et	al.	(2005)	and	Cory	(2011).	Mitomycin	C	from	Streptomyces	
caespitosus	(Sigma-Aldrich	Company	Ltd.)	was	supplied	as	2mg	vials.	Prior	to	use,	the	
contents	of	each	vial	were	dissolved	in	200ml	of	serum-free	RPMI-1640	basal	medium	
to	 produce	 a	 solution	 with	 a	 final	 concentration	 of	 10μg/ml.	 This	 solution	 was	
protected	from	light	until	required	for	use	and	was	stored	in	a	refrigerator	maintained	
at	4oC	for	up	to	two	weeks.	Cells	were	seeded	in	triplicate	into	6-well	cluster	plates	and	
supplemented	 with	 0.2ml	 of	 medium	 per	 cm2	 surface	 area.	 Once	 coverage	 had	
reached	100%	confluency,	 spent	medium	was	 removed	 from	the	cell	monolayer	and	
two	 washes	 undertaken	 using	 PBS.	 Mitomycin	 C	 solution,	 freshly	 prepared	 using	
serum-free	 RPMI-1640	 basal	 medium	 at	 a	 concentration	 of	 10μg/ml,	 was	 added	 to	
completely	 cover	 the	 cell	 monolayer	 and	 then	 tissue	 culture	 vessels	 replaced	 in	
incubation	under	 standard	growth	 conditions	 for	 a	 three	hour	period.	 Subsequently,	
the	 Mitomycin	 C	 solution	 was	 removed	 and	 three	 washes	 of	 the	 cell	 monolayer	
undertaken	using	serum-free	basal	culture	medium.	A	200μl	pipette	tip	was	then	used	
to	make	a	linear	scratch	of	approximately	750μm	in	width	in	the	cell	monolayer.	Each	
well	was	then	washed	three	times	with	pre-warmed	complete	culture	medium	in	order	
to	completely	remove	cell	debris	 formed	during	the	 introduction	of	 the	scratch.	Two	
reference	 points	were	marked	 at	 either	 end	 of	 the	 scratch	 on	 the	 underside	 of	 the	
plate	under	low-magnification	(50X	magnification)	inverted	phase-contrast	microscopy	
using	a	permanent	marker	pen.	Images	were	immediately	captured	at	each	reference	
point	 under	 inverted	 phase-contrast	 microscopy	 at	 100X	 magnification	 and	 further	
images	captured	at	subsequent	time-intervals	in	an	identical	manner.	The	area	of	the	
scratch	within	each	 image	 field	was	measured	using	 the	open-source	 image	analysis	
platform	 ImageJ	 (Figure	 2.4.)	and	 the	percentage	closure	over	 the	assay	 time	period	
calculated.	
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Figure	2.4.	Scratch	Assay	Analysis	Using	ImageJ	Software	
Images	were	imported	into	ImageJ,	converted	to	grayscale	and	the	contrast	enhanced	in	order	to	allow	
the	scratch	border	to	be	readily	defined.	The	border	of	the	scratch	at	0	hours	(left)	and	24	hours	(right)	
was	 demarked	 using	 the	 freehand	 draw	 tool	 (yellow	 line).	 The	 physical	 pixel	 length	 according	 to	 the	
image	metadata	was	programmed	into	the	imageJ	scale	conversion	plugin	allowing	the	area	within	the	
scratch	to	be	automatically	calculated	for	each	image	and	the	percentage	closure	of	the	scratch	over	the	
time	period	determined.	
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2.3. Cell	Labelling	and	Immunostaining	
	
2.3.1. Vybrant®	Lipophilic	Tracer	Dye	Staining	
	
Vybrant®	DiO,	CM-DiI	and	DiD	were	purchased	from	Life	Technologies	Ltd.	All	lipophilic	
dye	 staining	was	 undertaken	 in	 suspension	 at	 a	 density	 of	 1.0	 x	 106	 cells	 in	 1ml	 of	
serum-free	 basal	 culture	 medium	 in	 accordance	 with	 the	 supplier’s	 instructions.	
Vybrant®	DiO	and	DiD	dye	solutions	were	used	at	a	final	concentration	of	5μM	while	
Vybrant®	 CM-DiI	 dye	 solution	 was	 used	 at	 a	 final	 concentration	 of	 2μM;	 the	
appropriate	 volume	 of	 each	 staining	 solution	 was	 added	 directly	 to	 cell	 suspension	
before	samples	were	vortexed	 thoroughly	and	placed	 into	 incubation	within	a	water	
bath	maintained	at	37oC	for	a	period	of	exactly	5	minutes	while	protected	from	light.	
Vybrant®	 DiO	 or	 DiD	 staining	 required	 samples	 to	 be	 incubated	 for	 a	 further	 15	
minutes	 at	 37oC	 while	 Vybrant®	 CM-DiI	 staining	 required	 cells	 to	 be	 immediately	
transferred	 to	 ice	 for	 the	 subsequent	 15	 minute	 period.	 Following	 the	 appropriate	
incubation	period,	 samples	were	 centrifuged	 for	 5	minutes	 at	 150	 x	g,	 the	 resultant	
supernatant	 discarded	 and	 the	 cell	 pellet	 resuspended	 in	 an	 equal	 amount	 of	 fresh	
serum-free	 culture	medium.	 Centrifugation	 and	 resuspension	 in	 this	 way	were	 then	
repeated	two	further	times	before	the	stained	cells	were	ready	for	use	in	subsequent	
applications.	
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2.3.2. Immunostaining	for	Fluorescence	Microscopy	
	
2.3.2.1. Sample	Preparation	by	Cytocentrifugation	
	
Samples	 of	 cells	 for	 immunostaining	 were	 deposited	 onto	 Superfrost	 Plus™	 glass	
microscopy	 slides	 by	 cytocentrifugation	 using	 the	 Shandon™	 Cytospin™	 3	
cytocentrifuge	(both	from	Thermo	Fisher	Scientific).	Cytocentrifuge	funnels	were	first	
fitted	with	a	single	glass	microscopy	slide	and	white	filter	card	and	held	together	with	
a	metal	clip	(Figure	2.5.).	Funnels	were	loaded	with	200μl	of	complete	culture	medium	
and	then	placed	into	the	cytocentrifuge.	Centrifugation	was	undertaken	at	150	x	g	for	
3	 minutes	 in	 order	 to	 pre-wet	 the	 filter	 card.	 Each	 cytocentrifuge	 funnel	 was	 then	
loaded	with	a	200μl	volume	of	cell	suspension	containing	the	desired	number	of	cells	
for	 deposition.	 Centrifugation	 was	 then	 repeated	 for	 3	 minutes	 at	 150	 x	 g	 using	
medium	 acceleration	 in	 order	 to	 deposit	 cells	 directly	 onto	 the	 slides.	 Each	 glass	
microscopy	slide	was	then	separated	from	the	cytocentrifuge	funnel	and	blotting	card,	
and	transferred	into	a	slide	rack.	Slides	were	immediately	plunged	into	ice-cold	fixative	
solution	 (either	 4%	 (v/v)	 methanol-free	 formaldehyde	 in	 PBS	 or	 4%	 (w/v)	
paraformaldehyde	 in	 PBS)	 and	 allowed	 to	 incubate	 on	 ice	 for	 a	 10-minute	 period.	
Washing	 was	 subsequently	 undertaken	 in	 two	 changes	 of	 PBS	 before	 cells	 were	
progressed	to	immunostaining.	Where	staining	was	not	carried	out	immediately	post-
fixation,	slides	were	stored	at	4oC	immersed	in	PBS	until	required	for	staining.	
	
2.3.2.2. Indirect	Immunostaining	of	Intracellular	Markers	for	Immunofluorescence	
	
Fixed	 cytocentrifuge	 samples	 were	 drained	 of	 PBS	 and	 a	 hydrophobic	 barrier	 pen	
(Vector	 Laboratories	 Ltd.,	 Peterborough,	 U.K.)	 used	 to	 draw	 a	 circular	 hydrophobic	
barrier	 around	 each	 cell	 spot.	 All	 slides	 were	 placed	 onto	 a	 slide	 tray	 and	 a	 200μl	
volume	of	 permeabilisation	 buffer	 (0.1%	 (v/v)	 Triton™	X-100	 in	 PBS)	 deposited	 onto	
each	cell	 spot.	 Incubation	 in	 the	presence	of	permeabilisation	buffer	was	carried	out	
for	 5	 minutes	 at	 ambient	 temperature.	 Permeabilisation	 buffer	 was	 removed	 by	
tapping	the	slides	onto	tissue	before	three	washes	were	undertaken	using	PBS-Tween®	
20	 (PBST)	wash	buffer	 (0.01%	 (v/v)	 Tween®	20	 in	 PBS),	 each	 for	 5	minutes.	 A	 200μl	
volume	of	blocking	buffer	(10%	(v/v)	normal	serum	+	1%	(w/v)	bovine	serum	albumin	
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(BSA)	in	PBST)	was	pipetted	onto	slides	and	incubation	undertaken	for	1	hour.	Normal	
serum	 used	 for	 blocking	 during	 any	 particular	 experiment	was	matched	 to	 the	 host	
species	in	which	the	secondary	antibody	being	used	was	raised.	All	normal	sera	were	
sourced	either	from	Vector	Laboratories	Ltd.	or	Sigma-Aldrich	Company	Ltd.	During	the	
blocking	 incubation	 period,	 primary	 antibodies	 and	 corresponding	 isotype	 control	
antibodies	were	diluted	to	the	desired	concentration	in	antibody	diluent	(1%	(w/v)	BSA	
in	PBST).	Following	the	blocking	incubation,	the	solution	on	all	samples	was	removed	
by	gently	tapping	the	slides	onto	tissue	and	a	200μl	volume	of	the	appropriate	primary	
antibody	solution	or	antibody	diluent	only	(primary	omitted	control	samples)	pipetted	
onto	each	cell	spot.	The	tissue	in	the	base	of	each	slide	tray	was	then	dampened	with	
distilled	water,	 the	 slide	 tray	 lid	 replaced	and	 the	 tray	placed	 into	 incubation	 at	 4oC	
overnight.	 On	 the	 subsequent	 day,	 the	 primary	 antibody	 solution	 or	 diluent	 was	
removed	 from	 all	 samples	 and	 three	 washes	 undertaken	 as	 described	 previously.	
During	 the	 final	 washing	 step,	 secondary	 antibodies	 were	 diluted	 to	 the	 desired	
concentration	 in	 antibody	 diluent	 solution.	 A	 200μl	 volume	 of	 dilute	 secondary	
antibody	 solution	 or	 antibody	 diluent	 only	 (secondary	 omitted	 control	 samples)	was	
then	 carefully	 pipetted	onto	each	 cell	 spot	 and	 incubation	undertaken	 for	 1	hour	 at	
ambient	 temperature.	 Following	 this	 incubation,	 the	 solution	 on	 all	 samples	 was	
removed	 by	 gently	 tapping	 the	 slides	 onto	 tissue	 and	 three	 washes	 undertaken	 as	
previously	described.	The	residual	wash	buffer	was	then	carefully	removed	from	each	
slide	 and	 mounting	 of	 samples	 undertaken	 using	 a	 0.12mm	 thickness	 round	 glass	
coverslip	 and	 a	 minimal	 volume	 (approximately	 10μl)	 of	 ProLong®	 Gold	 anti-fade	
mounting	medium	containing	4ʹ,6-diamidino-2-phenylindole	(DAPI)	 (Life	Technologies	
Ltd.).	Mounted	samples	were	cured	on	a	flat	surface,	completely	protected	from	light,	
for	a	period	of	24	hours	before	imaging.	
	
All	 information	 regarding	 specific	 primary,	 isotype	 control	 and	 secondary	 antibodies	
used	in	immunostaining	for	fluorescence	microscopy	is	detailed	later	in	the	respective	
methods	sections	of	the	experiments	in	which	they	were	used.	
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Figure	2.5.	Cytocentrifuge	Slide	Preparation	Apparatus	
The	apparatus	and	relative	configuration	required	for	preparation	of	samples	by	cytocentrifugation	are	
shown.	 A	 glass	 microscopy	 slide	 was	 first	 placed	 carefully	 into	 a	 metal	 cytocentrifuge	 clip	 with	 the	
electrostatically	positive	charged	side	onto	which	cells	would	be	deposited	facing	outward.	A	filter	card	
was	then	loosely	placed	in	apposition	to	this	surface	and	the	cytocentrifuge	funnel	placed	on	top.	The	
arm	 of	 the	 metal	 clip	 was	 then	 drawn	 down	 and	 clipped	 into	 place	 in	 order	 to	 securely	 hold	 all	
components	together.	The	entire	configuration	was	then	ready	for	loading	into	the	cytocentrifuge.	
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2.3.3. Immunostaining	for	Flow	Cytometry	
	
2.3.3.1. Direct	Immunostaining	of	Cell	Surface	Markers	for	Flow	Cytometry	
	
Samples	 of	 1.0	 x	 106	 live	 cells	 were	 prepared	 from	 harvested	 cell	 suspensions	 in	
microcentrifuge	 tubes	 and	 centrifuged	 for	 5	minutes	 at	 150	 x	g	 in	 a	 centrifuge	 pre-
cooled	 to	 4oC.	 Following	 centrifugation,	 the	 supernatant	 was	 discarded	 and	 the	
resultant	 cell	 pellet	washed	 twice	 by	 resuspension	 in	 a	 1ml	 volume	 of	 ice-cold	 flow	
cytometry	 buffer	 (5%	 (v/v)	 FBS	 in	 PBS)	 followed	 by	 immediate	 centrifugation	 as	
previously	 described.	 Directly	 conjugated	 primary	 antibodies	 and	 corresponding	
isotype	 controls	 were	 pre-diluted	 to	 the	 desired	 concentration	 in	 ice-cold	 flow	
cytometry	buffer.	Washed	cell	pellets	were	resuspended	in	100μl	of	primary	antibody	
solution	 and	 incubated	 for	 1	 hour	 at	 4oC	 in	 total	 darkness	 under	 constant	 agitation.	
Following	incubation,	a	900μl	volume	of	ice-cold	flow	cytometry	buffer	was	added	to	
all	tubes	and	centrifugation	undertaken	at	150	x	g	for	5	minutes.	The	stained	cell	pellet	
was	carefully	washed	 two	 further	 times	by	 resuspension	 in	a	1ml	volume	of	 ice-cold	
flow	cytometry	buffer	 followed	by	 immediate	centrifugation	as	previously	described.	
The	washed	cell	pellet	was	resuspended	in	1ml	of	 ice-cold	flow	cytometry	buffer	and	
strained	through	40μm	cell	strainer	into	round-bottomed	polystyrene	flow	cytometry	
tubes	(Beckton,	Dickenson	and	Co.	Plc.,	Oxford,	U.K.)	prior	to	immediate	analysis.	
	
2.3.3.2. Indirect	Immunostaining	of	Cell	Surface	Markers	for	Flow	Cytometry	
	
Samples	 of	 1.0	 x	 106	 live	 cells	 were	 prepared	 from	 harvested	 cell	 suspensions	 in	
microcentrifuge	tubes	and	stained	with	unconjugated	primary	antibodies	in	exactly	the	
same	 manner	 as	 described	 in	 Section	 2.3.3.1.	 Once	 washed	 three	 times	 following	
incubation	 in	 the	 presence	 of	 primary	 antibody	 solution,	 each	 cell	 pellet	 was	
resuspended	 in	 a	 100μl	 volume	 of	 fluorophore-conjugated	 secondary	 antibody	 pre-
diluted	 to	 the	desired	concentration	 in	 ice-cold	 flow	cytometry	buffer	and	 incubated	
for	 1	hour	 at	 4oC	 in	 total	 darkness	under	 constant	 agitation.	 Following	 incubation,	 a	
900μl	 volume	 of	 ice-cold	 flow	 cytometry	 buffer	 was	 added	 to	 all	 tubes	 and	
centrifugation	 undertaken	 at	 150	 x	 g	 for	 5	 minutes.	 Each	 stained	 cell	 pellet	 was	
carefully	washed	two	further	times	by	resuspension	 in	a	1ml	volume	of	 ice-cold	flow	
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cytometry	 buffer	 followed	 by	 immediate	 centrifugation	 as	 previously	 described.	
Washed	cell	pellets	were	each	 resuspended	 in	1ml	of	 ice-cold	 flow	cytometry	buffer	
and	 strained	 through	 a	 40μm	 cell	 strainer	 into	 a	 round-bottomed	 polystyrene	 flow	
cytometry	tube	prior	to	immediate	analysis.	
	
2.3.3.3. Indirect	Immunostaining	of	Intracellular	Markers	for	Flow	Cytometry	
	
Samples	 of	 1.0	 x	 106	 cells	 were	 prepared	 in	 pre-cooled	microcentrifuge	 tubes	 from	
retrieved	 cell	 suspensions	 following	 retrieval	 and	 haemocytometric	 counting.	 Cells	
were	collected	by	centrifugation	for	5	minutes	at	150	x	g	in	a	centrifuge	pre-cooled	to	
4oC.	 Following	 centrifugation,	 the	 supernatant	 was	 discarded	 and	 the	 resultant	 cell	
pellet	 resuspended	 in	a	1ml	volume	of	 ice-cold	 fixation	 solution	 (4%	 (v/v)	methanol-
free	 formaldehyde	 in	PBS).	 Fixation	was	undertaken	by	 incubation	of	 samples	on	 ice	
for	10	minutes.	Following	fixation,	samples	were	centrifuged	at	300	x	g	for	5	minutes	
and	 the	 resultant	 supernatant	 discarded.	 Each	 cell	 pellet	was	 resuspended	 in	 a	 1ml	
volume	 of	 permeabilisation	 and	 blocking	 solution	 (0.1%	 (v/v)	 Triton™	 X-100	 +	 10%	
(v/v)	normal	serum	in	PBS)	and	incubated	for	1	hour	at	ambient	temperature.	During	
this	period,	unconjugated	primary	antibodies	and	corresponding	isotype	controls	were	
pre-diluted	 to	 the	 desired	 concentration	 in	 intracellular	 flow	 cytometry	 buffer	 (1%	
(w/v)	 BSA	 +	 0.1%	 (v/v)	 Triton™	 X-100	 in	 PBS).	 Following	 blocking,	 samples	 were	
centrifuged	at	300	x	g	for	5	minutes	and	the	resultant	supernatant	discarded.	Each	cell	
pellet	was	resuspended	in	a	100µl	volume	of	pre-prepared	primary	antibody	solution	
and	incubated	for	1	hour	at	ambient	temperature	with	constant	agitation.	During	this	
period,	fluorophore	conjugated	secondary	antibodies	were	pre-diluted	to	the	desired	
concentration	 in	 intracellular	 flow	 cytometry	 buffer.	 Following	 incubation,	 a	 900μl	
volume	 of	 ice-cold	 intracellular	 flow	 cytometry	 buffer	 was	 added	 to	 all	 tubes	 and	
centrifugation	 undertaken	 at	 300	 x	 g	 for	 5	 minutes.	 The	 cell	 pellet	 was	 carefully	
washed	 two	 further	 times	 by	 resuspension	 in	 a	 1ml	 volume	 of	 ice-cold	 intracellular	
flow	 cytometry	 buffer	 followed	 by	 immediate	 centrifugation	 as	 previous.	 Washed	
samples	were	resuspended	in	100μl	of	pre-prepared	secondary	antibody	solution	and	
incubated	for	1	hour	at	ambient	temperature	in	total	darkness.	Following	incubation,	a	
900μl	volume	of	ice-cold	intracellular	flow	cytometry	buffer	was	added	to	all	tubes	and	
centrifugation	 undertaken	 at	 300	 x	 g	 for	 5	 minutes.	 Each	 stained	 cell	 pellet	 was	
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carefully	 washed	 two	 further	 times	 by	 resuspension	 in	 a	 1ml	 volume	 of	 ice-cold	
intracellular	flow	cytometry	buffer	followed	by	immediate	centrifugation	as	previously	
described.	 Each	 sample	was	 finally	 resuspend	 in	 1ml	 of	 intracellular	 flow	 cytometry	
buffer	and	strained	 through	a	40μm	cell	 strainer	 into	a	 round-bottomed	polystyrene	
flow	cytometry	tube	prior	to	immediate	analysis.	
	
All	 information	 regarding	 specific	 primary,	 isotype	 control	 and	 secondary	 antibodies	
used	in	immunostaining	for	flow	cytometry	is	detailed	later	in	the	respective	methods	
sections	of	the	experiments	in	which	they	were	used.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 55	
2.4. Microscopic	Imaging	
	
All	 fluorescent	 and	 phase-contrast	 imaging	 was	 carried	 out	 using	 the	 AF6000LX	
Integrated	 Live	 Cell	 Workstation	 from	 Leica	Microsystems	 U.K.	 Ltd.	 (Milton	 Keynes,	
U.K.).	 This	microscope	 is	 fitted	with	 filter	 cubes	 for	 imaging	 a	 range	of	 fluorophores	
(Table	2.3.),	as	well	as	an	environmental	chamber	maintained	at	37oC	and	fed	with	a	
gas	mixer	supplying	95%	air	and	5%	CO2,	thereby	enabling	live	cell	imaging.	The	Leica	
DMI4000B	 inverted	microscope	was	used	for	bright-field	transmitted	 light	 imaging	 in	
full	colour,	as	was	required	during	β-galactosidase	assays	(Section	2.8.1.).	
	
Table	2.3.	Specification	of	Filter	Cubes	Available	on	the	Leica	AF6000LX	
Filter	
Cube	
Excitation	
Range	
Excitation	
Filter	Type	
Dichromatic	
Mirror	
Suppression	
Filter	Type	
Example	
Fluorophore	
A4	 Ultraviolet	 BP	360/40	 400	 LP	425	 DAPI	
L5	 Blue	 BP	480/40	 505	 BP	527/30	 AlexaFluor®	488,	Vybrant®	DiO	
N3	 Green	 BP	546/12	 565	 BP	600/40	 Vybrant®	CM-DiI	
Y5	 Red	 BP	620/60	 750	 BP	810/90	 Vybrant®	DiD	
	
LP:	longpass	filter	,	BP:	bandpass	filter	
	
During	analysis	of	immunofluorescent	staining	by	manual	scoring	of	positively	stained	
cell	events,	three	representative	non-overlapping	fields	were	required	for	each	sample	
type	 within	 three	 technical	 replicate	 sample	 sets	 across	 each	 of	 three	 biologically	
independent	 repeats	 of	 each	 experiment.	 In	 order	 to	 acquire	 these	 images	 in	 a	
reproducible	and	non-biased	manner,	the	tile-scan	function	of	the	AF6000LX	was	used	
in	order	 to	produce	a	3	x	3	 field	 image	of	 the	total	area	of	each	 immunostained	cell	
spot	 (Figure	2.6.).	The	three	central	cross	sectional	 fields	were	used	 in	each	case	 for	
manual	 scoring	 of	 total	 events	 (indicated	 by	 staining	 of	 cell	 nuclei)	 and	 events	
positively	stained	for	the	marker	of	interest	(indicated	by	immunostaining).	
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Figure	2.6.	Acquisition	of	Non-Overlapping	Fields	for	Scoring	of	Immunostaining	
Once	the	microscope	had	been	set	up	for	Köhler	illumination	and	focussed	on	the	cell	spot	(represented	
here	 by	 a	 grey	 circle),	 the	 upper-left	 margin	 (quadrant	 1)	 was	 located.	 Having	 recorded	 an	 X,	 Y	
coordinate,	 the	microscope	 stage	 was	 then	 sequentially	 panned	 to	 the	 upper	 right,	 lower	 right,	 and	
lower	 left	 margins	 (quadrants	 3,	 9	 and	 7,	 respectively)	 and	 X,	 Y	 coordinates	 recorded	 for	 each.	 The	
coordinates	 recorded	were	used	to	define	 the	boundaries	of	 the	sample,	which	was	divided	 into	nine	
equal	 fields	 for	 imaging.	 These	 fields	were	 then	 imaged	 in	order	 from	1	 -	 9	 in	 an	automated	manner	
using	the	tile	scan	function	of	 the	Leica	AF6000LX.	 Images	of	 fields	4,	5	and	6	were	used	to	provide	a	
representative	cross	section	of	the	each	sample	and	were	then	scored	manually	for	total	number	of	cells	
and	positively	stained	events	present.	
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2.5. Flow	Cytometry	and	Fluorescence	Activated	Cell	Sorting	
	
All	flow	cytofluorimetric	analyses	were	undertaken	using	either	the	BD™	FACSCalibur™	
or	 BD™	 LSR-II™	 platform,	 while	 fluorescence	 activated	 cell	 sorting	 (FACS)	 was	
undertaken	using	the	BD™	FACSAria™	platform	(Beckton,	Dickenson	and	Co.	Plc.).	All	
flow	cytometry	data	were	analysed	using	the	FlowJo®	flow	cytometry	analysis	platform	
(FlowJo	LLC,	Ashland,	Oregon,	U.S.A.).	
	
2.5.1. General	Experimental	Design	
	
An	 unstained	 sample	 of	 cells	 was	 prepared	 within	 each	 experimental	 sample	 set.	
Unstained	 samples	 were	 grown	 and	 processed	 in	 an	 identical	 manner	 to	 all	
corresponding	stained	samples	except	that	they	were	not	exposed	to	any	fluorescent	
molecules	(e.g.	lipophilic	dyes	or	antibodies).	Unlabelled	samples	were	used	in	order	to	
measure	 the	 autofluorescence	 of	 the	 population	 of	 interest	 and	 to	 calibrate	 the	
cytometer	 by	 setting	 the	 voltage	 applied	 to	 each	 fluorescence	 detector	 channel	 in	
order	 that	 unlabelled	 cells	 were	 detected	 as	 negative	 events	 within	 the	 first	
logarithmic	decade	of	the	corresponding	graphical	output.	
	
For	assessment	of	live	cell	viability,	1μM	TO-PRO®-3	iodide	(Life	Technologies	Ltd.)	was	
used	 when	 experimental	 samples	 were	 labelled	 with	 green	 or	 red	 fluorescent	
fluorophores,	while	75μM	propidium	iodide	(Sigma-Aldrich	Company	Ltd.)	was	used	in	
all	 experiments	 involving	 the	 labelling	 of	 cells	 with	 fluorophores	 emitting	 far	 red	
fluorescence.	A	5μl	volume	of	the	appropriate	viability	dye	was	added	per	millilitre	of	
cell	 suspension	 followed	 by	 through	 mixing	 and	 a	 1-minute	 incubation	 period	 in	
complete	 darkness	 immediately	 prior	 to	 analysis	 of	 samples.	 During	 cytometric	
analysis	or	FACS,	the	removal	of	cellular	debris,	identification	of	single	cell	events	and	
removal	 of	 non-viable	 cells	 was	 routinely	 undertaken	 according	 to	 a	 gating	 tree	
depicted	 in	 Figure	 2.7.	 The	 gating	 trees	 showing	 subsequent	 stages	 of	 gating	 for	
specific	applications	are	depicted	in	the	respective	section	describing	the	methodology	
for	these	assays.	
	
	
	 58	
	
Figure	2.7.	Initial	Gating	Strategy	for	Flow	Cytofluorimetric	Analyses	
A:	Cellular	debris,	identified	by	low	particle	size	or	forward-scatter	(FSC)	and	granularity	or	side-scatter	
(SSC),	was	 first	 gated-out	 of	 the	 event	 population.	B:	 The	 resultant	 population	was	 then	divided	 into	
single	cell	and	non-single	cell	events.	C:	Single	cell	events	were	 further	divided	 into	 live	and	dead	cell	
populations	 based	 on	 fluorescence	 intensity	 of	 viability	 dye	 (propidium	 iodide	 or	 TO-PRO®-3	 iodide)	
staining	relative	to	autofluorescence	of	an	unlabelled	cell	sample	analysed	at	the	same	detector	channel	
voltage.	
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Isotype	control	samples	were	prepared	in	all	immunostaining	experiments	in	order	to	
determine	 non-epitope-specific	 binding	 of	 the	 primary	 antibody	 being	 used.	 Isotype	
control	 antibodies	 lacking	 antigenic	 specificity	 were	 matched	 to	 the	 host	 species,	
clonality,	 isotype	 and	 conjugation	 format	 of	 the	 corresponding	 primary	 antibody.	
Isotype	control	antibodies	were	always	used	at	the	same	protein	concentration	as	the	
primary	 antibody	 to	 which	 it	 was	 matched.	 Secondary	 antibody	 controls	 were	
prepared	when	a	secondary	antibody	was	used	in	an	indirect	immunostaining	protocol	
(Section	 2.3.3.2.	 and	Section	 2.3.3.3.).	 These	controls	were	prepared	by	omission	of	
the	 primary	 antibody	 during	 sample	 preparation	 and	 functioned	 to	 determine	 non-
specific	binding	of	 the	secondary	antibody	 to	 low	affinity	sites	 in	 the	absence	of	any	
primary	antibody.	
	
In	order	 to	determine	any	spectral	overlap	of	 fluorophores	used	 in	multi-colour	 flow	
cytometry	experiments,	a	series	of	fluorescence	minus-one	(FMO)	control	samples	was	
prepared.	Each	FMO	control	in	a	series	was	prepared	by	staining	a	sample	with	all	the	
fluorescent	conjugates	to	be	used	in	the	final	procedure	except	for	one,	allowing	the	
contribution	of	the	fluorophores	present	to	the	signal	in	the	unlabelled	channel	to	be	
determined	 and	 correctly	 compensated	 as	 required.	 Single	 colour	 compensation	
controls	were	prepared	 in	multi-colour	experiments	 to	 this	end,	 in	order	 to	calibrate	
the	 cytometer	 for	 removal	 of	 spectral	 overlap.	 Spectral	 overlap	was	 also	 prevented,	
where	 possible,	 by	 selecting	 fluorophores	 that	 could	 be	 excited	 and	 detected	 by	
separate	laser-detector	combinations.	
	
Positive	 control	 samples	 were	 also	 included,	 where	 available,	 by	 preparation	 of	 a	
sample	of	cells	known	to	express	the	target	protein	of	interest	or	by	including	a	sample	
stained	for	a	marker	that	 is	known	to	be	expressed	in	the	test	cell	population.	These	
were	processed	in	the	same	manner	as	stained	experimental	samples	and	were	used	
to	 eliminate	 the	 possibility	 of	 false	 negative	 results	 caused	 by	 sub-optimal	
immunostaining	due	to	a	procedural	error	or	ineffective	antibodies.	
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2.5.2. Cytofluorimetric	Assessment	of	Cell	Cycle	Status	
	
2.5.2.1. Univariant	Cell	Cycle	Analysis	Using	Propidium	Iodide	
	
Samples	 of	 1.0	 x	 106	 cells	were	 removed	 from	harvested	 cell	 suspensions	 and	were	
transferred	to	separate	15ml	centrifuge	tubes.	Centrifugation	was	then	undertaken	for	
5	minutes	at	150	x	g	and	25oC.	The	resultant	supernatant	was	removed	from	each	cell	
pellet	 and	 was	 discarded.	 Cells	 were	 washed	 twice	 by	 resuspension	 in	 PBS	 and	
repeating	centrifugation	as	previous.	The	washed	cell	pellets	were	then	simultaneously	
fixed	 and	 permeabilised	 by	 resuspension	 in	 a	 1ml	 volume	 of	 an	 ice-cold	 solution	 of	
70%	 (v/v)	 ethanol	 in	 ultra-pure	 (18MΩ)	 distilled	 water	 that	 was	 added	 drop-wise	
during	 low	 speed	 vortexing.	 All	 ethanolic	 cell	 suspensions	 were	 placed	 inside	 a	
refrigerator	maintained	at	4oC	overnight.	On	 the	 following	day,	a	5ml	volume	of	 ice-
cold	 PBS	was	 added	 to	 each	 ethanolic	 cell	 suspension	 followed	 by	 gentle	 vortexing,	
and	then	centrifugation	undertaken	at	1000	x	g	 for	a	5-minute	period.	The	resultant	
supernatant	was	 carefully	discarded	 from	 the	 cell	 pellet	before	addition	of	 a	 further	
5ml	of	 ice-cold	PBS.	 Centrifugation	was	 then	undertaken	exactly	 as	 previous.	During	
this	 time,	 Ribonuclease	 A	 (RNase	 A)	 from	 bovine	 pancreas	 (Sigma-Aldrich	 Company	
Ltd.)	was	 added	 to	 a	 75μM	 solution	 of	 propidium	 iodide	 to	 a	 final	 concentration	 of	
0.002%	 (w/v).	 Once	 centrifugation	 was	 complete,	 the	 resultant	 supernatant	 was	
discarded	and	each	cell	pellet	resuspended	in	a	500μl	volume	of	the	freshly	prepared	
propidium	 iodide-RNase	 A	 solution.	 Samples	 were	 then	 protected	 from	 light	 and	
incubated	for	at	least	60	minutes	before	being	analysed	by	flow	cytometry.	
	
2.5.2.2. Univariant	Cell	Cycle	Analysis	in	Live	Cells	Using	Hoechst	33342	
	
Hoechst	 33342	 stock	 solution	 was	 purchased	 from	 Life	 Technologies	 Ltd.	 and	 was	
supplied	at	a	concentration	of	10mg/ml	in	distilled	water.	Immediately	prior	to	use,	an	
appropriate	volume	of	a	1mg/ml	working	solution	was	prepared	by	undertaking	a	1:10	
dilution	of	 the	Hoechst	 33342	 stock	 solution	using	distilled	water	 as	diluent.	 Freshly	
prepared	 Hoechst	 33342	 working	 solution	 was	 stored	 at	 ambient	 temperature	
protected	 from	 light	 until	 required.	 Samples	 of	 1.0	 x	 106	 cells	 were	 prepared	 from	
harvested	cell	suspensions	inside	separate	15ml	centrifuge	tubes	and	centrifuged	for	5	
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minutes	at	150	x	g	and	25oC.	The	resultant	supernatant	was	removed	from	each	cell	
pellet	and	was	discarded.	Cells	were	 then	gently	 resuspended	 in	1ml	of	pre-warmed	
serum-free	 basal	 cell	 culture	 medium.	 A	 5μl	 volume	 of	 the	 1mg/ml	 Hoechst	 33342	
working	stock	solution	was	added	to	all	samples	(f.c.	5μg/ml),	which	were	then	mixed	
well	by	rapid	vortexing,	protected	from	light	and	incubated	in	a	water	bath	maintained	
at	37°C	for	a	45	minute	period.	Following	 incubation,	samples	were	strained	through	
40μm	 cell	 strainers	 into	 round-bottomed	 polystyrene	 flow	 cytometry	 tubes	 and	
immediately	analysed	by	flow	cytometry.	
	
2.5.3. Aldehyde	Dehydrogenase	Activity	Assay	
	
Aldehyde	 dehydrogenase	 (ALDH)	 activity	 was	 determined	 using	 the	 non-
immunological	 ALDEFLUOR™	 assay	 kit	 available	 from	 STEMCELL™	 Technologies	 U.K.	
Ltd.	(Cambridge,	U.K.).	The	inactive	ALDEFLUOR™	reagent	BODIPY-aminoacetaldehyde-
diethylacetate	(BAAA-DA)	was	supplied	as	a	dry	solid.	The	dry	BAAA-DA	was	dissolved	
in	DMSO	and	converted	to	the	activated	fluorescent	form	BODIPY-aminoacetaldehyde	
(BAAA)	 by	 treatment	 with	 2N	 hydrochloric	 acid	 prior	 to	 use,	 according	 to	 the	
manufacturers	instructions.	Briefly,	25μl	of	DMSO	was	added	to	the	vial	of	dry	BAAA-
DA,	 followed	by	 immediate	thorough	mixing	and	 incubation	 for	1	minute	at	ambient	
temperature	while	 protected	 from	 light.	 A	 25μl	 volume	of	 2N	hydrochloric	 acid	was	
then	 added	 to	 the	 vial,	 which	 was	 again	 mixed	 thoroughly	 and	 incubated	 for	 15	
minutes	 at	 ambient	 temperature	 while	 protected	 from	 light.	 A	 360μl	 volume	 of	
ALDEFLUOR™	assay	buffer	was	then	added	to	the	vial	and	mixed	thoroughly.	The	dilute	
activated	 ALDEFLUOR™	 reagent	 was	 aliquoted	 and	 store	 at	 -20oC	 until	 required	 for	
use.	
	
Samples	 of	 1.0	 x	 106	 cells	 were	 removed	 from	 retrieved	 cell	 suspensions	 and	
transferred	to	separate	microcentrifuge	tubes.	Centrifugation	was	undertaken	at	150	x	
g	for	5	minutes	and	the	resultant	supernatant	discarded.	Cell	pellets	were	washed	by	
resuspension	in	1ml	of	PBS	followed	by	immediate	centrifugation	as	previous.	Washed	
samples	were	resuspended	in	1ml	of	ALDEFLUOR™	assay	buffer.	A	5μl	volume	of	the	
activated	 ALDEFLUOR™	 reagent	 was	 added	 to	 each	 millilitre	 of	 sample	 followed	 by	
gentle	vortexing.	A	0.5ml	volume	of	suspension	was	then	removed	and	transferred	to	
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a	 separate	 control	 tube	 containing	 5μl	 of	 the	 specific	 aldehyde	 dehydrogenase	
inhibitor	diethylaminobenzaldehyde	 (DEAB)	 followed	by	 immediate	mixing.	Both	 test	
and	 corresponding	 control	 tubes	 were	 incubated	 for	 45	 minutes	 at	 37°C	 protected	
from	 light.	Following	 incubation,	all	 tubes	were	centrifuged	 for	5	minutes	at	150	x	g	
and	 the	 supernatant	 discarded.	 Each	 resultant	 pellet	 was	 resuspended	 in	 0.5ml	 of	
ALDEFLUOR™	assay	buffer	and	each	tube	placed	on	 ice	prior	to	flow	cytofluorimetric	
analysis	(Figure	2.8.).	
	
	
Figure	2.8.	Flow	Cytometric	Detection	of	Cellular	ALDH	Activity	
A:	 A	 sample	 of	 cells	 treated	 with	 the	 specific	 aldehyde	 dehydrogenase	 (ALDH)	 inhibitor	
diethylaminobenzaldehyde	(DEAB)	was	used	to	set	the	gate	in	the	appropriate	detector	channel	for	the	
detection	 of	 oxidised	 BODIPY-aminoacetaldehyde	 (BAAA)	 that	 indicates	 cellular	 ALDH	 activity	 B:	
Experimental	 samples	 were	 analysed	 using	 the	 gating	 strategy	 pre-set	 using	 DEAB	 treated	 controls,	
thereby	allowing	detection	of	ALDH	positive	cells	as	events	exceeding	the	relative	fluorescence	profile	of	
the	corresponding	DEAB	treated	control.	
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2.6. Establishing	Drug	Dose-Response	Curves	
	
2.6.1. Preparation	of	MTT	Reagent	
	
Methylthiazolyltetrazolium	bromide	(MTT)	was	prepared	as	a	0.5%	(w/v)	stock	solution	
in	PBS;	1g	of	MTT	powder	(Sigma-Aldrich	Company	Ltd.)	was	added	to	a	final	volume	of	
200ml	of	PBS.	Complete	dissolution	was	achieved	by	continuous	stirring	for	a	one-hour	
period	 on	 a	 heated	 magnetic	 stirrer	 plate	 maintained	 at	 37oC.	 The	 solution	 was	
protected	 from	 light	 throughout.	 Once	 dissolved,	 the	 MTT	 stock	 was	 sterilised	 by	
filtration	through	a	0.2μm	polycarbonate	filter	and	was	then	aliquoted	as	5ml	volumes	
and	 stored	 at	 -20oC	 until	 required.	 Immediately	 prior	 to	 use,	 frozen	 aliquots	 were	
thawed	 rapidly	by	placing	 into	a	water	bath	maintained	at	37oC	 for	approximately	5	
minutes,	after	which	they	were	mixed	thoroughly	by	vortexing	before	being	diluted	1:5	
in	complete	growth	medium	to	produce	a	working	solution	with	a	final	concentration	
of	0.1%	(w/v).	
	
2.6.2. Optimisation	of	MTT	Assay	Conditions	
	
The	optimal	MTT	concentration	and	 incubation	time	for	use	during	MTT	assays	were	
originally	 established	 by	 (Mosmann,	 1983)	 and	 (Denizot	 and	 Lang,	 1986);	 the	
recommended	MTT	concentration	of	1mg/ml	and	an	incubation	period	of	3	hours	was	
used	 in	accordance	with	 these	pre-validated	recommendations.	A	standard	curve	 for	
both	 MCF-7	 and	 MDA-MB-231	 cell	 lines	 was	 generated	 in	 order	 to	 establish	 the	
linearity	 of	 the	 relationship	 between	 cell	 number	 and	 the	 absorbance	 reading	 at	
540nm	obtained	 following	 the	MTT	assay	procedure	 in	order	 to	ensure	 that	 the	 cell	
line	specific	optimal	seeding	densities	to	be	used	in	subsequent	cytotoxicity	assays	did	
not	 lead	 to	 delineation	 of	 this	 relationship	 after	 the	 intended	 assay	 period.	 Briefly,	
both	 MCF-7	 and	 MDA-MB-231	 cells	 were	 seeded	 into	 the	 wells	 of	 a	 high-quality	
polystyrene	96-well	flat-bottomed	cluster	plate	(Scientific	Laboratory	Supplies	Ltd.)	in	
triplicate	at	a	range	of	densities	(1000	-	20,	000	cells	per	well)	and	supplemented	with	
100μl	of	complete	growth	medium.	A	row	of	blank	wells	containing	medium	alone	(no	
cells)	was	prepared	at	either	end	of	the	plate.	Plates	were	incubated	overnight	under	
standard	growth	conditions	in	order	to	allow	cells	to	recover	and	adhere	to	the	base	of	
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the	wells.	All	wells	 (including	blank	wells)	were	then	completely	drained	and	re-filled	
with	a	100μl	volume	of	freshly	prepared	MTT	reagent	prepared	as	described	previously	
(Section	 2.6.1.).	 Plates	 were	 then	 replaced	 in	 incubation	 for	 a	 period	 of	 3	 hours.	
Subsequently,	all	wells	were	once	again	drained	of	their	contents	and	100μl	of	DMSO	
added.	Plates	were	then	protected	from	light	by	wrapping	in	aluminium	foil	and	placed	
on	a	plate-shaker	set	to	180	revolutions	per	minute	for	a	15-minute	duration	prior	to	
being	read	spectrophotometrically	at	a	wavelength	of	570nm	using	a	SpectraMax®	M5	
multi-mode	plate	reader	(Molecular	Devices	U.K.	Ltd.,	Wokingham,	U.K.).	
	
2.6.3. Drug	Dose-Response	Assay	Procedure	
	
Cells	 were	 seeded	 at	 the	 cell	 line	 specific	 optimal	 density	 into	 the	 wells	 of	 a	 high-
quality	polystyrene	96-well	 flat-bottomed	cluster	plate	and	supplemented	with	100μl	
of	complete	growth	medium.	A	row	of	blank	wells	containing	medium	alone	(no	cells)	
was	 prepared	 at	 either	 end	 of	 the	 plate	 according	 to	 the	 plate	 set-up	 schematic	
depicted	 in	 Figure	 2.9.	 Plates	 were	 incubated	 overnight	 under	 standard	 growth	
conditions	 in	order	 to	allow	cells	 to	recover	and	adhere	to	the	base	of	 the	wells.	On	
the	subsequent	day,	drug	solutions	were	 freshly	prepared	along	with	solvent	control	
solutions	 composed	 of	 complete	 growth	 medium	 and	 the	 percentage	 of	 solvent	
equivalent	 to	 that	present	 in	 the	highest	drug	 concentration	being	 tested.	 Following	
overnight	 incubation,	 the	 spent	medium	was	 removed	 from	all	wells.	 Each	well	was	
filled	 with	 a	 200μl	 volume	 of	 complete	 growth	 medium	 (growth	 controls),	 the	
appropriate	 solvent	 control	 solution	 (vehicle	 controls),	 or	 one	 of	 the	 pre-prepared	
drug-containing	 solutions	 according	 to	 the	plate	 set-up	 schematic	depicted	 in	Figure	
2.9.	 Plates	 were	 then	 replaced	 in	 incubation	 for	 a	 period	 of	 time	 equivalent	 to	 the	
duration	of	the	logarithmic	phase	of	culture	growth	specific	to	the	cell	line	being	used.	
Following	 incubation	 in	 the	 presence	 of	 drug	 for	 the	 appropriate	 period,	 all	 wells	
(including	blank	wells)	were	completely	drained	and	re-filled	with	a	100μl	volume	of	
freshly	prepared	MTT	reagent	prepared	as	described	previously	(Section	2.6.1.).	Plates	
were	 then	 replaced	 in	 incubation	 for	 a	 further	 period	 of	 3	 hours.	 Subsequently,	 all	
wells	 were	 once	 again	 drained	 of	 their	 contents	 and	 100μl	 of	 DMSO	 added.	 Plates	
were	then	protected	from	light	by	wrapping	 in	aluminium	foil	and	placed	on	a	plate-
shaker	set	to	180	revolutions	per	minute	for	a	15-minute	duration	prior	to	being	read	
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spectrophotometrically	 at	 a	 wavelength	 of	 570nm	 using	 a	 SpectraMax®	 M5	 multi-
mode	plate	reader.	
	
	
	
Figure	2.9.	Plate	Configuration	for	Drug-Dose	Response	Assessment	by	MTT	Assay	
Peripheral	 wells	were	 filled	with	 200μl	 of	 0.2μm	 filter-sterilised	 ultrapure	 (18MΩ)	water.	 Blank	wells	
containing	only	 complete	 culture	medium	were	prepared	 at	 either	 end	of	 the	plate.	Growth	 controls	
(denoted	 as	 "Growth	 Ctrl"	 here)	 contained	 adherent	 cells	 and	 a	 200μl	 volume	 of	 complete	 growth	
medium	 only	 while	 vehicle	 controls	 (denoted	 as	 "Vehicle	 Ctrl"	 here)	 contained	 adherent	 cells	 and	 a	
200μl	volume	of	complete	growth	medium	along	with	the	equivalent	percentage	of	solvent	present	in	
the	 highest	 drug	 concentration	 being	 tested.	 Drug	 solutions	 were	 added	 to	 each	 plate	 in	 order	 of	
decreasing	concentration	from	left	to	right.	
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2.7. Western	Blotting	
	
2.7.1. Preparation	of	Whole	Cell	Lysate	
	
Culture	 vessels	 were	 placed	 on	 ice	 and	 the	 cells	 washed	 twice	 with	 ice-cold	 PBS.	
Cultures	 were	 harvested	 into	 0.2ml	 PBS	 per	 cm2	 growth	 area	 using	 a	 plastic	 cell	
scraper.	 The	 retrieved	 cell	 suspensions	 were	 transferred	 to	 separate	 pre-cooled	
centrifuge	 tubes	 and	 the	 vessels	washed	with	 an	 equivalent	 volume	 of	 ice-cold	 PBS	
that	 was	 also	 transferred	 to	 the	 corresponding	 centrifuge	 tube.	 Samples	 were	
subjected	 to	 centrifugation	 for	 5	minutes	 at	 150	 x	g	 and	 4oC.	 The	 supernatant	was	
drained	and	the	cell	pellet	resuspended	in	100μl	of	RIPA	lysis	buffer	(150mM	sodium	
chloride,	 1.0%	 (v/v)	 IGEPAL®	 CA-630,	 0.5%	 (w/v)	 sodium	 deoxycholate,	 0.1%	 (w/v)	
sodium	dodecyl	sulphate	(SDS)	and	50mM	Tris	in	18MΩ	distilled	water,	pH	8.0	at	4oC)	
with	 0.1%	 (v/v)	 protease	 inhibitor	 cocktail	 (all	 from	 Sigma-Aldrich	 Company	 Ltd.).	
Samples	 were	 incubated	 on	 ice	 with	 constant	 agitation	 maintained	 for	 30	 minutes	
before	 being	 subjected	 to	 centrifugation	 at	 10,000	 x	 g	 for	 10	minutes.	 Tubes	 were	
placed	 directly	 on	 ice	 subsequently	 and	 the	 supernatant	 (lysate)	 transferred	 to	 a	
separate	pre-cooled	microcentrifuge	tube	while	the	pellet	(cell	debris)	was	discarded.	
Lysates	were	routinely	used	immediately	but	can	be	stored	at	-20oC	short-term	or	at	-
80oC	for	a	longer	duration.	
	
2.7.2. Determination	of	Lysate	Protein	Concentration	
	
A	 series	of	 five	BSA	protein	 standard	solutions	were	prepared	by	dilution	of	1mg/ml	
BSA	protein	standard	(Sigma-Aldrich	Company	Ltd.)	in	lysis	buffer	to	concentrations	of	
0	 -	 800μg/ml.	 Cell	 lysates	were	 diluted	 1:10	 in	 lysis	 buffer.	 BCA	 (bicinchoninic	 acid)	
protein	assay	 reagent	was	composed	by	addition	of	1	part	0.1M	copper	 (II)	 sulphate	
solution	 to	 50	 parts	 bicinchoninic	 acid	 solution	 (both	 from	 Sigma-Aldrich	 Company	
Ltd.).	 A	 200μl	 volume	 of	 this	 solution	 was	 added	 to	 10μl	 volumes	 of	 samples	 and	
standard	solutions	pipetted	into	triplicate	wells	of	a	96-well	assay	plate.	The	plate	was	
covered	with	paraffin	film	and	incubation	undertaken	at	ambient	temperature	for	30	
minutes.	 The	 final	 absorbance	 was	 read	 at	 a	 wavelength	 of	 500nm	 using	 a	
SpectraMax®	M5	multi-mode	plate	reader.	
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2.7.3. Electrophoresis	
	
Protein	 samples	 were	 prepared	 in	 4x	 protein	 sample	 buffer	 (40%	 (v/v)	 glycerol,	 8%	
(w/v)	 SDS,	 0.04%	 (w/v)	 bromophenol	 blue	 and	 240mM	 Tris	 hydrochloride	 in	 18MΩ	
distilled	 water,	 pH	 6.8	 at	 37oC)	 with	 50mM	 dithiothreitol	 added	 at	 the	 time	 of	
formulation.	Final	total	protein	per	sample	was	typically	20	-	40μg	(depending	on	the	
protein	concentration	of	cell	lysates).	Volumes	were	made	up	to	a	final	volume	of	15μl	
using	18MΩ	distilled	water.	Denaturation	of	protein	was	achieved	by	heating	at	95oC	
for	10	minutes	 followed	by	a	brief	 centrifugation	 to	ensure	any	evaporated	 liquid	 in	
the	 cap	 of	 the	 microcentrifuge	 tube	 was	 returned	 to	 the	 bottom.	 The	 total	 15μl	
volume	of	 each	 sample	was	 loaded	 into	 the	wells	 of	 a	 4-20%	Mini-PROTEAN®	TGX™	
precast	 polyacrylamide	 gel	 (Bio-Rad	 Laboratories	 Ltd.,	 Hemel	 Hempstead,	 U.K.).	 A	
gradient	gel	such	as	this	was	routinely	used	for	electrophoresis	of	whole	cell	lysates	as	
the	acrylamide	concentration	gradient	from	the	beginning	(top)	to	end	(bottom)	of	the	
sample	 path	 allows	 the	 separation	 of	 a	 broad	 range	 of	 protein	 sizes.	 One	well	 was	
loaded	 with	 a	 7μl	 volume	 of	 Precision	 Plus	 Protein™	 Dual	 Xtra	 Pre-stained	 Protein	
Standards	 (Bio-Rad	 Laboratories	 Ltd.)	 used	 as	 molecular	 weight	 markers.	
Electrophoresis	was	undertaken	at	130V	for	1	–	2	hours.	
	
2.7.4. Transfer	
	
A	single	piece	of	Polyvinylidene	 fluoride	 (PVDF)	membrane	 (Thermo	Fisher	Scientific)	
cut	 to	 the	 exact	 size	 of	 the	 gel	 was	 soaked	 in	 absolute	 methanol	 for	 30	 seconds	
followed	 by	washing	 in	 18MΩ	 distilled	water	 for	 5	minutes	with	 constant	 agitation.	
Following	washing,	the	membrane	was	placed	in	transfer	buffer	(0.025M	Tris,	0.192M	
glycine	and	10%	(v/v)	methanol	in	18MΩ	distilled	water,	pH	8.5	at	37oC)	and	allowed	
to	equilibrate	for	5	minutes.	Four	pieces	of	blotting	paper	and	transfer	sponges	were	
also	 soaked	 in	 transfer	 buffer	 during	 this	 time.	 The	 gel	 was	 sandwiched	 within	 the	
blotting	 module	 between	 sponges	 and	 blotting	 paper	 as	 depicted	 in	 Figure	 2.10.	
ensuring	 that	no	air	bubbles	were	 trapped	between	 layers.	The	blotting	module	was	
placed	 into	the	gel	tank	along	with	an	 ice	pack	before	the	tank	was	completely	filled	
with	transfer	buffer.	The	transfer	was	then	undertaken	at	70V	for	1.5	–	2	hours.	
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Figure	2.10.	Western	Blot	Transfer	Module	Configuration	
Prior	to	performing	a	wet	transfer,	the	polyacrylamide	gel	was	first	equilibrated	in	transfer	buffer	before	
being	 placed	 in	 the	 “transfer	 sandwich”	 (filter	 cards-membrane-gel-filter	 cards)	 cushioned	 by	 sponge	
pads	 and	 held	 together	 by	 a	 support	 grid.	 All	 components	 of	 the	 transfer	 sandwich	 were	 pre-
equilibrated	in	transfer	buffer.	
	
2.7.5. Protein	Detection	
	
Following	transfer,	the	PVDF	membrane	was	placed	in	a	blocking	solution	of	10%	(w/v)	
non-fat	milk	powder	in	Tris-buffered	saline	(25mM	Tris,	0.15M	sodium	chloride,	pH	7.5	
at	37oC)	with	0.05%	(v/v)	Tween®20	(TBST)	 for	30	minutes.	During	this	time,	primary	
antibodies	 against	 the	 protein	 of	 interest	 and	 a	 pre-selected	 housekeeping	 protein	
were	 diluted	 to	 the	 desired	 concentration	 in	 a	 solution	 of	 5%	 (w/v)	 non-fat	 milk	
powder	 in	TBST	to	produce	a	5ml	 final	volume	of	dilute	antibody	solution.	The	PVDF	
membrane	was	loaded	into	a	50ml	centrifuge	tube	and	the	total	5ml	volume	of	dilute	
primary	antibody	solution	added.	Tubes	were	placed	onto	a	roller	and	incubated	at	4oC	
overnight.	 On	 the	 subsequent	 day,	 the	 PVDF	 membrane	 was	 removed	 from	 the	
primary	antibody	solution	and	washed	three	times	 in	TBST	 for	10	minutes	per	wash.	
Horseradish	 peroxidase	 (HRP)	 conjugated	 polyclonal	 secondary	 antibodies	 were	
diluted	 to	 the	 desired	 concentration	 in	 5%	 (w/v)	 non-fat	 milk	 powder	 in	 TBST	 to	
produce	 a	 5ml	 final	 volume	 of	 dilute	 antibody	 solution.	 The	 PVDF	 membrane	 was	
incubated	 in	 the	 presence	 of	 secondary	 antibody	 solution	 for	 1	 hour	 at	 ambient	
temperature.	The	membrane	was	then	washed	with	TBST	three	times	for	10	minutes	
per	wash.	 SuperSignal™	West	 Pico	 Chemiluminescent	 HRP	 substrate	 (Thermo	 Fisher	
Scientific)	 was	 used	 for	 detection	 and	 localisation	 of	 antibody	 bound	 to	 the	 PVDF	
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membrane;	 equal	 volumes	 of	 peroxide	 and	 luminol	 enhancer	 solutions	 were	mixed	
and	subsequently	used	to	cover	the	PVDF	membrane.	The	membrane	was	then	imaged	
immediately	 using	 the	 Bio-Rad	 ChemiDoc™	 MP	 Imaging	 System	 with	 Image	 Lab™	
software	(Bio-Rad	Laboratories	Ltd.).	
	
All	 information	 regarding	 specific	primary	and	 secondary	antibodies	used	 in	western	
blot	 procedures	 are	 detailed	 later	 in	 the	 respective	 methods	 sections	 of	 the	
experiments	in	which	they	were	used.	
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2.8. Biochemical	Assays	
	
2.8.1. β-Galactosidase	Assay	
	
The	activity	of	β-galactosidase	at	pH	6.0	is	a	widely	used	marker	of	cellular	senescence	
and	is	not	found	in	pre-senescent,	quiescent	or	immortal	cells.	Cellular	β-galactosidase	
activity	at	pH	6.0	was	assayed	using	the	β-galactosidase	staining	kit	available	from	New	
England	Biolabs	U.K.	Ltd.	(Hitchin,	U.K.).	A	bone-homing	MDA-MB-231	variant	cell	line	
that	was	engineered	to	stably	express	β-galactosidase	(denoted	MDA-MB-231-BO2-β-
gal)	was	 used	 as	 a	 positive	 control	 for	 β-galactosidase	 activity.	 Briefly,	 experimental	
and	positive	control	samples	of	cells	were	seeded	in	triplicate	into	the	wells	of	6-well	
cluster	plates	at	the	cell-line	specific	optimal	density	supplemented	with	a	3ml	volume	
of	 complete	 culture	 medium	 and	 placed	 into	 incubation	 under	 standard	 growth	
conditions	 for	 24	 hours.	 For	 each	 35mm	 well	 to	 be	 stained,	 a	 staining	 solution	
comprised	 of	 930μl	 of	 1X	 staining	 solution	 (40mM	 citric	 acid/sodium	 phosphate,	
0.15M	 sodium	 chloride	 and	 2mM	 magnesium	 chloride),	 10μl	 of	 500mM	 potassium	
ferrocyanide,	10μl	of	500mM	potassium	ferricyanide	and	50μl	of	20mg/ml	5-bromo-4-
chloro-3-indolyl-β-D-galactopyranoside	 (X-gal)	 in	 dimethylformamide	 was	 composed	
inside	of	a	polypropylene	 tube	and	 the	pH	adjusted	 to	pH	6.0	using	2N	hydrochloric	
acid	immediately	prior	to	requirement.	Growth	medium	was	removed	from	all	wells	to	
be	 stained	and	 the	adherent	 cells	 rinsed	once	with	a	2ml	volume	of	PBS.	Cells	were	
fixed	in	2%	(v/v)	formaldehyde	and	0.2%	(v/v)	glutaraldehyde	in	PBS	for	15	minutes	at	
ambient	 temperature.	 All	wells	were	 then	 rinsed	 two	 times	with	 PBS	 as	 previous.	 A	
1ml	volume	of	 freshly	prepared	staining	solution	was	added	to	each	35mm	well,	 the	
plate	 edges	 sealed	with	 paraffin	 film	 in	 order	 to	 prevent	 evaporation	 and	 all	 plates	
placed	 into	 a	 non-humidified	 CO2-free	 incubator	 maintained	 at	 37°C	 overnight.	
Following	 overnight	 incubation,	 positive	 control	 wells	 were	 checked	 for	 the	
development	of	 the	green/blue	staining	 indicative	of	β-galactosidase	activity	prior	 to	
photomicroscopic	image	acquisition.	
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2.8.2. Determination	of	D-Glucose	Concentration	in	Culture	Medium	
	
The	 concentration	 of	 D-glucose	 present	 in	 solution	 was	 determined	 using	 the	 D-
glucose	assay	kit	available	from	Eton	Bioscience	Inc.	(San	Diego,	CA,	U.S.A.).	Briefly,	the	
800μM	D-glucose	standard	and	glucose	assay	solution	contained	within	 the	assay	kit	
were	removed	from	storage	at	-80oC	and	thawed	on	ice	overnight	at	in	a	refrigerator	
maintained	 at	 4oC.	 Once	 thawed,	 the	 D-glucose	 standard	 and	 experimental	 samples	
were	 allowed	 to	 equilibrate	 to	 ambient	 temperature	 prior	 to	 undertaking	 the	 assay	
procedure,	 while	 the	 assay	 reagent	 was	 kept	 on	 ice	 protected	 from	 light.	 The	 D-
glucose	standard	was	first	diluted	1:2	with	dH2O;	500μl	of	standard	(as	supplied)	was	
diluted	with	500μl	of	dH2O.	This	dilute	D-glucose	standard	(f.c.	400μM)	was	then	used	
to	 compose	 a	 series	 of	 eight	 D-glucose	 standard	 solutions	 with	 concentrations	
between	400μM	and	8μM	along	with	a	0μM	dH2O	blank	control	solution.	Experimental	
samples	were	then	diluted	according	to	the	maximal	D-glucose	content	present	in	the	
basal	 medium	 as	 stated	 by	 the	 respective	 supplier	 in	 order	 to	 ensure	 that	 optical	
density	 readings	 post-assay	would	 fall	 into	 the	 range	 of	 the	 standard	 curve.	 A	 50μl	
volume	 of	 each	 standard	 solution	 and	 experimental	 sample	 was	 then	 added	 in	
duplicate	directly	to	the	wells	of	a	standard	96-well	assay	plate.	A	50μl	volume	of	D-
glucose	assay	reagent	was	then	added	to	all	wells,	the	plate	sealed	with	paraffin	film	
and	 placed	 into	 incubation	 for	 15	 minutes	 at	 37oC	 in	 a	 non-humidified	 CO2-free	
incubator.	Following	incubation,	the	reaction	within	all	wells	was	stopped	by	addition	
of	a	50μl	volume	of	0.5M	acetic	acid	followed	by	gentle	agitation.	The	absorbance	was	
measured	spectrophotometrically	at	a	wavelength	of	490nm	using	a	SpectraMax®	M5	
multi-mode	 plate	 reader.	 The	D-glucose	 concentration	 of	 experimental	 samples	was	
determined	 by	 interpolation	 of	 the	 recorded	 absorbance	 measurement	 from	 the	
standard	curve.	
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2.8.3. Determination	of	L-Lactate	Concentration	in	Culture	Medium	
	
The	concentration	of	L-lactate	present	in	solution	was	determined	using	the	L-lactate	
assay	kit	available	 from	Eton	Bioscience	 Inc.	Briefly,	 the	3mM	L-lactate	standard	and	
lactate	assay	solution	contained	within	the	assay	kit	were	removed	from	storage	at	-
80oC	and	thawed	on	ice	overnight	at	in	a	refrigerator	maintained	at	4oC.	Once	thawed,	
the	 L-lactate	 standard	 and	 experimental	 samples	 were	 allowed	 to	 equilibrate	 to	
ambient	 temperature	 prior	 to	 undertaking	 the	 assay	 procedure,	 while	 the	 assay	
reagent	was	kept	on	ice	protected	from	light.	The	L-lactate	standard	was	then	used	to	
compose	 a	 series	 of	 eight	 L-lactate	 standard	 solutions	with	 concentrations	 between	
3mM	and	60μM	along	with	a	0μM	dH2O	blank	control	solution.	Experimental	samples	
were	 then	diluted	according	 to	 the	maximal	possible	 L-lactate	content	 that	 could	be	
present	based	on	complete	homolactic	 fermentation	of	 the	entire	D-glucose	content	
of	the	basal	medium	according	to	the	respective	supplier.	This	process	was	necessary	
to	ensure	that	the	optical	density	readings	post-assay	would	fall	into	the	range	of	the	
standard	curve.	A	50μl	volume	of	each	standard	solution	and	experimental	sample	was	
then	added	in	duplicate	directly	to	the	wells	of	a	standard	96-well	assay	plate.	A	50μl	
volume	of	 L-lactate	assay	 reagent	was	 then	added	 to	all	wells,	 the	plate	 sealed	with	
paraffin	 film	 and	 placed	 into	 incubation	 for	 30	minutes	 at	 37oC	 in	 a	 non-humidified	
CO2-free	incubator.	Following	incubation,	the	reaction	within	all	wells	was	stopped	by	
addition	 of	 a	 50μl	 volume	 of	 0.5M	 acetic	 acid	 followed	 by	 gentle	 agitation.	 The	
absorbance	was	measured	spectrophotometrically	at	a	wavelength	of	490nm	using	a	
SpectraMax®	 M5	 multi-mode	 plate	 reader.	 The	 L-lactate	 concentration	 of	
experimental	 samples	 was	 determined	 by	 interpolation	 of	 the	 recorded	 absorbance	
measurement	from	the	standard	curve.	
	
2.9. Statistical	Analyses	
	
All	 statistical	analyses	were	undertaken	using	GraphPad	Prism	7	 (GraphPad	Software	
Inc.,	La	Jolla,	U.S.A.).	All	data	were	expressed	as	the	mean	average	±	the	standard	error	
of	 the	 mean	 (SEM).	 The	 statistical	 analysis	 applied	 to	 data,	 where	 undertaken,	 is	
indicated	 within	 the	 respective	 figure	 legend.	 Statistical	 significance	 was	 attributed	
when	P	<	0.05.	
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Chapter	3	
	
	
Establishing	an	In	Vitro	Model	for	the	Study	
of	Mitotically	Quiescent	Breast	
	 Cancer	Cells	
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3.1. Summary	
	
Emerging	 evidence	 strongly	 suggests	 that	 putative	 cancer	 stem	 cells	 are	 the	
metastasis-initiating	 population	 in	 breast	 cancer.	 Breast	 cancer	 stem	 cells	 are	
presumed	 to	 be	 mitotically	 quiescent,	 like	 their	 non-malignant	 counterparts,	 and	
therefore	 capable	 of	 evading	 conventional	 anti-neoplastic	 therapy	 and	 driving	 both	
tumour	 relapse	 and	 recurrence	 at	 secondary	 sites.	Detailed	 insight	 into	 cancer	 stem	
cell	biology	 is	 therefore	 likely	 to	be	 critical	 to	 the	development	of	novel	 therapeutic	
strategies	 for	 prevention	 and	 effective	 treatment	 of	 metastatic	 breast	 cancer.	
Contemporary	means	 of	 identifying	 cancer	 stem	 cells	 based	 on	 specific	 cell	 surface	
marker	signatures	have	proved	controversial	due	to	the	transience	of	this	population	
and	 the	 lack	 functional	 significance	 associated	with	 this	 approach.	 The	 requirement	
exists,	 therefore,	 for	 reliable	 and	 functionally	 informed	model	 systems	 enabling	 the	
characterisation	 of	 cancer	 stem	 cell	 populations.	 Relatively	 recently,	 pulse-chase	
techniques	for	assessment	of	stem	cells	based	on	their	inherent	quiescent	nature	has	
undergone	something	of	a	renaissance	due	to	the	advent	of	lipophilic	tracer	dyes	that	
have	enabled	the	isolation	and	analysis	of	live	cells.	While	a	number	of	studies	in	other	
cancer	types	have	demonstrated	the	prospective	identification	of	cancer	stem	cells	or	
stem-like	populations	using	this	approach,	it's	potential	utility	in	breast	cancer	remains	
virtually	unexplored.	This	chapter	describes	the	development	of	a	highly	reproducible	
in	vitro	model	system	enabling	prospective	functional	isolation	of	a	putative	stem-like	
mitotically	 quiescent	 sub-population	 from	 human	 breast	 cancer	 cell	 lines	 using	 a	
lipophilic	dye	retention	method.	
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3.2. Introduction	
	
A	 substantial	 body	 of	 evidence	 indicates	 that	 the	 pathogenesis	 of	 many	 cancers,	
including	 breast	 cancer,	 is	 driven	 by	 a	 sub-population	 that	 displays	 stem	 cell	
properties.	These	so-called	cancer	stem	cells	(CSCs)	are	thought	to	be	responsible	not	
only	 for	 initiation	 and	 growth	 of	 the	 primary	 tumour	 but	 also	 for	 therapeutic	
resistance	 and	 the	 initiation	 of	 metastatic	 lesions	 (recently	 reviewed	 by	 Luo	 et	 al.,	
2015).	 Cancer	 stem	 cell	 populations,	 like	 their	 non-malignant	 counterparts,	 are	
hierarchically	 organised	 and	maintained	 by	 a	 process	 of	 self-renewal	 in	which	 slow-
cycling	 stem	 cells	 divide	 asymmetrically	 to	 generate	 new	 stem	 cells	 and	 rapidly	
dividing	transit-amplifying	cells	(Oakes	et	al.,	2014).	Cells	that	exist	in	a	slow-cycling	or	
an	 absolute	 quiescent	 state	 are	 inherently	 less	 susceptible	 to	 traditional	
chemotherapeutic	 agents	 that	 rely	 on	mitotic	 activity	 to	 initiate	 cytotoxicity	 (Moore	
and	Lyle,	2011).	This	observation	suggests	an	inherent	recurrence	mechanism	in	which	
CSCs	evade	therapeutic	targeting.	A	detailed	insight	into	the	biology	of	quiescent	CSCs	
is	 therefore	 likely	 to	 be	 critical	 to	 the	 development	 of	 effective	 novel	 therapeutic	
strategies	for	prevention	of	cancer	relapse	and	recurrence.	However,	in	order	to	study	
CSCs	it	is	first	necessary	to	isolate	them	using	techniques	that	enable	their	differential	
identification	amongst	the	bulk	tumour	cell	population.	
	
Contemporary	 approaches	 for	 selective	 identification	 of	 CSCs	 primarily	 rely	 on	
expression	of	specific	cell	 surface	marker	profiles.	Bonnet	and	Dick	 (1997)	originated	
this	technique	when	they	first	demonstrated	initiation	of	acute	myeloid	leukaemia	by	a	
self-renewing,	 primitive	 hematopoietic	 cell	 sub-set	 with	 a	 unique	 CD34+CD38-	
phenotype.	 Since	 this	pioneering	 study,	CSC	populations	have	been	 identified	 in	 this	
manner	 in	multiple	cancers	 including	those	of	breast,	prostate,	pancreas,	colon,	 liver	
ovaries,	head	and	neck,	and	the	brain	(Al-Hajj	et	al.,	2003;	Singh	et	al.,	2004;	Collins	et	
al.,	2005;	Li	et	al.,	2007;	Ma	et	al.,	2007;	O'Brien	et	al.,	2007;	Prince	et	al.,	2007;	Gao	et	
al.,	 2010).	 In	 breast	 cancer,	 a	 tumour	 initiating	 stem	 cell-like	 population	 was	 first	
identified	by	way	of	their	EpCAM+CD44+CD24-/low	surface	marker	expression	profile	(Al-
Hajj	et	al.,	2003).	When	injected	into	immunocompromised	mice,	the	gold	standard	for	
assessing	 breast	 CSC	 activity,	 EpCAM+CD44+CD24-/low	 cells	 exhibited	 over	 100-fold	
greater	 tumourigenicity	 than	 cells	 lacking	 this	 phenotype	 and	 were	 also	 able	 to	
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recapitulate	 the	 cell-type	heterogeneity	of	 the	original	 tumour.	More	 recently	 it	 has	
been	reported	that	both	normal	breast	stem	cells	and	their	malignant	counterparts	are	
demarked	 by	 increased	 expression	 of	 ALDH,	 a	 known	 predictor	 of	 poor	 clinical	
outcome	 (Khoury	 et	 al.,	 2012;	 Papadaki	 et	 al.,	 2014;	 Yang	 et	 al.,	 2016).	 Both	 the	
CD44+CD24-/low	 and	 ALDH+	 phenotypes	 have	 been	 extensively	 used	 for	 prospective	
isolation	 of	 CSCs	 from	 different	 molecular	 sub-types	 of	 breast	 cancer	 over	 recent	
years.	 However,	 a	 study	 by	 Ginestier	 et	 al.	 (2007)	 conclusively	 demonstrated	 that	
CD44+CD24-/low	 and	 ALDH+	 phenotypes	 identify	 minimally	 overlapping	 stem-like	
populations	that	are	genetically,	phenotypically	and	spatially	distinct	but	dynamically	
transitioning.	Meyer	et	al.	(2010)	more	recently	reported	that	both	CD44+CD24-/low	and	
CD44+CD24+	 phenotypic	 sub-sets	 identified	 in	 oestrogen	 receptor-negative	 breast	
cancer	are	tumourigenic	in	mouse	xenograft	models.	These	contrasting	and	sometimes	
confounding	results	illustrate	the	issues	that	can	arise	due	to	the	plasticity	of	the	CSC	
population	and	the	uncertainty	that	surrounds	the	functional	implications	of	putative	
CSC	 surface	 markers.	 These	 issues	 highlight	 the	 requirement	 for	 incorporating	
functionally	significant	means	of	identifying	CSCs.	
	
Functional	approaches	to	isolation	of	CSCs	can	primarily	be	sub-divided	into	vital	dye	
exclusion	and	 label-retention	assays.	 The	dye	exclusion	method	 is	predicated	on	 the	
observation	 that	 both	 normal	 and	malignant	 stem	 cell	 populations	 demonstrate	 up-
regulated	 expression	 of	 adenosine	 5'-triphosphate-binding	 cassette	 transporter	
proteins	and	therefore	possess	an	increased	capability	to	efflux	fluorescent	vital	dyes	
(Bunting,	 2002).	 This	 dye-exclusion	 activity	 results	 in	 a	 side-population	 that	 can	 be	
isolated	 for	 further	 study	 by	 FACS	 (Hadnagy	 et	 al.,	 2006).	 A	 number	 of	 studies	
employing	 this	 technique	 have	 demonstrated	 the	 existence	 of	 side-populations	
enriched	 for	stem-like	properties	and	enhanced	tumourigenicity	 in	various	molecular	
sub-types	 of	 human	 breast	 cancer	 (Patrawala	 et	 al.,	 2005;	 Nakanishi	 et	 al.,	 2010;	
Britton	et	al.,	2012).	
	
The	 elucidation	 of	 the	 hierarchical	 self-renewal	 process	 employed	 by	 stem	 cell	
populations	 resulted	 in	 the	 development	 of	 pulse-chase	 label-retention	 approach	 to	
identification	 and	 isolation	 of	 quiescent	 CSCs.	 In	 early	 studies	 that	 employed	 this	
technique,	 cells	 were	 initially	 labelled	 with	 either	 tritiated	 thymidine	 (3H-TdR)	 or	 5-
	 77	
bromo-2-deoxyuridine	 (BrdU)	 which	 then	 partition	 equally	 between	 dividing	 transit	
amplifying	 cells	 and	 their	 progeny	 on	 subsequent	 cell	 divisions	 resulting	 in	 an	
exponential	 decrease	 in	 signal	 intensity;	 as	 a	 result	 of	 their	 mitotically	 quiescent	
nature,	 stem	cells	 retain	 their	 initial	 label	and	 therefore	 remain	 identifiable	amongst	
the	non-label	 retaining	population	 (Cotsarelis	et	al.,	1990;	Potten	et	al.,	1992).	More	
recently,	nucleotide	analogues	such	as	3H-TdR	and	BrdU,	which	require	cell	membrane	
permeabilisation	and	antibody	labelling	for	their	detection,	have	been	superseded	by	
lipophilic	fluorescent	membrane	dyes	for	this	purpose,	thereby	enabling	live	sorting	of	
cells	for	subsequent	study	(Figure	3.1.).	
	
	
	
	
Figure	3.1.	Detection	of	Quiescent	Cells	by	Lipophilic	Dye	Label-Retention	Assay	
Cell	cultures	are	initially	labelled	homogenously	with	a	highly	lipophilic	fluorescent	dye.	The	dye	label	is	
then	 subsequently	 lost	 from	 the	 rapidly	 dividing	 bulk	 cell	 population	 by	 progressive	 dilution	 during	
subsequent	mitotic	divisions	while	slowly	dividing	or	mitotically	quiescent	cells	remain	identifiable	as	a	
persistent	bright	fluorescent	signal	over	time.	
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Using	 this	 approach,	 Yumoto	 et	 al.	 (2014)	 described	 the	 identification	 of	 a	 slowly	
cycling	sub-population	 in	a	number	of	human	prostate	cancer	cell	 lines	based	on	the	
persistent	 retention	 of	 the	 lipophilic	 tracer	 dye	 Vybrant®	 DiD.	 Expanding	 on	 these	
findings,	Wang	et	al.	(2015a)	demonstrated	that	the	label-retaining	quiescent	prostate	
cancer	 cell	 population	 possessed	 a	 unique	 gene	 expression	 profile,	 mimicking	 the	
deployment	 of	 a	 number	 of	 haematopoietic	 stem	 cell	 niche-associated	 markers.	 In	
addition,	these	cells	were	found	to	be	significantly	more	bone	tropic	and	tumourigenic	
in	 vivo	 compared	 to	 the	 rapidly	 dividing	 cell	 population	 isolated	 from	 the	 same	
parental	 culture.	 Label-retaining	 cells	 did	 however	 lack	 differential	 expression	 of	
commonly	used	prostate	cancer	stem	cell	markers	(CD133,	CD44	and	α2/β1	integrins),	
suggesting	that	mitotic	quiescence	is	associated	with	a	unique	phenotype	that	partially	
overlaps	 with	 stemness	 defined	 by	 cell	 surface	 marker	 expression.	 Similar	 findings	
were	reported	in	a	study	of	pancreatic	adenocarcinoma	undertaken	by	Dembinski	and	
Krauss	 (2009).	 In	 this	 study,	 a	 slow-cycling	 label-retaining	 population	 comprising	
approximately	3%	of	 total	cell	mass	was	shown	to	possess	a	 fibroblastic	morphology	
and	marker	profile	 indicative	of	 epithelial-mesenchymal	 transition,	were	 significantly	
more	 invasive	 in	 vitro,	 and	were	 ten-times	more	 tumourigenic	 in	 vivo	 than	 the	non-
label	 retaining	 population.	 Interestingly,	 when	 assessed	 for	 common	 CSC	 surface	
markers,	label-retaining	cells	were	enriched	for,	but	only	partially	overlapped	with,	the	
common	 CD24+CD44+CD133+	 marker	 profile	 thought	 to	 demark	 pancreatic	 cancer	
stem	cells.	
	
In	breast	cancer,	use	of	the	 lipophilic	membrane	dye	retention	technique	has	almost	
entirely	 been	 restricted	 to	 retrospective	 validation	 of	 putative	 cancer	 stem	 cell	
populations	 isolated	 using	 cell	 surface	 markers.	 Quiescent	 breast	 tumour	 cell	
populations	have	therefore	remained	relatively	poorly	characterised	and	the	degree	of	
non-mutual	 exclusivity	 between	 this	 population	 and	 stem-like	 cells	 isolated	 using	
common	surface	marker	profiles	unexplored.	As	a	consequence,	 it	 is	entirely	feasible	
that	our	current	understanding	of	breast	cancer	stem	cell	biology	is	not	truly	reflective	
of	 the	 entire	 CSC	 population	 and	 the	 true	 potential	 for	 their	 therapeutic	 targeting	
remains	only	partially	realised.	
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3.3. Aims,	Hypothesis	and	Objectives	
	
The	 aim	 of	 the	work	 described	 in	 this	 chapter	was	 to	 establish	 a	 robust	 and	 highly	
reproducible	 in	 vitro	 model	 system	 enabling	 the	 isolation	 and	 subsequent	
characterisation	of	mitotically	quiescent	breast	cancer	cells.	
	
The	key	hypothesis	pertaining	to	the	work	described	 in	this	chapter	was	that	human	
breast	 cancer	 cell	 lines	 contain	 a	 latent	 mitotically	 quiescent	 sub-population	 that	
persists	amongst	the	rapidly	dividing	bulk	cell	population.	
	
The	following	objectives	were	defined	in	order	to	test	this	hypothesis:	
	
1. Characterise	 the	 growth	 kinetics	 of	 a	 panel	 of	 human	 breast	 cancer	 cell	 lines	 in	
order	to	facilitate	definition	of	the	interval	at	which	lipophilic	dye	retention	would	
be	measured	in	each	case.	
	
2. Determine	 the	 suitability	 of	 select	 fluorescent	 lipophilic	 tracer	 dyes	 for	 the	
application	of	detecting	mitotically	quiescent	cells.	
	
3. Establish	 whether	 or	 not	 a	 quiescent	 sub-population	 was	 existent	 within	 each	
model	cell	line	by	pulse-chase	analysis	of	fluorescent	lipophilic	tracer	dye	labelling.	
	
4. Determine	whether	dye-retaining	cells	were	senescent,	absolutely	quiescent	(non-
senescent	and	non-dividing)	or	relatively	quiescent	(slowly	cycling).	
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3.4. Method	Development	and	Results	
	
3.4.1. Characterising	the	Growth	of	Breast	Cancer	Cell	Lines	in	Monolayer	Culture	
	
Establishing	the	growth	characteristics	of	a	model	cell	culture	under	optimal	conditions	
facilitates	comparison	of	the	effects	of	exogenous	factors	to	an	established	baseline.	In	
addition,	the	descriptive	statistics	that	describe	the	growth	profile	of	any	given	culture	
can	 be	 used	 to	 inform	 subsequent	 experimental	 procedures.	 The	 growth	 profiles	 of	
MCF-7,	 ZR-75-1,	MDA-MB-231,	MDA-MB-468	 and	 SK-BR-3	 human	 breast	 cancer	 cell	
lines	 were	 therefore	 established	 initially.	 Growth	 profiles	 were	 constructed	 by	
monitoring	the	number	of	viable	cells	present	within	each	culture	at	24-hour	intervals	
post-seeding	 according	 to	 the	 methods	 described	 in	 Section	 2.2.5.	 The	 resultant	
growth	curves	are	depicted	in	Figure	3.2.	
	
All	growth	profiles	largely	followed	the	classic	sigmoidal	pattern.	In	each	case,	an	initial	
period	of	delayed	growth	(lag	phase)	was	followed	by	a	rapid	 increase	 in	the	culture	
growth	rate	that	preceded	a	period	of	 linear	expansion	of	viable	cell	number	 in	each	
culture	 over	 time	 (logarithmic	 phase).	 Gradually,	 a	 reduction	 in	 the	 rate	 of	 culture	
expansion	 was	 recorded	 in	 all	 instances,	 likely	 due	 to	 the	 exhaustion	 of	 available	
nutrients	 and	 a	 build-up	 of	 waste	 metabolites	 in	 the	 culture	 medium	 (stationary	
phase).	 In	 the	 case	 of	MDA-MB-231,	MDA-MB-468	 and	 SK-BR-3	 cell	 lines,	 a	 decline	
phase	 was	 also	 evident	 at	 later	 time-points,	 during	 which	 there	 was	 a	 progressive	
reduction	in	the	number	of	viable	cells	present	within	cultures.	Growth	profiles	were	
used	to	define	the	time	of	onset,	end-point	and	duration	of	the	 logarithmic	phase	of	
growth	and	 the	 log-phase	doubling	 time	of	 the	 respective	 culture.	 These	descriptive	
parameters	are	summarised	for	each	model	cell	line	in	Table	3.1.	Growth	profiles	were	
also	 used	 to	 define	 the	 time-point	 at	 which	 cultures	 were	 approximately	 80%	
confluent	 and	 at	 which	 sub-culture	 would	 therefore	 be	 undertaken	 during	 routine	
maintenance	 and	 pulse-chase	 experiments.	 The	 respective	 sub-culture	 interval	 for	
each	cell	line	is	displayed	in	Table	3.1.	
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Figure	3.2.	Model	Cell	Line	Growth	Curves	
The	proliferation	curves	for	the	MCF-7,	MDA-MB-231,	MDA-MB-468,	SK-BR-3	and	ZR-75-1	human	breast	
cancer	cell	lines	are	shown;	the	number	of	viable	cells	(Y-axis)	is	plotted	against	the	duration	of	culture	
post-seeding	(X-axis)	in	each	case.	Data	are	expressed	as	the	mean	average	±	SEM	for	n	=	3	biologically	
independent	repeat	experiments.	
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Table	3.1.	Summary	of	Descriptive	Statistics	for	Model	Culture	Growth	Curves	
	
Cell	Line	
	
MCF-7	 ZR-75-1	 MDA-MB-468	 MDA-MB-231	 SK-BR-3	
	
Molecular	Sub-Type	
	
Luminal	A	 Luminal	B	 Basal	 Claudin	Low	 HER-2	
Log-Phase	Start	
(Hours)	 24	 24	 48	 24	 48	
Log-Phase	End	
(Hours)	 96	 168	 144	 96	 144	
Log-Phase	Duration	
(Hours)	 72	 144	 96	 72	 96	
Log-Phase	Doubling	Time	
(Hours)	 25	 60	 36	 17	 44	
Sub-Culture	Interval	
(Hours)	 96	 144	 120	 72	-	96	 120	
	
The	descriptive	statistics	describing	the	key	features	of	the	respective	growth	curve	for	each	model	cell	
line	are	shown.	All	times	displayed	are	stated	to	the	nearest	24-hour	period,	as	determined	graphically,	
with	the	exception	of	 the	 log-phase	doubling	time	which	was	calculated	as	described	 in	Section	2.2.5.	
using	graphically	determined	input	variables.	
	
3.4.2. Selection	of	Tracer	Dyes	for	Identification	of	Quiescent	Sub-Clones	
	
The	 lipid	 intercalating	 long	 alkyl	 side-chain	 carbocyanine	 derivatives,	 such	 as	 the	
Vybrant®	dye	 series,	 and	 the	 structurally	 related	PKH	dye	 series	 are	by	 far	 the	most	
frequently	 used	 supravital	 lipophilic	 fluorochromes	 for	 cell	 tracing	 and	 tracking	
applications	 in	cancer	 studies	 (Progatzky	 et	al.,	2013;	 Luo	 et	al.,	2015).	Dyes	of	both	
series	 are	 stably	 incorporated	 into	 the	 lipid	 bilayer	 of	 cell	 membranes	 and	
subsequently	 diffuse	 laterally	 to	 result	 in	 uniform	 staining	 of	 individual	 cells	 and	
homogenous	staining	of	cultures.	When	present	within	biological	membranes,	dyes	of	
both	series	characteristically	exhibit	strong	fluorescence	and	photostability	as	a	result	
of	 their	 extremely	 high	 extinction	 coefficients,	 modest	 quantum	 yields,	 and	 short	
excited-state	 lifetimes	within	 lipid	environments,	making	 their	 lipid	 intercalating	 and	
photochemical	 properties	 ideally	 suited	 to	 long-term	 lineage	 tracing	 applications	
(Horan	 and	 Slezak,	 1989;	 Samlowski	 et	 al.,	 1991).	 However,	 the	 potential	 for	
confounding	 results	 due	 to	 inadvertent	 lateral	 dye	 transfer,	 cytotoxicity	 and	 loss	 of	
cellular	 function	 following	 initial	 staining	 is	 greater	 when	 using	 PKH	 rather	 than	
Vybrant®	 dyes	 based	 on	 literary	 reports	 (Li	 et	 al.,	 2013;	 Progatzky	 et	 al.,	 2013).	 In	
addition,	the	initial	labelling	of	cells	with	PKH	dyes	requires	resuspension	of	cells	in	an	
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isosmotic	 mannitol-based	 loading	 medium	 while	 the	 Vybrant®	 dyes	 can	 be	 added	
directly	to	culture	medium,	making	handling	less	complicated	and	permitting	uniform	
labelling	of	cells	either	in	suspension	or	when	growing	as	adherent	monolayers	(Honig	
and	Hume,	1986).	The	Vybrant®	dyes	DiO,	CM-DiI	and	DiD	were	therefore	chosen	for	
further	 assessment	 of	 their	 suitability	 for	 tracing	 mitotically	 quiescent	 cells	 (Figure	
3.3.).	Vybrant®	CM-DiI	 is	a	modified	analogue	of	Vybrant®	DiI	 that	exhibits	 the	same	
photochemical	 properties	 but	 incorporates	 a	 thiol-reactive	 chloromethylbenzamido	
group.	Unlike	Vybrant®	DiI	and	the	equivalent	PKH26,	Vybrant®	CM-DiI	 is	 retained	 in	
cells	 following	 aldehyde	 fixation	 and	 permeabilisation	 procedures	 as	 a	 result	 of	 dye	
conjugation	 to	 membrane-bound	 sulfhydryl-containing	 peptides	 and	 proteins	
(Andrade	et	al.,	1996).	Owing	to	the	potential	utility	of	these	additional	properties	 in	
later	experiments,	Vybrant®	CM-DiI	was	chosen	for	initial	assessment	of	suitability	for	
mitotically	quiescent	cell	tracing	over	Vybrant®	DiI.	
	
	
	
Figure	3.3.	Fluorescence	Spectra	of	Vybrant®	Lipophilic	Tracer	Dyes	
Vybrant®	 dyes	 DiO	 (Ex.	 484,	 Em.	 501),	 CM-DiI	 (Ex.	 549,	 Em.	 565)	 and	 DiD	 (Ex.	 644,	 Em.	 665)	 exhibit	
green,	orange-red	and	far-red	fluorescence	respectively.	DiO	and	CM-DiI	are	detectable	using	standard	
fluorescein	and	rhodamine	optical	filters	while	DiD	has	much	longer-wavelength	excitation	and	emission	
spectra	and	requires	a	670nm	long-pass	optical	filter	or	a	close	equivalent	for	detection.	Original	image	
generated	 using	 Thermo	 Fisher	 Scientific	 Fluorescence	 SpectraViewer	 available	 at	
https://www.thermofisher.com/uk/en/home/lifescience/cellanalysis/labelingchemistry/fluorescence-
spectraviewer.html	-	Last	Accessed:	01/08/2017.	
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3.4.2.1. Cytofluorimetric	Assessment	of	Vybrant®	Dye	Staining	
	
The	identification	of	mitotically	quiescent	cells	by	label	retention	methods	is	reliant	on	
the	persistent	 retention	of	a	bright	 fluorescent	 label	 following	 loss	of	 this	 label	 from	
the	 mitotically	 active	 bulk	 cell	 population	 after	 numerous	 passages	 of	 continuous	
culture.	Homogenous	initial	staining	of	cultures	and	the	brightness	of	staining	are	the	
two	critical	considerations	when	assessing	the	staining	produced	by	a	fluorescent	dye.	
The	suitability	of	the	Vybrant®	dyes	DiO,	CM-DiI	and	DiD	for	tracing	quiescent	cells	was	
therefore	initially	assessed	for	the	ability	to	homogenously	stain	cells	and	the	relative	
brightness	of	the	staining	produced.	
	
MDA-MB-231	cells	were	stained	in	suspension	according	to	the	supplier	instructions	as	
detailed	 in	 Section	 2.3.1.	 and	 were	 analysed	 cytofluorimetrically	 immediately	 after	
staining.	During	 flow	 cytometric	 analyses,	 single	 live	 cell	 events	were	determined	as	
described	 in	 Section	 2.5.1.	 Negativity	 was	 defined	 as	 having	 the	 same	 fluorescence	
profile	 in	 the	 respective	 detector	 channel	 as	 an	 unlabelled	 sample	 of	 cells	 while	
positivity	 was	 initially	 defined	 by	 events	 possessing	 relative	 fluorescence	 exceeding	
that	of	events	within	the	negative	gate	(Figure	3.4.).	
	
	
Figure	3.4.	Cytofluorimetric	Analysis	of	Newly	Vybrant®	Dye-Stained	Samples	
Gates	for	the	analysis	of	Vybrant®	dye	labelling	were	initially	defined	by	the	fluorescence	profile	of	an	
unlabelled	sample	when	the	detector	channel	voltage	was	adjusted	to	centre	this	population	in	the	first	
decade	of	the	respective	graphical	output.	The	fluorescence	profiles	of	samples	stained	with	Vybrant®	
DiO	(A)	Vybrant®	CM-DiI	(B)	and	Vybrant®	DiD	(C)	immediately	after	labelling	are	shown.	
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The	 percentage	 of	 positive	 events	 within	 freshly	 labelled	 samples	 can	 be	 used	 to	
provide	 an	 indication	 of	 homogeneity	 of	 staining	 while	 the	 fold-change	 in	 median	
fluorescence	intensity	(MFI)	of	stained	samples	relative	to	unlabelled	control	samples	
can	provide	an	indication	of	relative	brightness	of	staining.	The	staining	index	(Figure	
3.5.)	is	a	more	comprehensive	assessment	of	relative	brightness	that	accounts	for	peak	
separation,	 which	 is	 dictated	 by	 the	 width	 of	 the	 negative	 peak	 produced	 by	 the	
unlabelled	control	sample.	Comparison	of	staining	indices	calculated	for	Vybrant®	DiO,	
CM-DiI	 and	 DiD	 based	 on	 initial	 staining	 are	 displayed	 in	 Figure	 3.6.	 Representative	
images	of	initial	staining	of	MDA-MB-231	cells	are	also	depicted	in	Figure	3.6.	
	
	
Figure	3.5.	Calculation	of	Staining	Index	
Staining	 index	 is	 calculated	 as	 the	 ratio	 of	 the	 difference	 in	 negative	 and	 positive	 peak	 median	
fluorescence	 intensity	 (MFI)	 (D)	 and	 the	 width	 of	 the	 negative	 peak	 (W),	 which	 is	 twice	 the	 robust	
standard	deviation.	The	width	of	the	negative	peak	affects	the	separation	of	the	positive	and	negative	
signals;	 as	 exemplified	 by	 the	 figure,	 a	 sample	 with	 a	 narrow	 spread	 (W1)	 and	 a	 wide	 spread	 (W2)	
possess	 the	 same	 MFI	 but	 different	 staining	 indices,	 making	 staining	 index	 the	 preferred	 means	 of	
comparing	fluorophore	staining	brightness.	
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Figure	3.6.	Initial	Staining	of	MDA-MB-231	Cultures	by	Vybrant®	Dyes	
A:	The	percentage	of	stained	viable	cells	 is	 shown	for	each	of	 the	Vybrant®	dyes	DiO,	CM-DiI	and	DiD	
immediately	after	staining	was	undertaken.	B:	The	 fold-change	 in	median	 fluorescence	 intensity	 (MFI)	
relative	 to	 cellular	 autofluorescence	 in	 the	appropriate	 flow	cytometer	detector	 channel	 is	 shown	 for	
each	 dye.	 C:	 Staining	 indices	 calculated	 for	 initial	 staining	 of	 Vybrant®	 dyes	 compared	 to	 unlabelled	
controls.	 Data	 are	 expressed	 as	 the	 mean	 average	 ±	 SEM	 for	 n	 =	 3	 biologically	 independent	 repeat	
experiments.	 D:	 Representative	 images	 of	 initial	 staining	 produced	 by	 Vybrant®	 DiO	 (top)	 CM-DiI	
(middle)	and	DiD	(bottom).	All	images	were	captured	using	a	10x	objective	lens	(scale	bar	=	100μm).	
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All	dyes	initially	stained	100%	of	cells	when	gating	during	flow	cytofluorimetric	analysis	
was	set	as	described	in	Figure	3.4.	The	average	fold-change	in	MFI	for	samples	labelled	
with	Vybrant®	DiO-	and	Vybrant®	CM-DiI	was	469	and	211	times	that	of	an	unstained	
sample,	 respectively,	 while	 samples	 labelled	 with	 Vybrant®	 DiD	 showed	 an	 average	
632-fold	increase	in	MFI.	All	stained	samples	were	measured	relative	to	an	unlabelled	
MDA-MB-231	sample,	meaning	that	the	negative	peak	in	all	cases	was	very	similar	and	
that	 staining	 index	was	 therefore	primarily	 reliant	on	MFI.	As	a	 result,	both	MFI	and	
staining	index	measurements	follow	the	same	pattern	and	indicated	that	Vybrant®	DiD	
resulted	in	the	brightest	labelling	of	cultures.	
	
Based	 solely	 on	 the	 assessment	 of	 their	 initial	 staining	 characteristics,	 any	 of	 the	
Vybrant®	dyes	used	might	have	been	suitable	for	long-term	tracer	applications;	each	of	
the	three	dyes	tested	demonstrated	homogenous	and	relatively	bright	initial	staining.	
However,	 while	 no	 significant	 effects	 on	 breast	 cancer	 cell	 growth	 or	 function	 has	
previously	 been	 reported,	 some	 carbocyanine	 dyes	 have	 been	 shown	 to	 cause	
concentration-dependent	 inhibition	 of	 the	 mitochondrial	 electron	 transport	 chain,	
thereby	 having	 the	 potential	 to	 impact	 cell	 growth	 and	 functions	 such	 as	 motility	
(Anderson	and	Trgovcich-Zacok,	1995).	 It	was	deemed	prudent	 to	 first	ascertain	 that	
Vybrant®	dye	staining	did	not	impact	the	growth	or	basic	functional	characteristics	of	
stained	 cells	 before	 selecting	 a	 dye	 for	 use	 in	 identifying	mitotically	 quiescent	 cells,	
due	 to	 the	 requirement	 to	 identify	 an	 intrinsic	 sub-population	 without	 altering	 the	
inherent	properties	of	the	parent	culture.	
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3.4.2.2. Establishing	the	Effects	of	Vybrant®	Dye	Staining	on	Cell	Function	
	
The	 growth	 profile	 of	 MDA-MB-231	 human	 breast	 cancer	 cells	 was	 established	
following	 staining	 with	 Vybrant®	 DiO,	 CM-DiI	 and	 DiD.	 The	 growth	 profile	 of	 each	
stained	culture	was	compared	to	the	growth	profile	obtained	for	an	unstained	control	
sample	grown	under	identical	conditions	in	order	to	determine	whether	staining	with	
Vybrant®	 dyes	 significantly	 altered	 culture	 growth.	 Samples	 of	 1.0	 x	 106	 cells	 were	
prepared	in	serum-free	basal	culture	medium	and	stained	in	suspension	according	to	
the	 supplier	 instructions	 (Section	 2.3.1.).	 Stained	 cells	 were	 seeded	 at	 the	 optimal	
density	 and	 growth	 profiles	 established	 by	 monitoring	 the	 number	 of	 viable	 cells	
present	within	 each	 culture	 at	 24-hour	 intervals	 post-seeding,	 as	 detailed	 in	Section	
2.2.5.	 The	 results	 are	 displayed	 in	 Figure	 3.7.	 The	 intrinsic	 growth	 characteristics	 of	
MDA-MB-231	 cells	 remained	unaltered	 following	 staining	with	Vybrant®	DiO,	CM-DiI	
and	DiD;	 there	was	no	 significant	difference	 in	 the	number	of	viable	cells	present	at	
any	 time	 point	 following	 staining	 across	 all	 three	 of	 the	 dyes	 tested.	 This	 lack	 of	
alteration	 to	 the	 inherent	 growth	 properties	 indicated	 no	 evidence	 of	 cytotoxicity	
following	Vybrant®	dye	staining.	While	these	results	suggested	it	was	also	unlikely	that	
Vybrant®	 dye	 staining	 would	 have	 any	 profound	 effect	 on	 other	 basic	 functional	
properties	 of	 cell	 behaviour,	 colony	 forming	 ability	 and	 migratory	 capability	 were	
subsequently	assayed	to	ensure	that	this	was	the	case.	
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Figure	3.7.	Growth	Profiles	of	Vybrant®	Dye-Stained	MDA-MB-231	Cultures	
The	 growth	 profiles	 of	 unstained	 and	 Vybrant®	 DiO-,	 CM-DiI-	 and	 DiD-stained	 MDA-MB-231	 human	
breast	cancer	cells	grown	in	vitro	as	adherent	monolayer	cultures	are	shown;	viable	cell	count	(Y-axis)	is	
plotted	 against	 the	 duration	 of	 culture	 (X-axis)	 in	 each	 case.	 Data	 obtained	 for	 stained	 cultures	 was	
compare	 to	 those	 recorded	 for	 unstained	 cultures	 using	 two-way	 ANOVA	 followed	 by	 Dunnett’s	
Multiple	 Comparison	 Test.	 No	 statistically	 significant	 difference	 was	 found	 between	 unstained	 and	
stained	samples	at	any	time	point.	Data	are	expressed	as	the	mean	average	±	SEM	for	n	=	3	biologically	
independent	repeat	experiments.	
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Colony	 forming	 ability	 of	 Vybrant®	DiO-,	 CM-DiI-	 and	DiD-stained	MDA-MB-231	 cells	
was	 assessed	 in	 order	 confirm	 the	 findings	 of	 proliferation	 assays	 and	 thereby	
demonstrate	that	staining	does	not	significantly	affect	cell	growth	capability.	Samples	
of	1.0	x	106	MDA-MB-231	cells	were	prepared	in	serum-free	basal	culture	medium	and	
stained	 in	 suspension	 according	 to	 the	 supplier	 instructions	 (Section	 2.3.1.).	 Stained	
cells	were	seeded	at	a	clonogenic	density	of	20	cells	per	cm2	of	growth	area	 in	high-
quality	polystyrene	60mm	tissue	culture	dishes,	supplemented	with	0.2ml	of	complete	
growth	medium	per	cm2	and	placed	into	incubation	under	standard	growth	conditions	
for	 6	 days;	 a	 time	 period	 covering	 at	 least	 six	 log-phase	 doubling	 times,	 which	 for	
MDA-MB-231	cells	was	previously	determined	as	approximately	17	hours.	The	number	
of	 colonies	 formed	by	unstained	 and	 stained	 cells	was	 established	 following	 fixation	
and	 crystal	 violet	 staining	 as	 described	 in	 Section	 2.2.6.1.	 The	 results,	 depicted	 in	
Figure	 3.8.,	 demonstrated	 no	 significant	 difference	 in	 the	 colony	 forming	 ability	 of	
Vybrant®	 DiO-	 CM-DiI-	 or	 DiD-stained	 cells	 compared	 to	 unstained	 control	 cells,	
supporting	 the	 findings	 of	 proliferation	 assays	 which	 indicated	 that	 Vybrant®	 dye	
staining	did	not	alter	cell	growth.	
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Figure	3.8.	Clonogenic	Assays	for	Vybrant®	Dye-Stained	MDA-MB-231	Cells	
A:	The	number	of	colonies	formed	by	Vybrant®	DiO-,	CM-DiI-	and	DiD-stained	MDA-MB-231	cells	were	
compared	to	data	obtained	for	unstained	cells	grown	under	identical	conditions	using	one-way	ANOVA	
followed	 by	 Dunnett’s	 Multiple	 Comparison	 Test.	 No	 statistically	 significant	 difference	 was	 found	
between	 stained	 and	 unstained	 groups.	 Data	 are	 expressed	 as	 the	 mean	 average	 ±	 SEM	 for	 n	 =	 3	
biologically	 independent	 repeat	 experiments.	 B:	 Representative	 images	 of	 a	 crystal	 violet-stained	
clonogenic	assay	plates	 for	unstained	and	Vybrant®	DiO-,	CM-DiI-	and	DiD-stained	MDA-MB-231	cells.	
All	images	were	captured	using	a	2x	stereomicroscopic	objective	lens.	
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In	order	 to	determine	whether	Vybrant®	dye	 staining	 inhibits	 the	 intrinsic	 functional	
behaviour	of	cells,	such	as	motility	and	migratory	capability,	scratch	closure	migration	
assays	were	undertaken	post-staining	with	Vybrant®	dyes.	The	general	scratch	closure	
assay	procedure	can	be	found	in	Section	2.2.7.	Briefly,	samples	of	1.0	x	106	MDA-MB-
231	cells	were	prepared	in	serum-free	basal	culture	medium	and	stained	in	suspension	
according	to	the	supplier’s	instructions	(Section	2.3.1.).	Stained	cells	were	seeded	at	a	
density	 of	 7.7	 x	 105	 into	 triplicate	 wells	 of	 6-well	 culture	 plates	 and	 placed	 into	
incubation	 for	a	period	of	24	hours	 to	 form	a	confluent	monolayer.	Cell	 growth	was	
subsequently	arrested	by	incubation	under	standard	growth	conditions	for	3	hours	in	
the	 presence	 of	 the	 potent	 DNA	 cross-linking	 agent	Mitomycin	 C.	 The	Mitomycin	 C	
solution	was	removed	before	a	linear	scratch	was	made	in	the	monolayer	using	a	200μl	
pipette	tip.	Each	well	was	then	washed	in	order	to	completely	remove	cell	debris.	Two	
reference	 points	were	marked	 at	 either	 end	 of	 the	 scratch	 on	 the	 underside	 of	 the	
plate	 under	 low-magnification	 (50X)	 inverted	 phase-contrast	 microscopy	 using	 a	
permanent	marker	 pen.	 Images	were	 immediately	 captured	 at	 each	 reference	 point	
under	 inverted	phase-contrast	microscopy	at	 100X	magnification	and	 further	 images	
captured	after	24	hours.	The	area	of	the	scratch	within	each	image	field	was	measured	
using	 the	open-source	 image	analysis	platform	 ImageJ	as	described	 in	Section	 2.2.7.	
and	 the	 percentage	 closure	 over	 the	 assay	 time	 period	 calculated.	 The	 results	 are	
depicted	in	Figure	3.9.	No	significant	difference	in	the	migratory	capability	of	cells	was	
found	post-staining	with	Vybrant®	DiO,	CM-DiI	and	DiD.	
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Figure	3.9.	Migration	Assays	for	Vybrant®	Dye-Stained	MDA-MB-231	Cells	
A:	The	migratory	capability	of	Vybrant®	DiO-,	CM-DiI-	and	DiD-stained	MDA-MB-231	cells	assessed	by	
scratch	 closure	 assay	 was	 compared	 to	 data	 obtained	 for	 unstained	 cells	 grown	 under	 identical	
conditions	 using	 one-way	 ANOVA	 followed	 by	 Dunnett’s	 Multiple	 Comparison	 Test.	 No	 statistically	
significant	 difference	 was	 found	 between	 stained	 and	 unstained	 groups.	 Data	 are	 expressed	 as	 the	
mean	average	±	SEM	for	n	=	3	biologically	independent	repeat	experiments.	B:	Representative	examples	
of	 images	 taken	 during	 the	 scratch	 closure	 assay	 of	 unstained	 and	 Vybrant®	 DiO-,	 CM-DiI-	 and	 DiD-
stained	MDA-MB-231	cells	immediately	after	the	scratch	was	established	and	then	at	a	subsequent	24	
hour	time-point.	All	images	were	captured	using	a	10x	objective	lens	(scale	bar	=	100μm).	
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Based	 on	 the	 results	 of	 proliferation,	 colony	 formation	 and	migration	 assays	 it	 was	
possible	to	conclude	that	any	inhibition	of	the	mitochondrial	electron	transport	chain	
that	might	have	occurred	as	a	 result	of	 staining	with	 carbocyanine-derived	Vybrant®	
dyes,	 as	 was	 reported	 by	 Anderson	 and	 Trgovcich-Zacok	 (1995),	 did	 not	 result	 in	
altered	cell	culture	growth,	colony	formation	or	migratory	capability.	The	assessment	
of	 cytofluorimetric	 staining	 indicated	 that	any	of	 the	dyes	assayed	might	be	 suitable	
for	 use	 in	mitotically	 quiescent	 cell	 tracing	 applications	 and	 these	 data	 support	 this	
conclusion.	Vybrant®	DiD	was	chosen	over	Vybrant®	DiO	and	CM-DiI	for	routine	use	in	
lipophilic	dye	retention	pulse-chase	assays.	This	decision	was	made	based	on	the	fact	
that	 initial	 staining	 with	 Vybrant®	 DiD	 was	 more	 homogenous	 and	 considerably	
brighter	 than	 that	 resulting	 from	 the	 use	 of	 DiO	 and	 CM-DiI,	 making	 Vybrant®	 DiD	
better	suited	to	long-term	cell	tracing.	
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3.4.3. Identifying	Dye-Retaining	Sub-Clones	in	Human	Breast	Cancer	Cell	Lines	
	
Cells	were	initially	stained	in	suspension	with	Vybrant®	DiD	according	to	the	supplier's	
instructions	 as	 detailed	 in	 Section	 2.3.1.	 At	 the	 outset	 of	 each	 dye-retention	 assay,	
flow	cytometric	calibration	and	setting	of	gates	for	detection	of	positively	labelled	cells	
was	 undertaken	 using	 an	 unlabelled	 sample	 and	 a	 freshly	 labelled	 sample	 of	 cells.	
During	flow	cytometric	analyses,	single	live	cell	events	were	determined	as	described	
in	Section	2.5.1.	The	gates	defining	event	negativity	and	positivity	were	set	according	
to	 the	 fluorescence	profile	 of	 an	unlabelled	 sample	 and	 a	 freshly	 labelled	 sample	of	
cells,	respectively,	in	the	appropriate	detector	channel	(Figure	3.10.).	
	
	
Figure	3.10.	Cytofluorimetric	Detection	of	Dye-Retaining	Sub-Clones	
A:	 The	 flow	 cytometer	was	 initially	 calibrated	 for	 detection	 of	 negatively	 and	 positively	 labelled	 cells	
using	an	unlabelled	sample	(grey)	and	a	freshly	labelled	sample	(red),	respectively.	B:	Stained	samples	of	
cells	were	continuously	cultured	for	up	to	six	consecutive	passages	and	the	percentage	positivity	at	any	
given	sub-culture	 interval	determined	using	the	 initial	gate	configuration	defined	for	 that	dye	and	cell	
line.	Over	time,	the	initial	positive	fluorescence	peak	migrated	to	the	left	towards,	and	eventually	into,	
the	negative	gate	as	 the	 fluorescence	 intensity	of	 rapidly	dividing	cells	was	 lost,	 leaving	only	 the	 least	
mitotically	active	cells	in	the	positive	gate.	
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Following	 definition	 of	 the	 flow	 cytofluorimetric	 gating	 strategy,	 stained	 cells	 and	
unlabelled	 controls	 to	 be	 grown	 concomitantly	were	 seeded	 at	 the	 cell	 line	 specific	
optimal	density	and	maintained	as	described	in	Section	2.2.1.1.	At	the	pre-determined	
sub-culture	 interval	 (Table	 3.1.),	 cells	 were	 retrieved	 and	 counted	 as	 detailed	
previously	(Section	2.2.1.2.	and	Section	2.2.3.).	At	each	sub-culture,	samples	of	1.0	x	
106	cells	were	prepared	for	cytofluorimetric	analysis	by	undertaking	centrifugation	at	
150	x	g	for	5	minutes	followed	by	resuspension	in	serum-free	basal	medium.	Samples	
were	 analysed	 to	 determine	 the	 percentage	 of	 positive	 events	 present	 within	 each	
sample	 using	 the	 gating	 tree	 pre-set	 at	 the	 beginning	 of	 the	 experiment.	 The	
percentage	 positivity	 of	 each	 cell	 line	 was	 monitored	 in	 this	 way	 for	 up	 to	 six	
consecutive	passages	of	growth;	the	results	are	depicted	in	Figure	3.11.	-	Figure	3.15.	
inclusive.	 Fluorescence	 photomicroscopy	 was	 also	 undertaken	 in	 order	 to	 visually	
demonstrate	the	changes	in	Vybrant®	DiD	staining	of	cultures	over	the	duration	of	dye	
retention	assays.	Representative	images	are	depicted	within	the	respective	figure.	
	
When	 grown	 as	 adherent	 monolayer	 cultures,	 a	 dye-retaining	 sub-population	 was	
identified	within	each	of	the	MCF-7,	ZR-75-1,	MDA-MB-231,	MDA-MB-468	and	SK-BR-3	
cell	 lines.	 Initial	 staining	 in	 all	 cultures	 resulted	 in	 100%	 of	 cells	 being	 labelled	with	
Vybrant®	 DiD.	 In	 all	 cases,	 a	 steep	 decline	 in	 the	 positively	 labelled	 population	
occurred	 at	 passage	 3	 and	 continued	 until	 passage	 5,	 at	 which	 the	 rate	 of	 dye	 loss	
reduced.	Dye-retaining	sub-clones	comprised	<	0.5%	of	the	total	cell	population	at	the	
final	 passage	 of	 dye	 measurement	 across	 all	 cell	 lines.	 In	 all	 cases,	 there	 was	 a	
statistically	 significant	 reduction	 in	 the	 median	 fluorescence	 intensity	 (relative	
brightness)	 of	 the	Vybrant®	DiD-positive	 population,	 falling	 from	approximately	 260,	
000	relative	fluorescence	units	(RFU)	at	passage	0	to	between	20,000	and	10,000	RFU	
between	passages	0	and	6	(P	≤	0.0001).	Whether	these	dye-retaining	cells	represent	a	
phenotypically	distinct	population	and	whether	they	possess	stem	cell-like	properties	
(such	as	the	ability	to	survive	chemotherapy	and	repopulate	the	cancer	cell	population	
post-cessation	of	treatment)	will	be	explored	in	subsequent	chapters.	
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Figure	3.11.	Dye-Retaining	Cell	Frequency	in	the	MCF-7	Cell	Line	
A:	 The	 percentage	 of	 Vybrant®	DiD-stained	MCF-7	 cells	 in	 adherent	monolayer	 cultures	 grown	under	
optimal	conditions	was	measured	at	the	time	of	sub-culture	undertaken	at	96	hour	intervals.	Data	are	
expressed	as	the	mean	average	±	SEM	for	n	=	3	biologically	independent	repeat	experiments;	the	mean	
average	 value	 is	 denoted	 above	 the	 respective	 data	 bar.	B:	 A	 statistically	 significant	 decrease	 in	 the	
relative	brightness	of	dye-retaining	cells	was	revealed	when	the	median	fluorescence	intensity	(MFI)	of	
the	 gated	 Vybrant®	 DiD-positive	 cell	 population	 was	 compared	 between	 samples	 immediately	 post-
staining	 and	 following	 6	 subsequent	 passages	 of	 culture	 growth	 using	 an	 unpaired	 t-test	 (****	 =	 P	 ≤	
0.0001).	 Data	 are	 expressed	 as	 the	 mean	 average	 ±	 SEM	 for	 n	 =	 3	 biologically	 independent	 repeat	
experiments.	 RFU	 =	 relative	 fluorescence	 units.	C:	 Representative	 images	 of	 Vybrant®	DiD	 staining	 in	
monolayer	MCF-7	cultures	at	6	hours	(left),	passage	3	(centre)	and	passage	6	(right)	post-staining;	the	
white	arrow	 indicates	a	dye	 retaining	cell	evident	 in	 the	 image.	All	 images	were	captured	using	a	10x	
objective	lens	(scale	bar	=	100μm).	
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Figure	3.12.	Dye-Retaining	Cell	Frequency	in	the	ZR-75-1	Cell	Line	
A:	The	percentage	of	Vybrant®	DiD-stained	ZR-75-1	cells	 in	adherent	monolayer	cultures	grown	under	
optimal	conditions	was	measured	at	the	time	of	sub-culture	undertaken	at	144	hour	intervals.	Data	are	
expressed	as	the	mean	average	±	SEM	for	n	=	3	biologically	independent	repeat	experiments;	the	mean	
average	 value	 is	 denoted	 above	 the	 respective	 data	 bar.	B:	 A	 statistically	 significant	 decrease	 in	 the	
relative	brightness	of	dye-retaining	cells	was	revealed	when	the	median	fluorescence	intensity	(MFI)	of	
the	 gated	 Vybrant®	 DiD-positive	 cell	 population	 was	 compared	 between	 samples	 immediately	 post-
staining	 and	 following	 6	 subsequent	 passages	 of	 culture	 growth	 using	 an	 unpaired	 t-test	 (****	 =	 P	 ≤	
0.0001).	 Data	 are	 expressed	 as	 the	 mean	 average	 ±	 SEM	 for	 n	 =	 3	 biologically	 independent	 repeat	
experiments.	 RFU	 =	 relative	 fluorescence	 units.	C:	 Representative	 images	 of	 Vybrant®	DiD	 staining	 in	
monolayer	ZR-75-1	cultures	at	6	hours	(left),	passage	3	(centre)	and	passage	6	(right)	post-staining;	the	
white	arrow	 indicates	a	dye	 retaining	cell	evident	 in	 the	 image.	All	 images	were	captured	using	a	10x	
objective	lens	(scale	bar	=	100μm).	
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Figure	3.13.	Dye-Retaining	Cell	Frequency	in	the	MDA-MB-231	Cell	Line	
A:	 The	percentage	of	Vybrant®	DiD-stained	MDA-MB-231	 cells	 in	 adherent	monolayer	 cultures	 grown	
under	optimal	conditions	was	measured	at	the	time	of	sub-culture	undertaken	at	72	hour	intervals.	Data	
are	expressed	as	 the	mean	average	±	SEM	for	n	=	3	biologically	 independent	repeat	experiments;	 the	
mean	average	value	 is	denoted	above	the	respective	data	bar.	B:	A	statistically	significant	decrease	 in	
the	relative	brightness	of	dye-retaining	cells	was	revealed	when	the	median	fluorescence	intensity	(MFI)	
of	the	gated	Vybrant®	DiD-positive	cell	population	was	compared	between	samples	 immediately	post-
staining	 and	 following	 6	 subsequent	 passages	 of	 culture	 growth	 using	 an	 unpaired	 t-test	 (****	 =	 P	 ≤	
0.0001).	 Data	 are	 expressed	 as	 the	 mean	 average	 ±	 SEM	 for	 n	 =	 3	 biologically	 independent	 repeat	
experiments.	 RFU	 =	 relative	 fluorescence	 units.	C:	 Representative	 images	 of	 Vybrant®	DiD	 staining	 in	
monolayer	MDA-MB-231	cultures	at	6	hours	(left),	passage	3	(centre)	passage	6	(right)	post-staining;	the	
white	arrow	 indicates	a	dye	 retaining	cell	evident	 in	 the	 image.	All	 images	were	captured	using	a	10x	
objective	lens	(scale	bar	=	100μm).	
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Figure	3.14.	Dye-Retaining	Cell	Frequency	in	the	MDA-MB-468	Cell	Line	
A:	 The	percentage	of	Vybrant®	DiD-stained	MDA-MB-468	 cells	 in	 adherent	monolayer	 cultures	 grown	
under	optimal	 conditions	was	measured	 at	 the	 time	of	 sub-culture	undertaken	at	 120	hour	 intervals.	
Data	are	expressed	as	the	mean	average	±	SEM	for	n	=	3	biologically	independent	repeat	experiments;	
the	mean	average	value	is	denoted	above	the	respective	data	bar.	B:	A	statistically	significant	decrease	
in	 the	 relative	 brightness	 of	 dye-retaining	 cells	was	 revealed	when	 the	median	 fluorescence	 intensity	
(MFI)	of	the	gated	Vybrant®	DiD-positive	cell	population	was	compared	between	samples	immediately	
post-staining	and	following	6	subsequent	passages	of	culture	growth	using	an	unpaired	t-test	(****	=	P	
≤	 0.0001).	 Data	 are	 expressed	 as	 the	mean	 average	 ±	 SEM	 for	 n	 =	 3	 biologically	 independent	 repeat	
experiments.	 RFU	 =	 relative	 fluorescence	 units.	C:	 Representative	 images	 of	 Vybrant®	DiD	 staining	 in	
monolayer	 MDA-MB-468	 cultures	 at	 6	 hours	 (left),	 passage	 3	 (centre)	 and	 passage	 6	 (right)	 post-
staining;	the	white	arrow	indicates	a	dye	retaining	cell	evident	in	the	image.	All	 images	were	captured	
using	a	10x	objective	lens	(scale	bar	=	100μm).	
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Figure	3.15.	Dye-Retaining	Cell	Frequency	in	the	SK-BR-3	Cell	Line	
A:	The	percentage	of	Vybrant®	DiD-stained	SK-BR-3	cells	 in	adherent	monolayer	cultures	grown	under	
optimal	conditions	was	measured	at	the	time	of	sub-culture	undertaken	at	120	hour	intervals.	Data	are	
expressed	as	the	mean	average	±	SEM	for	n	=	3	biologically	independent	repeat	experiments;	the	mean	
average	 value	 is	 denoted	 above	 the	 respective	 data	 bar.	B:	 A	 statistically	 significant	 decrease	 in	 the	
relative	brightness	of	dye-retaining	cells	was	revealed	when	the	median	fluorescence	intensity	(MFI)	of	
the	 gated	 Vybrant®	 DiD-positive	 cell	 population	 was	 compared	 between	 samples	 immediately	 post-
staining	 and	 following	 6	 subsequent	 passages	 of	 culture	 growth	 using	 an	 unpaired	 t-test	 (****	 =	 P	 ≤	
0.0001).	 Data	 are	 expressed	 as	 the	 mean	 average	 ±	 SEM	 for	 n	 =	 3	 biologically	 independent	 repeat	
experiments.	 RFU	 =	 relative	 fluorescence	 units.	C:	 Representative	 images	 of	 Vybrant®	DiD	 staining	 in	
monolayer	SK-BR-3	cultures	at	6	hours	(left),	passage	3	(centre)	and	passage	6	(right)	post-staining;	the	
white	 arrows	 indicate	 dye	 retaining	 cells	 evident	 in	 the	 image	 All	 images	were	 captured	 using	 a	 10x	
objective	lens	(scale	bar	=	100μm).	
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3.4.4. Identification	of	Dye-Retaining	Sub-Clones	is	Not	Limited	to	One	Dye	Type	
	
In	 order	 to	 demonstrate	 that	 the	 detection	 of	 a	 dye	 retaining	 population	 was	 not	
limited	to	the	use	of	Vybrant®	DiD	only,	lipophilic	dye	retention	assays	were	repeated	
in	 the	 MDA-MB-231	 cell	 line	 using	 Vybrant®	 CM-DiI.	 Cells	 were	 initially	 stained	 in	
suspension	with	Vybrant®	CM-DiI	according	to	the	supplier's	instructions	as	detailed	in	
Section	2.3.1.	The	assay	procedure	for	detection	of	Vybrant®	CM-DiI	positive	cells	was	
undertaken	exactly	as	described	previously	for	detection	of	Vybrant®	DiD-positive	cells	
(Section	3.4.3.).	The	results,	depicted	in	Figure	3.16.,	demonstrated	that	dye-retaining	
sub-clones	were	also	evident	in	MDA-MB-231	cells	initially	labelled	with	Vybrant®	CM-
DiI	 following	 dye	 loss	 from	 the	 bulk	 cell	 population.	 At	 the	 outset,	 MDA-MB-231	
cultures	were	 100%	positively	 labelled	with	Vybrant®	 CM-DiI.	 A	 steep	decline	 in	 the	
percentage	of	positively	 labelled	cells	occurred	after	 just	one	passage	of	growth	and	
continued	up	to	passage	3,	at	which	point	the	rate	of	dye	loss	reduced	considerably.	As	
previously	observed	using	Vybrant®	DiD,	dye-retaining	sub-clones	comprised	<	0.1%	of	
the	 total	cell	population	at	 the	 final	passage	of	dye	measurement,	although	dye	 loss	
from	the	bulk	cell	population	occurred	at	an	earlier	time	point	using	Vybrant®	CM-DiI.	
This	was	almost	certainly	due	 to	 the	 lower	 relative	brightness	of	 the	 initial	Vybrant®	
CM-DiI	label	and	the	resultant	shorter	time	period	required	for	sufficient	loss	of	dye	to	
result	in	migration	out	of	the	positive	gate.	As	was	previously	observed	with	Vybrant®	
DiD,	the	relative	intensity	of	the	label	in	the	dye-retaining	population	was	statistically	
significantly	diminished	between	the	first	and	last	passages,	falling	from	approximately	
130,000	 RFU	 immediately	 after	 initial	 staining	 to	 13,000	 RFU	 after	 4	 subsequent	
passages	of	culture	growth	(P	≤	0.0001).	
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Figure	3.16.	Dye-Retention	in	Vybrant®	CM-DiI	Stained	MDA-MB-231	Cells	
A:	The	percentage	of	Vybrant®	CM-DiI-stained	MDA-MB-231	cells	in	adherent	monolayer	cultures	grown	
under	optimal	conditions	was	measured	at	the	time	of	sub-culture	undertaken	at	72	hour	intervals.	Data	
are	expressed	as	 the	mean	average	±	SEM	for	n	=	3	biologically	 independent	repeat	experiments;	 the	
mean	average	value	 is	denoted	above	the	respective	data	bar.	B:	A	statistically	significant	decrease	 in	
the	relative	brightness	of	dye-retaining	cells	was	revealed	when	the	median	fluorescence	intensity	(MFI)	
of	 the	 gated	 Vybrant®	 CM-DiI-positive	 cell	 population	 was	 compared	 between	 samples	 immediately	
post-staining	and	following	6	subsequent	passages	of	culture	growth	using	an	unpaired	t-test	(****	=	P	
≤	 0.0001).	 Data	 are	 expressed	 as	 the	mean	 average	 ±	 SEM	 for	 n	 =	 3	 biologically	 independent	 repeat	
experiments.	RFU	=	relative	fluorescence	units.	
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3.4.5. Cell	Division	is	the	Primary	Determinant	of	Vybrant®	Dye	Loss	
	
In	 order	 to	 demonstrate	 that	 cell	 division	was	 the	 primary	 determinant	 of	 lipophilic	
fluorescent	 dye	 loss,	 and	 by	 extension	 that	 dye	 retention	 was	 indicative	 of	 mitotic	
inactivity,	samples	of	MDA-MB-231	cells	were	pre-treated	with	the	potent	DNA	cross	
linking	agent	Mitomycin	C	to	induce	growth	arrest	prior	to	staining.	Briefly,	monolayer	
cultures	were	incubated	under	standard	growth	conditions	for	3	hours	in	the	presence	
of	 Mitomycin	 C	 freshly	 prepared	 in	 serum-free	 RPMI-1640	 basal	 medium	 at	 a	
concentration	 of	 10μg/ml	 before	 being	 retrieved	 as	 previously	 described	 (Section	
2.2.1.2.).	 Growth-arrested	 cells	 were	 stained	 with	 Vybrant®	 DiD	 in	 suspension	
according	to	the	supplier	instructions,	as	described	in	Section	2.3.1.	Once	stained,	cells	
were	 seeded	 into	75cm2	 tissue	 culture	 flasks	 at	 a	 density	 of	 1.0	 x	 104	 cells	 per	 cm2.	
Equivalent	 unstained	 samples	 were	 prepared	 in	 the	 same	 manner	 and	 grown	
concomitantly	 in	 order	 to	 facilitate	 flow	 cytometric	 analysis	 at	 the	 appropriate	 time	
point.	 Sufficient	 stained	 and	 unstained	 growth	 arrested	 samples	 were	 prepared	 to	
allow	 measurement	 across	 the	 entire	 assay	 duration	 of	 18	 days	 (equivalent	 to	 six	
passages	of	culture	growth	in	non-arrested	cultures).	The	percentage	of	cells	retaining	
the	Vybrant®	DiD	dye	was	monitored	as	previously	described	(Section	3.4.3.)	at	time	
points	equivalent	to	those	used	to	monitor	dye	retention	in	growing	cultures.	
	
Mitomycin	C-induced	growth	arrest	resulted	in	the	retention	of	Vybrant®	DiD	in	a	high	
percentage	 of	 cells	 at	 all	 time	 points	 during	 the	 assay	 period;	 at	 passage	 6	 in	 non-
growth	 arrested	 cultures	 0.08%	 of	 cells	 retained	 their	 Vybrant®	 DiD	 label,	 whereas	
99.33%	were	positively	labelled	on	average	in	mitomycin	C	pre-treated	cultures	at	the	
equivalent	 time	 point.	 The	 high	 level	 of	 dye	 retention	 by	 growth-arrested	 cells	
throughout	 the	 assay	 period	 is	 clearly	 depicted	 in	 fluorescence	 photomicroscopic	
images	of	cultures	taken	at	each	time	point	(Figure	3.17.).	
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Figure	3.17.	Inhibition	of	Lipophilic	Dye	Loss	Following	Growth	Arrest	
A:	 The	 percentage	 of	 Vybrant®	 DiD-stained	 MDA-MB-231	 cells	 in	 Mitomycin	 C	 (MMC)	 pre-treated	
adherent	 monolayer	 cultures	 grown	 under	 optimal	 conditions	 was	 measured	 at	 72	 hour	 intervals	
equivalent	 to	 the	 time	of	 sub-culture	 in	 growing	 cultures.	Data	 are	expressed	as	 the	mean	average	±	
SEM	for	n	=	3	biologically	 independent	repeat	experiments.	B:	Representative	 images	of	Vybrant®	DiD	
staining	 in	 growth-arrested	MDA-MB-231	 cultures	at	6	hours	 (left),	 216	hours	 (centre)	 and	432	hours	
(right)	post-staining.	All	images	were	captured	using	a	10x	objective	lens	(scale	bar	=	100μm).	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 106	
3.4.6. Dye-Retaining	Cells:	Senescent,	Absolutely	Quiescent	or	Slowly	Cycling?	
	
In	 order	 to	 first	 determine	whether	 dye-retention	 represented	 a	 senescent	 state	 of	
mitotic	inactivity,	the	activity	of	senescence-associated	β-galactosidase	was	assayed	at	
pH	6.0	due	to	the	frequent	use	of	this	enzyme	as	a	biomarker	of	cellular	senescence.	
Wild	type	MDA-MB-231	cells	were	stained	in	suspension	with	Vybrant®	DiD	according	
to	the	manufacturer	instructions	(Section	2.3.1.),	seeded	at	the	optimal	density	of	1.0	
x	 104	 cells	 per	 cm2	 into	 75cm2	 high-quality	 polystyrene	 tissue	 culture	 flasks	 and	
cultured	continuously	for	five	passages.	Following	retrieval	of	cultures	at	five	passages	
post-staining,	Vybrant®	DiD-positive	cells	were	isolated	by	FACS	and	were	reseeded	in	
triplicate	into	the	wells	of	6-well	cluster	plates.	Samples	of	the	BO2	variant	MDA-MB-
231	 cell	 line	 engineered	 to	 stably	 express	 β-galactosidase	 were	 prepared	
concomitantly	 as	 a	 positive	 control.	 Cluster	 plates	 were	 placed	 into	 incubation	
overnight	to	allow	cells	to	adhere	to	the	growth	surface.	Adherent	cells	were	stained	
for	senescence-associated	β-galactosidase	activity	at	pH	6.0	using	the	β-galactosidase	
staining	 kit	 available	 from	 New	 England	 Biolabs	 U.K.	 Ltd.	 according	 to	 the	
manufacturer	 instructions	 (Section	 2.8.1.).	 Stained	 samples	 were	 immediately	
assessed	 for	 positive	 staining	 under	 inverted	 phase-contrast	 microscopy	 and	
representative	 images	 captured.	 A	 strong	 blue	 coloured	 staining	 in	 the	 BO2	 variant	
MDA-MB-231	stably	expressing	β-galactosidase	 indicated	that	 the	assay	was	working	
correctly.	The	complete	absence	of	this	staining	in	isolated	Vybrant®	DiD-positive	cells	
demonstrated	 that	 dye	 retention	 in	 this	 fraction	 was	 not	 the	 result	 of	 entry	 into	 a	
permanent	state	of	mitotic	arrest	due	to	cellular	senescence	(Figure	3.18.).	
	
	
	
	
	
	
	
	
	
	
	 107	
	
	
Figure	3.18.	β-galactosidase	Activity	in	Vybrant®	DiD-Retaining	MDA-MB-231	Cells	
A:	 BO2-variant	 MDA-MB-231	 cells	 stably	 expressing	 β-galactosidase	 used	 as	 a	 positive	 control	 for	
assessment	 of	 intracellular	 β-galactosidase	 activity	 at	 pH	 6.0;	 blue	 coloured	 staining	 is	 due	 to	 5,5'-
dibromo-4,4'-dichloro-indigo	 resulting	 from	 β-galactosidase-catalysed	 X-gal	 metabolism.	 B:	 Isolated	
Vybrant®	DiD-positive	MDA-MB-231	cells	at	12-hours	post-seeding	showing	negativity	for	5,5'-dibromo-
4,4'-dichloro-indigo	 staining	 indicative	 of	 senescence-associated	 β-galactosidase	 activity	 at	 pH	 6.0.	 All	
images	were	captured	using	a	20x	objective	lens	(scale	bar	=	50μm).	
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During	lipophilic	fluorescent	dye	pulse-chase	assays,	a	statistically	significant	reduction	
in	 the	 median	 fluorescence	 intensity	 of	 the	 Vybrant®	 dye-positive	 population	 was	
observed	between	the	first	and	final	passages	of	culture	growth	in	all	cell	lines	assayed	
(Figure	3.11.	-	Figure	3.16.).	Following	the	demonstration	that	dye	retaining	cells	were	
not	 senescent,	 and	 given	 that	 previous	 experiments	 demonstrated	 that	 a	 significant	
reduction	 in	 fluorescence	 intensity	 of	 dye	 staining	was	 indicative	 of	mitotic	 activity,	
these	results	were	seen	to	indicate	that	dye-retaining	cells	were	in	fact	a	slow-cycling,	
relatively	 quiescent	 population.	 Indeed,	 using	 the	 median	 fluorescence	 intensity	 of	
Vybrant®	DiD	staining	to	compare	the	dye-retaining	population	(MFI	=	31744.33	RFU)	
and	the	dye-negative	population	 (MFI	=	559	RFU)	within	MDA-MB-231	cultures	after	
five	passages	post-staining	(Figure	3.19.),	Vybrant®	DiD-positive	cells	were	determined	
to	be	approximately	six	cell	divisions	behind	the	bulk	dye-negative	population.	
	
	
Figure	3.19.	Comparison	of	the	MFI	of	Dye-Retaining	and	Negative	Populations	
A:	Representative	flow	cytometric	analysis	of	Vybrant®	DiD-stained	adherent	MDA-MB-231	cultures	at	
five	 passages	 post-staining.	 The	 gates	 for	 detection	 of	 the	 Vybrant®	 DiD-negative	 (grey)	 and	 most	
intensely	 stained	Vybrant®	DiD-positive	 (bright	 red)	 populations	were	 pre-set	 at	 the	 beginning	 of	 the	
pulse-chase	 period	 using	 unlabelled	 and	 freshly	 labelled	 samples	 respectively,	 allowing	 the	 median	
fluorescence	 intensity	 (MFI)	 of	 the	population	defined	by	 each	 gate	 to	be	determined.	B:	 The	MFI	 of	
Vybrant®	DiD-negative	and	Vybrant®	DiD-positive	populations	at	five	passages	post-staining	are	shown.	
Data	are	expressed	as	the	mean	average	±	SEM	for	n	=	3	biologically	independent	repeat	experiments.	
RFU	=	relative	fluorescence	units.	
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In	order	to	determine	how	dye-retaining	and	non-dye	retaining	cells	differed	 in	their	
cell	 cycle	 status,	 univariant	 cytofluorimetric	 analysis	 of	 the	 cell	 cycle	 distribution	 of	
Vybrant®	DiD-positive	and	negative	MDA-MB-231	cell	fractions	was	undertaken	using	
Hoechst	33342.	Briefly,	 unlabelled	and	Vybrant®	DiD-stained	wild-type	MDA-MB-231	
cells	were	 seeded	at	 the	optimal	density	of	 1.0	 x	 104	 cells	 per	 cm2	 into	75cm2	high-
quality	 polystyrene	 tissue	 culture	 flasks	 and	 cultured	 continuously	 for	 five	 passages.	
Cultures	were	 retrieved	 at	 passage	 five	 post-staining	 and	 samples	 of	 1.0	 x	 106	 cells	
prepared	 in	 serum-free	 basal	 culture	 medium.	 Samples	 were	 stained	 with	 5μg/ml	
Hoechst	 33342,	 as	 described	 in	 Section	 2.5.2.2.,	 prior	 to	 flow	 cytometric	 cell	 cycle	
profile	 analysis.	 During	 cytofluorimetric	 analyses,	 Vybrant®	 DiD	 staining	 status	 was	
used	 to	 differentiate	 populations	 of	 interest	 using	 the	 gating	 configuration	 pre-set	
using	unlabelled	samples.	Vybrant®	DiD-positive	and	negative	populations	were	 then	
concomitantly	 analysed	 for	 relative	 Hoechst	 33342	 content,	 allowing	 assessment	 of	
the	 cell	 cycle	profile	of	each	population	 (Figure	 3.20.).	 The	outcome	of	 these	assays	
revealed	that	dye-retaining	cells	collected	in	the	G2/M-phase	of	the	cell	cycle	relative	
to	the	dye-negative	population	(Figure	3.21.);	approximately	26.73%	of	Vybrant®	DiD-
positive	 cells	 were	 found	 to	 exist	 in	 the	 G2/M-phase	 compared	 to	 just	 15.40%	 of	
Vybrant®	 DiD-negative	 cells	 (P	 ≤	 0.0001).	 A	 corresponding	 decrease	 in	 the	 G0/G1	
fraction	was	observed	in	the	dye-retaining	cell	population	with	49.87%	being	observed	
in	this	phase	compared	to	63.60%	of	dye-negative	cells	on	average	(P	≤	0.0001).	These	
observations	were	seen	to	indicate	that	the	slow	cycling,	relatively	quiescent	nature	of	
the	 dye-retaining	 MDA-MB-231	 cell	 fraction	 was,	 at	 least	 in	 part,	 the	 result	 of	 an	
extended	G2/M-phase	transition.	
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Figure	3.20.	Cell	Cycle	Analysis	in	Dye-Retaining	and	Negative	Populations	
Cellular	debris	was	gated-out	of	the	event	population	(A)	and	the	resultant	events	divided	into	Vybrant®	
DiD-negative	and	positive	populations	using	gates	defined	by	unlabelled	and	 freshly	 labelled	 samples,	
respectively	 (B).	The	single	cell	events	within	each	sub-population	were	 then	 identified	 (C)	before	 the	
cell	cycle	distribution	of	the	Vybrant®	DiD-negative	(D)	and	Vybrant®	DiD-positive	(E)	populations	were	
analysed	 based	 on	 Hoechst	 33342	 fluorescence	 which	 estimates	 relative	 DNA	 content	 based	 on	
stoichiometric	binding	of	the	Hoechst	dye	to	cellular	DNA.	
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Figure	3.21.	Cell	Cycle	Profiles	of	Dye-Retaining	and	Negative	Populations	
A:	The	univariant	relative	cell	cycle	distribution	of	Vybrant®	DiD-positive	(red	dotted	line)	and	negative	
(grey)	 MDA-MB-231	 cells	 at	 five	 passages	 post-staining	 are	 shown.	 The	 location	 of	 the	 G0/G1-phase	
(haploid	chromosome	number),	S-phase	(intermediate	chromosome	number)	and	G2/M-phase	(diploid	
chromosome	number)	peaks	are	 illustrated.	B:	 The	percentage	of	 total	 cells	 in	each	phase	of	 the	 cell	
cycle	were	compared	between	Vybrant®	DiD-positive	and	negative	populations	using	two-way	ANOVA	
followed	by	Sidak’s	Multiple	Comparison	Test	 (NS	=	not	statistically	significant	or	P	>	0.05,	****	=	P	≤	
0.0001).	 Data	 are	 expressed	 as	 the	 mean	 average	 ±	 SEM	 for	 n	 =	 3	 biologically	 independent	 repeat	
experiments.	
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Univariant	 cell	 cycle	 analyses	 indicated	 that	 Vybrant®	 DiD-retaining	 cells	 were	
relatively	slow	cycling	due	to	an	extended	G2/M-phase	transition.	However,	it	was	also	
possible	 that	 the	 Vybrant®	 DiD-retaining	 fraction	 was	 made	 up	 of	 both	 absolutely	
quiescent	 (G0	 arrested)	 and	 relatively	 quiescent	 and	 slowly	 cycling	 cells.	 In	 order	 to	
establish	whether	 this	was	 the	 case,	 immunofluorescent	 staining	 for	 Ki67	was	 used.	
The	Ki67	protein	 is	a	positive	marker	of	active	cell	proliferation	required	to	maintain	
individual	mitotic	chromosomes	and	is	therefore	expressed	within	the	nucleus	of	cells	
at	all	active	stages	of	the	cell	cycle	(G1,	S,	G2	and	M-phases)	but	absent	during	G0.	 In	
order	to	determine	differential	expression	of	Ki67	between	Vybrant®	DiD-retaining	and	
non-dye-retaining	 cells,	 each	 population	 was	 isolated	 by	 FACS	 at	 passage	 five	 post-
staining	 and	 2000	 cells	 of	 each	 type	 deposited	 onto	 glass	microscope	 slides	 using	 a	
cytocentrifuge	 as	 described	 in	 Section	 2.3.2.1.	 Samples	 were	 immunostained	 for	
expression	of	Ki67	using	antibodies	detailed	in	Table	3.2.	according	to	the	protocol	for	
detection	of	intracellular	antigens	by	indirect	immunofluorescence	outlined	in	Section	
2.3.2.2.	The	final	working	protein	concentration	of	antibodies	used	was	determined	by	
preliminary	 assays	 carried	out	 in	 the	 same	manner	 in	which	 a	 range	of	 final	 protein	
concentrations	 of	 primary	 and	 secondary	 antibodies	 were	 used;	 primary	 antibody	
concentrations	 ranged	 from	 0.1μg/ml	 to	 10μg/ml,	 while	 secondary	 antibody	
concentrations	 ranged	 from	 2μg/ml	 to	 10μg/ml,	 as	 recommended	 by	 the	 supplier.	
Immunostained	samples	were	 imaged	under	fluorescence	microscopy	and	a	series	of	
three	 non-overlapping	 fields	 captured	 at	 100X	 magnification	 using	 the	 tile	 scan	
function	of	 the	 Leica	AF6000LX	microscope	 for	manual	 scoring	of	marker	expression	
(as	described	in	Section	2.4.).	
	
Table	3.2.	Antibodies	Used	in	Immunostaining	for	Ki67	Expression	
	
Target	
	
Host	
Species	 Clonality	 Isotype	 Conjugate	
Final	Conc.	
(μg/ml)	 Supplier	 Cat.	No.	
Ki67	 Rabbit	 Poly	 IgG	 None	 1	 Abcam	 ab15580	
None	 Rabbit	 Poly	 IgG	 None	 1	 Abcam	 ab171870	
Rabbit	IgG	H&L	 Goat	 Poly	 IgG	 AlexaFluor®	488	 4	 Abcam	 ab150077	
	
An	unconjugated	 anti-Ki67	 primary	 antibody,	 a	matched	 isotype	 control	 antibody	 and	 an	AlexaFluor®	
488-conjugated	 secondary	 antibody	 were	 sourced	 from	 Abcam	 Plc.	 (Cambridge,	 U.K.).	 The	 working	
concentration	of	the	isotype	control	antibody	was	matched	to	the	exact	working	protein	concentration	
of	the	primary	antibody.	
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Samples	 that	 were	 immunostained	 for	 Ki67	 expression	 were	 imaged	 under	
fluorescence	 microscopy;	 representative	 images	 depicting	 the	 staining	 pattern	
produced	 within	 Vybrant®	 DiD-positive	 and	 DiD-negative	 samples	 were	 initially	
captured	at	200X	magnification	(Figure	3.22.).	A	series	of	three	non-overlapping	fields	
for	 each	 of	 three	 technical	 repeats	 of	 both	 Vybrant®	 DiD-positive	 and	 DiD-negative	
samples	across	three	biologically	independent	sample	sets	were	also	captured	at	100X	
magnification	 using	 the	 tile	 scan	 function	 of	 the	 Leica	 AF6000LX	 microscope	 for	
manual	 scoring	of	Ki67	expression,	 the	 results	of	which	are	displayed	 in	Figure	 3.22.	
The	outcome	of	this	scoring	for	Ki67	expression	revealed	that	approximately	15%	more	
dye-negative	 cells	 express	Ki67	 than	 in	 the	dye-retaining	 cell	 population	 (P	≤	0.001).	
This	result	suggests	that	the	overall	slow-cycling	nature	of	the	dye-retaining	MDA-MB-
231	 cell	 fraction	 is	 the	 net	 result	 of	 being	 comprised	 of	 a	 greater	 number	 of	 G0	
arrested	 cells	 along	with	 the	 remaining	 population	 having	 an	 extended	 G2/M-phase	
transition,	as	was	revealed	during	cell	cycle	distribution	analyses.	
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Figure	3.22.	Ki67	Expression	in	Dye-Retaining	and	Negative	Cell	Populations	
A:	 The	 percentage	 expression	 of	 Ki67	 in	 Vybrant®	 DiD-negative	 and	 Vybrant®	 DiD-positive	 sub-
populations	 in	 the	MDA-MB-231	 cell	 line	 at	 five	 passages	 post-staining.	Data	were	 compared	 using	 a	
two-tailed	unpaired	t-test	(***	=	P	≤	0.001).	Data	are	expressed	as	the	mean	average	±	SEM	for	n	=	3	
biologically	 independent	 repeat	 experiments.	 B:	 The	 immunofluorescent	 staining	 pattern	 for	 Ki67	
(green)	is	shown	along	with	nuclear	counterstaining	with	DAPI	(blue).	Specificity	of	staining	in	each	case	
is	indicated	by	the	absence	of	staining	in	the	matched	isotype	control	sample.	All	images	were	captured	
using	a	20x	objective	lens	(scale	bar	=	50μm).	
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3.4.7. Suitability	of	Tumour	Spheroid	Cultures	for	Pulse-Chase	Analyses	
	
A	 number	 of	 three-dimensional	 systems	 for	 the	 culture	 of	 both	 primary	 and	
immortalised	cancer	cell	 lines	 in	vitro	have	been	developed.	These	so-called	spheroid	
cultures	 aim	 to	 recapitulate	 tumour	 microenvironmental	 complexities	 and	 better	
reflect	 the	 nutrient,	waste	metabolite	 and	 oxygen	 tension	 gradients	 experienced	 by	
cells	 in	 vivo	 (Ishiguro	 et	 al.,	 2017).	 Interestingly,	 three-dimensional	 in	 vitro	 culture	
systems	have	been	reported	to	enrich	for	stem	cell	traits	 in	some	instances	(Fillmore	
and	Kuperwasser,	2008;	Pece	et	al.,	2010;	Raimondi	et	al.,	2016).	Given	the	implicit	link	
between	 stemness	 and	 quiescence,	 the	 potential	 utility	 of	 spheroid	 cultures	 for	 the	
purpose	 of	 prospective	 isolation	 of	 mitotically	 quiescent	 breast	 cancer	 cells	 by	
lipophilic	dye	retention	was	investigated.	
	
A	 multitude	 of	 techniques	 have	 been	 described	 for	 establishing	 three-dimensional	
spheroid	 cultures.	 These	 techniques	 vary	 in	 their	 suitability	 for	 generation	 of	 tightly	
formed	 spheroids	 and	 their	 ability	 to	 recapitulate	 basic	 characteristics	 of	 tumours	
depending	on	the	cell	types	used	(Friedrich	et	al.,	2007;	Lin	and	Chang,	2008;	Friedrich	
et	al.,	2009).	Notably,	it	has	been	reported	that	the	MDA-MB-231	human	breast	cancer	
lineage	does	not	 readily	 form	uniform	and	compact	spheroid	cultures	which	develop	
regions	 of	 hypoxia	 and	 a	 necrotic	 core	 by	 conventional	 generation	methods	 such	 as	
the	hanging	drop	or	agarose-liquid	overlay	culture	(Ivascu	and	Kubbies,	2006;	Moore	
et	 al.,	 2012;	 Nagelkerke	 et	 al.,	 2013).	 In	 order	 to	 circumvent	 this	 issue,	 Ivascu	 and	
Kubbies	 (2006)	 developed	 a	 modified	 version	 of	 the	 non-adherent	 liquid	 overlay	
technique	 that	 reliably	 produced	 spheroid	 cultures	 with	 the	 desired	 characteristics	
from	the	MDA-MB-231	cell	line.	The	effectiveness	and	reproducibility	of	this	approach	
was	later	validated	by	Nagelkerke	et	al.	(2013).	
	
Three	dimensional	spheroid	cultures	of	MDA-MB-231	cells	were	established	using	the	
Ivascu	 and	 Kubbies	 (2006)	method	 (described	 in	 detail	 in	 Section	 2.2.2.1.	 -	 Section	
2.2.2.2.)	 immediately	 after	 staining	 with	 Vybrant®	 DiD.	 Spheroid	 samples	 were	
collected	and	digested	to	form	single	cell	suspensions	as	described	in	Section	2.2.2.3.	
at	72-hour	intervals,	the	time-point	equivalent	to	the	sub-culture	interval	in	monolayer	
cultures.	At	each	time	point,	samples	of	spheroid-derived	single	cell	suspensions	were	
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analysed	 cytofluorimetrically	 and	 the	 percentage	 of	 Vybrant®	 DiD-positive	 events	
present	 within	 each	 sample	 was	 determined	 using	 the	 gating	 tree	 pre-set	 at	 the	
beginning	 of	 the	 experiment	 as	 previously	 detailed	 (Section	 3.4.3.).	 Fluorescence	
photomicroscopy	was	also	undertaken	in	order	to	visually	demonstrate	the	changes	in	
Vybrant®	DiD	staining	over	the	duration	of	the	assay.	Assay	results	and	representative	
images	are	depicted	in	Figures	3.23.	
	
MDA-MB-231	 spheroid	 cultures	 were	 relatively	 poorly	 proliferative,	 resulting	 in	
retention	 of	 dye	 by	 a	 large	 proportion	 of	 cells	 at	 all	 time	 points.	 After	 18	 days	 of	
continuous	 culture	 post-staining	 68.63%	 of	 cells	 remained	 positively	 stained	 with	
Vybrant®	DiD	on	average	while	only	0.08%	of	cells	retained	dye	at	the	equivalent	time	
point	when	grown	as	an	adherent	monolayer.	Flow	cytometric	cell	cycle	profiling	using	
propidium	 iodide	 (Section	 2.5.2.1.)	 illustrated	 that	 when	 grown	 as	 spheroids,	 the	
MDA-MB-231	 cell	 cycle	 profile	 was	 significantly	 skewed	 towards	 the	 G0/G1	 peak	
compared	 to	 rapidly	 dividing	 cells	 grown	 as	 adherent	 monolayer	 cultures	 (Figure	
3.24.);	74.07%	of	cells	grown	as	three-dimensional	spheroids	were	found	to	be	in	the	
G0/G1	 phase	 compared	 to	 38.83%	 of	 cells	 grown	 as	 an	 adherent	 monolayer	 (P	 ≤	
0.0001).	 This	 G0/G1	 skewing	 resulted	 in	 a	 significant	 reduction	 in	 the	 S-phase	
population	 from	 35.90%	 to	 14.97%	 (P	 ≤	 0.0001)	 and	 in	 the	 G2/M-phase	 population	
from	 19.37%	 to	 4.57%	 (P	 ≤	 0.001).	 This	 loss	 of	 proliferative	 capability	 and	 resultant	
retention	of	fluorescence	by	the	bulk	cell	mass	indicated	that	spheroid	cultures	are	not	
suitable	for	prospective	identification	of	quiescent	cells	by	pulse-chase	analyses	in	this	
cell	line.	
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Figure	3.23.	Dye-Retaining	Cell	Frequency	in	MDA-MB-231	Spheroid	Cultures	
A:	 The	 percentage	 of	 Vybrant®	 DiD-stained	 MDA-MB-231	 cells	 in	 non-adherent	 three-dimensional	
spheroid	cultures	was	measured	at	72	hour	intervals.	Data	are	expressed	as	the	mean	average	±	SEM	for	
n	 =	 3	 biologically	 independent	 repeat	 experiments;	 the	 mean	 average	 value	 is	 denoted	 above	 the	
respective	data	bar.	B:	Representative	images	of	Vybrant®	DiD	staining	in	three-dimensional	MDA-MB-
231	cultures	at	3	days	(left),	9	days	(centre)	and	18	days	(right)	post-staining.	All	images	were	captured	
using	a	5x	objective	lens	(scale	bar	=	250μm).	
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Figure	3.24.	Cell	Cycle	Profiling	of	Two-	and	Three-Dimensional	Cultures	
A:	The	univariant	cell	cycle	analysis	profiles	of	MDA-MB-231	cells	grown	as	two-dimensional	monolayer	
cultures	 (red)	and	 three-dimensional	 spheroid	cultures	 (yellow)	are	 shown.	The	 location	of	 the	G0/G1-
phase	 (haploid	 chromosome	 number),	 S-phase	 (intermediate	 chromosome	 number)	 and	 G2/M-phase	
(diploid	chromosome	number)	peaks	are	illustrated.	B:	The	percentage	of	total	cells	in	each	phase	of	the	
cell	 cycle	 were	 compared	 between	 two-dimensional	 monolayer	 and	 three-dimensional	 spheroid	
cultures	using	two-way	ANOVA	followed	by	Sidak’s	Multiple	Comparison	Test	(***	=	P	≤	0.001,	****	=	P	
≤	 0.0001).	 Data	 are	 expressed	 as	 the	mean	 average	 ±	 SEM	 for	 n	 =	 3	 biologically	 independent	 repeat	
experiments.	
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3.5. Discussion	
	
In	this	chapter,	the	utility	of	Vybrant®	fluorescent	dyes	for	pulse-chase	tracing	of	cell	
proliferation	 in	 monolayer	 breast	 cancer	 cell	 cultures	 has	 been	 demonstrated.	 This	
technique	 was	 shown	 to	 have	 no	 significant	 effect	 on	 cellular	 function	 or	 culture	
growth	 and	 has	 proved	 to	 be	 both	 effective	 and	 highly	 reproducible	 in	 facilitating	
identification	of	mitotically	inactive	cells	across	cell	lines	of	contrasting	molecular	sub-
types.	 Using	 a	 similar	 method	 to	 the	 one	 described	 herein,	 Moore	 et	 al.	 (2012)	
previously	identified	a	slow-cycling	sub-population	in	the	MDA-MB-231	cell	line	when	
grown	as	adherent	monolayer	cultures.	Quiescent	cells	were	isolated	in	this	case	based	
on	 persistent	 retention	 of	 the	 fluorescent	 dye	 carboxyfluorescein	 diacetate	
succinimidyl	ester	(CFSE)	and	were	found	to	represent	approximately	0.1%	of	the	total	
cell	population.	Comparative	analysis	of	fluorescence	intensity	and	cell	cycle	profiling	
of	 dye-retaining	 and	non-dye-retaining	populations	 by	Moore	 et	 al.	 (2012)	 indicated	
that	the	dye-retaining	cells	were	slowly	cycling.	The	significant	decrease	in	the	relative	
brightness	of	Vybrant®	dye-retaining	populations	compared	to	freshly	labelled	samples	
observed	here	suggests	some	degree	of	mitotic	activity	resulting	in	very	gradual	loss	of	
the	 initial	 dye	 label.	 Consequently,	 it	 appears	 that	 dye-retaining	 cells	 are	 likely	 to	
represent	a	relatively	slow	cycling	sub-population.	Moore	et	al.	(2012)	also	attempted	
to	determine	whether	growing	cells	as	 three-dimensional	 spheroid	cultures	enriched	
for	 cells	 with	 the	 quiescent	 phenotype,	 but	 found	 that	 MDA-MB-231	 cells	 formed	
poorly	 proliferative	 spheroids	 and	 that	 this	 impeded	 effective	 application	 of	 the	
lipophilic	pulse-chase	methodology,	as	was	also	demonstrated	here.	
	
Although	 the	description	of	a	 label-retaining	 cell	 sub-set	 in	MDA-MB-231	cells	 is	not	
entirely	 novel,	 prospective	 functional	 identification	 of	 a	 mitotically	 quiescent	 sub-
population	 has	 not	 been	 reported	 for	MCF-7,	 ZR-75-1,	MDA-MB-468	 or	 SK-BR-3	 cell	
lines.	 Interestingly,	 the	 identification	 of	 a	 discreet	 population	 of	 dye-retaining	 cells	
after	5	or	6	passages	of	continuous	culture	across	multiple	cell	lines	not	only	indicates	
the	presence	of	relatively	or	absolutely	mitotically	inactive	sub-clones	in	each	case,	but	
also	 suggests	 that	 these	 sub-clones	 are	 an	 intrinsic	 feature	 of	 breast	 cancer.	 The	
considerable	degree	of	continuity	between	the	average	quiescent	cell	population	size	
identified	here	and	that	described	by	Moore	et	al.	(2012)	might	be	seen	as	supporting	
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this	 hypothesis.	Moreover,	 the	 notable	 comparability	 between	 the	 size	 of	 the	 label-
retaining	 cell	 population	 described	 in	 these	 studies	 and	 of	 those	 described	 in	 the	
closely	 related	 works	 of	 Wang	 et	 al.	 (2015a)	 and	 Dembinski	 and	 Krauss	 (2009)	 in	
models	of	prostate	and	pancreatic	cancer,	respectively,	suggest	that	a	slow	cycling	or	
quiescent	population	is	an	intrinsic	feature	of	multiple	cancer	types.	Given	that	cancer	
stem	cells	have	already	been	isolated	from	multiple	cancer	types	and	are	supposed	to	
exist	 in	 a	 transient	 state	 of	 quiescence	 like	 their	 non-malignant	 counterparts,	 the	
isolation	 of	 label-retaining	 cell	 sub-sets	 across	 multiple	 cancer	 types	 might	 indicate	
that	 quiescent	 and	 stem	 cell	 populations	 are	 non-mutually	 exclusive.	 The	
aforementioned	 studies	 by	 Wang	 et	 al.	 (2015a)	 and	 Dembinski	 and	 Krauss	 (2009)	
concurrently	 indicated	 that	 label-retaining	quiescent	 cells	 do	possess	 stem	cell	 traits	
and	 significant	 metastasis-initiating	 capacity,	 despite	 displaying	 incomplete	 overlap	
with	 supposed	 stem	 cell	marker	 proteins.	While	Moore	 et	 al.	 (2012)	were	 relatively	
limited	 in	 their	 characterisation	 of	 quiescent	 MDA-MB-231	 sub-clones,	 failing	 to	
address	 both	 breast	 cancer	 stem	 cell	 marker	 expression	 and	 many	 functional	
parameters,	 their	demonstration	of	significant	 therapeutic	 resistance	and	tumour	re-
initiating	capability	also	implies	non-mutual	exclusivity	between	quiescent	and	cancer	
stem	 cell	 populations.	 As	 such,	 redressing	 a	more	 extensive	 characterisation	of	 dye-
retaining	 breast	 cancer	 cells	 and	 their	 deployment	 of	 accepted	 stem	 cell	 traits	 will	
form	a	key	focus	of	work	described	in	subsequent	chapters.	
	
While	 it	 is	entirely	feasible	that	a	population	of	cells	that	had	entered	into	a	state	of	
irreversible	 cell	 cycle	 arrest	or	 senescence	would	 retain	a	 lipophilic	 fluorescent	 label	
post-staining,	 the	 dye-retaining	 cell	 population	 identified	 here	 was	 shown	 to	 be	
negative	 for	 senescence-associated	 β-galactosidase	 activity	 at	 pH	 6.0.	 Furthermore,	
analysis	of	both	cell	cycle	distribution,	changes	in	average	fluorescence	of	the	retained	
dye	 label	and	Ki67	expression	collectively	 indicated	 that	Vybrant®	dye	 retaining	cells	
were	primarily	actively	dividing	but	slow-cycling	relative	to	the	non-label-retaining	bulk	
cell	population.	Analysis	of	Ki67	expression	also	showed	that,	although	the	majority	of	
dye-retaining	 cells	 existed	 in	 a	 Ki67	positive	 state	 and	 therefore	 likely	 to	 be	 actively	
dividing,	a	 significantly	 lower	proportion	were	Ki67	positive	 than	 in	 the	dye-negative	
fraction.	 When	 taken	 together,	 these	 observations	 indicate	 that	 the	 dye-retaining	
fraction	is	comprised	of	both	absolutely	quiescent	(G0	arrested	and	Ki67	negative)	and	
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relatively	 quiescent	 but	 slow	 cycling	 (extended	 G2/M	 and	 Ki67	 positive)	 cells	 that	
contribute	 to	 an	 overall	 lower	 mitotic	 activity.	 This	 suggests	 a	 possible	 hierarchic	
organisation	within	 this	 fraction	 in	which	 intermittently	 cycling	 quiescent	 cells	 gives	
rise	 to	 a	 relatively	 quiescent	 transit	 amplifying	 population,	 such	 has	 recently	 been	
shown	 to	 characterise	 the	 cellular	 hierarchy	 of	 normal	 mammary	 tissue	 and	 is	 an	
emerging	 feature	 of	 breast	 cancer	 (Skibinski	 and	 Kuperwasser,	 2015).	 Interestingly,	
those	cells	which	appear	to	comprise	the	most	immature	sub-set	in	the	breast	cancer	
cellular	 hierarchy	 and	 demonstrate	 features	 of	 the	 putative	 metastasis-initiating	
population	 (chemoresistance,	 high	 metastatic	 and	 invasive	 capability,	 dormancy	
competence	 and	 stemness)	 are	 also	 characterised	 by	 cycling	 quiescence	 and	 a	 long	
doubling	time	(Patel	et	al.,	2012).	
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3.6. Conclusions	
	
The	Vybrant®	dyes	DiO,	CM-DiI	and	DiD	each	stained	human	breast	cancer	cell	cultures	
in	a	homogenous	manner.	Cell	viability,	clonogenicity	and	migratory	capability	were	all	
unaffected	following	labelling	of	cultures	with	each	of	these	dyes,	as	were	net	culture	
growth	 characteristics.	 Vybrant®	 DiD	 resulted	 in	 the	 greatest	 increase	 in	 median	
fluorescence	 intensity	 relative	 to	 that	 of	 unlabelled	 cultures	 under	 cytofluorimetric	
analysis	 and	 was	 therefore	 deemed	 best	 suited	 for	 use	 in	 lipophilic	 dye	 retention	
assays.	 Adherent	monolayer	 cultures	were	 determined	 to	 be	better	 suited	 to	 use	 in	
dye-retention	assays	than	three-dimensional	spheroid	cultures,	owing	to	the	relatively	
poorly	proliferative	nature	of	 the	 latter	 leading	 to	a	high	proportion	of	dye-retaining	
cells	 up	 to	 18	 days	 post-staining.	 Dye	 retention	 assays	 undertaken	 in	 monolayer	
cultures	 of	 five	 distinct	 human	 breast	 cancer	 cell	 lines	 revealed	 a	 slow-cycling,	
relatively	quiescent	 sub-population	of	 cells	after	 five	passages	of	 continuous	culture.	
The	exact	nature	of	these	dye-retaining	quiescent	cells	and	the	effects	that	modifying	
the	 culture	 environment	 have	 on	 the	 dye-retaining	 quiescent	 population	 will	 be	
explored	in	subsequent	chapters.	
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Chapter	4	
	
	
The	Effects	of	Modulating	In	Vitro	
Conditions	on	the	Mitotically	Quiescent	
Sub-Population	in	Breast	Cancer	
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4.1. Summary	
	
The	 contemporary	 plasticity	 model	 of	 tumoural	 heterogeneity	 and	 emerging	
experimental	 evidence	 both	 strongly	 suggest	 that	mitotic	 quiescence	 is	 an	 inducible	
phenomenon	that	 is	 instructed	by	the	tumoural	microenvironment,	 thereby	 implying	
that	controlled	modulation	of	in	vitro	culture	conditions	could	facilitate	the	generation	
of	relatively	large	numbers	of	quiescent	tumour	cells	for	further	study.	This	possibility	
is	 a	 highly	 desirable	 prospect	 as	 the	 limiting	 cost	 and	 technical	 difficulty	 associated	
with	 acquisition	 of	 sufficient	 numbers	 of	 quiescent	 cancer	 cells	 from	 extant	 in	 vivo	
model	 systems	 has	 been	 one	 of	 the	 principal	 factors	 impeding	 progress	 in	
understanding	 the	 biological	 processes	 that	 underpin	 tumour	 cell	 quiescence.	 This	
chapter	describes	a	series	of	experiments	designed	to	enable	a	better	understanding	
of	 how	 in	 vitro	 microenvironmental	 conditions	 give	 rise	 to	 tumour	 cells	 with	 a	
mitotically	quiescent	phenotype.	
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4.2. Introduction	
	
According	to	a	position	paper	which	was	the	result	of	the	collaborative	efforts	of	over	
one	 hundred	 internationally	 recognised	 specialist	 breast	 cancer	 scientists,	 clinicians	
and	 healthcare	 professionals,	 "understanding	 the	 molecular	 mechanisms	 of	 tumour	
heterogeneity,	dormancy,	de	novo	or	acquired	resistance	and	how	to	target	key	nodes	
in	 these	 dynamic	 processes"	 was	 one	 of	 ten	 critical	 research	 gaps	 and	 translational	
priorities	 identified	 for	 the	 successful	 prevention	 and	 treatment	 of	 breast	 cancer	
(Eccles	 et	 al.,	 2013).	 While	 there	 is	 an	 obvious	 requirement	 for	 significant	
advancement	 in	 this	 preeminent	 area,	 furthering	 extant	 knowledge	 of	 these	
phenomena	 has	 been	 significantly	 hampered	 by	 the	 difficulty	 of	 obtaining	 sufficient	
numbers	 of	 quiescent	 cells	 from	 the	 existing	 in	 vivo	 model	 systems	 used	 to	 study	
breast	cancer	metastasis.	
	
Previous	in	vivo	studies	undertaken	within	the	Holen	group	have	demonstrated	that	a	
sub-clonal	population	present	in	both	human	breast	and	prostate	tumour	cell	lines	are	
capable	of	successful	engraftment	in	the	long	bones	of	immunocompromised	mice	but	
are	 able	 to	 remain	 non-proliferative	 for	 a	 protracted	 period	 of	 time	 (Figure	 4.1.)	
(Ottewell	et	al.,	2014a;	Ottewell	et	al.,	2014b;	Wang	et	al.,	2015b;	Wang	et	al.,	2015c).	
In	 the	preceding	 chapter,	 a	 similar	 sub-clonal	population	of	 cells	 shown	 to	be	either	
non-dividing	or	very	slowly	cycling	over	an	extended	time	period	(up	to	six	passages	of	
culture	growth)	was	identified	within	multiple	human	breast	cancer	cell	lines	grown	in	
vitro	 using	 a	 fluorescent	 lipophilic	 dye	 retention	 method.	 Fluorescent	 dye-retaining	
human	 prostate	 cancer	 cells	 that	 were	 identified	 by	 similar	 means	 in	 the	 closely	
related	work	of	Wang	et	al.	(2015b)	were	shown	to	be	significantly	more	metastatic	in	
vivo	 than	 the	 corresponding	 rapidly	 dividing	 population,	 and	 had	 a	 propensity	 to	
colonise	the	long	bones	in	particular.	Taken	together,	these	findings	not	only	suggest	
that	a	mitotically	quiescent	 sub-population	 is	a	 feature	of	multiple	cancer	 types,	but	
that	 these	 slow-cycling	 cells	 possess	 enhanced	 metastatic	 potential.	 Given	 the	
discussed	 limitations	 of	 acquiring	metastasis-initiating	 cells	 from	 in	 vivo	models,	 the	
ability	 to	 identify,	 isolate	 and	 characterise	 a	 relatively	 large	 number	 of	 inherently	
quiescent	cells	 from	human	breast	cancer	cell	 lines	using	the	 lipophilic	dye	retention	
model	described	previously	herein	is	seemingly	a	highly	attractive	prospect	that	could	
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potentially	 enable	 significant	 advances	 in	 current	 knowledge	 of	 the	 biological	
processes	underpinning	population	heterogeneity,	the	quiescent	state	and	associated	
enhanced	metastatic	potential	in	breast	cancer.	
	
	
	
Figure	4.1.	Non-Proliferative	Tumour	Cells	in	Proximal	Trabecular	Bone	of	Mice	
Vybrant®	DiD-labelled	MDA-MB-231	cells	(red	fluorescent	events	highlighted	by	yellow	arrows)	present	
in	 the	 proximal	 trabecular	 region	 of	 the	 tibiae	 of	 immunocompromised	 mice	 at	 35	 days	 post-
intravenous	 injection.	These	 findings	demonstrate	 that	 tumour	cells	have	successfully	homed	 to	bone	
and	 engrafted	 but	 remain	 non-proliferative	 for	 a	 protracted	 period	 of	 time.	 Image	 modified	 from	
Ottewell	et	al.	(2014).	Zoledronic	acid	has	differential	antitumor	activity	in	the	pre-	and	postmenopausal	
bone	 microenvironment	 in	 vivo.	 Clin	 Cancer	 Res,	 20,	 2922-32	 with	 permission	 from	 American	
Association	for	Cancer	Research.	
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Given	that	conditional	cellular	mitotic	quiescence	(previously	discussed	in	Section	1.6.	
-	 Section	 1.7.)	 is	 suggested	 to	 arise	 at	 either	 pre-metastatic	 or	 post-metastatic	 sites	
due	 to	 a	 non-growth	 permissive	 cellular	 microenvironment,	 it	 is	 plausible	 that	 the	
quiescent	 cell	 population	 identified	 within	 in	 vitro	 cultures	 is,	 at	 least	 partially,	
influenced	by	microenvironmental	stimuli.	A	greater	understanding	of	how	the	culture	
conditions	 present	 in	 vitro	 either	 give	 rise	 to	 or	 might	 be	 used	 to	 enrich	 the	 dye-
retaining	cell	population	could	provide	critical	 insight	 into	the	mechanisms	governing	
the	existence	and	survival	of	cell	populations	with	 reduced	mitotic	activity	or	enable	
isolation	of	 greater	 cell	 numbers	 for	 elucidation	of	 these	as	 yet	undefined	biological	
processes.	Consequently,	the	work	described	within	this	chapter	primarily	focuses	on	
the	degree	to	which	the	intrinsic	quiescent	cell	population	size	and	overt	outgrowth	of	
these	quiescent	sub-clones	are	influenced	by	in	vitro	culture	conditions.	The	MDA-MB-
231	human	breast	cancer	cell	line,	the	predominant	lineage	used	for	in	vivo	modelling	
of	 breast	 cancer	 bone	 metastasis,	 was	 the	 principal	 cell	 line	 used	 in	 this	 and	
subsequent	 chapters	 due	 to	 the	 necessity	 of	 planned	 future	 in	 vivo	 experiments	 to	
determine	 the	 intrinsic	 metastatic	 potential	 of	 dye-retaining	 and	 non-dye-retaining	
populations	and	 to	ascertain	how	 findings	 from	the	 in	vitro	models	described	herein	
translate	to	the	in	vivo	setting.	
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4.3. Aims,	Hypothesis	and	Objectives	
	
The	 aim	 of	 the	 work	 described	 in	 this	 chapter	 was	 to	 explore	 how	 in	 vitro	 culture	
conditions	 affect	 the	 mitotically	 quiescent	 breast	 cancer	 cell	 population	 identified	
using	the	fluorescent	 lipophilic	dye	retention	method	and	to	determine	whether	this	
population	 is	 an	 intrinsic	 feature	 of	 breast	 cancer	 cell	 lines	 or	 if	 it	 emerges	 under	
inductive	microenvironmental	conditions	within	growing	cultures.	
	
The	key	hypothesis	pertaining	to	the	work	described	in	this	chapter	was	that	the	latent	
mitotically	quiescent	sub-populations	identified	within	human	breast	cancer	cell	lines	
are	not	an	inherent	intrinsic	feature	but	arise	due	to	microenvironmental	induction.	
	
The	following	objectives	were	defined	in	order	to	test	this	hypothesis:	
	
1. Determine	how	monolayer	culture	conditions	affect	the	size	of	the	slow-cycling	cell	
population	(as	determined	by	dye-retention	at	passage	6	post-staining).	
	
2. Establish	whether	or	 not	 the	 slow-cycling	population	 is	 able	 to	 re-emerge	within	
cultures	of	isolated	rapidly	dividing	cells.	
	
3. Determine	how	culture	 conditions	affect	 the	clonogenicity	of	 the	 rapidly	dividing	
and	slow-cycling	cell	populations	in	monolayer	colony	formation	assays.	
	
4. Ascertain	whether	cells	held	in	a	quiescent	state	by	modulating	culture	conditions	
can	 be	 stimulated	 to	 form	 colonies	 by	 re-establishing	 a	 standard	 culture	
environment.	
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4.4. Materials	and	Methods	
	
4.4.1. Assay	of	the	Effect	of	Confluency	at	Sub-Culture	on	Dye-Retention	
	
Wild	type	MDA-MB-231	and	MCF-7	cells	were	stained	in	suspension	with	Vybrant®	DiD	
or	 Vybrant®	 CM-DiI	 according	 to	 the	 manufacturer	 instructions	 (Section	 2.3.1.).	
Stained	 cells	 were	 seeded	 at	 the	 cell	 line-specific	 optimal	 density	 (Table	 2.2.)	 into	
75cm2	 high-quality	 polystyrene	 tissue	 culture	 flasks	 along	 with	 unlabelled	 control	
samples	 and	 cultured	 continuously.	 The	 passage-length	 used	 for	 maintaining	 sub-
confluency	in	growing	cultures	was	3	days	for	both	MDA-MB-231	and	MCF-7	cell	lines,	
while	full	confluency	was	reached	after	4	days	in	both	cases.	Configuration	of	the	flow	
cytometer	was	undertaken	at	 the	outset	of	each	experiment	as	described	previously	
(Section	3.4.3.).	At	each	sub-culture	interval,	cells	were	retrieved	and	counted	before	
being	 assessed	 cytofluorimetrically	 for	 percentage	 dye-positivity.	 Briefly,	 samples	 of	
1.0	x	106	cells	were	prepared	from	each	retrieved	culture	for	cytofluorimetric	analysis	
by	 undertaking	 centrifugation	 at	 150	 x	g	 for	 5	minutes	 followed	 by	 resuspension	 in	
serum-free	basal	medium.	Prepared	cell	suspensions	were	analysed	by	flow	cytometry	
in	order	 to	determine	 the	percentage	of	Vybrant®	dye-positive	events	present	using	
the	gating	tree	pre-set	at	the	beginning	of	the	experiment.	The	percentage	positivity	of	
each	cell	 line	was	monitored	in	this	way	for	up	to	six	consecutive	passages	of	culture	
growth.	
	
	
	
	
	
	
	
	
	
	
	
	
	 130	
4.4.2. Establishing	Dye-Retaining	Cell	Re-Emergence	in	Rapidly	Dividing	Cultures	
	
After	 a	 total	 of	 five	 consecutive	 passages	 of	 culture	 post-staining,	 Vybrant®	 DiD-
stained	 MDA-MB-231	 cultures	 were	 sorted	 into	 dye-negative	 and	 dye-positive	
fractions	by	FACS.	The	isolated	dye-negative	fraction	was	then	re-stained	according	to	
the	manufacturer's	 instructions	(Section	2.3.1.)	and	seeded	at	the	optimal	density	of	
1.0	x	104	cells	per	cm2	into	75cm2	high-quality	polystyrene	tissue	culture	flasks,	along	
with	 unlabelled	 control	 samples	 prepared	 concomitantly	 in	 the	 same	 manner.	 Re-
stained	cultures	were	grown	for	a	further	six	consecutive	passages,	with	dye-retention	
being	 monitored	 at	 each	 consecutive	 sub-culture	 in	 the	 same	 manner	 as	 outlined	
previously	(Section	3.4.3.).	
	
4.4.3. Assessing	HIF-1α	Expression	in	Dye-Negative	and	Dye-Retaining	Cells	
	
Staining	 of	 wild	 type	 MDA-MB-231	 cells	 with	 Vybrant®	 DiD	 was	 undertaken	 in	
suspension	 according	 to	 the	manufacturer	 instructions	 (Section	 2.3.1.).	 Stained	 cells	
were	seeded	at	the	recommended	optimal	density	(Table	2.2.)	into	75cm2	high-quality	
polystyrene	 tissue	 culture	 flasks	 and	 cultured	 continuously	 for	 five	 subsequent	
passages.	Following	retrieval	of	stained	cultures	at	passage	five	post-staining,	Vybrant®	
DiD-positive	and	DiD-negative	cells	were	isolated	by	FACS	and	2000	cells	of	each	type	
deposited	onto	glass	microscope	slides	using	a	cytocentrifuge	as	described	in	Section	
2.3.2.1.	 Samples	 were	 immunostained	 for	 expression	 of	 HIF-1α	 using	 antibodies	
detailed	in	Table	4.1.	according	to	the	protocol	for	detection	of	intracellular	antigens	
by	indirect	immunofluorescence	outlined	in	Section	2.3.2.2.	The	final	working	protein	
concentration	of	antibodies	used	was	determined	by	preliminary	assays	carried	out	in	
the	 same	 manner	 in	 which	 a	 range	 of	 final	 protein	 concentrations	 of	 primary	 and	
secondary	antibodies	were	used;	primary	antibody	concentrations	ranged	from	1μg/ml	
to	 10μg/ml,	 while	 secondary	 antibody	 concentrations	 ranged	 from	 1.875μg/ml	 to	
15μg/ml,	 as	 recommended	 by	 the	 supplier.	 Immunostained	 samples	 were	 imaged	
under	 fluorescence	microscopy	and	a	series	of	 three	non-overlapping	fields	captured	
at	100X	magnification	using	 the	 tile	 scan	 function	of	 the	Leica	AF6000LX	microscope	
for	manual	scoring	of	marker	expression	(as	described	in	Section	2.4.).	Representative	
images	of	the	staining	pattern	were	also	captured	at	200X	magnification.	
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Table	4.1.	Antibodies	Used	in	Immunostaining	for	HIF-1α	Expression	
	
Target	
	
Host	
Species	 Clonality	 Isotype	 Clone	No.	 Conjugate	
Final	Conc.	
(μg/ml)	 Supplier	
HIF-1α	 Mouse	 Mono	 IgG2b	 H1alpha67	 None	 5	 Abcam	
None	 Mouse	 Mono	 IgG2b	 7E10G10	 None	 5	 Abcam	
Mouse	IgG+M	 Goat	 Poly	 IgG	 -	 AlexaFluor®	488	 3.75	 Stratech	
	
An	unconjugated	antibody	against	HIF-1α	and	a	matched	 isotype	control	antibody	were	sourced	 from	
Abcam	 Plc.	 (Cambridge,	 U.K.).	 An	 AlexaFluor®	 488-conjugated	 secondary	 antibody	 was	 sourced	 from	
Stratech	 Scientific	 Ltd.	 (Newmarket,	U.K.).	 The	working	 concentration	of	 the	 isotype	 control	 antibody	
was	matched	to	the	exact	working	protein	concentration	of	the	primary	antibody.	
	
4.4.4. Serum	and	Glucose	Titration	Assays	
	
Cells	were	seeded	in	triplicate	wells	of	24-well	cluster	plates	at	the	optimal	density	and	
supplemented	with	 0.2ml	 of	 complete	 growth	medium	 per	 cm2	 growth	 area.	 Plates	
were	placed	into	incubation	under	standard	growth	conditions	for	a	12-hour	period	in	
order	 to	 allow	 cells	 to	 settle	 and	 adhere	 to	 the	 plate	 surface.	 For	 glucose	 titration	
assays,	 the	medium	contained	within	each	well	was	 carefully	 removed	and	 replaced	
with	 an	 equivalent	 volume	 of	 growth	 medium	 containing	 10%	 (v/v)	 supplemental	
dialysed	FBS	and	a	final	concentration	of	glucose	between	0mM	and	16.4mM.	Glucose	
concentrations	 above	 11mM	 were	 achieved	 by	 addition	 of	 the	 required	 volume	 of	
0.56M	D-(+)-glucose	 solution	 (Sigma-Aldrich	 Company	 Ltd.).	 For	 FBS	 titration	 assays,	
the	medium	contained	within	each	well	was	carefully	removed	and	replaced	with	an	
equal	 volume	of	 growth	medium	 containing	 the	 standard	11mM	glucose	 and	 a	 final	
dialysed	FBS	concentration	between	0%	and	15%	(v/v).	At	the	end	of	the	 logarithmic	
phase	 of	 growth	 (Table	 3.1.),	 all	wells	were	 retrieved	 by	 trypsinisation	 as	 described	
previously	 (Section	 2.2.1.2.)	 and	 the	 viable	 cell	 number	 determined	 by	
haemocytometric	 counting	 using	 the	 trypan	 blue	 dye	 exclusion	 method	 (Section	
2.2.3.).	
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4.4.5. Monitoring	Dye-Retention	in	Serum-	or	Glucose-Depleted	Cultures	
	
Staining	 of	 MDA-MB-231	 cells	 with	 Vybrant®	 DiD	 was	 undertaken	 in	 suspension	
according	to	 the	manufacturer's	 instructions	 (Section	2.3.1.).	A	series	of	75cm2	high-
quality	polystyrene	tissue	culture	 flasks	were	pre-filled	with	RPMI-1640	basal	culture	
medium	 containing	 either	 11mM	 glucose	 and	 10%	 FBS	 (control	 samples),	 11mM	
glucose	 and	 the	 EC50	 concentration	 of	 FBS	 (4%	 (v/v))	 or	 the	 EC50	 concentration	 of	
glucose	 (2.2mM)	 and	 10%	 (v/v)	 FBS.	 Stained	 cells	 and	 unlabelled	 samples	 used	 for	
cytofluorimetric	configuration	were	seeded	into	these	flasks	at	the	optimal	density	of	
1.0	 x	 104	 cells	 per	 cm2	 and	 cultured	 continuously	 for	 six	 passages;	 sub-culture	 was	
undertaken	at	72-hour	intervals.	At	each	sub-culture,	cells	were	retrieved	and	counted	
before	 being	 assessed	 cytofluorimetrically	 for	 percentage	 dye-positivity	 as	 described	
previously	(Section	3.4.3.).	
	
4.4.6. Cell	Cycle	Profiling	Under	Varied	Culture	Conditions	Using	Propidium	Iodide	
	
Wild-type	MDA-MB-231	cells	were	seeded	at	the	optimal	density	of	1.0	x	104	cells	per	
cm2	into	a	series	of	25cm2	high-quality	polystyrene	tissue	culture	flasks	pre-filled	with	
RPMI-1640	 culture	 medium	 containing	 either	 11mM	 glucose	 and	 10%	 FBS	 (control	
samples),	 11mM	 glucose	 and	 the	 EC50	 concentration	 of	 FBS	 (4%	 (v/v)),	 or	 the	 EC50	
concentration	of	glucose	(2.2mM)	and	10%	(v/v)	FBS.	Cells	were	placed	into	incubation	
for	 3	 days	 post-seeding	 before	 being	 retrieved	 and	 counted	 (Section	 2.2.1.2	 and	
Section	2.2.3.).	Samples	of	1.0	x	106	cells	from	each	cell	suspension	were	fixed	in	70%	
(v/v)	 ethanol	 and	 incubated	 with	 a	 mixture	 of	 0.002%	 (w/v)	 RNase	 A	 in	 75μM	
propidium	 iodide	 solution	 prior	 to	 cytofluorimetric	 cell	 cycle	 profile	 analysis,	 as	
described	previously	(Section	2.5.2.1.).	
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4.4.7. Western	Blot	Analysis	of	ERR-α	Expression	in	Breast	Cancer	Cell	Lines	
	
Cultures	 of	MCF-7,	 ZR-75-1,	MDA-MB-231,	MDA-MB-468	 and	 SK-BR-3	 human	 breast	
cancer	 cell	 lines	were	 grown	as	 detailed	 in	Section	 2.2.1.1.	 until	 approximately	 70%	
confluency	 was	 reached.	 Whole	 cell	 lysate	 were	 prepared	 from	 each	 cell	 line	 and	
western	 blot	 analysis	 for	 oestrogen-related	 receptor-alpha	 (ERR-α)	 and	 the	
constitutively	expressed	 cytoskeletal	protein	 vinculin	 (used	as	a	 loading	 control)	was	
carried	out	according	to	the	methods	detailed	in	Section	2.7.	The	antibodies	used	are	
detailed	 in	 Table	 4.2.	 below.	 The	 final	 working	 protein	 concentration	 of	 antibodies	
used	was	determined	by	preliminary	assays	carried	out	in	the	same	manner	in	which	a	
range	 of	 final	 protein	 concentrations	 of	 primary	 antibodies	 were	 used;	 primary	
antibody	concentrations	ranged	from	1μg/ml	to	5μg/ml,	while	the	secondary	antibody	
concentration	used	was	always	0.1μg/ml,	as	recommended	by	the	supplier.	
	
Table	4.2.	Antibodies	Used	in	Western	Blot	Analysis	of	ERR-α	Expression	
	
Target	
	
Host	
Species	 Clonality	 Isotype	 Conjugate	
Final	Conc.	
(μg/ml)	 Supplier	 Cat.	No.	
ERR-α	 Rabbit	 Poly	 IgG	 None	 2.5	 Abcam	 ab93173	
Vinculin	 Rabbit	 Poly	 IgG	 None	 1	 Abcam	 ab73412	
Rabbit	IgG	 Goat	 Poly	 IgG	 Horseradish	Peroxidase	 2	 Agilent	 P0448	
	
Unconjugated	 anti-ERR-α	 and	 anti-vinculin	 primary	 antibodies	 were	 sourced	 from	 Abcam	 Plc.	
(Cambridge,	 U.K.),	 while	 a	 horseradish	 peroxidase-conjugated	 secondary	 antibody	 was	 sourced	 from	
Agilent	Technologies	LDA	U.K.	Ltd.	(Stockport,	U.K.).	
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4.4.8. Flow	Cytometric	Analysis	of	ERR-α	Expression	in	MDA-MB-231	Cells	
	
MDA-MB-231	 cells	 were	 cultured	 according	 to	 the	 methods	 described	 in	 Section	
2.2.1.1.	 Following	 harvesting	 once	 cultures	 had	 reached	 approximately	 70%	
confluency,	 samples	 of	 1.0	 x	 106	 cells	were	 prepared	 and	 immunostained	 for	 ERR-α	
according	 to	 the	 general	 protocol	 for	 flow	 cytometric	 assessment	 of	 intracellular	
markers	 by	 indirect	 immunofluorescence	 outlined	 in	 Section	 2.3.3.3.	 using	 the	
antibodies	 detailed	 in	 Table	 4.3.	 below.	 The	 final	 working	 protein	 concentration	 of	
antibodies	used	was	determined	by	preliminary	assays	carried	out	in	the	same	manner	
in	which	a	range	of	final	protein	concentrations	of	primary	and	secondary	antibodies	
were	used;	primary	antibody	concentrations	ranged	from	10μg/ml	to	50μg/ml,	while	
secondary	antibody	concentrations	ranged	from	0.5μg/ml	to	1μg/ml,	as	recommended	
by	the	supplier.	
	
Table	4.3.	Antibodies	Used	in	Flow	Cytometric	Analysis	of	ERR-α	Expression	
	
Target	
	
Host	
Species	 Clonality	 Isotype	 Conjugate	
Final	Conc.	
(μg/ml)	 Supplier	 Cat.	No.	
ERR-α	 Rabbit	 Poly	 IgG	 None	 10	 Abcam	 ab93173	
None	 Rabbit	 Poly	 IgG	 None	 10	 Abcam	 ab171870	
Rabbit	IgG	H&L	 Goat	 Poly	 IgG	 AlexaFluor®	488	 0.5	 Abcam	 ab150077	
	
An	unconjugated	anti-ERR-α	primary	antibody,	a	matched	isotype	control	antibody	and	an	AlexaFluor®	
488-conjugated	secondary	antibody	were	all	 sourced	 from	Abcam	Plc.	 (Cambridge,	U.K.).	The	working	
concentration	of	the	isotype	control	antibody	was	matched	to	the	exact	working	protein	concentration	
of	the	primary	antibody.	
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4.4.9. Preparation	of	Conditioned	Medium	
	
Wild-type	MDA-MB-231	cells	were	seeded	 into	75cm2	high-quality	polystyrene	tissue	
culture	flasks	at	the	optimal	density	of	1.0	x	104	cells	per	cm2	and	supplemented	with	
0.2ml	of	complete	culture	medium	per	cm2	of	culture	vessel	surface	area.	Conditioned	
culture	medium	was	removed	from	growing	cultures	at	the	appropriate	time	interval,	
which	 was	 pre-determined	 as	 96	 hours	 post-seeding	 for	 production	 of	 glucose-
depleted	 conditioned	 medium	 using	 the	 MDA-MB-231	 cell	 line	 (Section	 4.5.7.).	
Conditioned	medium	was	immediately	centrifuged	at	150	x	g	for	5	minutes	in	order	to	
remove	any	residual	cells	contained	within	the	medium.	Following	centrifugation,	the	
supernatant	 was	 decanted	 and	 then	 sterile	 filtered	 using	 a	 0.2μm	 polycarbonate	
syringe	 filter.	 Conditioned	medium	was	 kept	 in	 a	 refrigerator	maintained	 at	 4oC	 for	
short-term	storage	or	at	-80oC	for	long-term	storage.	
	
4.4.10. Measurement	of	Glucose	and	Lactate	in	MDA-MB-231	Culture	Medium	
	
Wild-type	 MDA-MB-231	 cells	 were	 seeded	 into	 a	 series	 of	 25cm2	 high-quality	
polystyrene	 tissue	 culture	 flasks	 at	 the	 optimal	 density	 of	 1.0	 x	 104	 cells	 per	 cm2.	
Conditioned	 medium	 was	 collected	 at	 24-hour	 intervals	 over	 a	 7-day	 period	 and	
prepared	as	described	above	 (Section	 4.4.9.).	 The	 concentration	of	D-glucose	and	 L-
lactate	present	in	each	solution	was	determined	using	the	D-glucose	or	L-lactate	assay	
kit	available	from	Eton	Bioscience	Inc.	as	described	previously	(Section	2.8.2.	-	Section	
2.8.3.).	
	
4.4.11. Colony	Formation	Assays	Under	Varied	Culture	Conditions	
	
After	 a	 total	 of	 five	 consecutive	 passages	 of	 culture	 post-staining,	 Vybrant®	 DiD-
stained	 MDA-MB-231	 cultures	 were	 sorted	 into	 dye-negative	 and	 dye-positive	
fractions	by	FACS.	Cells	from	each	fraction	were	seeded	at	a	clonogenic	density	of	20	
cells	per	cm2	into	triplicate	wells	of	6-well	cluster	plates	pre-filled	with	3ml	of	culture	
medium	 in	which	either	 the	glucose	or	 serum	content	had	been	reduced	 to	 the	EC0,	
EC25,	 EC50	 or	 EC100	 concentration	 (Table	 4.4.),	 or	which	 contained	 0mM	glucose	 and	
22mM	lactate	(conditioned	medium	collected	from	growing	MDA-MB-231	cultures	at	
	 136	
4-days	 post-seeding	 with	 10%	 FBS	 added).	 Seeded	 cluster	 plates	 were	 placed	 into	
incubation	under	standard	growth	conditions	for	a	period	of	6	days.	Colony	formation	
assays	 were	 subsequently	 undertaken	 (as	 described	 in	 Section	 2.2.6.1.)	 and	 the	
number	 of	 colonies	 formed	 by	 Vybrant®	 DiD-positive	 and	 Vybrant®	 DiD-negative	
fractions	under	each	set	of	conditions	quantified.	
	
4.4.12. Colony	Formation	Stimulation	Assays	
	
Following	 five	 consecutive	 passages	 of	 culture	 post-staining,	 Vybrant®	 DiD-stained	
MDA-MB-231	 cultures	 were	 sorted	 into	 dye-negative	 and	 dye-positive	 fractions	 by	
FACS.	Cells	from	each	fraction	were	seeded	at	a	clonogenic	density	of	20	cells	per	cm2	
into	 triplicate	wells	 of	 6-well	 cluster	 plates	 pre-filled	with	 3ml	 of	 culture	medium	 in	
which	either	the	glucose	or	serum	content	had	been	reduced	to	either	the	EC0	or	EC25	
concentration	 (Table	 4.4.),	 or	 conditioned	 medium	 containing	 22mM	 lactate	
previously	collected	from	growing	MDA-MB-231	cultures	at	4-days	post-seeding	with	
10%	 FBS	 added.	 Seeded	 cluster	 plates	 were	 placed	 into	 incubation	 under	 standard	
growth	conditions	for	a	period	of	6	days.	After	6	days	of	growth	post-seeding,	colony	
formation	 assays	 were	 performed	 on	 half	 of	 each	 sample	 set.	 The	 culture	 medium	
within	the	wells	of	the	remaining	half	of	each	sample	set	was	exchanged	for	an	equal	
volume	 of	 fresh	 complete	 culture	 medium	 (RPMI-1640	 with	 11mM	 glucose	 +	 10%	
supplemental	FBS),	effectively	replenishing	the	component	from	which	cells	had	been	
deprived.	 These	 plates	 were	 subsequently	 replaced	 in	 incubation	 under	 standard	
growth	 conditions	 for	 another	 period	 of	 6	 days.	 Colony	 formation	 assays	were	 then	
undertaken	 (as	described	 in	Section	 2.2.6.1.)	and	 the	number	of	 colonies	 formed	by	
Vybrant®	 DiD-positive	 and	 Vybrant®	 DiD-negative	 fractions	 under	 each	 set	 of	
conditions	quantified.	A	summary	of	 the	experimental	 timeline	for	assays	dependent	
on	colony	formation	stimulation	is	depicted	in	Figure	4.2.	
	
	
	
	
	
	
	 137	
	
	
Figure	4.2.	Timeline	for	Colony	Formation	Stimulation	Assays	
Vybrant®	DiD-stained	cells	were	cultured	continuously	for	five	passages	prior	to	being	reseeded	into	6-
well	cluster	plates	and	exposed	to	nutrient	deficient	medium	for	six	days.	Colony	formation	assays	were	
performed	on	half	 of	 each	 sample	 set.	 The	 culture	medium	within	 the	wells	 of	 the	 remaining	 half	 of	
each	 sample	 set	was	 exchanged	 for	 an	 equal	 volume	 of	 fresh	 complete	 culture	medium	 (RPMI-1640	
with	 11mM	 glucose	 +	 10%	 supplemental	 FBS),	 replenishing	 the	 component	 to	 which	 cells	 had	 been	
deprived.	A	further	six	day	incubation	period	was	undertaken	prior	to	determination	of	the	number	of	
colonies	 formed	 by	 Vybrant®	 DiD-positive	 and	 negative	 cells	 within	 each	 treatment	 group	 post-
stimulation.	
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4.4.13. Colony	Formation	Assays	in	the	Presence	of	ERR-α	Inhibitors	
	
Vybrant®	DiD	dye-negative	and	dye-positive	MDA-MB-231	populations	were	 isolated	
by	FACS	following	five	consecutive	passages	of	culture	post-staining.	Each	fraction	was	
then	seeded	at	a	clonogenic	density	of	20	cells	per	cm2	 into	triplicate	wells	of	6-well	
cluster	 plates	 pre-filled	with	 3ml	 of	 pre-conditioned	 culture	medium	 (22mM	 lactate	
with	10%	FBS	added)	that	contained	either	Cpd29	or	XCT790	at	a	final	concentration	of	
10μM.	 Untreated	 control	 samples	 were	 composed	 concomitantly.	 Seeded	 cluster	
plates	were	placed	into	incubation	under	standard	growth	conditions	for	a	period	of	6	
days.	 After	 6	 days	 of	 growth	 post-seeding,	 the	 culture	 medium	 in	 all	 wells	 was	
removed	and	replaced	with	an	equal	volume	of	complete	RPMI-1640	culture	medium	
with	 11mM	 glucose	 and	 10%	 FBS.	 Plates	 were	 subsequently	 replaced	 in	 incubation	
under	 standard	 growth	 conditions	 for	 another	 period	 of	 6	 days.	 Colony	 formation	
assays	 were	 then	 undertaken	 as	 described	 in	 Section	 2.2.6.1.	 and	 the	 number	 of	
colonies	 formed	by	Vybrant®	DiD-positive	and	Vybrant®	DiD-negative	fractions	under	
each	set	of	conditions	quantified.	A	summary	of	the	experimental	timeline	is	depicted	
in	Figure	4.3.	
	
	
	
Figure	4.3.	Timeline	for	Colony	Formation	Assays	Post-ERR-α	inhibitor	Treatment	
Vybrant®	DiD-stained	cells	were	cultured	continuously	for	five	passages	prior	to	being	reseeded	into	6-
well	 cluster	 plates	 under	 glucose	 depleted,	 lactate	 rich	 conditions	 in	 the	 presence	 of	 selective	 ERR-α	
inhibitors	Cpd29	or	XCT790	at	a	final	concentration	of	10μM	for	six	days.	After	the	initial	six-day	period,	
the	 culture	 medium	 within	 all	 wells	 was	 exchanged	 for	 an	 equal	 volume	 of	 fresh	 complete	 culture	
medium	 (RPMI-1640	 with	 11mM	 glucose	 +	 10%	 supplemental	 FBS),	 effectively	 removing	 drug	 from	
culture	 medium,	 reducing	 lactate	 levels	 and	 replenishing	 glucose	 levels	 to	 normal.	 A	 further	 six	 day	
incubation	period	was	undertaken	prior	to	determination	of	the	number	of	colonies	formed	by	Vybrant®	
DiD-positive	and	negative	cells	within	each	treatment	group.	
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4.4.14. Drug-Resistant	Colony	Formation	Assays	in	the	Presence	of	ERR-α	Inhibitors	
	
Fluorescence	activated	cell	sorting	was	used	to	isolate	Vybrant®	DiD-positive	MDA-MB-
231	cells	at	passage	five	post-staining.	Cells	were	seeded	at	a	clonogenic	density	of	20	
cells	per	cm2	 into	triplicate	wells	of	6-well	cluster	plates	pre-filled	with	3ml	of	either	
pre-conditioned	culture	medium	 (22mM	 lactate	with	10%	FBS	added)	 containing	 the	
IC95	of	doxorubicin	(321nM)	either	alone	or	in	combination	with	Cpd29	or	XCT790	at	a	
final	 concentration	 of	 10μM.	 Untreated	 control	 samples	 were	 composed	
concomitantly.	 Seeded	 cluster	 plates	 were	 placed	 into	 incubation	 under	 standard	
growth	 conditions	 for	 a	 period	 of	 6	 days.	 After	 6	 days	 of	 growth	 post-seeding,	 the	
culture	 medium	 in	 all	 wells	 was	 removed	 and	 replaced	 with	 an	 equal	 volume	 of	
complete	RPMI-1640	 culture	medium	with	11mM	glucose	and	10%	FBS.	Plates	were	
subsequently	 replaced	 in	 incubation	 under	 standard	 growth	 conditions	 for	 another	
period	 of	 6	 days.	 Colony	 formation	 assays	 were	 then	 undertaken	 as	 described	 in	
Section	 2.2.6.1.	 and	 the	 number	 of	 colonies	 formed	 within	 each	 treatment	 group	
quantified.	A	summary	of	the	experimental	timeline	is	depicted	in	Figure	4.4.	
	
	
	
Figure	4.4.	Timeline	for	Drug-Resistant	Colony	Formation	Assays	
Vybrant®	DiD-retaining	cells	were	isolated	at	passages	five	post-staining	prior	to	being	reseeded	into	6-
well	cluster	plates	and	exposed	to	pre-conditioned	culture	medium	(22mM	lactate	with	10%	FBS	added)	
either	alone	or	containing	the	IC95	of	doxorubicin	(321nM)	with	or	without	Cpd29	or	XCT790	at	a	final	
concentration	of	10μM.	After	six	days	of	exposure	to	test	conditions	the	culture	medium	was	exchanged	
for	 an	equal	 volume	of	 fresh	 complete	 culture	medium	 (RPMI-1640	+	10%	FBS)	 and	a	 further	 six-day	
incubation	period	undertaken	prior	to	determination	of	the	number	of	colonies	formed	by	cells	within	
each	treatment	group	post-stimulation.	
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4.5. Results	
	
4.5.1. Sub-Culture	at	Full	Confluency	Does	Not	Affect	Dye-Retaining	Population	Size	
	
The	 established	 plasticity	 model	 of	 tumoural	 heterogeneity	 and	 emerging	
experimental	 evidence	 both	 imply	 that	 microenvironmental	 stimuli	 are	 able	 to	
influence	the	generation,	size	and	rapid	outgrowth	of	the	quiescent	or	slow-cycling	cell	
population	(Rich,	2016;	Fluegen	et	al.,	2017).	During	earlier	experiments	to	determine	
the	 existence	 of	 a	 latent	 slow-cycling	 or	 quiescent	 population	 within	 human	 breast	
cancer	cell	 lines,	growing	cultures	were	maintained	at	sub-confluent	 levels	and	were	
not	 allowed	 to	 progress	 further	 than	 the	 logarithmic	 phase	 of	 culture	 growth.	
Undertaking	 sub-culture	 at	 the	 point	 of	 complete	 surface	 coverage	 and	 allowing	
cultures	to	progress	into	the	stationary	phase	of	culture	growth	was	therefore	used	to	
test	 the	 hypothesis	 that	 culture	 overgrowth,	 and	 the	 resultant	 metabolic	 stress	
induced	due	to	loss	of	metabolic	substrates	and	build-up	of	metabolic	waste	products,	
would	increase	the	size	of	the	latent	quiescent	population.	
	
In	both	MDA-MB-231	and	MCF-7	cell	 lines,	undertaking	sub-culture	at	full	confluency	
did	 not	 result	 in	 a	 significant	 increase	 in	 the	 overall	 size	 of	 the	 slow-cycling	 dye-
retaining	 cell	 population	 at	 the	 final	 passage	 of	 measurement	 compared	 to	 when	
cultures	were	maintained	at	sub-confluent	levels,	irrespective	of	the	Vybrant®	dye	that	
was	 used	 and	 the	 resultant	 duration	 of	 the	 assay	 (Figure	 4.5.).	 Univariant	
cytofluorimetric	analysis	of	the	cell	cycle	distribution	of	MDA-MB-231	cells	maintained	
at	 confluent	 and	 sub-confluent	 levels	 revealed	 that	 cultures	 maintained	 at	 full	
confluency	 tended	 to	 be	 distributed	 more	 towards	 the	 G0/G1-phase	 and	 were	
therefore	likely	slower	cycling	then	cultures	maintained	at	sub-confluent	levels	(Figure	
4.6.);	an	average	of	54.73	±	1.53%	of	cells	from	fully	confluent	cultures	were	found	to	
exist	 in	 the	G0/G1-phase	 compared	 to	 just	49.43	±	0.55%	of	 cells	maintained	at	 sub-
confluency	(P	≤	0.01).	Small	but	statistically	insignificant	decreases	in	the	S-phase	and	
G2/M-phase	 fractions	 were	 also	 measured	 in	 cells	 maintained	 at	 confluent	 levels,	
corresponding	with	(and	likely	cumulatively	contributing	to)	the	observed	collection	of	
cells	in	the	G0/G1-phase.	In	Vybrant®	DiD	retention	assays,	22.23	±	2.34%	of	MDA-MB-
231	 cells	were	 dye-positive	 after	 four	 consecutive	 passages	 post-staining	when	 sub-
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cultured	at	full	confluency,	compared	to	just	14.94	±	1.47%	in	cultures	maintained	at	
sub-confluent	 levels,	 despite	 passage	 four	 being	 16	 days	 post-staining	 in	 confluent	
cultures	 but	 just	 12	 days	 post-staining	 in	 sub-confluent	 cultures.	 The	 degree	 of	
confluency	 at	 the	 time	of	 sub-culture	was	 therefore	deemed	 to	 primarily	 determine	
the	overall	cell	cycle	status	of	a	growing	population	and	thus	how	rapidly	dye	was	lost	
from	 the	 majority	 of	 cells	 to	 reveal	 the	 latent	 slow-cycling	 population.	 Due	 to	 the	
possibility	 that	 relatively	 subtle	 metabolic	 stressors	 in	 culture	 might	 take	 a	 longer	
period	 of	 time	 to	 generate	 slow-cycling	 populations,	 or	 that	 additional	 regulatory	
factors	within	a	growing	culture	determine	the	size	of	a	particular	cell	compartment,	
these	results	were	not	initially	deemed	to	invalidate	the	presiding	hypothesis	that	the	
slow-cycling	 populations	 in	 breast	 cancer	 cell	 lines	 arise	 due	 to	microenvironmental	
induction.	In	order	to	test	this	hypothesis	more	directly,	it	was	subsequently	proposed	
to	isolate	the	rapidly	dividing	cell	fraction	and	establish	whether	a	latent	dye-retaining	
population	was	evident	following	a	period	of	continuous	culture.	Further	experiments	
to	 test	 the	 effects	 of	more	 extreme	metabolic	 stress	 on	 the	 size	 of	 the	 slow-cycling	
population	were	also	planned.	
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Figure	4.5.	Dye	Retention	in	Confluent	and	Sub-Confluent	Cell	Cultures	
The	 percentage	 of	 Vybrant®	 DiD-stained	 or	 Vybrant®	 CM-DiI-stained	 MDA-MB-231	 cells	 (A	 and	 B,	
respectively)	or	MCF-7	cells	(C	and	D,	respectively)	in	adherent	monolayer	cultures	was	measured	over	
successive	passages	at	the	time	of	sub-culture,	undertaken	at	either	sub-confluency	(72	hour	intervals)	
or	 full	 confluency	 (96	 hour	 intervals).	 The	 percentage	 of	 Vybrant®	 dye-stained	 cells	 was	 compared	
between	 samples	 over	 successive	 time-points	 using	 two-way	 ANOVA	 followed	 by	 Sidak’s	 Multiple	
Comparison	Test	(NS	=	not	statistically	significant	or	P	>	0.05,	*	=	P	≤	0.05,	***	=	P	≤	0.001,	****	=	P	≤	
0.0001).	 Data	 are	 expressed	 as	 the	 mean	 average	 ±	 SEM	 for	 n	 =	 3	 biologically	 independent	 repeat	
experiments.	
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Figure	4.6.	Cell	Cycle	Profile	of	Confluent	and	Sub-Confluent	Cultures	
A:	The	univariant	cell	cycle	analysis	profiles	of	adherent	monolayer	cultures	of	MDA-MB-231	cells	grown	
in	complete	RPMI-1640	culture	medium	(10%	supplemental	FBS)	when	maintained	at	sub-confluent	or	
fully	confluent	levels	at	the	time	of	sub-culture.	The	location	of	the	G0/G1-phase	(haploid	chromosome	
number),	S-phase	(intermediate	chromosome	number)	and	G2/M-phase	(diploid	chromosome	number)	
peaks	 are	 illustrated.	B:	 The	 percentage	 of	 total	 cells	 in	 each	 phase	 of	 the	 cell	 cycle	 was	 compared	
between	MDA-MB-231	cultures	sub-cultured	when	at	sub-confluent	or	fully	confluent	levels	using	two-
way	ANOVA	followed	by	Sidak’s	Multiple	Comparison	Test	(NS	=	not	statistically	significant	or	P	>	0.05,	
**	=	P	≤	0.01).	Data	are	expressed	as	the	mean	average	±	SEM	for	n	=	3	biologically	independent	repeat	
experiments.	
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4.5.2. Dye-Retaining	Cells	Can	Re-Emerge	from	the	Rapidly	Dividing	Population	
	
In	order	to	test	the	hypothesis	that	rapidly-dividing	cells	within	human	breast	cancer	
cultures	 were	 able	 to	 give	 rise	 to	 the	 latent	 slow-cycling	 population	 previously	
identified,	dye-retention	assays	were	carried	out	following	isolation	and	re-staining	the	
rapidly-dividing	 (dye-negative)	MDA-MB-231	population	 (Section	 4.4.2.).	 In	 these	 re-
stained	 cultures,	 dye-loss	 occurred	 much	 more	 rapidly	 than	 in	 the	 parental	 control	
cultures	(Figure	4.7.);	 there	were	47.77	±	2.32%	(P	≤	0.0001)	and	20.26	±	2.43%	(P	≤	
0.0001)	 fewer	dye-stained	cells	within	re-stained	samples	at	passages	three	and	four	
post-staining,	 respectively.	 In	 addition,	 the	 number	 of	 dye-retaining	 cells	 present	
reached	<	1%	by	passage	five,	one	passage	of	growth	earlier	than	when	this	occurred	
in	parental	control	samples.	This	rapid	dye-loss	was	likely	a	reflection	of	the	inherently	
rapidly	dividing	nature	of	the	isolated	dye-negative	fraction,	allowing	effective	dilution	
of	the	Vybrant®	DiD	label	upon	successive	divisions	to	achieve	non	dye-positive	levels	
over	a	much	shorter	timeframe.	Interestingly,	progressive	dye	loss	ceased	at	passage	
five	 within	 the	 re-stained	 cultures	 and	 the	 number	 of	 dye-retaining	 cells	 stabilised	
between	 passages	 five	 and	 six	 at	 approximately	 0.04%,	 a	 level	 which	 was	 not	
significantly	different	from	the	0.077	±	0.015%	dye-retaining	fraction	measured	in	the	
parental	 MDA-MB-231	 cultures.	 The	 re-emergence	 of	 the	 dye-retaining	 population	
within	 rapidly	 dividing	 cultures	 suggested	 that	 factors	 within	 the	 culture	
microenvironment	 were	 indeed	 responsible	 for	 formation	 of	 the	 dye-retaining	
population.	Future	experiments	aimed	to	determine	which	factors	could	potentially	be	
responsible	for	this	phenomenon.	
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Figure	4.7.	Vybrant®	DiD	Retention	in	Isolated	Dye-Negative	Cells	after	Re-Staining	
A:	The	percentage	Vybrant®	DiD-stained	cells	within	adherent	monolayer	cultures	of	parental	MDA-MB-
231	cells	and	re-stained	dye-negative	cells	(previously	isolated	from	parental	MDA-MB-231	cultures	by	
FACS	at	passage	5	post-staining	with	Vybrant®	DiD)	was	measured	over	successive	passages	at	the	time	
of	 sub-culture	 undertaken	 at	 72	 hour	 intervals.	 The	 percentage	 of	 Vybrant®	 DiD-stained	 cells	 was	
compared	 between	 samples	 over	 successive	 time-points	 using	 two-way	 ANOVA	 followed	 by	 Sidak’s	
Multiple	 Comparison	 Test	 (NS	 =	 not	 statistically	 significant	 or	 P	 >	 0.05,	 ****	 =	 P	 ≤	 0.0001).	 Data	 are	
expressed	 as	 the	 mean	 average	 ±	 SEM	 for	 n	 =	 3	 biologically	 independent	 repeat	 experiments.	 B:	
Representative	 images	of	Vybrant®	DiD	retention	within	cultures	of	re-stained	dye-negative	MDA-MB-
231	 cells	 at	 6	 hours	 (left),	 passage	 3	 (centre)	 and	 passage	 6	 (right)	 post-staining;	 the	 white	 arrows	
indicate	dye	 retaining	 cells	 evident	 in	 the	 image.	All	 images	were	 captured	using	a	10x	objective	 lens	
(scale	bar	=	100μm).	
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4.5.3. Hypoxia	as	a	Potential	Mechanism	Giving	Rise	to	Slow-Cycling	Cells	
	
Based	 on	 experimental	 observations	 that	 a	 dye-retaining	 population	was	 able	 to	 re-
emerge	 within	 a	 rapidly	 dividing	 culture,	 it	 was	 hypothesised	 that	 the	 localised	
consumption	 of	 oxygen	 and/or	 nutrients	 by	 rapidly	 dividing	 clones	 in	 wild-type	
cultures	might	lead	to	induction	of	a	slow-cycling	phenotype	in	neighbouring	cells	and	
therefore	 that	 dye-retaining	 cells	 would	 express	 higher	 levels	 of	 markers	 indicating	
metabolic	stress.	In	order	to	test	this	hypothesis,	HIF-1α	was	selected	for	assessment	
due	to	being	regarded	as	 the	master	 transcriptional	 regulator	of	cellular	 response	to	
hypoxic	stress,	and	was	assayed	in	isolated	dye-retaining	and	non-dye-retaining	MDA-
MB-231	populations	(Section	4.4.3.).	Using	the	tile	scan	function	of	the	Leica	AF6000LX	
microscope	 as	 described	 in	 Section	 2.4.,	 nine	 non-overlapping	 fields	 covering	 the	
entire	 immunostained	 sample	 were	 captured	 at	 100X	magnification.	 Representative	
images	of	the	HIF-1α	staining	pattern	were	also	captured	at	200X	magnification	(Figure	
4.8.).	
	
Immunostaining	was	deemed	specific	given	that	 the	green	fluorescent	signal	used	to	
localise	HIF-1α	was	undetectable	 in	 isotype	control	samples.	Upon	assessment	of	the	
immunostaining	 produced	 within	 both	 Vybrant®	 dye-retaining	 and	 dye-negative	
sample	sets	it	became	obvious	that	HIF-1α	was	ubiquitously	expressed	irrespective	of	
the	 initial	dye-retention	status	of	 the	population	 i.e.	100%	of	cells	expressed	HIF-1α.	
However,	it	was	also	clear	that	Vybrant®	DiD-positive	cells	were	considerably	brighter	
across	all	technical	and	biological	repeat	samples,	indicating	that	HIF-1α	was	present	at	
higher	 levels	 in	 association	with	 reduced	mitotic	 activity.	While	 this	 is	 an	 interesting	
preliminary	finding,	it	is	insufficient	to	definitively	conclude	that	HIF-1α	regulated	gene	
expression	governs	the	quiescent	phenotype	and	as	such	further	experiments	will	be	
required	to	test	this	hypothesis	in	a	more	robust	manner.	
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Figure	4.8.	Immunofluorescent	HIF-1α	Staining	In	Dye-Retaining	and	Negative	Cells	
The	immunofluorescent	staining	pattern	for	HIF-1α	(green)	is	shown	along	with	nuclear	counterstaining	
with	DAPI	(blue)	in	Vybrant®	DiD-negative	and	positive	MDA-MB-231	cell	populations	isolated	by	FACS	
and	deposited	onto	glass	microscope	slides	by	cytocentrifugation.	Specificity	of	staining	was	 indicated	
by	 the	 complete	 absence	 of	 green	 fluorescence	 (AlexaFluor®488)	 used	 to	 localise	 HIF-1α	 in	matched	
isotype	 control	 samples,	 shown	here	 at	 the	 top.	All	 images	were	 captured	using	 a	 20x	 objective	 lens	
(scale	bar	=	50μm).	
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4.5.4. Defining	Sub-Optimal	Culture	Conditions	
	
In	order	to	begin	testing	the	hypothesis	that	metabolic	stress	induced	by	sub-optimal	
culture	 conditions	 could	 increase	 the	 size	 of	 the	 slow-cycling	 dye-retaining	 fraction	
within	growing	cultures,	it	was	first	necessary	to	define	a	series	of	sub-optimal	culture	
conditions.	As	the	supplementary	FBS	added	to	culture	medium	provides	the	principal	
mitogenic	 stimulus	 for	 growing	 cells	 and	 the	 propagation	 of	 cells	 within	 culture	 is	
primarily	reliant	on	glucose	metabolism	(be	it	glycolytic	or	oxidative),	these	two	factors	
were	deemed	 to	be	most	 suited	 to	modulation	 for	controlled	provision	of	metabolic	
stress	to	cells.	Titration	assays	were	initially	carried	out	in	order	to	define	sub-optimal	
concentrations	 of	 FBS	 and	 glucose	 to	which	 levels	 could	 be	 depleted	 in	 subsequent	
experiments,	the	results	of	which	are	depicted	in	Figure	4.9.	and	Figure	4.10.	The	final	
EC25	and	EC50	for	FBS	and	glucose	used	in	all	assays	was	according	to	the	actual	dilution	
used	during	titration	experiments	that	was	closest	to	the	value	determined	graphically.	
All	 of	 the	 final	 serum	 and	 glucose	 concentrations	 that	 were	 defined	 for	 use	 in	
subsequent	 assays	 are	 summarised	 in	 Table	 4.4.	 Proliferation	 assays	 using	 the	 pre-
defined	 EC50	 of	 either	 FBS	 or	 glucose	were	 also	 initially	 used	 to	 determine	whether	
culture	growth	under	adverse	conditions	was	possible,	 in	turn	allowing	dye-retention	
assays	 to	be	undertaken	to	determine	the	effects	on	the	size	of	 the	slow-cycling	cell	
population	(Figure	4.9.	and	Figure	4.10.).	
	
In	 cultures	 grown	 in	 medium	 containing	 only	 the	 EC50	 concentration	 of	 FBS,	 the	
maximal	number	of	viable	cells	reached	at	the	end	of	the	log-phase	of	culture	growth	
was	37.25	±	2.39	x	104	cells;	a	6.50	±	4.00	x	104	reduction	(~15%)	compared	to	control	
samples	 (P	 ≤	 0.01).	 In	 addition,	 the	 log-phase	 population	 doubling	 time	 was	
determined	 to	 be	 20.14	 hours,	 3.32	 hours	 longer	 than	 the	 16.82	 hour	 log-phase	
doubling	 time	 recorded	 for	 control	 cultures.	 Similarly,	 in	 cultures	 grown	 in	medium	
containing	 the	 EC50	 concentration	 of	 glucose,	 the	 maximal	 number	 of	 viable	 cells	
reached	was	26.00	±	1.47	x	104	cells,	a	significant	reduction	of	10.38	±	3.16	x	104	cells	
(~30%)	when	compared	to	36.38	±	1.69	x	104	cells	in	control	samples	(P	≤	0.0001),	and	
the	 log-phase	 doubling	 time	 was	 extended	 by	 11.95	 hours	 to	 28.77	 hours.	 These	
results	indicated	that	the	effective	induction	of	culture	stress	was	successful	while	still	
permitting	net	culture	growth.	
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Figure	4.9.	MDA-MB-231	Serum	Titration	and	EC50	[Serum]	Proliferation	Assay	
A:	Dose-response	curve	for	MDA-MB-231	cells	grown	in	RPMI-1640	basal	culture	medium	with	varying	
concentrations	of	 supplemental	FBS	 (0	 -	15%	 (v/v)).	B:	 The	proliferation	curves	 for	MDA-MB-231	cells	
grown	in	RPMI-1640	culture	medium	containing	either	the	EC100	(control)	or	EC50	concentration	of	FBS	
(10%	 and	 4%	 (v/v),	 respectively).	 The	 number	 of	 viable	 cells	 was	 between	 treatment	 groups	 over	
successive	 time-points	using	 two-way	ANOVA	followed	by	Sidak’s	Multiple	Comparison	Test	 (NS	=	not	
statistically	significant	or	P	>	0.05,	*	=	P	≤	0.05,	**	=	P	≤	0.01).	Data	are	expressed	as	the	mean	average	±	
SEM	for	n	=	3	biologically	independent	repeat	experiments.	
	
	
	
	
Figure	4.10.	MDA-MB-231	Glucose	Titration	and	EC50	[Glucose]	Proliferation	Assay	
A:	 Dose-response	 curve	 for	 MDA-MB-231	 cells	 grown	 in	 complete	 RPMI-1640	 culture	 medium	 (10%	
supplemental	FBS)	and	varying	concentrations	of	glucose	(0	-	16.5mM).	B:	The	proliferation	curves	for	
MDA-MB-231	cells	grown	in	complete	RPMI-1640	culture	medium	containing	either	the	EC100	(control)	
or	 EC50	 concentration	 of	 glucose	 (11mM	 and	 2.2mM,	 respectively).	 The	 number	 of	 viable	 cells	 was	
between	 treatment	 groups	 over	 successive	 time-points	 using	 two-way	 ANOVA	 followed	 by	 Sidak’s	
Multiple	Comparison	Test	(NS	=	not	statistically	significant	or	P	>	0.05,	*	=	P	≤	0.05,	**	=	P	≤	0.01,	****	=	
P	≤	0.0001).	Data	are	expressed	as	the	mean	average	±	SEM	for	n	=	3	biologically	 independent	repeat	
experiments.	
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Table	4.4.	Composition	of	Reduced	Serum	or	Glucose	Culture	Media	
Medium	Type	
Vol.	RPMI-1640	
11mM	D-glucose	
(%	v/v)	
Vol.	RPMI-1640	
0mM	D-glucose	
(%	v/v)	
Vol.	Dialysed	FBS	
(%	v/v)	
EC0	Glucose	 -	 90	 10	
EC25	Glucose	 9	 81	 10	
EC50	Glucose	 18	 72	 10	
EC100	Glucose	 90	 -	 10	
EC0	FBS	 100	 -	 -	
EC25	FBS	 98	 -	 2	
EC50	FBS	 96	 -	 4	
EC100	FBS	 90	 -	 10	
	
The	EC0	-	EC100	concentrations	of	both	FBS	and	glucose	stated	were	calculated	by	interpolation	from	the	
respective	titration	curve	determined	previously	for	the	MDA-MB-231	cell	line.	
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4.5.5. Effects	of	Modulating	Serum	and	Glucose	Concentration	on	Dye	Retention	
	
In	 order	 to	 test	 the	 hypothesis	 that	 metabolic	 stress	 induced	 by	 deprivation	 of	
mitogenic	 stimuli	 (via	 reduction	 of	 the	 FBS	 content	 within	 culture	 medium)	 could	
induce	 an	 increase	 in	 the	 number	 of	 latent	 slow-cycling	 cells	 present	 in	 a	 culture,	
pulse-chase	 dye-retention	 assays	 were	 undertaken	 in	 cultures	 grown	 in	 medium	
containing	serum	levels	reduced	to	the	pre-determined	EC50	concentration	of	4%	(v/v)	
(Figure	4.11.).	These	experiments	were	also	repeated	in	parallel	using	cultures	grown	
in	 medium	 containing	 glucose	 levels	 reduced	 to	 the	 pre-determined	 EC50	
concentration	 of	 2.2mM	 in	 order	 to	 test	 the	 comparable	 hypothesis	 that	metabolic	
stress	induced	by	deprivation	of	metabolic	energy	supply	(via	depletion	of	the	glucose	
content	within	culture	medium)	could	induce	an	increase	in	the	number	of	latent	slow-
cycling	cells	present	in	a	culture	(Figure	4.13.).	
	
In	serum-deprived	cultures,	there	was	no	significant	increase	in	the	overall	size	of	the	
slow-cycling	 dye-retaining	 cell	 population	 at	 the	 final	 passage	 of	 measurement	
compared	to	when	cultures	were	maintained	in	complete	medium	containing	the	EC100	
concentration	of	FBS	(Figure	4.11.).	The	rate	of	dye	loss	from	serum-deprived	cultures	
did	 however	 appear	 reduced	 compared	 to	 control	 cultures,	 as	 denoted	 by	 the	
significantly	greater	dye-retaining	cell	population	over	the	duration	of	passages	three	
to	five	(P	≤	0.0001	in	all	cases),	during	which	dye	was	lost	to	residual	levels	revealing	
the	latent	slow-cycling	population	in	control	cultures.	The	reduced	proliferative	rate	of	
serum-deprived	 cultures	 indicated	 during	 dye-retention	 assays	 was	 reflected	 in	
univariant	 cytofluorimetric	 analysis	 of	 the	 cell	 cycle	 distribution	 in	 serum-deprived	
cultures,	 which	 were	 skewed	 more	 towards	 the	 G0/G1-phase	 and	 therefore	 most	
probably	 slower	 cycling	 then	 control	 cultures	 (Figure	 4.12.).	 An	 average	 of	 42.80	 ±	
0.27%	of	cells	within	serum-deprived	cultures	were	found	to	exist	in	the	G0/G1-phase	
compared	to	38.83	±	0.67%	of	control	cells	maintained	in	culture	medium	containing	
10%	(v/v)	FBS	(P	≤	0.0001).	A	small	but	statistically	significant	(P	≤	0.05)	decrease	in	the	
G2/M-phase	fraction	was	also	measured	in	serum-deprived	cultures	relative	to	control	
samples,	while	no	change	in	the	S-phase	fraction	was	observed.	
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In	contrast,	a	significant	increase	in	the	overall	size	of	the	dye-retaining	cell	population	
at	the	final	passage	of	measurement	was	recorded	in	glucose-deprived	cultures	when	
compared	 to	 control	 cultures	 maintained	 in	 complete	 medium	 containing	 the	 EC100	
concentration	 of	 glucose	 (Figure	 4.13.).	 However,	 in	 accordance	 with	 the	 assays	
undertaken	using	 reduced	 serum	concentration,	 glucose-deprived	 cultures	were	also	
significantly	 slower	 cycling	 than	 control	 cultures	 (Figure	 4.14.).	 In	 fact,	 the	 re-
distribution	 of	 the	 cell	 population	 towards	 the	 G0/G1-phase	 was	 considerably	 more	
pronounced	 in	 glucose-deprived	 cultures.	 On	 average,	 49.97	 ±	 0.19%	 of	 glucose-
deprived	cells	were	 found	to	exist	 in	 the	G0/G1-phase	compared	to	38.83	±	0.67%	of	
control	cells	maintained	 in	culture	medium	containing	11mM	glucose	(P	≤	0.0001).	A	
6.47	±	1.48%	reduction	in	the	S-phase	fraction	and	a	3.50	±	1.73	reduction	in	the	G2/M-
phase	 fraction	 (P	≤	0.001	and	P	≤	0.05,	 respectively)	were	also	recorded	for	glucose-
deprived	 cultures	 relative	 to	 control	 samples.	 These	 alterations	 to	 the	 cell	 cycle	
distribution	were	 likely	 the	 factor	 underpinning	 the	 significantly	 larger	 dye-retaining	
fraction	recorded	across	passages	three	to	five	(P	≤	0.0001	in	all	cases).	
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Figure	4.11.	Vybrant®	Dye	Retention	in	the	Presence	of	EC50	[Serum]	
The	 percentage	 Vybrant®	DiD-stained	 cells	within	 adherent	monolayer	 cultures	 of	MDA-MB-231	 cells	
grown	in	RPMI-1640	culture	medium	containing	either	the	EC100	or	EC50	concentration	of	FBS	(10%	and	
4%	(v/v),	respectively)	was	measured	over	successive	passages	at	the	time	of	sub-culture	undertaken	at	
72	hour	 intervals.	The	percentage	of	Vybrant®	DiD-stained	cells	was	compared	between	samples	over	
successive	 time-points	using	 two-way	ANOVA	followed	by	Sidak’s	Multiple	Comparison	Test	 (NS	=	not	
statistically	significant	or	P	>	0.05,	****	=	P	≤	0.0001).	Data	are	expressed	as	the	mean	average	±	SEM	
for	n	=	3	biologically	independent	repeat	experiments.	
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Figure	4.12.	Cell	Cycle	Profile	of	MDA-MB-231	Cells	Grown	in	EC50	[Serum]	
A:	The	univariant	cell	cycle	analysis	profiles	of	adherent	monolayer	cultures	of	MDA-MB-231	cells	grown	
in	 RPMI-1640	 culture	medium	 containing	 either	 the	 EC100	 or	 EC50	 concentration	 of	 FBS	 (10%	 and	 4%	
(v/v),	respectively)	are	shown.	The	location	of	the	G0/G1-phase	(haploid	chromosome	number),	S-phase	
(intermediate	 chromosome	 number)	 and	 G2/M-phase	 (diploid	 chromosome	 number)	 peaks	 are	
illustrated.	B:	The	percentage	of	total	cells	in	each	phase	of	the	cell	cycle	was	compared	between	MDA-
MB-231	cultures	grown	in	RPMI-1640	culture	medium	containing	either	the	EC100	or	EC50	concentration	
of	 FBS	 using	 two-way	 ANOVA	 followed	 by	 Sidak’s	 Multiple	 Comparison	 Test	 (NS	 =	 not	 statistically	
significant	or	P	>	0.05,	*	=	P	≤	0.05,	****	=	P	≤	0.0001).	Data	are	expressed	as	the	mean	average	±	SEM	
for	n	=	3	biologically	independent	repeat	experiments.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 155	
	
	
Figure	4.13.	Vybrant®	Dye	Retention	in	the	Presence	of	EC50	[Glucose]	
The	 percentage	 Vybrant®	DiD-stained	 cells	within	 adherent	monolayer	 cultures	 of	MDA-MB-231	 cells	
grown	 in	complete	RPMI-1640	culture	medium	(10%	supplemental	FBS)	containing	either	 the	EC100	or	
EC50	concentration	of	glucose	(2.2mM	and	11mM,	respectively)	was	measured	over	successive	passages	
at	the	time	of	sub-culture	undertaken	at	72	hour	intervals.	The	percentage	of	Vybrant®	DiD-stained	cells	
was	compared	between	samples	over	successive	time-points	using	two-way	ANOVA	followed	by	Sidak’s	
Multiple	Comparison	Test	(NS	=	not	statistically	significant	or	P	>	0.05,	**	=	P	≤	0.01,	****	=	P	≤	0.0001).	
Data	are	expressed	as	the	mean	average	±	SEM	for	n	=	3	biologically	independent	repeat	experiments.	
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Figure	4.14.	Cell	Cycle	Profile	of	MDA-MB-231	Cells	Grown	in	EC50	[Glucose]	
A:	The	univariant	cell	cycle	analysis	profiles	of	adherent	monolayer	cultures	of	MDA-MB-231	cells	grown	
in	 complete	 RPMI-1640	 culture	 medium	 (10%	 supplemental	 FBS)	 containing	 either	 the	 EC100	 or	 EC50	
concentration	of	glucose	(2.2mM	and	11mM,	respectively)	are	shown.	The	location	of	the	G0/G1-phase	
(haploid	chromosome	number),	S-phase	(intermediate	chromosome	number)	and	G2/M-phase	(diploid	
chromosome	number)	peaks	are	 illustrated.	B:	 The	percentage	of	 total	 cells	 in	each	phase	of	 the	 cell	
cycle	was	 compared	 between	MDA-MB-231	 cultures	 grown	 in	 RPMI-1640	 culture	medium	 containing	
either	 the	 EC100	 or	 EC50	 concentration	 of	 glucose	 using	 two-way	 ANOVA	 followed	 by	 Sidak’s	Multiple	
Comparison	Test	 (*	=	P	≤	0.05,	***	=	P	≤	0.001,	****	=	P	≤	0.0001).	Data	are	expressed	as	 the	mean	
average	±	SEM	for	n	=	3	biologically	independent	repeat	experiments.	
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4.5.6. Effects	of	Modulating	Serum	and	Glucose	Concentration	on	Clonogenicity	
	
Based	on	experimental	 observations	 that	 both	 rapidly	 dividing	 and	 slow-cycling	 sub-
clones	were	able	to	overtly	outgrow	when	isolated	from	parental	cultures,	clonogenic	
assays	were	used	as	an	alternative	means	of	assessing	the	effects	of	in	vitro	conditions	
on	both	rapidly-	and	slowly-dividing	sub-populations.	Due	to	the	greater	requirement	
for	both	mitogenic	stimuli	and	metabolic	energy	supply	in	rapidly	dividing	cells,	it	was	
hypothesised	 that	 slow-cycling	 cells	 would	 have	 greater	 survivability	 following	
reduction	of	 the	supplied	concentration	of	FBS	or	glucose	and	 therefore	would	 form	
more	colonies	than	the	rapidly	dividing	fraction	following	replenishment	of	the	factor	
to	which	cells	were	deprived.	
	
Clonogenic	 assays	undertaken	over	 a	 six-day	period	post-isolation	of	 rapidly	dividing	
and	dye-retaining	MDA-MB-231	fractions	by	FACS	revealed	a	dose-dependent	increase	
in	the	number	of	colonies	formed	by	both	dye-negative	and	dye-positive	cells	between	
the	EC0	and	EC100	concentration	of	both	FBS	and	glucose	(Figure	4.15.).	Most	notably,	
while	there	was	a	trend	towards	dye-positive	cells	forming	fewer	colonies,	there	was	
no	 significant	difference	between	 the	 clonogenicity	of	dye-negative	and	dye-positive	
populations	at	any	of	the	FBS	or	glucose	concentrations	assayed.	Across	both	sets	of	
assays,	 deprivation	 of	 FBS	 appeared	 to	 have	 a	 greater	 impact	 on	 clonogenicity;	 the	
average	number	of	colonies	formed	by	both	dye-negative	and	dye-positive	populations	
at	 the	EC0	glucose	concentration	was	approximately	20-25%,	while	no	colonies	were	
detected	at	the	EC0	FBS	concentration,	and	the	average	colony	count	at	the	EC25	was	
less	than	20%.	
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Figure	4.15.	Sub-Population	Clonogenicity	at	Varied	[Serum]	or	[Glucose]	
A:	The	percentage	colony	formation	of	Vybrant®	DiD-negative	and	Vybrant®	DiD-positive	MDA-MB-231	
cells	 isolated	by	 FACS	at	 five	passages	post-staining	 following	a	7	day	period	of	 growth	 in	RPMI-1640	
basal	medium	containing	either	the	EC0,	EC25,	EC50	or	EC100	concentration	of	supplemental	FBS	(0,	2,	4	
and	10%	(v/v),	respectively).	ND	=	not	detected.	B:	The	percentage	colony	formation	of	Vybrant®	DiD-
negative	and	Vybrant®	DiD-positive	MDA-MB-231	cells	 isolated	by	FACS	at	 five	passages	post-staining	
following	 a	 7	 day	 period	 of	 growth	 in	 complete	 RPMI-1640	 culture	medium	 (10%	 supplemental	 FBS)	
containing	either	the	EC0,	EC25,	EC50	or	EC100	concentration	of	glucose	(0mM,	1.1mM,	2.2mM	and	11mM,	
respectively).	 The	 percentage	 colony	 formation	was	 compared	 between	 the	 two	 populations	 at	 each	
FBS	or	glucose	concentration	using	two-way	ANOVA	followed	by	Sidak’s	Multiple	Comparison	Test	(NS	=	
not	 statistically	 significant	 or	 P	 >	 0.05).	 Data	 are	 expressed	 as	 the	 mean	 average	 ±	 SEM	 for	 n	 =	 3	
biologically	independent	repeat	experiments.	
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In	 order	 to	 determine	 whether	 the	 reduced	 colony	 formation	 at	 the	 EC0	 glucose	
concentration	 and	 the	 EC0	 and	EC25	 FBS	 concentrations	was	 the	 result	 of	 cell	 death,	
permanent	 senescence	 or	 entry	 into	 a	 reversible	 non-dividing	 dormant	 state,	
clonogenic	 assays	 were	 undertaken	 in	 which	 colony	 formation	was	 stimulated	 after	
the	initial	six	day	period	of	nutrient	withdrawal	by	replacing	the	component	to	which	
cells	had	been	deprived	(Figure	4.16.).	Irrespective	of	initial	dye-retention	status,	cells	
seeded	 into	 medium	 completely	 deficient	 of	 FBS	 (EC0)	 did	 not	 form	 any	 colonies	
following	 replenishment	 of	 the	 FBS	 concentration	 (data	 not	 shown)	 and	 no	 further	
colonies	were	formed	upon	FBS	replacement	 in	addition	to	those	 initially	established	
in	 the	 presence	 of	 the	 EC25	 concentration	 of	 FBS	 (Figure	 4.16.).	 Interestingly,	 a	
significant	increase	in	colony	formation	of	approximately	37%	(P	≤	0.01)	was	observed	
following	 replenishment	of	 glucose	 in	 samples	 initially	 seeded	 in	medium	containing	
the	 EC0	 glucose	 concentration,	 although	 there	 was	 no	 significant	 differential	
clonogenicity	recorded	between	cells	 that	were	 initially	dye-negative	or	dye-positive.	
In	fact,	in	both	populations	the	number	of	colonies	formed	following	replenishment	of	
glucose	 following	 initial	 deprivation	 returned	 to	 levels	 that	 were	 not	 significantly	
different	from	samples	seeded	directly	into	the	EC100	glucose	i.e.	a	complete	rescue	of	
clonogenicity	 was	 observed	 following	 replenishment	 of	 glucose	 concentration	 in	
initially	glucose-deprived	cultures	(Figure	4.16.).	
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Figure	4.16.	Stimulating	Clonogenicity	Following	Serum	or	Glucose	Deprivation	
A:	The	percentage	colony	formation	of	Vybrant®	DiD-negative	and	Vybrant®	DiD-positive	MDA-MB-231	
cells	isolated	by	FACS	at	five	passages	post-staining	following	an	initial	7	day	period	of	growth	in	RPMI-
1640	 basal	 medium	 containing	 2%	 supplemental	 FBS	 and	 then	 a	 further	 7	 day	 period	 of	 growth	
following	change	to	complete	RPMI-1640	culture	medium	containing	10%	supplemental	FBS.	ND	=	not	
detected.	 B:	 The	 percentage	 colony	 formation	 of	 Vybrant®	 DiD-negative	 and	 Vybrant®	 DiD-positive	
MDA-MB-231	 cells	 isolated	by	 FACS	 at	 five	 passages	 post-staining	 following	 an	 initial	 7	 day	 period	of	
growth	 in	complete	RPMI-1640	culture	medium	(10%	supplemental	FBS)	containing	0mM	glucose	and	
then	 a	 further	 7	 day	 period	 of	 growth	 following	 change	 to	 complete	 RPMI-1640	 culture	 medium	
containing	11mM	glucose.	For	each	population,	the	percentage	colony	formation	was	compared	across	
each	set	of	growth	conditions	by	two-way	ANOVA	followed	by	Sidak’s	Multiple	Comparison	Test	(NS	=	
not	statistically	significant	or	P	>	0.05,	**	=	P	≤	0.01).	Data	are	expressed	as	the	mean	average	±	SEM	for	
n	=	3	biologically	independent	repeat	experiments.	
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4.5.7. Effects	of	Lactate	on	the	Clonogenicity	of	Dye-Retaining	and	Negative	Cells	
	
A	 recent	 study	by	Park	 et	al.	 (2016)	demonstrated	 that	 some	breast	 cancer	cells	are	
capable	of	metabolic	switching	to	utilise	the	oxidation	of	lactate	as	a	primary	source	of	
energy,	 mediated	 by	 genes	 actively	 regulated	 by	 oestrogen-related	 receptor-alpha	
(ERR-α),	facilitating	their	survival	under	conditions	of	glucose	deprivation	for	extended	
periods	of	 time.	 It	was	 therefore	hypothesised	 that	 slow-cycling	cells	might	be	more	
capable	 of	 adapting	 to	 utilise	 lactic	 acid	 as	 a	 source	 of	 metabolic	 energy,	 thereby	
conferring	 a	 differential	 ability	 to	 survive	 under	 glucose-depleted,	 high-lactate	
conditions	similar	to	those	which	are	suggested	to	occur	within	the	quiescent	and/or	
cancer	stem	cell	niche	within	primary	tumours.	
	
In	order	to	begin	testing	this	hypothesis,	the	expression	of	ERR-α	by	the	MDA-MB-231	
cell	line	was	determined.	Western	blot	analysis	was	carried	out	on	whole	cell	lysates	of	
MDA-MB-231	 and	 four	 other	 distinct	 human	 breast	 cancer	 cell	 lines	 as	 described	 in	
Section	4.4.7.	The	results,	depicted	in	Figure	4.17.,	demonstrate	that	all	breast	cancer	
cell	 lines	tested	express	ERR-α	to	greater	or	 lesser	extent.	Due	to	the	relatively	weak	
expression	 of	 ERR-α	 in	 the	MDA-MB-231	 cell	 line	 relative	 to	 some	 of	 the	 other	 cell	
lines	tested,	the	proportion	of	MDA-MB-231	cells	expressing	ERR-α	was	determined	by	
intracellular	immunostaining	followed	by	flow	cytometric	analysis	(Section	4.4.8.).	The	
fluorescence	 profile	 produced	 during	 cytofluorimetric	 analysis	 demonstrated	 that	 all	
MDA-MB-231	cells	express	ERR-α	(Figure	4.17.).	
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Figure	4.17.	ERR-α	Expression	in	Human	Breast	Cancer	Cell	Lines	
A:	Western	blot	demonstrating	the	expression	of	ERR-α	in	a	number	of	distinct	human	breast	cancer	cell	
lines	relative	to	the	constitutively	expressed	cytoskeletal	protein	vinculin	used	as	a	loading	control.	B:	A	
representative	 flow	cytometric	analysis	plot	depicting	 the	degree	of	ERR-α	positivity	within	 the	MDA-
MB-231	 cell	 line	 is	 shown;	 an	 unlabelled	 control	 sample	 profile	 (grey)	 and	 the	 profile	 of	 an	 isotype	
control	 sample	 (dotted	 line)	 are	 depicted	 in	 addition	 to	 the	 positively	 stained	 experimental	 sample	
(green).	
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In	 order	 to	 provide	 glucose-depleted	 medium	 in	 which	 lactate	 was	 the	 primary	
metabolic	 substrate	 available,	 the	 concentration	 of	 D-glucose	 and	 L-lactate	 were	
measured	directly	 in	conditioned	medium	taken	from	growing	MDA-MB-231	cultures	
(Section	 4.4.10.).	 The	 results	 depicted	 in	 Figure	 4.18.	 demonstrate	 that	 culture	
medium	 removed	 from	 growing	 MDA-MB-231	 at	 96	 hours	 post-seeding	 of	 cells	
contained	 0mM	 D-glucose	 and	 22mM	 L-lactate.	 Consequently,	 conditioned	medium	
for	 use	 in	 all	 subsequent	 assays	 was	 prepared	 at	 this	 time	 point	 according	 to	 the	
method	previously	outlined	(Section	4.4.9.)	and	10%	supplemental	dialysed	FBS	added	
immediately	prior	to	use.	
	
No	colonies	were	formed	following	clonogenic	assays	undertaken	over	a	six-day	period	
in	 which	 rapidly	 dividing	 and	 dye-retaining	MDA-MB-231	 cells	 were	 seeded	 directly	
into	 conditioned	medium	 containing	 22mM	 lactate	 post-isolation	 by	 FACS	 (data	 not	
shown).	In	order	to	subsequently	determine	whether	this	absence	of	colony	formation	
under	 glucose-deprived,	 lactate-replete	 conditions	was	 the	 result	 of	 cell	 death,	 cells	
becoming	permanently	 senescent	or	entering	 into	a	 reversible	non-dividing	dormant	
state,	 clonogenic	 assays	were	undertaken	 in	which	 colony	 formation	was	 stimulated	
after	 the	 initial	six	day	period	by	removing	the	high-lactate	conditioned	medium	and	
replacing	 this	 with	 normal	 complete	 culture	medium	 containing	 11mM	 glucose	 and	
0mM	 lactate	 (Section	 4.4.12.).	 Interestingly,	 the	 results	 depicted	 in	 Figure	 4.19.	
showed	a	significant	increase	in	colony	formation	following	replenishment	of	glucose,	
irrespective	 of	 the	 initial	 dye-retention	 status	 of	 seeded	 cells;	 colony	 formation	was	
21.78	±	5.13%	of	the	total	number	of	cells	 initially	seeded	in	dye-negative	cells	while	
colony	formation	was	measured	at	28.17	±	4.92%	in	dye-positive	cells	(P	≤	0.01	in	both	
cases).	The	difference	in	colony	formation	between	the	two	fractions	post-stimulation	
was	not	significant.	
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Figure	4.18.	[Glucose]	and	[Lactate]	in	MDA-MB-231	Cultures	Over	Time	
The	 concentration	of	D-glucose	and	 L-lactate	 in	 the	 culture	medium	 (RPMI-1640	+	10%	 supplemental	
FBS)	 of	 growing	 MDA-MB-231	 cultures	 over	 time;	 the	 concentration	 of	 either	 compound	 (Y-axis)	 is	
plotted	against	 the	duration	of	 culture	post-seeding	of	 cells	 (X-axis).	Data	are	expressed	as	 the	mean	
average	±	SEM	for	n	=	3	biologically	independent	repeat	experiments.	
	
	
	
Figure	4.19.	Colony	Formation	in	22mM	Lactate	and	Post-Replacement	of	Glucose	
The	 percentage	 colony	 formation	 of	 Vybrant®	 DiD-negative	 and	 Vybrant®	 DiD-positive	 MDA-MB-231	
cells	 isolated	 by	 FACS	 at	 five	 passages	 post-staining	 following	 an	 initial	 7	 day	 period	 of	 growth	 in	
complete	RPMI-1640	culture	medium	containing	22mM	lactate	(0mM	glucose)	and	then	a	further	7	day	
period	of	growth	following	a	change	to	complete	RPMI-1640	culture	medium	containing	11mM	glucose.	
ND	=	not	detected.	For	each	population,	 the	percentage	colony	 formation	was	compared	across	each	
set	 of	 growth	 conditions	 by	 two-way	ANOVA	 followed	by	 Sidak’s	Multiple	 Comparison	 Test	 (**	 =	 P	 ≤	
0.01).	 Data	 are	 expressed	 as	 the	 mean	 average	 ±	 SEM	 for	 n	 =	 3	 biologically	 independent	 repeat	
experiments.	
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4.5.8. Effects	of	Inhibiting	ERR-α	on	the	Survival	of	Dye-Retaining	Cells	
	
A	 series	 of	 experiments	 described	 elsewhere	 in	 this	 thesis	 (Section	 5.5.1.)	
demonstrated	 that	 the	 latent	 slow-cycling	 population	 of	 cells	 identified	 by	 dye-
retention	 methods	 within	 human	 breast	 cancer	 cells	 lines	 are	 intrinsically	 more	
resistant	 to	 anti-neoplastic	 chemotherapeutics	 used	 to	 treat	 breast	 cancer	 and	
exclusively	 contain	 a	 sub-clonal	 population	 capable	 of	 initiating	 new	 colonies	 post-
cessation	of	drug-treatment.	It	was	hypothesised	that	these	drug-resistant	sub-clones	
were	also	capable	of	lactate	utilisation	and	survival	under	glucose-depleted	conditions,	
and	 that	 pharmacological	 inhibition	 of	 ERR-α	 can	 kill	 both	 the	 cells	 able	 to	 survive	
when	 lactate	was	 the	 primary	metabolic	 substrate	 and	 the	 drug-resistant	 sub-clonal	
population.	
	
Two	selective	ERR-α	inhibitors,	Cpd29	and	XCT790,	were	kindly	provided	by	Professor	
Donald	 P.	McDonnell	 (Duke	 University,	 Durham,	 North	 Carolina,	 U.S.A.).	 In	 order	 to	
first	demonstrate	that	these	compounds	selectively	compromise	lactate	utilisation	but	
not	glucose	consumption,	adherent	MDA-MB-231	cells	at	24-hours	post-seeding	were	
exposed	 to	 either	 complete	 culture	 medium	 (11mM	 glucose)	 or	 lactate-enriched	
conditioned	 medium	 (22mM	 lactate)	 in	 both	 the	 presence	 and	 absence	 of	 each	
inhibitor	 for	 a	 period	 of	 72-hours.	 Inhibitors	 were	 used	 at	 a	 final	 concentration	 of	
10μM	 according	 to	 data	 previously	 published	 for	 the	 MDA-MB-231	 cell	 line	 by	 the	
supplier	 (Park	et	al.,	2016).	At	each	time-interval,	 the	culture	medium	was	harvested	
from	one	flask	 in	each	treatment	group	and	assayed	for	either	D-glucose	or	L-lactate	
content	 as	 previously	 described	 (Section	 2.8.2.	 -	 Section	 2.8.3.).	 The	 results	 clearly	
demonstrated	 the	 selective	 inhibition	 of	 L-lactate	 consumption	 by	 both	 Cpd29	 and	
XCT790;	D-glucose	was	consumed	by	MDA-MB-231	cells	in	untreated	and	both	ERR-α	
inhibitor-treated	cultures	while	there	was	a	progressive	decline	in	L-lactate	levels	over	
the	 72	 hour	 assay	 period	 in	 untreated	MDA-MB-231	 cultures	 (Figure	 4.20.).	 A	 large	
statistically	 significant	 difference	 between	 untreated	 and	 inhibitor-treated	 cultures	
was	measured	at	each	time-point	(P	≤	0.0001	in	all	cases).	
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Figure	4.20.	Inhibition	of	ERR-α	Prevents	Consumption	of	Lactate	But	Not	Glucose	
A:	The	concentration	of	D-glucose	in	the	culture	medium	(RPMI-1640	with	11mM	D-glucose	and	0mM	L-
lactate	+	10%	supplemental	FBS)	of	either	untreated,	Cpd29-treated	(10μM)	or	XCT790-treated	(10μM)	
MDA-MB-231	 cultures	 over	 time	 post-treatment.	 B:	 The	 concentration	 of	 L-lactate	 in	 the	 culture	
medium	 (RPMI-1640	 with	 0mM	 D-glucose	 and	 22mM	 L-lactate	 +	 10%	 supplemental	 FBS)	 of	 either	
untreated,	 Cpd29-treated	 (10μM)	 or	 XCT790-treated	 (10μM)	 MDA-MB-231	 cultures	 over	 time	 post-
treatment.	The	concentration	of	either	D-glucose	or	L-lactate	was	compared	between	treatment	groups	
at	each	successive	time-points	using	two-way	ANOVA	followed	by	Sidak’s	Multiple	Comparison	Test	(NS	
=	not	statistically	significant	or	P	>	0.05,	****	=	P	≤	0.0001).	Data	are	expressed	as	the	mean	average	±	
SEM	for	n	=	3	biologically	independent	repeat	experiments.	
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Colony	 formation	 assays	 were	 subsequently	 undertaken	 to	 determine	 whether	
inhibition	 of	 ERR-α	 under	 glucose-deficient,	 lactate-rich	 conditions	 would	 kill	 both	
rapidly-	and	slowly-dividing	MDA-MB-231	cell	populations	(Figure	4.21.).	These	assays	
were	carried	out	as	described	in	Section	4.4.13.	Briefly,	dye-negative	and	dye-retaining	
MDA-MB-231	cells	were	isolated	by	FACS	at	passage	five	post-staining	with	Vybrant®	
DiD,	 seeded	 at	 clonogenic	 density	 into	 6-well	 cluster	 plates	 pre-filled	 with	 either	
lactate-rich	 conditioned	 medium	 (22mM	 lactate)	 only	 or	 which	 contained	 ERR-α	
inhibitors	Cpd29	or	XCT790	(f.c.	10μM).	After	six	days	incubation,	the	medium	within	
all	wells	was	replaced	with	drug-free	complete	culture	medium	(11mM	glucose)	and	a	
further	six	days	of	incubation	undertaken	prior	to	carrying	out	clonogenic	assays.	The	
number	of	colonies	formed	by	untreated	Vybrant®	DiD-negative	and	positive	cells	was	
comparable	 to	 the	 numbers	 observed	 in	 previous	 experiments;	 29.00	 ±	 1.26%	 of	
Vybrant®	DiD-negative	cells	and	26.33	±	1.20%	of	Vybrant®	DiD-positive	cells	 seeded	
formed	 colonies.	 No	 colonies	 were	 formed	 in	 either	 of	 the	 ERR-α	 inhibitor-treated	
groups,	 irrespective	of	the	intrinsic	mitotic	capacity	of	the	cells	seeded.	These	results	
supported	 the	 hypothesis	 that	 inhibition	 of	 ERR-α-regulated	 lactate	 metabolism	
prevents	cell	survival	under	nutrient-depleted	but	lactate-rich	conditions.	
	
In	order	to	directly	test	the	hypothesis	that	inhibition	of	ERR-α	under	glucose-depleted	
but	lactate-rich	conditions	was	able	to	kill	the	drug-resistant	sub-clonal	population	that	
is	 exclusive	 to	 the	 slow-cycling	 Vybrant®	 DiD-positive	 fraction	 in	 MDA-MB-231	
cultures,	 clonogenic	 assays	 were	 carried	 out	 as	 described	 in	 Section	 4.4.14.	 Briefly,	
Vybrant®	DiD-retaining	cells	were	isolated	from	MDA-MB-231	cultures	at	passage	five	
post-staining	 and	 were	 subsequently	 seeded	 into	 either	 lactate-rich	 conditioned	
medium	 (22mM	 Lactate)	 only,	 conditioned	 medium	 with	 the	 IC95	 concentration	 of	
doxorubicin	 (321nM),	 or	 conditioned	 medium	 with	 321nM	 doxorubicin	 and	 either	
Cpd29	 or	 XCT790	 (f.c.	 10μM).	 After	 a	 six-day	 initial	 incubation	 period,	 the	 medium	
within	all	samples	was	changed	to	complete	culture	medium	only	 (RPMI-1640	+	10%	
FBS)	and	a	further	six-day	period	of	incubation	undertaken	prior	to	carrying	out	assays	
of	 colony	 formation.	 The	 results	 are	 depicted	 in	 Figure	 4.22.	 As	 would	 have	 been	
expected	based	on	previous	 results,	Vybrant®	DiD-positive	cells	 seeded	 into	glucose-
depleted	 medium	 with	 22mM	 lactate	 formed	 24.33	 ±	 1.53%	 colonies	 on	 average.	
Treatment	 with	 doxorubicin	 only	 under	 lactate-rich	 conditions	 did	 significantly	
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decrease	the	number	of	colonies	formed	but	a	residual	population	of	viable	cells	was	
still	 present	 leading	 to	 2.33	 ±	 1.04%	 colonies	 formed	 post-stimulation	 by	
replenishment	 of	 glucose.	 Addition	 of	 either	 inhibitor	 of	 ERR-α	 in	 combination	with	
doxorubicin	 under	 the	 same	 conditions	 completely	 prevented	 colony	 formation,	
suggesting	 that	 blocking	 metabolic	 energy	 supply	 might	 be	 an	 effective	 means	 of	
eliminating	cells	inherently	resistant	to	anti-neoplastic	drugs.	
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Figure	4.21.	Colony	Formation	Following	Inhibition	of	ERR-α	
The	 percentage	 colony	 formation	 of	 Vybrant®	 DiD-negative	 and	 Vybrant®	 DiD-positive	 MDA-MB-231	
cells	 isolated	 by	 FACS	 at	 five	 passages	 post-staining	 following	 an	 initial	 7	 day	 period	 of	 growth	 in	
complete	RPMI-1640	culture	medium	containing	22mM	lactate	(0mM	glucose),	either	alone	(untreated)	
or	 in	combination	with	either	Cpd29	(10μM)	or	XCT790	(10μM),	 followed	by	a	further	7	day	period	of	
growth	following	a	change	to	complete	RPMI-1640	culture	medium	containing	11mM	glucose	only.	ND	=	
not	detected.	Data	are	expressed	as	the	mean	average	±	SEM	for	n	=	3	biologically	independent	repeat	
experiments.	
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Figure	4.22.	Inhibition	of	ERR-α	Can	Kill	Slow-Cycling	Drug-Resistant	Sub-Clones	
The	percentage	colony	 formation	of	Vybrant®	DiD-positive	MDA-MB-231	cells	 isolated	by	FACS	at	 five	
passages	post-staining	following	an	initial	7	day	period	of	growth	in	22mM	lactate	(0mM	glucose),	either	
alone	 (untreated),	 in	 the	presence	of	 321nM	doxorubicin	only,	 or	 321nM	doxorubicin	 in	 combination	
with	either	Cpd29	(10μM)	or	XCT790	(10μM),	followed	by	a	further	7	day	period	of	growth	following	a	
change	to	drug-free	complete	RPMI-1640	culture	medium.	ND	=	not	detected.	The	number	of	colonies	
formed	 within	 each	 treatment	 group	 was	 compared	 using	 one-way	 ANOVA	 followed	 by	 Dunnett's	
Multiple	Comparison	Test	(**	=	P	≤	0.01,	****	=	P	≤	0.0001).	Data	are	expressed	as	the	mean	average	±	
SEM	for	n	=	3	biologically	independent	repeat	experiments.	
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4.6. Discussion	
	
It	is	well	established	that	tumour	cell	populations,	whether	in	vivo	or	in	vitro,	are	often	
highly	 heterogeneous	 and	 are	 comprised	 of	 rapidly	 proliferating,	 slow-cycling	 and	
quiescent	cells,	cells	that	have	entered	into	senescence	and	cells	that	are	undergoing	
necrotic	 or	 apoptotic	 cell	 death.	Mitotic	 activity	 is	 not	 the	 sole	 functional	 trait	 that	
displays	 heterogeneity	 within	 tumour	 cell	 populations;	 disparities	 in	 invasive,	
migratory	 and	 clonogenic	 behaviour	 have	 also	 been	 widely	 reported	 (Marusyk	 and	
Polyak,	 2010;	 Gligorijevic	 et	 al.,	 2014).	 It	 is	 now	 generally	 accepted	 that	 primary	
tumoural	 microenvironments	 are	 heterogeneous	 in	 composition	 and	 that	 localised	
adverse	microenvironmental	conditions	can	strongly	influence	cellular	phenotype	and	
generate	 such	 population	 diversity	 (Bragado	 et	 al.,	 2012;	 Gilkes	 et	 al.,	 2014).	 Given	
that	 similar	 variance	 in	 factors	 such	 as	 oxygenation	 has	 also	 been	 reported	 in	 both	
three-dimensional	 and	 two-dimensional	 in	 vitro	 cell	 cultures	 (Malda	 et	 al.,	 2007;	
Demol	 et	 al.,	 2011;	 Kagawa	 et	 al.,	 2015),	 it	 does	 not	 seem	 unreasonable	 that	
spatiotemporal	 fluctuations	 in	 the	 tissue	 culture	 microenvironment	 or	 indeed	
controlled	modulation	of	culture	conditions	might	influence	the	size	and	behaviour	of	
intrinsic	 sub-populations,	 such	 as	 those	 tumour	 cells	 that	 maintain	 a	 quiescent	
phenotype.	
	
The	 numerous	 effects	 of	 increasing	 confluency	 on	 the	 biochemical	 and	 cell	 cycle	
profiles	 of	 growing	 in	 vitro	 cell	 cultures	 are	 well	 documented;	 one	 of	 the	 principal	
observations	being	the	progressive	net	redistribution	towards	the	G0/G1-phase	of	the	
cell	 cycle	 as	 the	 population	 density	 of	 a	 culture	 increases.	 These	 changes	 occur	 in	
response	 to	 the	 depletion	 of	 nutrients,	 rapid	 localised	 deoxygenation	 of	 culture	
medium,	accumulation	of	waste	metabolites	 and	decreased	pH,	 and	are	 reflected	 in	
the	gross	reduction	of	the	overall	culture	proliferation	rate	that	corresponds	with	the	
end	of	the	logarithmic	phase	of	culture	growth.	A	relatively	recent	study	by	Matthews	
et	al.	 (2010)	highlighted	the	 inherent	differences	 in	the	biochemical	profiles	of	single	
prostate	 cancer	 cells	 at	 varying	 degrees	 of	 culture	 confluency	 and	 cell	 cycle	
progression,	 indicating	 that	 individual	 clones	 within	 a	 culture	 can	 vary	 in	 their	
predisposition	 to	 the	 cellular	 events	 typically	 correlated	 with	 increased	 culture	
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confluency	 and	 therefore	 differ	 in	 their	 susceptibility	 to	 potential	 loss	 of	 mitotic	
activity	induced	by	the	adverse	conditions	arising	from	culture	overgrowth.	
	
Given	that	the	loss	of	fluorescent	dye	by	progressive	dilution	during	pulse-chase	assays	
is	primarily	dependent	on	the	rate	of	culture	proliferation,	it	was	not	unexpected	that	
extending	 the	 sub-culture	 interval	 and	 increasing	 the	 degree	 of	 culture	 confluency	
resulted	 in	a	diminished	absolute	 rate	of	 fluorescent	dye	 loss.	When	 the	duration	of	
fluorescence	 pulse-chase	 assays	 was	 expressed	 as	 the	 number	 of	 passages	 post-
staining,	 in	 order	 to	 account	 for	 the	 reduced	 rate	 of	 culture	 proliferation,	 the	 dye-
retaining	 population	 size	 was	 not	 significantly	 increased.	 The	 relatively	 modest	
increase	 in	 the	 magnitude	 of	 the	 G0/G1	 population	 measured	 in	 confluent	 cultures	
suggests	that	this	was	perhaps	due	to	the	cellular	metabolic	stress	exerted	by	allowing	
the	 culture	 to	 reach	 full	 confluency	 being	 sufficient	 to	 limit	 exponential	 growth	 but	
insufficient	 to	 induce	 reduced	 mitotic	 activity	 in	 potentially	 more	 susceptible	 sub-
clones.	 Although	 not	 undertaken	 here,	 it	 remains	 possible	 that	 a	 more	 profound	
overgrowth	of	cells	would	allow	generation	of	further	slow-cycling	cells;	evidence	from	
alternative	model	systems,	such	as	that	described	by	Pece	et	al.	(2010)	and	Akrap	et	al.	
(2016),	 suggest	 that	 de	 novo	 generation	 of	 quiescent	 sub-clones	 occurs	 due	 to	
microenvironmental	conditions	that	arise	within	high	cell	density	cultures.	
	
In	concurrence	with	previous	studies	by	Dembinski	and	Krauss	(2009)	and	Roesch	et	al.	
(2010),	dye-retaining	cells	were	shown	to	re-emerge	within	an	isolated	rapidly	dividing	
cell	 population,	 supporting	 the	 hypothesis	 that	 slow-cycling	 and	 quiescent	 cells	 can	
arise	 within	 a	 cell	 population	 under	 microenvironmental	 instruction.	 Interestingly,	
experimental	evidence	described	elsewhere	in	this	thesis	(Section	5.5.7.)	showed	that	
dye-retaining	cells	could	divide	asymmetrically	to	give	rise	to	non-dye	retaining	cells,	
thereby	 recapitulating	 population	 mitotic	 heterogeneity	 to	 some	 degree.	 A	
comparable	observation	by	Dembinski	and	Krauss	(2009)	led	to	their	proposal	of	two	
distinct	 possibilities;	 either	 that	 a	 unique	 latent	 tumour	 initiating	 cell	 sub-set	 is	
enriched	within	the	dye-retaining	population	but	 is	also	present	 in	non-dye-retaining	
cells	 and	 can	 therefore	 give	 rise	 to	 each	 cell	 type,	 or	 that	 a	 dynamic	 relationship	
between	 quiescent	 and	 tumour	 initiating	 cells	 exists	 that	 is	 context	 dependent	 and	
allows	 for	 interconversion	 between	 the	 two	 states	 under	 microenvironmental	
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regulation.	 These	 suggested	 possibilities	 now	 appear	 somewhat	 constrained	 to	 the	
classic	clonal	evolution	and	cancer	stem	cell	models	of	tumoural	heterogeneity	and	it	
could	therefore	be	argued	that	these	two	scenarios	are	more	likely	to	be	non-mutually	
exclusive	when	conceptualised	in	the	context	of	the	contemporary	plasticity	model	of	
tumoural	 heterogeneity.	 Further	 work	 to	 ascertain	 the	 degree	 of	 overlap	 between	
quiescent	 and	 putative	 tumour	 initiating	 phenotypes	 is	 described	 in	 the	 following	
chapter.	
	
During	dye-retention	assays	undertaken	following	re-staining	of	isolated	dye-negative	
cells,	 the	 rapid	 decline	 of	 dye	 levels	 and	 the	 subsequent	 stabilisation	 of	 the	 dye-
retaining	cell	number	to	one	comparable	to	that	observed	in	wild	type	cultures	suggest	
that	induction	of	the	quiescent	phenotype	perhaps	occurred	relatively	early	following	
re-establishment	of	cultures	 in	vitro.	Given	the	aforementioned	findings	of	Matthews	
et	 al.	 (2010)	 and	 that	 the	 isolated	 dye-negative	 population	 was	 inherently	 rapidly	
dividing,	 it	 appeared	 entirely	 plausible	 that	 the	 re-emergence	 of	 slow-cycling	 sub-
clones	 could	 be	 due	 to	 adverse	 paracellular	 conditions	 generated	 by	 aggressively	
growing	 sub-clones.	 Under	 these	 hypothetical	 conditions,	 a	 distinct	 latent	 sub-
population	could	have	been	generated	from	initially	more	susceptible	cells	with	a	size	
regulated	by	the	number	of	such	niche	inductive	microenvironments	that	exist	within	
the	culture.	This	suggestion	led	to	the	hypothesis	that	induction	of	a	HIF-1α-regulated	
gene	 expression	 profile	 was	 responsible	 for	 initiation	 of	 the	 quiescent	 phenotype.	
Indeed,	immunostaining	of	cytocentrifuge	preparations	showed	that	in	wild	type	MDA-
MB-231	 cultures,	 HIF-1α	 appeared	 to	 be	 present	 at	 a	much	 higher	 level	 within	 the	
slow-cycling	 dye-retaining	 population	 than	 in	 the	 rapidly	 dividing	 dye-negative	
population.	 In	 addition,	 HIF-1α	 staining	 appeared	 more	 frequently	 localised	 to	 the	
nuclei	of	dye-retaining	 cells,	while	 in	dye-negative	 cells	 it	 appeared	 to	be	associated	
with	the	cellular	periphery.	These	findings	closely	mirror	those	described	by	Docherty	
(2014),	 who	 indicated	 that	 both	 significantly	 increased	 levels	 of	 HIF-1α	 and	 the	
propensity	 for	 nuclear	 localisation	 that	 was	 observed	 in	 dye-retaining	 PC-3	 human	
prostate	cancer	cells	was	responsible	for	their	mitotically	quiescent	phenotype.	While	
further	work	will	be	 required	 to	confirm	 the	 findings	 reported	here	and	 to	ascertain	
which	 HIF-1α-regulated	 pathways	 are	 more	 active	 in	 quiescent	 cells	 in	 vitro,	 it	 has	
previously	been	demonstrated	that	HIF-1α	is	able	to	induce	quiescence	by	enhancing	
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expression	of	p21,	inhibiting	the	activity	of	cyclin-CDK2,	-CDK1,	and	-CDK4/6	complexes	
and	thereby	preventing	cell	cycle	progression	at	G1-	and	S-phase	(Koshiji	et	al.,	2004).	
Moreover,	 a	 recent	 report	 by	 Fluegen	 et	 al.	 (2017)	 supports	 that	 localised	 hypoxia	
generates	 therapy-resistant	 quiescent	 cells	 via	 induction	 of	 a	 hypoxia-associated	
transcriptomic	 signature.	 Interestingly,	 this	 study	 also	 reported	 that	 hypoxia	 is	 not	
required	to	maintain	this	phenotype	once	induced.	The	microenvironmental	induction	
of	 quiescence	 by	 hypoxia-regulated	 mechanisms	 suggests	 that	 other	 metabolic	
stressors	 could	 also	 contribute	 to	 induction	 of	 quiescence.	 Ascertaining	 whether	
nutrient-deprivation-induced	 gene	 signatures	 were	 associated	 with	 the	 quiescent	
phenotype	 fell	 outside	 of	 the	 achievable	 scope	 of	 this	 study.	 However,	 because	
isolating	 sufficient	 numbers	 of	 quiescent	 cells	 is	 one	 of	 the	 primary	 challenges	 of	
studying	quiescence,	 it	was	deemed	a	valid	 line	of	 investigation	to	establish	whether	
enrichment	of	this	population	was	possible	by	modulating	the	supply	of	nutrients	to	in	
vitro	cultures.	
	
A	 number	 of	 recent	 studies	 have	 investigated	 the	 effects	 of	 both	 partial	 and	 severe	
nutritional	deprivation	in	breast	tumour	cell	 lines	and	have	showed	that	the	principal	
net	effect	of	glucose	deprivation	is	cell	cycle	redistribution,	growth	arrest	and	loss	of	
cell	viability	(Visagie	et	al.,	2015;	Sudhagar	et	al.,	2016;	Di	Conza	et	al.,	2017).	Fewer	
studies	have	investigated	the	effects	of	serum	deprivation,	however,	there	have	been	
reports	 showing	 that	 partial	 serum	 deprivation	 is	 able	 to	 induce	 pro-survival	
mechanisms	 that	 enabling	 continued	 culture	 growth,	 but	 that	 more	 prolonged	 or	
acute	 severe	 serum	deprivation	 induces	multiple	 cell	 death	modalities	 (Braun	 et	 al.,	
2011;	 Bartkowiak	 et	 al.,	 2015;	 Jung	 et	 al.,	 2015).	 It	 was	 therefore	 not	 entirely	
unexpected	 that	 a	 significant	 reduction	 in	 the	 maximal	 viable	 cell	 number	 was	
observed	 despite	 continued	 culture	 growth	 upon	 reduction	 of	 the	 serum	or	 glucose	
concentration	to	the	respective	EC50	concentration	in	growing	MDA-MB-231	cultures.	
In	 each	 instance	 these	 observations	 were	 shown	 to	 correspond	 with	 a	 significant	
G0/G1-skewing	 of	 the	 cell	 cycle	 distribution,	 reduced	 overall	 rate	 of	 culture	
proliferation	and	 increased	retention	of	 fluorescent	dye	during	pulse-chase	assays.	 It	
appears	most	likely	that	the	cumulative	effects	of	reduced	proliferative	activity	across	
several	passages	of	culture	growth	were	primarily	responsible	for	slowing	the	net	rate	
of	dye	loss	from	cultures,	and	therefore	that	the	measured	increase	in	the	number	of	
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dye	retaining	cells	was	an	in	fact	the	result	of	this	effect	and	not	a	true	enrichment	for	
the	 slow-cycling	 phenotype.	 These	 observations	 did	 not	 nullify	 the	 hypothesis	 that	
nutritional	stress	could	be	responsible	for	induction	of	quiescence,	rather	they	showed	
that	 pulse-chase	 techniques	 are	 not	 well	 suited	 to	 measuring	 enrichment	 of	 a	
quiescent	 population	 under	 conditions	 that	 result	 in	 a	 lower	 rate	 of	 culture	
proliferation.	
	
Bartkowiak	 et	 al.	 (2015)	 recently	 reported	 that	 breast	 cancer	 sub-clones	 possessing	
distinct	 features	 of	 metastasis-initiating	 cells	 were	 able	 to	 preferentially	 survive	
nutrient	deprivation.	Given	the	emerging	association	of	the	quiescent	phenotype	with	
metastasis-initiating	 potential,	 it	 was	 hypothesised	 that	 the	 isolated	 slow-cycling	
fraction	would	preferentially	survive	severe	nutrient	deprivation	and	thereby	show	a	
differential	 ability	 to	 re-emerge	 following	 nutrient	 replenishment.	While	 the	 loss	 of	
clonogenicity	 following	 serum	 starvation	 could	 not	 be	 reversed,	 the	 reduced	 colony	
formation	 observed	 under	 severe	 glucose	 deprivation	 was	 completely	 rescued	
following	 replenishment	 of	 the	 glucose	 concentration,	 in	 line	 with	 the	 reported	
findings	of	Bartkowiak	 et	al.	 (2015)	and	Visagie	 et	al.	 (2015).	Despite	 this	 interesting	
finding,	 there	was	 no	 significant	 difference	 in	 the	 colony	 forming	 ability	 of	 the	 dye-
negative	 and	 dye-positive	 sub-populations	 following	 stimulation	 by	 glucose	
replenishment.	 When	 taken	 together,	 the	 results	 obtained	 during	 this	 series	 of	
experiments	 indicate	 that	 severe	 deprivation	 of	 FBS	 induces	 cell	 death	 and/or	
irreversible	mitotic	 arrest,	while	 glucose	 deprivation	 appears	 to	 significantly	 slow	 or	
halt	mitotic	activity	 in	an	entirely	reversible	manner	 in	 large	proportion	of	MDA-MB-
231	cells,	irrespective	of	the	intrinsic	mitotic	capacity	of	the	cell	population.	Whether	
the	localised	deprivation	of	glucose	results	in	cellular	stress	and	the	initial	induction	of	
mitotic	quiescence	in	pre-disposed	sub-clones	remains	to	be	elucidated.	
	
One	of	 the	historic	 fundamental	 questions	 in	primary	 tumour	biology	has	been	how	
tumor	cells	modulate	their	metabolic	activity	when	oxygen	tension	and	glucose	levels	
become	 limiting	 in	 the	 presence	 of	 high	 exogenous	 lactate,	 such	 as	 has	 long	 been	
known	 to	 occur	 within	 the	 tumoural	 microenvironment.	 Amongst	 a	 number	 of	 less	
well	characterised	potential	mechanisms,	the	recently	reported	metabolic	switch	from	
glycolytic	 metabolism	 to	 the	 ERR-α-regulated	 oxidative	 metabolism	 of	 lactate	 has	
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emerged	as	one	of	the	principal	cellular	mechanisms	underpinning	cancer	cell	survival	
under	nutrient	depleted	but	lactate	rich	conditions	(Kennedy	et	al.,	2013;	Allen	et	al.,	
2016;	 Park	 et	 al.,	 2016).	 In	 light	 of	 this,	 it	 was	 hypothesised	 that	 slow-cycling	 cells	
might	 be	 more	 capable	 of	 adapting	 to	 utilise	 lactic	 acid	 as	 a	 source	 of	 metabolic	
energy,	 thereby	 conferring	 a	 differential	 ability	 to	 survive	 under	 glucose-depleted,	
high-lactate	conditions.	Interestingly,	while	no	colonies	were	formed	by	either	rapidly	
dividing	 or	 slow-cycling	 MDA-MB-231	 fractions	 under	 nutrient	 depleted	 conditions	
after	 seven	days,	 replenishment	of	 nutrients	 and	 a	 further	 seven	day	 culture	period	
resulted	in	around	25%	colony	formation	in	both	fractions.	While	these	results	did	not	
indicate	that	inherently	slow-cycling	cells	were	more	capable	of	survival	under	glucose-
deficient	but	lactate-rich	conditions,	this	partial	rescue	of	clonogenicity	implies	that	a	
considerable	 proportion	 of	 cells	 within	MDA-MB-231	 cultures	 are	 able	 to	 switch	 to	
utilisation	of	oxidative	 lactate	metabolism	when	deprived	of	glucose	 for	use	as	 their	
primary	metabolic	substrate,	while	the	remainder	undergo	death	or	senescence.	This	
observation	might	 in	 its	self	have	direct	 implications	for	the	biological	processes	that	
underpin	formation	of	the	metastasis-initiating	population,	although	this	remains	to	be	
established.	 However,	 the	 exclusivity	 of	 cells	 able	 to	 re-emerge	 following	
chemotherapy	 to	 the	 slow-cycling	 population,	 as	 described	 elsewhere	 in	 this	 thesis	
(Section	5.5.1.),	and	the	demonstration	by	Park	et	al.	(2016)	of	ERR-α-regulated	lactate	
metabolism	to	contribute	to	therapy	resistance	led	to	the	hypothesis	that	inhibition	of	
this	 mechanism	 might	 eliminate	 chemotherapy	 resistant	 sub-clones.	 Indeed,	 while	
2.33	 ±	 0.60%	 of	 seeded	 cells	 formed	 colonies	 following	 treatment	 with	 the	 IC95	
concentration	 of	 doxorubicin	 for	 seven	 days,	 inhibiting	 ERR-α	 using	 two	 different	
pharmacological	agents	in	combination	with	doxorubicin	completely	prevented	colony	
formation.	While	these	preliminary	results	are	clearly	limited	by	the	inherent	simplicity	
and	limitations	of	the	model	systems	used	here,	it	does	provide	grounds	for	future	in	
vivo	 investigations	 to	 determine	 if	 inhibition	 of	 ERR-α	 can	 prevent	 metastatic	
colonisation	 of	 the	 bone	 and/or	 formation	 of	 overt	metastases	 by	 cells	 that	 escape	
initial	anti-neoplastic	drug	treatment.	
	
Throughout	 the	 investigations	 described	 in	 this	 chapter,	 the	 primary	 challenge	 has	
been	attempting	to	demonstrate	the	effects	of	exogenous	conditions	on	the	quiescent	
cell	population	while	being	reliant	on	dye-retention	to	identify	these	slow-cycling	cells.	
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In	the	case	of	experiments	designed	to	determine	whether	it	was	possible	to	induce	an	
increase	 in	 the	 quiescent	 sub-population	 size	 by	modulating	 culture	 conditions,	 this	
meant	that	discerning	a	true	enrichment	from	the	residual	effects	of	reduced	culture	
proliferation	 was	 impossible.	 In	 experiments	 in	 which	 colony	 formation	 was	 the	
primary	experimental	measurement,	isolating	the	quiescent	population	from	parental	
cultures	and	thereby	stimulating	overt	outgrowth	meant	that	the	quiescent	phenotype	
was	inherently	 lost	and	therefore	some	of	the	results	recorded	in	this	way	might	not	
reflect	 the	 true	 intrinsic	 properties	 of	 the	 quiescent	 population.	 In	 light	 of	 these	
limitations,	it	appears	critical	that	a	surrogacy	marker	profile	that	accurately	identifies	
quiescent	 cells	 will	 be	 required.	 Experiments	 that	 attempt	 to	 identify	 differentially	
expressed	markers	in	the	dye-retaining	population	are	described	in	the	next	chapter.	
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4.7. Conclusions	
	
Increasing	the	degree	of	culture	confluency	at	successive	sub-culture	intervals	did	not	
result	in	a	significant	increase	in	the	overall	number	of	slow	cycling,	dye-retaining	cells,	
irrespective	of	the	Vybrant®	dye	or	cell	line	used.	While	no	further	increase	in	the	size	
of	 the	 quiescent	 sub-population	was	 achieved	 by	 allowing	 culture	 overgrowth,	 dye-
retaining	 cells	 were	 shown	 to	 re-emerge	 within	 isolated	 rapidly	 dividing	 (non-dye-
retaining)	 cultures,	 probably	 due	 to	 the	 influence	 of	microenvironmental	 conditions	
and	 seemingly	 involving	 the	 HIF-1α	 signalling	 cascade.	 When	 taken	 together,	 these	
results	 indicate	 that	 the	 quiescent	 sub-population	 identified	 within	 human	 breast	
cancer	cell	lines	initially	arise	due	to	microenvironmental	induction.	
	
Partial	 deprivation	 of	 either	 serum	 or	 glucose	 in	 growing	 MDA-MB-231	 cultures	
resulted	 in	 redistribution	 of	 the	 culture	 cell	 cycle	 profile	 that	 led	 to	 increased	 dye-
retention	during	pulse-chase	assays	but	was	not	seen	to	represent	a	true	enrichment	
for	 quiescent	 sub-clones.	Moderate	 to	 severe	 deprivation	 of	 serum	 or	 glucose	 both	
decreased	 the	 monolayer	 colony	 formation	 in	 both	 rapidly-	 and	 slowly-dividing	 cell	
populations	 but	 no	 differential	 colony	 forming	 ability	 was	 observed	 between	 these	
populations	 under	 any	 of	 the	 conditions	 tested.	 While	 colony	 formation	 in	 both	
rapidly-	and	slowly-dividing	cell	populations	was	not	rescued	upon	re-establishment	of	
standard	 culture	 conditions	 following	 serum	 starvation,	 the	 absence	 of	 colony	
formation	resulting	from	severe	glucose	deprivation	was	shown	to	be	reversible.	The	
utilisation	 ERR-α-regulated	 oxidative	 lactate	 metabolism	 was	 shown	 to	 be	 one	
potential	mechanism	by	which	cells	can	survive	under	glucose	deprivation,	irrespective	
of	 their	 intrinsic	mitotic	capacity.	 Inhibition	of	ERR-α	and	blockade	of	 this	potentially	
critical	survival	mechanism	was	shown	to	be	effective	in	preventing	colony	formation	
by	sub-clones	capable	of	evading	anti-neoplastic	drug	treatment.	
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Chapter	5	
	
	
Phenotypic	Characterisation	of	the	
Mitotically	Quiescent	Sub-Population	in	
Breast	Cancer	
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5.1. Summary	
	
The	 current	 literature	 contains	 a	 myriad	 of	 evidence	 for	 mitotic	 quiescence	 being	
associated	 with	 both	 stemness	 and	 inherent	 resistance	 to	 anti-proliferative	
chemotherapeutic	 agents.	 These	 associations	 suggest	 a	mechanism	of	 recurrence	 or	
relapse	that	enables	mitotically	inactive	tumour-initiating	cell	populations	to	evade	the	
effects	of	chemotherapeutics	and	re-emerge	following	cessation	of	treatment	at	either	
local	or	post-metastatic	sites.	The	identification	of	a	latent	sub-population	of	cells	with	
reduced	 mitotic	 activity	 within	 several	 distinct	 human	 breast	 cancer	 cell	 lines	 (as	
described	 in	 the	 third	 chapter	 of	 this	 thesis)	 was	 seen	 to	 represent	 a	 unique	
opportunity	 to	 further	 characterise	 a	 potentially	 biologically	 and	 clinically	 important	
cellular	 sub-set	 and	 to	 elucidate	 a	 functionally	 informed	 marker	 signature	 enabling	
future	 isolation	 of	 this	 sub-set	 from	 in	 vitro	 and	 in	 vivo	 models,	 without	 the	
requirement	 for	 fluorescence	 dye-dependent	 lineage	 tracing.	 This	 chapter	 describes	
the	phenotypic	characterisation	of	mitotically	quiescent	cells	 identified	within	human	
breast	 cancer	 cell	 lines	 using	 a	 lipophilic	 dye	 retention	 method,	 with	 a	 particular	
emphasis	on	cancer	stem	cell	marker	expression	and	chemotherapeutic	resistance.	
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5.2. Introduction	
	
Cancer	stem	cell	(CSC)	populations	have	been	shown	to	contribute	to	chemoresistance	
in	 a	 number	 of	 cancer	 types.	 Studies	 of	 breast,	 prostate,	 ovarian	 and	 pancreatic	
cancers	 in	 vivo	 have	 demonstrated	 the	 ability	 of	 CSCs	 to	 survive	 concentrations	 of	
chemotherapeutic	 agents	 in	 excess	 of	 twice	 that	 required	 to	 elicit	 cytotoxicity	 in	
proliferating	cell	populations	(Naumov	et	al.,	2003;	Dembinski	and	Krauss,	2009;	Gao	
et	al.,	 2010;	 Liu	 et	al.,	 2010).	 In	one	 such	 study,	 a	 significant	enrichment	of	 the	CSC	
compartment	 was	 observed	 following	 culture	 of	 patient-derived	 primary	 breast	
tumour	 cells	 in	 vitro	 in	 the	 presence	 of	 clinically	 relevant	 concentrations	 of	
cyclophosphamide,	 5-fluoruracil	 and	 either	 epirubicin,	 doxorubicin	 or	methotrexate.	
Subsequent	 quantification	 of	 the	 number	 of	 CSCs	 present	 in	 paired	 pre-	 and	 post-
chemotherapy	 tumour	 biopsies	 indicated	 an	 approximate	 10-fold	 increase	 in	 CSC	
frequency	in	patient	samples	post-treatment	(Yu	et	al.,	2007).	
	
A	multitude	of	drug-resistance	mechanisms	have	been	suggested	to	contribute	to	the	
ability	of	CSCs	to	resist	chemotherapy-induced	cell	death	(Figure	5.1.).	Enhanced	DNA	
damage	 repair,	 up-regulation	 of	 xenobiotic	 pumps	 such	 as	 the	multi-drug	 resistance	
protein	 and	 adenosine	 5'-triphosphate-binding	 cassette	 transporters,	 increased	
enzymatic	metabolism	by	enzymes	such	as	ALDH,	expression	of	anti-apoptotic	proteins	
such	as	BCL-2	and	BCL-XL,	and	activation	of	key	pro-survival	signalling	molecules	such	
as	 NOTCH	 and	 nuclear	 factor-κB	 (NF-κB)	 have	 all	 been	 associated	 with	 increased	
survivability	 of	 CSCs	 treated	 with	 chemotherapeutic	 drugs	 (Eyler	 and	 Rich,	 2008;	
Holohan	et	al.,	2013;	Cree	and	Charlton,	2017).	At	present	it	remains	unclear	how	the	
quiescent	phenotype	contributes	to	these	mechanisms,	but	it	does	seem	plausible	that	
a	reduced	proliferative	rate	would	only	act	to	augment	their	effectiveness.	Quiescent	
cells	 that	 resist	 chemotherapy	 have	 been	 shown	 to	 either	 completely	 avert	 drug-
induced	cell	cycle	arrest	or	quickly	re-enter	 the	cell	cycle	once	treatment	was	halted	
(Fillmore	 and	 Kuperwasser,	 2008).	 Whether	 CSC-associated	 drug-resistance	
mechanisms	are	 selectively	enriched	within	quiescent	cell	populations	 remains	 to	be	
elucidated.	 However,	 the	 established	 ubiquitous	 association	 of	 stemness	 and	
quiescence	in	the	normal	and	neoplastic	cellular	hierarchies	and	the	observation	of	a	
protracted	 period	 of	 dormancy	 in	 the	 natural	 history	 of	 metastatic	 disease	 does	
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suggests	 that	 mitotically	 quiescent	 and	 stem-like	 cell	 populations	 in	 cancer	 are	 not	
mutually	exclusive	 (Moore	and	Lyle,	2011;	Cojoc	et	al.,	2015).	The	key	 implication	of	
this	suggestion	 is	a	potential	unified	cellular	mechanism	of	 tumour	 initiation,	 relapse	
and	 recurrence	 in	 which	 mitotically	 inactive	 CSCs	 would	 evade	 the	 effects	 of	
chemotherapeutics	 and	 re-emerge	 at	 either	 primary	 or	 secondary	 sites	 following	
cessation	of	treatment.	The	series	of	experiments	described	within	this	chapter	were	
aimed	 at	 furthering	 understanding	 of	 the	 degree	 to	 which	 mitotic	 quiescence,	
chemotherapeutic	 resistance	 and	 the	 putative	 breast	 cancer	 stem	 cell	 phenotype	
overlap.	
	
	
	
Figure	5.1.	Cellular	Mechanisms	of	Drug	Resistance	in	Cancer	Stem	Cells	
The	hallmarks	of	chemotherapeutic	resistance	in	putative	cancer	stem	cell	populations;	individual	cells	
might	 modulate	 or	 alter	 expression	 of	 drug	 targets,	 up-regulate	 expression	 of	 xenobiotic	 pumps,	
increase	the	activity	or	expression	of	drug-metabolising	enzymes,	increase	expression	of	anti-apoptotic	
proteins	 or	 increase	 DNA	 damage	 repair	 pathways.	 The	 direct	 role	 of	 and	 degree	 to	 which	 these	
mechanisms	 are	 associated	 with	 the	 mitotically	 quiescent	 phenotype	 associated	 with	 stem	 cell	
populations	remains	to	be	elucidated.	
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5.3. Aims,	Hypothesis	and	Objectives	
	
The	 aim	 of	 the	 work	 described	 in	 this	 chapter	 was	 to	 undertake	 phenotypic	 and	
functional	 characterisation	 of	mitotically	 quiescent	 breast	 cancer	 cells	 isolated	 using	
the	fluorescent	lipophilic	dye	retention	method	and	to	determine	whether	they	share	
characteristics	with	the	purported	metastasis-initiating	cancer	stem	cell	population	in	
breast	cancer.	
	
The	key	hypothesis	pertaining	to	the	work	described	in	this	chapter	was	that	the	latent	
mitotically	quiescent	sub-population	contained	within	human	breast	cancer	cell	lines	
shows	phenotypic	overlap	with	the	putative	cancer	stem	cell	population.	
	
The	following	objectives	were	defined	in	order	to	test	this	hypothesis:	
	
1. Determine	 whether	 the	 dye-retaining	 sub-population	 was	 more	 resistant	 to	 the	
effects	of	anti-neoplastic	drugs	than	the	non-dye-retaining	cell	population.	
	
2. Establish	 whether	 cells	 within	 dye-retaining	 and	 non-dye-retaining	 populations	
that	 survive	 anti-neoplastic	 drug	 treatment	 were	 able	 to	 form	 new	 clonal	
populations	following	cessation	of	treatment.	
	
3. Ascertain	whether	the	dye-retaining	sub-population	expressed	markers	frequently	
associated	with	stem	cell-like	behaviour	and	compare	how	the	expression	of	these	
markers	differed	with	their	rapidly	proliferating	counterparts.	
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5.4. Materials	and	Methods	
	
5.4.1. Establishing	Dose-Response	Curves	for	Doxorubicin	and	Paclitaxel	
	
Pegylated	 liposomal	 doxorubicin,	 sourced	 from	 the	 Clinical	 Research	 Pharmacy,	
Weston	Park	Hospital,	 Sheffield,	U.K.,	was	 supplied	 as	 an	 aqueous	dispersion	 in	 PBS	
with	a	concentration	of	3.4μM.	This	solution	was	sterilised	through	a	0.2μm	filter	into	
a	 light	 protected	 container	 and	 stored	 in	 a	 refrigerator	 maintained	 at	 4oC	 until	
required.	 Immediately	 prior	 to	 use,	 stock	 solution	was	 diluted	 1:3.4	 using	 complete	
growth	medium	as	the	diluent	in	order	to	produce	a	1mM	working	stock.	This	working	
stock	was	then	used	to	carry	out	a	number	of	1:10	serial	dilutions	in	complete	growth	
medium	 to	 produce	 a	 series	 of	working	 solutions	 ranging	 in	 concentration	 between	
100μM	and	1pM.	
	
Paclitaxel	(Abcam	Plc.)	was	supplied	as	10mg	of	white	crystalline	solid.	A	10mM	stock	
solution	 of	 paclitaxel	 was	 prepared	 by	 dissolving	 the	 total	 10mg	 mass	 supplied	 in	
1170μl	of	absolute	ethanol.	This	solution	was	then	stored	in	a	freezer	maintained	at	-
20oC	until	required.	Immediately	prior	use,	the	stock	solution	was	used	to	undertake	a	
number	of	1:10	serial	dilutions	in	complete	growth	medium	in	order	to	achieve	a	series	
of	working	solutions	ranging	in	concentration	between	1μM	and	1fM.	
	
The	 method	 for	 seeding	 of	 cells	 and	 plate	 configuration	 for	 cytotoxicity	 in	 96-well	
plates	 is	 described	 in	 detail	 in	 Section	 2.6.3.	 Working	 solutions	 of	 each	 drug	 were	
added	 sequentially	 to	 adherent	MCF-7	 or	MDA-MB-231	 cells	 that	 had	 been	 seeded	
into	the	wells	of	96-well	cluster	plates	at	the	respective	optimal	density	(Table	2.2.)	24	
hours	 prior.	 Cells	 were	 incubated	 in	 the	 presence	 of	 drug	 for	 72	 hours,	 a	 period	
equivalent	 to	 the	 logarithmic	 phase	 of	 culture	 growth	 for	 these	 cell	 lines,	 prior	 to	
determination	 of	 the	 viability	 of	 cultures	 at	 each	 drug	 concentration	 using	 the	MTT	
assay	(Section	2.6.3.).	
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5.4.2. Establishing	Sensitivity	of	Dye-Retaining	Cells	to	Anti-Neoplastic	Drugs	
	
Wild	type	MCF-7	or	MDA-MB-231	cells	were	stained	in	suspension	with	Vybrant®	DiD	
according	 to	 the	manufacturer's	 instructions	 (Section	 2.3.1.)	and	 then	seeded	at	 the	
optimal	density	 (Table	 2.2.)	 into	75cm2	high-quality	polystyrene	 tissue	culture	 flasks.	
Stained	 cultures	 and	 unstained	 control	 samples	 were	 cultured	 for	 five	 consecutive	
passages	 of	 growth.	 Following	 retrieval	 of	 stained	 cultures	 at	 passage	 five,	 both	
stained	and	unstained	cells	were	reseeded	at	the	optimal	density	 into	triplicate	wells	
of	6-well	cluster	plates	pre-filled	with	3ml	of	complete	culture	medium	and	were	then	
placed	into	incubation	overnight	to	allow	cell	adhesion	to	the	growth	surface.	Stained	
cultures	and	unstained	cultures	were	exposed	to	chemotherapeutic	drugs	in	complete	
culture	medium	for	a	period	of	72	hours	 (either	doxorubicin	or	paclitaxel	at	 the	pre-
determined	 IC95	 concentration,	 or	 a	 combination	 of	 each	 at	 the	 respective	 IC50	
concentration).	Following	72	hours	of	incubation	in	the	presence	of	drugs,	the	culture	
medium	was	removed	from	all	wells	and	the	remaining	cells	washed	twice	with	PBS.	
Adherent	 cells	 were	 retrieved	 by	 trypsinisation	 (Section	 2.2.1.2.)	 and	 prepared	 as	
suspensions	 in	serum-free	basal	medium	for	haemocytometric	counting	as	described	
previously	 (Section	 2.2.3.).	 Haemocytometric	 counting	 was	 used	 to	 determine	 the	
number	of	viable	cells	present	within	each	well	prior	 to	undertaking	 flow	cytometric	
analysis	 to	 determine	 the	 percentage	 of	 Vybrant®	 DiD-positive	 cells.	 During	 flow	
cytometric	 analyses,	 unlabelled	 samples	 of	 either	 untreated,	 doxorubicin-treated	 or	
paclitaxel-treated	 cells	 were	 used	 to	 set	 the	 gating	 strategy	 for	 the	 corresponding	
experimental	sample	set	and	propidium	iodide	(f.c.	7.5μM)	was	used	as	a	viability	dye	
to	 ensure	only	 live	 single	 cells	were	 analysed	 for	 dye-retention.	 The	percentage	dye	
retention	and	haemocytometric	viable	cell	counts	were	used	to	derive	the	number	of	
viable	 dye-retaining	 and	 dye-negative	 cells	 present	 in	 untreated	 and	 drug	 treated	
samples.	The	relative	survivability	of	Vybrant®	DiD-positive	and	negative	fractions	was	
also	 calculated	 as	 a	 percentage	 of	 the	 untreated	 control	 for	 doxorubicin-	 and	
paclitaxel-treated	 cultures.	 A	 summary	 of	 the	 experimental	 timeline	 for	 establishing	
intrinsic	drug	resistance	in	Vybrant®	DiD-positive	and	negative	fractions	is	depicted	in	
Figure	5.2.	
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5.4.3. Determination	of	the	Presence	of	Drug-Resistant	Sub-Clones	
	
Dye-retaining	and	dye-negative	MDA-MB-231	cells	 that	 remained	viable	 following	72	
hours	 exposure	 to	 the	 IC95	 concentration	 of	 either	 doxorubicin	 or	 paclitaxel	 (as	
described	 in	 Section	 5.4.2.)	 were	 isolated	 by	 FACS	 and	 seeded	 in	 triplicate	 at	 a	
clonogenic	 density	 of	 20	 cells	 per	 cm2	 into	 the	 wells	 of	 6-well	 cluster	 plates,	 each	
containing	a	3ml	volume	of	drug-free	complete	culture	medium.	Cluster	plates	were	
placed	into	incubation	under	standard	growth	conditions	for	a	period	of	6	days.	Colony	
formation	assays	were	subsequently	undertaken	as	described	 in	Section	2.2.6.1.	and	
the	 number	 of	 colonies	 formed	 by	 Vybrant®	 DiD-positive	 and	 negative	 fractions	
treated	 with	 either	 paclitaxel	 and	 doxorubicin	 quantified.	 A	 summary	 of	 the	
experimental	 timeline	 for	 establishing	 intrinsic	 drug	 resistance	 and	 determining	
presence	of	drug-resistant	sub-clones	in	Vybrant®	DiD-positive	and	negative	fractions	
is	depicted	in	Figure	5.2.	
	
	
	
Figure	5.2.	Timeline	for	Investigating	Drug-Resistance	in	Dye-Retaining	Cells	
Cells	stained	with	Vybrant®	DiD	were	cultured	continuously	for	five	passages	post-staining	before	being	
reseeded	 into	6-well	 cluster	plates	and	exposed	 to	 the	pre-determined	 IC95	 concentration	of	 the	drug	
being	tested	for	a	72	hour	period.	Following	drug	treatment,	viable	cells	were	retrieved	and	quantified	
by	 haemocytometric	 counting.	 The	 percentage	 Vybrant®	 DiD	 positivity	 of	 this	 surviving	 fraction	 was	
determined	 during	 the	 FACS	 process	 used	 to	 isolate	 Vybrant®	DiD-positive	 and	 negative	 populations.	
These	 isolated	populations	were	then	re-plated	 in	the	absence	of	drug	to	allow	colony	formation.	The	
number	 of	 colonies	 formed	 by	 Vybrant®	 DiD-positive	 and	 negative	 cells	 that	 initially	 survived	 drug	
treatment	was	determined	after	6	days	of	incubation	post-cessation	of	drug	exposure.	
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5.4.4. CD24	and	CD44	Expression	in	Dye-Negative	and	Dye-Retaining	Populations	
	
Staining	of	wild	type	MCF-7	or	MDA-MB-231	cells	with	Vybrant®	DiD	was	undertaken	
in	 suspension	 according	 to	 the	 manufacturer's	 instructions	 (Section	 2.3.1.).	 Stained	
cells	were	seeded	at	the	recommended	optimal	density	(Table	2.2.)	 into	75cm2	high-
quality	polystyrene	tissue	culture	flasks	and	cultured	continuously	for	five	subsequent	
passages	 alongside	 unlabelled	 control	 samples.	 Following	 retrieval	 of	 cultures	 at	
passage	 five	 post-staining,	 samples	 of	 1.0	 x	 106	 cells	 were	 prepared	 and	
immunostained	 for	 CD24	 and	 CD44	 concomitantly	 using	 directly	 conjugated	 primary	
antibodies	(Table	5.1.)	according	to	the	general	protocol	for	detection	of	cell	surface	
markers	by	direct	 immunofluorescence	outlined	 in	Section	2.3.3.1.	The	 final	working	
protein	 concentration	 of	 antibodies	 used	 was	 pre-determined	 and	 validated	 by	 the	
supplier.	 Stained	 cultures	 were	 analysed	 cytofluorimetrically	 for	 expression	 of	 CD24	
and	 CD44	 using	 the	 gating	 tree	 pre-set	 with	 an	 unlabelled	 control	 sample	 while	
Vybrant®	 DiD	 staining	 status	 was	 used	 to	 differentiate	 the	 two	 cell	 populations	 of	
interest	(Figure	5.3.).	
	
Table	5.1.	Antibodies	Used	in	CD24	and	CD44	Immunostaining	
	
Target	
	
Host	
Species	 Clonality	 Isotype	 Clone	No.	 Conjugate	
Final	Conc.	
(μg/ml)	 Supplier	
CD24	 Mouse	 Mono	 IgG1	 SN3	 Phycoerythrin	 6	 Abcam	
None	 Mouse	 Mono	 IgG1	 B11/6	 Phycoerythrin	 6	 Abcam	
CD44	 Mouse	 Mono	 IgG2b	 G44-26	 BV421	 10	 BD	
None	 Mouse	 Mono	 IgG2b	 27-35	 BV421	 10	 BD	
	
A	 phycoerythrin-conjugated	 anti-CD24	 primary	 antibody	 and	matched	 isotype	 control	 antibody	 were	
sourced	from	Abcam	Plc.	(Cambridge,	U.K.)	while	a	Brilliant	Violet	421™-conjugated	anti-CD44	primary	
antibody	 and	matched	 isotype	 control	 antibody	 were	 sourced	 from	 Beckton,	 Dickenson	 and	 Co.	 Plc.	
(Oxford,	U.K.).	The	working	concentration	of	each	 isotype	control	antibody	was	matched	 to	 the	exact	
working	protein	concentration	of	the	primary	antibody	to	which	it	was	paired.	
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Figure	5.3.	CD24	and	CD44	Expression	by	Dye-Retaining	and	Negative	Populations	
Cellular	debris	was	gated-out	of	 the	event	population	 (A),	 the	resultant	population	divided	 into	single	
cell	and	non-single	cell	events	(B),	and	then	Vybrant®	DiD-negative	and	positive	populations	 identified	
using	 gates	 predefined	 by	 unlabelled	 and	 freshly	 labelled	 samples,	 respectively	 (C).	 Vybrant®	 DiD-
negative	(D)	and	Vybrant®	DiD-positive	(E)	populations	were	analysed	for	expression	of	CD24	and	CD44	
concomitantly.	
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5.4.5. Aldehyde	Dehydrogenase	Activity	of	Dye-Negative	and	Dye-Retaining	Cells	
	
Wild	type	MCF-7	or	MDA-MB-231	cells	were	stained	in	suspension	with	Vybrant®	DiD	
according	 to	 the	 manufacturer's	 instructions	 (Section	 2.3.1.)	 and	 seeded	 at	 the	
recommended	optimal	density	into	75cm2	high-quality	polystyrene	tissue	culture	flasks	
(Table	 2.2.).	 Stained	 cells	 were	 cultured	 continuously	 for	 five	 subsequent	 passages	
alongside	unlabelled	control	samples.	Following	retrieval	of	stained	cultures	at	passage	
five	post-staining,	cultures	were	assayed	non-immunologically	for	ALDH	activity	using	
the	ALDEFLUOR™	assay,	as	described	in	Section	2.5.3.	During	flow	cytometric	analysis,	
an	unlabelled	control	sample	was	used	to	pre-set	the	gating	strategy	for	determination	
of	 Vybrant®	DiD	 staining	 status	which	 facilitated	differentiation	of	 dye-retaining	 and	
dye-negative	sub-populations	prior	to	analysis	of	their	respective	ALDH	positivity.	The	
gate	 for	 determination	 of	 ALDH	 positivity,	 as	 indicated	 by	 fluorescence	 due	 to	
oxidation	 of	 BODIPY-aminoacetaldehyde	 (BAAA),	 was	 pre-set	 using	 samples	 pre-
treated	with	the	specific	ALDH	inhibitor	diethylaminobenzaldehyde	(DEAB).	The	gating	
strategy	for	concomitant	cytofluorimetric	assessment	of	the	ALDH	activity	of	Vybrant®	
DiD-retaining	and	DiD-negative	populations	is	depicted	in	Figure	5.4.	
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Figure	5.4.	ALDH	Analysis	in	Dye-Retaining	and	Negative	Populations	
Cellular	 debris	 was	 gated-out	 of	 the	 event	 population	 (A)	 and	 the	 resultant	 population	 divided	 into	
single	 cell	 and	 non-single	 cell	 events	 (B).	 The	 Vybrant®	 DiD-negative	 and	 positive	 populations	 within	
samples	were	identified	using	gates	predefined	by	unlabelled	and	freshly	labelled	samples,	respectively	
(C).	A	 control	 sample	of	Vybrant®	DiD	 stained	cells	 treated	with	 the	 specific	aldehyde	dehydrogenase	
(ALDH)	 inhibitor	 diethylaminobenzaldehyde	 (DEAB)	 was	 used	 to	 set	 the	 gating	 for	 the	 detection	 of	
oxidised	 BODIPY-aminoacetaldehyde	 (BAAA)	 indicative	 of	 cellular	 ALDH	 activity	 in	 Vybrant®	 DiD-
negative	and	Vybrant®	DiD-positive	populations.	Experimental	samples	that	were	not	treated	with	DEAB	
were	 then	 analysed	 using	 the	 pre-set	 gating	 strategy,	 thereby	 allowing	 specific	 detection	 of	 ALDH	
positive	cells	in	Vybrant®	DiD-negative	(D)	and	Vybrant®	DiD-positive	(E)	populations.	
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5.4.6. Assessing	EMT	Marker	Expression	in	Dye-Negative	and	Dye-Retaining	Cells	
	
Staining	 of	 wild	 type	 MDA-MB-231	 cells	 with	 Vybrant®	 DiD	 was	 undertaken	 in	
suspension	 according	 to	 the	 manufacturer	 instructions	 (Section	 2.3.1.)	 before	 cells	
were	seeded	at	the	recommended	optimal	density	(Table	2.2.)	into	75cm2	high-quality	
polystyrene	 tissue	 culture	 flasks	 and	 cultured	 continuously	 for	 five	 subsequent	
passages.	Following	retrieval	of	stained	cultures	at	passage	five	post-staining,	Vybrant®	
DiD-positive	and	DiD-negative	cells	were	isolated	by	FACS	and	2000	cells	of	each	type	
deposited	onto	glass	microscope	slides	using	a	cytocentrifuge	as	described	in	Section	
2.3.2.1.	 Samples	 were	 immunostained	 for	 markers	 of	 EMT	 detailed	 in	 Table	 5.2.	
according	 to	 the	 protocol	 for	 detection	 of	 intracellular	 antigens	 by	 indirect	
immunofluorescence	 outlined	 in	 Section	 2.3.2.2.	 The	 final	 working	 protein	
concentration	of	antibodies	used	was	determined	by	preliminary	assays	carried	out	in	
the	 same	 manner	 in	 which	 a	 range	 of	 final	 protein	 concentrations	 of	 primary	 and	
secondary	 antibodies	 were	 used;	 primary	 antibody	 concentrations	 ranged	 from	
0.1μg/ml	 to	 20μg/ml,	 while	 secondary	 antibody	 concentrations	 ranged	 from	
1.875μg/ml	 to	 15μg/ml,	 as	 recommended	 by	 the	 supplier.	 Immunostained	 samples	
were	 imaged	 under	 fluorescence	 microscopy	 at	 100X	 magnification	 and	 a	 series	 of	
three	 non-overlapping	 fields	 captured	 using	 the	 tile	 scan	 function	 of	 the	 Leica	
AF6000LX	 microscope	 for	 manual	 scoring	 of	 marker	 expression	 (Section	 2.4.).	
Representative	images	of	the	staining	pattern	in	each	instance	were	also	captured	at	
200X	magnification.	
	
Table	5.2.	Antibodies	Used	in	EMT	Marker	Immunostaining	
	
Target	
	
Host	
Species	 Clonality	 Isotype	 Clone	No.	 Conjugate	
Final	Conc.	
(μg/ml)	 Supplier	
β-Catenin	 Mouse	 Mono	 IgG1	 12F7	 None	 2	 Abcam	
Vimentin	 Mouse	 Mono	 IgG1	 RV202	 None	 1	 Abcam	
None	 Mouse	 Mono	 IgG1	 15-6E10A7	 None	 -	 Abcam	
Mouse	IgG+M	 Goat	 Poly	 IgG	 -	 AlexaFluor®	488	 3.75	 Stratech	
	
Unconjugated	 antibodies	 against	 β-catenin	 and	 vimentin,	 along	 a	 matched	 isotype	 control	 antibody	
were	 sourced	 from	 Abcam	 Plc.	 (Cambridge,	 U.K.)	 while	 an	 AlexaFluor®	 488-conjugated	 secondary	
antibody	was	sourced	from	Stratech	Scientific	Ltd.	(Newmarket,	U.K.).	A	specific	dilution	is	not	stated	for	
the	 isotype	 control	 antibody,	 as	 this	 was	 dependent	 on	 matching	 the	 exact	 working	 protein	
concentration	of	the	primary	antibody	to	which	it	was	paired	in	a	particular	experiment.	
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5.4.7. Stem	Cell	Marker	Expression	in	Dye-Negative	and	Dye-Retaining	Cells	
	
Wild	 type	 MDA-MB-231	 cells	 that	 were	 stained	 in	 suspension	 with	 Vybrant®	 DiD	
according	to	the	manufacturer	instructions	(Section	2.3.1.)	were	seeded	at	the	optimal	
density	 of	 1.0	 x	 104	 cells	 per	 cm2	 into	 75cm2	 high-quality	 polystyrene	 tissue	 culture	
flasks	and	cultured	continuously	for	five	passages	post-staining.	Following	retrieval	of	
stained	cultures	at	passage	five	post-staining,	samples	of	1.0	x	106	cells	were	prepared	
and	 subsequently	 immunostained	 using	 a	 panel	 of	 unconjugated	 primary	 antibodies	
for	 the	 detection	 of	 human	 embryonic	 stem	 cells	 (hES)	 and	 embryocarcinoma	 stem	
cells	 (hEC),	 depicted	 in	Table	 5.3.	 Immunostaining	was	 undertaken	 according	 to	 the	
general	protocol	for	detection	of	cell	surface	markers	by	indirect	immunofluorescence	
outlined	 in	Section	 2.3.3.2.	 The	 final	working	protein	 concentration	of	 all	 antibodies	
used	 was	 pre-determined	 and	 validated	 by	 the	 supplier.	 Stained	 cultures	 were	
analysed	cytofluorimetrically	for	marker	positivity	using	the	gating	tree	pre-set	with	an	
unlabelled	control	sample	while	Vybrant®	DiD	staining	status	was	used	to	differentiate	
the	two	cell	populations	of	interest	(Figure	5.5.).	
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Table	5.3.	Antibodies	Used	in	Stem	Cell	Marker	Immunostaining	
	
Target	
	
Host	
Species	 Clonality	 Isotype	 Clone	No.	 Conjugate	
Final	Conc.	
(μg/ml)	 Supplier	
SSEA-3	 Mouse	 Mono	 IgM	 -	 None	 1	 UoS	CSCB	
SSEA-4	 Mouse	 Mono	 IgG3	 -	 None	 10	 UoS	CSCB	
TRA-1-60S	 Mouse	 Mono	 IgM	 -	 None	 10	 UoS	CSCB	
TRA-1-60R	 Mouse	 Mono	 IgM	 -	 None	 10	 UoS	CSCB	
TRA-1-81	 Mouse	 Mono	 IgM	 -	 None	 10	 UoS	CSCB	
TRA-2-49	 Mouse	 Mono	 IgG1	 -	 None	 10	 UoS	CSCB	
TRA-2-54	 Mouse	 Mono	 IgG1	 -	 None	 10	 UoS	CSCB	
SSEA-1	 Mouse	 Mono	 IgM	 -	 None	 10	 UoS	CSCB	
GD2	 Mouse	 Mono	 IgM	 -	 None	 10	 UoS	CSCB	
GD3	 Mouse	 Mono	 IgM	 -	 None	 10	 UoS	CSCB	
GT3	 Mouse	 Mono	 IgM	 -	 None	 5	 UoS	CSCB	
CD46	 Mouse	 Mono	 IgG1	 -	 None	 10	 UoS	CSCB	
CD56	 Mouse	 Mono	 IgG1	 -	 None	 10	 UoS	CSCB	
CD57	 Mouse	 Mono	 IgM	 -	 None	 10	 UoS	CSCB	
CD271	 Mouse	 Mono	 IgM	 -	 None	 10	 UoS	CSCB	
AA11	 Mouse	 Mono	 IgM	 -	 None	 10	 UoS	CSCB	
AG10	 Mouse	 Mono	 IgM	 -	 None	 10	 UoS	CSCB	
EF12	 Mouse	 Mono	 IgM	 -	 None	 10	 UoS	CSCB	
BE12	 Mouse	 Mono	 IgM	 -	 None	 10	 UoS	CSCB	
BF4	 Mouse	 Mono	 IgM	 -	 None	 10	 UoS	CSCB	
CC9	 Mouse	 Mono	 IgM	 -	 None	 10	 UoS	CSCB	
CH8	 Mouse	 Mono	 IgG1	 -	 None	 10	 UoS	CSCB	
DA9	 Mouse	 Mono	 IgM	 -	 None	 10	 UoS	CSCB	
CD147	 Mouse	 Mono	 IgG1	 -	 None	 2	 UoS	CSCB	
None	 Mouse	 Mono	 IgG1	 15-6E10A7	 None	 -	 Abcam	
None	 Mouse	 Mono	 IgG3	 PPV-07	 None	 -	 Abcam	
None	 Mouse	 Mono	 IgM	 B11/7	 None	 -	 Abcam	
Mouse	
IgG+M	 Goat	 Poly	 IgG	 -	 AlexaFluor®	488	 15	 Stratech	
	
All	 primary	 antibodies	 were	 raised	 in-house,	 pre-validated	 and	 supplied	 by	 the	 Centre	 for	 Stem	 Cell	
Biology,	University	of	Sheffield	 (Sheffield,	U.K.),	while	 isotype	control	and	AlexaFluor®	488-conjugated	
secondary	 antibodies	 were	 sourced	 from	 Abcam	 Plc.	 (Cambridge,	 U.K.)	 and	 Stratech	 Scientific	 Ltd.	
(Newmarket,	 U.K.),	 respectively.	 The	 pan-human	 antigen	 CD147	 was	 used	 as	 a	 positive	 control	 for	
immunostaining.	Specific	dilutions	are	not	stated	for	isotype	control	antibodies,	as	this	was	dependent	
on	the	exact	working	protein	concentration	of	the	primary	antibody	to	which	they	were	matched	in	any	
particular	experiment.	
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Figure	5.5.	Stem	Cell	Marker	Analysis	in	Dye-Retaining	and	Negative	Populations	
Cellular	debris	was	gated-out	of	 the	event	population	 (A),	 the	resultant	population	divided	 into	single	
cell	and	non-single	cell	events	(B),	and	then	Vybrant®	DiD-negative	and	positive	populations	 identified	
using	 gates	 predefined	 by	 unlabelled	 and	 freshly	 labelled	 samples,	 respectively	 (C).	 Vybrant®	 DiD-
negative	(D)	and	Vybrant®	DiD-positive	(E)	populations	were	then	concomitantly	analysed	for	expression	
of	hES	or	hEC	markers	according	to	AlexaFluor®	488	staining	status.	
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5.4.8. Assessment	of	Mammosphere	Formation	in	Dye-Retaining	Cells	
	
After	a	 total	of	 five	consecutive	passages	of	culture	post-staining	with	Vybrant®	DiD,	
MDA-MB-231	cultures	were	sorted	into	dye-negative	and	dye-positive	populations	by	
FACS	and	reseeded	at	a	density	of	20	cells	per	cm2	in	a	total	volume	of	3ml	complete	
culture	medium	into	the	wells	of	ultra-low	attachment	6-well	cluster	plates	pre-coated	
with	 1.5%	 (w/v)	 agarose	 as	 described	 previously	 (Section	 2.2.6.2.).	 Plates	 were	
subsequently	placed	into	incubation	for	a	period	of	6	days	before	the	mammosphere	
forming	efficiency	of	the	two	fractions	under	routine	culture	conditions	was	assessed	
according	to	the	general	protocol	described	in	Section	2.2.6.2.	
	
5.4.9. Establishing	Mitotic	Dynamics	of	Dye-Retaining	Cells	
	
Vybrant®	 DiD-retaining	MDA-MB-231	 cells	 that	were	 isolated	 by	 FACS	 following	 five	
consecutive	passages	of	culture	growth	post-staining	were	reseeded	 in	triplicate	 into	
the	wells	of	6-well	cluster	plates	pre-filled	with	3ml	complete	culture	medium	at	the	
clonogenic	 density	 of	 20	 cells	 per	 cm2.	 Following	 an	 initial	 incubation	 period	 of	 24	
hours	to	allow	cells	to	adhere	to	the	plate	growth	surface,	single	Vybrant®	DiD-positive	
cells	were	located	under	inverted	phase	contrast	microscopy	using	the	Leica	AF6000LX	
integrated	 live	cell	 imaging	station	and	 their	X	and	Y	coordinates	 recorded	using	 the	
"mark	 and	 trace"	 function	 of	 the	 automated	microscope	 stage	 and	 proprietary	 LAS	
imaging	 software.	 At	 subsequent	 24	 hour	 intervals	 the	 specimen	 position	 was	
relocated	and	images	recorded.	
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5.5. Results	
	
5.5.1. Dye-Retaining	Cells	are	Resistant	to	Anti-Neoplastic	Drugs	
	
Conventional	 chemotherapeutic	 agents	 require	 that	 cells	 are	 actively	 progressing	
through	the	cell	cycle	in	order	to	elicit	their	cytotoxic	effects	(Moore	and	Lyle,	2011).	
Mitotically	 quiescent	 or	 slow-cycling	 cell	 populations	 are	 therefore	 likely	 to	 be	 less	
susceptible	to	such	drugs,	suggesting	an	inherent	mechanism	of	recurrence	or	relapse	
in	which	these	populations	are	able	to	evade	the	effects	of	chemotherapeutics	and	re-
emerge	 at	 either	 the	 primary	 or	 secondary	 sites	 following	 cessation	 of	 treatment.	
Vybrant®	 DiD-stained	 MCF-7	 and	 MDA-MB-231	 cultures	 were	 treated	 with	 either	
doxorubicin,	paclitaxel	or	a	 combination	 thereof	 in	order	 to	 test	 the	hypothesis	 that	
the	 slow-cycling	 nature	 of	 the	 label-retaining	 population	 conferred	 inherent	
chemotherapeutic	resistance.	The	IC50	and	IC95	of	each	drug	was	first	determined	using	
the	MTT	 assay	 (Figure	 5.6.	 and	 Figure	 5.7.)	 before	 Vybrant®	 DiD-stained	MCF-7	 or	
MDA-MB-231	 cultures	 were	 treated	 with	 drugs	 for	 72	 hours	 (Section	 5.4.2.).	 The	
relative	 survivability	 of	 the	 dye-negative	 and	 dye-retaining	 fractions	 was	 compared	
when	expressed	as	a	percentage	of	untreated	control	samples	(Figure	5.8.	and	Figure	
5.9.).	
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Figure	5.6.	MCF-7	Doxorubicin	and	Paclitaxel	Dose-Response	Curves	
A:	Absorbance	values	measured	spectrophotometrically	at	a	wavelength	of	570nm	(Abs570nm)	following	
MTT	assays	undertaken	on	growth	control	and	vehicle	control	samples	included	during	establishment	of	
the	MCF-7	 dose-response	 curves	 for	 doxorubicin	 and	 paclitaxel.	 In	 both	 cases	 growth	 controls	 were	
grown	 in	 complete	 culture	 medium	 only	 (RPMI-1640	 +	 10%	 (v/v)	 FBS).	 Vehicle	 controls	 for	 samples	
treated	with	doxorubicin	and	paclitaxel	 contained	4.17%	 (v/v)	PBS	or	1%	 (v/v)	ethanol	 respectively	 in	
addition	to	complete	culture	medium.	Data	were	compared	using	a	two-tailed	unpaired	t-test	(NS	=	not	
statistically	 significant	 or	 P	 >	 0.05).	B:	MCF-7	 dose-response	 curves	 established	 using	 the	MTT	 assay	
following	a	72-hour	period	of	exposure	to	either	doxorubicin	(1pM	-	100μM)	or	paclitaxel	(10fM	-	1μM).	
Cell	survival	at	each	drug	concentration	is	expressed	as	a	percentage	of	Abs570nm	recorded	for	samples	
exposed	to	the	respective	vehicle	control	solution.	Data	are	expressed	as	the	mean	average	±	SEM	for	n	
=	3	biologically	independent	repeat	experiments.	
	
	
	
	
	
	
	
	
	
	 198	
	
	
Figure	5.7.	MDA-MB-231	Doxorubicin	and	Paclitaxel	Dose-Response	Curves	
A:	Absorbance	values	measured	spectrophotometrically	at	a	wavelength	of	570nm	(Abs570nm)	following	
MTT	assays	undertaken	on	growth	control	and	vehicle	control	samples	included	during	establishment	of	
the	MDA-MB-231	dose-response	 curves	 for	 doxorubicin	 and	paclitaxel.	 In	 both	 cases	 growth	 controls	
were	grown	in	complete	culture	medium	only	(RPMI-1640	+	10%	(v/v)	FBS).	Vehicle	controls	for	samples	
treated	with	doxorubicin	and	paclitaxel	 contained	4.17%	 (v/v)	PBS	or	1%	 (v/v)	ethanol	 respectively	 in	
addition	to	complete	culture	medium.	Data	were	compared	using	a	two-tailed	unpaired	t-test	(NS	=	not	
statistically	 significant	 or	 P	 >	 0.05).	B:	MDA-MB-231	 dose-response	 curves	 established	 using	 the	MTT	
assay	following	a	72-hour	period	of	exposure	to	either	doxorubicin	(1pM	-	100μM)	or	paclitaxel	(1pM	-	
1μM).	 Cell	 survival	 at	 each	 drug	 concentration	 is	 expressed	 as	 a	 percentage	 of	 Abs570nm	 recorded	 for	
samples	exposed	to	the	respective	vehicle	control	solution.	Data	are	expressed	as	the	mean	average	±	
SEM	for	n	=	3	biologically	independent	repeat	experiments.	
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In	MCF-7	cultures	treated	with	doxorubicin	(IC95	=	2.36μM)	for	72	hours	(Figure	5.8.),	
the	Vybrant®	DiD-retaining	fraction	demonstrated	significantly	increased	survival	over	
the	non-label-retaining	bulk	cell	population,	with	22.68	±	1.91%	of	the	label	retaining	
population	 remaining	 viable	 following	 doxorubicin	 treatment	 compared	 with	 5.48	 ±	
0.53%	of	 the	bulk	 cell	population	 (P	≤	0.001).	 Similarly,	when	 treated	with	paclitaxel	
(IC95	=	46.45nM)	for	a	72-hour	period,	24.08	±	1.24%	of	Vybrant®	DiD-retaining	MCF-7	
cells	survived	compared	with	just	6.34	±	0.58%	of	the	non-labelled	bulk	population	(P	≤	
0.001)	 (Figure	 5.8.).	 These	 findings	were	 reiterated	when	doxorubicin	 and	 paclitaxel	
were	 used	 at	 lower	 concentrations	 in	 combination	 (doxorubicin	 IC50	 =	 0.11μM,	
paclitaxel	IC50	=	0.12nM)	(Figure	5.8.);	93.72	±	12.84%	of	Vybrant®	DiD-retaining	cells	
survived	compared	with	just	22.60	±	0.24%	of	the	Vybrant®	DiD-negative	population	(P	
≤	0.01).	
	
In	MDA-MB-231	cultures	treated	with	doxorubicin	(IC95	=	321nM)	for	72	hours	(Figure	
5.9.),	 the	 Vybrant®	 DiD-retaining	 MDA-MB-231	 fraction	 demonstrated	 significantly	
increased	survival	over	the	non-label-retaining	bulk	cell	population,	with	40.76	±	4.60%	
of	 the	 label	 retaining	 population	 remaining	 viable	 following	 doxorubicin	 treatment	
compared	with	1.63	±	0.22%	of	 the	bulk	 cell	 population	 (P	≤	0.0001).	When	 treated	
with	paclitaxel	 (IC95	 =	20.80nM)	 for	 a	72-hour	period,	 102	±	5.57%	of	Vybrant®	DiD-
retaining	MDA-MB-231	 cells	 survived	 compared	 with	 just	 4.47	 ±	 0.25%	 of	 the	 non-
labelled	 bulk	 population	 (P	 ≤	 0.0001)	 (Figure	 5.9.).	 Similarly,	 when	 treated	 with	 a	
combination	of	doxorubicin	and	paclitaxel	(doxorubicin	IC50	=	12.14nM,	paclitaxel	IC50	
=	 4.60nM),	 81.43	 ±	 5.84%	 of	 Vybrant®	 DiD-retaining	 MDA-MB-231	 cells	 survived	
compared	 with	 44.41	 ±	 1.03%	 of	 the	 Vybrant®	 DiD-negative	 population	 (P	 ≤	 0.01)	
(Figure	 5.9.).	 The	 combined	outcome	of	 these	assays	 indicated	 that	 the	 slow-cycling	
nature	of	 the	dye-retaining	fraction	 is	associated	with	an	enhanced	resistance	to	the	
cytotoxic	effects	of	anti-neoplastic	chemotherapeutic	agents.	
	
	
	
	
	
	
	 200	
	
	
Figure	5.8.	Chemoresistance	in	Dye-Retaining	and	Negative	MCF-7	Cells	
The	 total	 viable	 number	 of	 Vybrant®	 DiD-negative	 and	 Vybrant®	 DiD-positive	 cells	 present	 in	MCF-7	
cultures	 expressed	 as	 a	 percentage	 of	 the	 corresponding	 population	 present	 in	 untreated	 control	
samples	 following	72	hours	 treatment	with	either	 the	 IC95	concentration	of	doxorubicin	 (A),	paclitaxel	
(B),	or	a	combination	of	both	at	the	respective	IC50	concentration	(C)	at	five	passages	post-staining.	Data	
were	compared	using	one-way	ANOVA	followed	by	Dunnett's	Multiple	Comparison	Test	(**	=	P	≤	0.01,	
***	=	P	≤	0.001).	All	data	are	expressed	as	 the	mean	±	SEM	for	n	=	3	biologically	 independent	repeat	
experiments.	
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Figure	5.9.	Chemoresistance	in	Dye-Retaining	and	Negative	MDA-MB-231	Cells	
The	total	viable	number	of	Vybrant®	DiD-negative	and	Vybrant®	DiD-positive	cells	present	in	MDA-MB-
231	cultures	expressed	as	a	percentage	of	 the	corresponding	population	present	 in	untreated	control	
samples	 following	72	hours	 treatment	with	either	 the	 IC95	concentration	of	doxorubicin	 (A),	paclitaxel	
(B),	or	a	combination	of	both	at	the	respective	IC50	concentration	(C)	at	five	passages	post-staining.	Data	
were	compared	using	one-way	ANOVA	followed	by	Dunnett's	Multiple	Comparison	Test	(**	=	P	≤	0.01,	
****	=	P	≤	0.0001).	All	data	are	expressed	as	the	mean	±	SEM	for	n	=	3	biologically	independent	repeat	
experiments.	
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In	order	to	determine	whether	cells	 that	survived	chemotherapeutic	drug	treatment,	
such	 as	 those	 depicted	 in	 Figure	 5.10.,	 were	 capable	 of	 further	mitotic	 activity	 and	
subsequent	formation	of	new	clonal	populations,	viable	cells	from	both	Vybrant®	DiD-
negative	and	Vybrant®	DiD-positive	fractions	were	isolated	by	FACS	following	72	hours	
exposure	to	the	IC95	concentration	of	either	doxorubicin	or	paclitaxel	and	reseeded	at	
a	 clonogenic	 density	 in	 drug-free	 medium	 (Section	 5.4.3.).	 Following	 six	 days	
incubation	 post-cessation	 of	 chemotherapeutic	 drug	 exposure,	 an	 average	 of	 4.11	 ±	
0.77	 colonies	 had	 been	 formed	 by	 Vybrant®	 DiD-positive	 cells	 that	 initially	 survived	
doxorubicin	 treatment	 and	 4.44	 ±	 0.56	 colonies	 had	 been	 formed	 by	 Vybrant®	 DiD-
positive	 cells	 that	 initially	 survived	 paclitaxel	 treatment.	 In	 contrast,	 no	 detectable	
colonies	 were	 formed	 by	 Vybrant®	 DiD-negative	 cells	 that	 had	 initially	 survived	
treatment	with	either	drug	(Figure	5.11.)	and	no	undivided	single	cells	were	evident	in	
any	of	 the	wells	when	Vybrant®	DiD-negative	cell	assay	plates	were	examined	under	
inverted	phase	contrast	microscopy	immediately	prior	to	the	colony	formation	assay.	
These	 data	 demonstrate	 that	 cells	 capable	 of	 escaping	 anti-neoplastic	 therapy	 exist	
within	 the	 quiescent	 fraction.	 In	 order	 to	 determine	 whether	 stem-like	 cells	 were	
equally	prevalent	within	both	dye	retaining	and	rapidly	dividing	cell	fractions,	or	were	
exclusive	to	the	former	population,	the	expression	of	widely	used	breast	cancer	stem	
cell	markers	CD24	and	CD44	was	next	determined.	
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Figure	5.10.	Dye-Retaining	MDA-MB-231	Cells	Surviving	Chemotherapy	
Representative	 images	 of	 MDA-MB-231	 cultures	 (five	 passages	 post-staining	 with	 Vybrant®	 DiD)	
following	 72-hours	 treatment	with	 the	 IC95	 concentration	 of	 either	 doxorubicin	 (321nM)	 or	 paclitaxel	
(20.80nM).	Untreated	control	cultures	are	also	shown	on	the	left.	Dye-retaining	cells	(red,	indicated	by	
white	 arrows)	 in	 drug-treated	 cultures	 appear	 to	possess	 relatively	 normal	morphology	despite	many	
surrounding	dye-negative	cells	showing	clear	evidence	of	cell	death.	All	 images	were	captured	using	a	
20x	objective	lens	(scale	bar	=	50μm).	
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Figure	5.11.	Colony	Formation	by	Dye-Retaining	Cells	Surviving	Chemotherapy	
A:	The	number	of	colonies	formed	by	viable	Vybrant®	DiD-negative	and	Vybrant®	DiD-positive	MDA-MB-
231	cells	 isolated	following	72	hours	treatment	with	the	 IC95	concentration	of	doxorubicin	(321nM)	or	
paclitaxel	(20.80nM)	at	five	passages	post-staining.	Data	were	compared	using	a	two-tailed	unpaired	t-
test	 (****	 =	 P	 ≤	 0.0001).	 Data	 are	 expressed	 as	 the	 mean	 average	 ±	 SEM	 for	 n	 =	 3	 biologically	
independent	repeat	experiments.	B:	Representative	images	of	a	crystal	violet-stained	clonogenic	assay	
plates	for	Vybrant®	DiD-negative	and	Vybrant®	DiD-positive	MDA-MB-231	cells	isolated	from	untreated,	
paclitaxel-	 and	 doxorubicin-treated	 cultures.	 All	 images	 were	 captured	 using	 a	 2x	 stereomicroscopic	
objective	lens.	
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5.5.2. CD24	and	CD44	Co-Expression	is	Increased	in	Dye-Retaining	Cells	
	
Since	 the	 pioneering	 study	 of	 Al-Hajj	 et	 al.	 (2003)	 the	 CD44+CD24-/low	 signature,	 has	
been	 widely	 used	 to	 demark	 a	more	 tumourigenic	 putative	 breast	 cancer	 stem	 cell	
population.	 In	 order	 to	 provide	 an	 initial	 indication	 of	 the	 presence	 and	 relative	
distribution	 of	 supposed	 stem-like	 cells	 between	 rapidly	 dividing	 and	 slowly	 dividing	
dye-retaining	 populations,	 these	 fractions	 were	 distinguished	 cytofluorimetrically	
based	on	Vybrant®	DiD	staining	status	 following	 five	consecutive	passages	of	 culture	
growth	post-staining	and	then	each	analysed	for	CD24	and	CD44	expression	(Section	
5.4.4.).	
	
During	 CD24	 and	 CD44	 co-expression	 analyses	 it	 was	 immediately	 evident	 that	 all	
MDA-MB-231	cells	express	CD44	irrespective	of	their	mitotic	activity	and	consequent	
dye-retention	 status	 but	 that	 the	 Vybrant®	 DiD-negative	 and	 Vybrant®	 DiD-positive	
populations	differed	considerably	in	their	relative	expression	of	CD24	(Figure	5.12.).	A	
mean	average	of	0.55	±	0.01%	of	Vybrant®	DiD-negative	cells	were	CD24+	while	28.99	±	
3.01%	 of	 Vybrant®	 DiD-positive	 cells	 were	 CD24+	 (P	 ≤	 0.0001).	 Although	 the	 overall	
distribution	of	 the	CD24	and	CD44	markers	was	different	 in	 the	MCF-7	 cell	 line,	 the	
same	 pattern	 of	 increased	 CD24	 and	 CD44	 dual	 positive	 expression	 status	 was	
observed	 in	 the	Vybrant®	DiD-positive	 cell	 population;	Vybrant®	DiD-negative	MCF-7	
cells	were	52.11	±	1.39%	CD44+CD24+	while	the	corresponding	Vybrant®	DiD-positive	
population	was	81.23	±	0.78%	CD44+CD24+	(P	≤	0.0001).	
	
The	 observation	 of	 significantly	 increased	 dual	 CD24	 and	 CD44	 positivity	 in	 the	
Vybrant®	 DiD-positive	 fraction	 of	 both	 MDA-MB-231	 and	 MCF-7	 cell	 lines	 was	 a	
somewhat	unexpected	finding.	Relatively	recently	Liu	et	al.	(2014)	demonstrated	that	
the	CD44+CD24-/low	and	ALDH+	signatures	identify	minimally	overlapping	breast	cancer	
stem	cell	populations	that	differ	with	respect	to	transcriptomic	signatures	of	EMT.	This	
raised	 the	 question	 as	 to	 whether	 the	 observed	 alterations	 in	 CD24	 and	 CD44	
expression	was	 related	 to	 increased	 relative	ALDH	activity	 and	 altered	expression	of	
EMT	markers	 within	 the	 Vybrant®	 DiD-positive	 population;	 subsequent	 experiments	
were	therefore	designed	in	order	to	address	these	issues.	
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Figure	5.12.	CD24	and	CD44	Expression	in	Dye-Retaining	and	Negative	Cells	
The	percentage	co-expression	of	breast	cancer	stem	cell-associated	markers	CD24	and	CD44	in	Vybrant®	
DiD-negative	 and	 Vybrant®	 DiD-positive	 sub-populations	 in	 the	 MCF-7	 (A)	 and	MDA-MB-231	 (B)	 cell	
lines	after	five	consecutive	passages	post-staining.	ND	=	not	detected.	Comparison	of	marker	expression	
between	 Vybrant®	 DiD-negative	 and	 Vybrant®	 DiD-positive	 populations	 was	 achieved	 using	 two-way	
ANOVA	followed	by	Sidak’s	Multiple	Comparison	Test	(NS	=	not	statistically	significant	or	P	>	0.05,	****	
=	P	≤	0.0001).	Data	are	expressed	as	the	mean	average	±	SEM	for	n	=	3	biologically	independent	repeat	
experiments.	
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5.5.3. Dye	Retaining	Cells	Possess	Increased	ALDH	Activity	
	
Aldehyde	 dehydrogenase	 (ALDH)	 represents	 a	 superfamily	 of	 NADP+-dependent	
enzymes	responsible	for	the	intracellular	oxidation	of	aldehydes	thought	to	be	critical	
to	 regulating	 stem	cell	differentiation	 through	 their	 role	 in	 retinol	metabolism	 (Clark	
and	 Palle,	 2016).	 ALDH	 has	 been	 successfully	 used	 as	 a	marker	 for	 isolation	 of	 cells	
with	 stem	 cell	 properties	 from	 multiple	 cancers	 and	 non-malignant	 tissues.	 In	
particular,	seminal	studies	by	Ginestier	et	al.	(2007)	and	Charafe-Jauffret	et	al.	(2009)	
demonstrated	the	utility	of	ALDH	activity	for	isolation	of	stem	cell-like	properties	from	
normal	human	breast	 tissue	and	breast	carcinomas.	On	this	basis,	 the	 intrinsic	ALDH	
activity	of	Vybrant®	DiD-negative	and	Vybrant®	DiD-positive	populations	was	assessed	
cytofluorimetrically	 using	 the	 ALDEFLUOR™	 assay	 (Section	 5.4.5.)	 in	 order	 to	 better	
distinguish	whether	any	differential	cancer	stem	cell	activity	was	present	within	each	
fraction.	 A	 significantly	 greater	 number	 of	 ALDH-positive	 cells	 were	 detected	within	
the	 Vybrant®	 DiD-positive	 population	 in	 both	 MDA-MB-231	 and	 MCF-7	 cell	 lines	
compared	 to	 the	 corresponding	 Vybrant®	 DiD-negative	 population	 (Figure	 5.13.).	 In	
the	MDA-MB-231	cell	 line,	an	average	of	7.68	±	0.29%	of	Vybrant®	DiD-positive	cells	
were	 ALDH	 positive	 compared	 to	 3.5	 ±	 0.21%	 of	 Vybrant®	 DiD-negative	 cells	 (P	 ≤	
0.001).	 In	 the	MCF-7	 lineage,	8.81	±	1.27%	of	Vybrant®	DiD-positive	cells	were	ALDH	
positive	compared	to	1.24	±	0.14%	positivity	in	the	Vybrant®	DiD-negative	population	
(P	 ≤	 0.01).	 When	 taken	 together,	 CD24	 and	 CD44	 expression	 and	 ALDH	 assays	
suggested	 that	 the	 slowly	 cycling	 dye-retaining	 phenotype	 is	 associated	 with	
enrichment	for	CD44+CD24+	and	ALDH+	cells	that	might	represent	a	distinct	relatively	
quiescent	stem	cell-like	phenotype.	
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Figure	5.13.	ALDH	Expression	in	Dye-Retaining	and	Negative	Cells	
The	 percentage	 expression	 of	 breast	 cancer	 stem	 cell-associated	 marker	 enzyme	 aldehyde	
dehydrogenase	(ALDH)	in	Vybrant®	DiD-negative	and	Vybrant®	DiD-positive	sub-populations	in	the	MCF-
7	 (A)	 and	 MDA-MB-231	 (B)	 cell	 lines	 after	 five	 consecutive	 passages	 post-staining.	 The	 relative	
expression	 of	 ALDH	 by	 Vybrant®	 DiD-negative	 and	 Vybrant®	 DiD-positive	 populations	 was	 compared	
using	 a	 two-tailed	 unpaired	 t-test	 (**	 =	 P	 ≤	 0.01,	 ***	 =	 P	 ≤	 0.001).	 Data	 are	 expressed	 as	 the	mean	
average	±	SEM	for	n	=	3	biologically	independent	repeat	experiments.	
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5.5.4. EMT	Marker	Positivity	is	Unaltered	in	Dye-Retaining	MDA-MB-231	Cells	
	
Given	 that	 emerging	 evidence	 in	 breast	 cancer	 and	 other	 cancer	 types	 suggest	 that	
stem-like	 and	 non-stem-like	 phenotypes	 exist	 along	 a	 dynamically	 transitioning	
spectrum	of	states	regulated	by	the	EMT	programme	(Recently	reviewed	by	Fabregat	
et	 al.,	 2016),	 and	 that	 the	 dye-retaining	 quiescent	 phenotype	 appeared	 to	 be	
associated	with	 CD44+CD24+	 and	 ALDH+	 status,	 it	 was	 hypothesised	 that	markers	 of	
EMT	 are	 differentially	 regulated	 between	 the	 slow-cycling	 and	 rapidly	 dividing	
populations.	Consequently,	the	expression	of	vimentin	and	β-catenin	was	assessed	by	
scoring	of	immunofluorescent	staining	in	cytocentrifuge	preparations	of	the	Vybrant®	
DiD-positive	and	Vybrant®	DiD-negative	MDA-MB-231	cell	populations	following	their	
isolations	by	FACS	 (Section	 5.4.6.).	 These	markers	were	chosen	 from	those	 to	which	
antibodies	were	readily	available	due	to	their	central	roles	in	the	process	of	EMT	and	
consequent	 utility	 as	 key	 indicators	 of	 cellular	 EMT-MET	 status;	 vimentin	 is	 an	
intermediate	 filament	 of	 mesenchymal	 origin	 being	 correlated	 with	 the	 post-EMT	
phenotype,	 while	 β-catenin	 is	 a	 key	 downstream	 effector	 in	 the	 Wnt	 signalling	
pathway	 that	plays	a	key	 regulatory	 role	 in	both	EMT	and	stemness	 (Fabregat	et	al.,	
2016).	Representative	images	of	staining	for	each	marker	in	the	Vybrant®	DiD-positive	
and	Vybrant®	DiD-negative	MDA-MB-231	cell	populations	are	displayed	in	Figure	5.14.	
and	Figure	5.15.	
	
No	 significant	differences	 in	 the	percentage	of	 cells	 expressing	either	 vimentin	or	β-
catenin	were	observed	when	 immunofluorescent	staining	was	quantified	 in	Vybrant®	
DiD-positive	 and	 Vybrant®	 DiD-negative	 MDA-MB-231	 cell	 populations;	 both	
populations	 were	 100%	 positive	 for	 both	 markers	 (data	 not	 shown).	 Interestingly,	
although	 scoring	was	undertaken	on	 the	basis	of	 any	 level	of	positive	 staining	being	
considered	 a	 positive	 event,	 the	 Vybrant®	 DiD-positive	 cell	 population	 consistently	
demonstrated	 less	 intense	 staining	 than	 the	 Vybrant®	 DiD-negative	 population	 for	
both	 markers;	 this	 was	 most	 evident	 in	 the	 case	 of	 vimentin	 which	 was	 seemingly	
distributed	slightly	differently	in	the	Vybrant®	DiD-positive	cell	population.	
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Figure	5.14.	Immunofluorescent	Staining	of	EMT	Marker	Vimentin	
The	 immunofluorescent	 staining	 pattern	 for	 vimentin	 (green)	 is	 shown	 along	 with	 nuclear	
counterstaining	 with	 DAPI	 (blue).	 Specificity	 of	 staining	 in	 each	 case	 is	 indicated	 by	 the	 absence	 of	
staining	 in	 the	matched	 isotype	 control	 sample.	 All	 images	were	 captured	 using	 a	 20x	 objective	 lens	
(scale	bar	=	50μm).	
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Figure	5.15.	Immunofluorescent	Staining	of	EMT	Marker	β-catenin	
The	 immunofluorescent	 staining	 pattern	 for	 β-catenin	 (green)	 is	 shown	 along	 with	 nuclear	
counterstaining	 with	 DAPI	 (blue).	 Specificity	 of	 staining	 in	 each	 case	 is	 indicated	 by	 the	 absence	 of	
staining	 in	 the	matched	 isotype	 control	 sample.	 All	 images	were	 captured	 using	 a	 20x	 objective	 lens	
(scale	bar	=	50μm).	
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5.5.5. MDA-MB-231	Cells	Express	Human	Embryonal	Stem	Cell	Markers	
	
A	number	of	 relatively	 recent	 studies	have	demonstrated	 that	markers	expressed	by	
human	 embryonic	 stem	 cells	 or	 embryocarcinoma	 stem	 cells	 also	 demark	
dedifferentiated	and	stem-like	cell	populations	in	a	number	of	non-germ	line	cancers,	
including	those	of	colon,	prostate	and	breast	(Battula	et	al.,	2010;	Battula	et	al.,	2012;	
Sivasubramaniyan	et	al.,	2015).	In	contrast	to	many	of	the	markers	used	to	identify	cell	
populations	 associated	 with	 enhanced	 population	 tumourigenicity	 following	
xenotransplantation	 assays,	 hES	 and	 hEC	markers	 were	 initially	 identified	 in	 cells	 of	
true	 multipotent	 nature.	 Expression	 of	 these	 markers	 has	 been	 associated	 with	
enhanced	metastatic	potential	and	a	worsened	prognosis	in	oropharyngeal,	lung,	and	
breast	cancer	(Gottschling	et	al.,	2013;	Hung	et	al.,	2013;	Noto	et	al.,	2013).	
	
The	 antibody	 panel	 used	 by	 the	 International	 Stem	 Cell	 Initiative	 (ISCI)	 for	
immunophenotype	characterisation	of	hES	and	hEC	populations	was	chosen	 for	 flow	
cytometric	 assays	 intended	 to	 test	 the	 hypothesis	 that	 slow	 cycling	 Vybrant®	 DiD-
retaining	 cells	 differentially	 expresses	 stem	 cell	 markers	 other	 than	 those	 assayed	
previously,	 with	 the	 aim	 of	 developing	 a	 surrogacy	 marker	 signature	 for	 the	 slow-
cycling	phenotype.	A	 second	panel	of	eight	 fully	validated	novel	antibodies	 raised	 to	
undifferentiated	 hES	 and	 hEC	 cell	 lines,	 originally	 described	 by	Wright	 et	 al.	 (2011),	
was	also	used	to	augment	the	ability	of	the	ISCI	panel	to	recognise	unique	sub-states	
within	any	extant	stem	cell	compartment	within	the	rapidly-	and	slowly-dividing	MDA-
MB-231	cell	populations.	 Immunostaining	and	cytofluorimetric	analyses	were	carried	
out	according	to	the	methods	described	previously	(Section	5.4.7.).	
	
The	 results,	 depicted	 in	 Figure	 5.16	 -	 Figure	 5.18	 and	 summarised	 in	 Table	 5.4.,	
indicate	 that	 the	MDA-MB-231	 lineage	expressed	a	number	of	hES	and	hEC	markers	
but	exhibited	disparities	in	expression	of	five	markers	that	would	otherwise	demark	a	
true	embryonal	stem	cell	population.	 In	terms	of	differential	marker	expression,	very	
little	 difference	 was	 detected	 between	 rapidly-	 and	 slowly-dividing	 populations.	 A	
small	 but	 statistically	 significant	 reduction	 in	 the	 AG10	marker	was	 observed	 in	 the	
Vybrant®	DiD-positive	fraction	(P	≤	0.05)	while	small,	statistically	significant	 increases	
in	 expression	 of	 BF4	 and	 CC9	 antigens	 (P	 ≤	 0.01	 and	 P	 ≤	 0.05,	 respectively)	 were	
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detected	in	the	Vybrant®	DiD-positive	population.	The	differential	expression	of	these	
markers	 between	 Vybrant®	 DiD-negative	 and	 Vybrant®	 DiD-positive	 fractions	 was	
deemed	to	be	too	small	to	be	of	any	practical	utility;	the	reduction	in	AG10	expression	
was	 only	 around	 9.5%	 between	 Vybrant®	 DiD-negative	 and	 Vybrant®	 DiD-positive	
populations,	while	BF4	and	CC9	were	 increased	by	2.77%	and	2.02%,	 respectively,	 in	
the	Vybrant®	DiD-positive	sub-population.	These	findings,	while	interesting	in	terms	of	
future	 study	 of	 the	 MDA-MB-231	 cell	 line	 and	 the	 potential	 implications	 of	 the	
expression	of	markers	observed	here,	did	not	identify	a	specific	marker	that	could	be	
used	 in	 conjunction	with	 CD24	 as	 a	 surrogate	marker	 profile	 to	 denote	 slow	 cycling	
cells.	
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Figure	5.16.	Expression	of	Pre-Differentiation	hES	and	hEC	Markers	
The	 percentage	 expression	 of	 pre-differentiation	 human	 embryonal	 and	 embryocarcinoma	 stem	 cell-
associated	markers	 in	Vybrant®	DiD-negative	and	Vybrant®	DiD-positive	MDA-MB-231	sub-populations	
after	 five	 consecutive	 passages	 post-staining,	 as	 determined	 cytofluorimetrically	 based	 on	
immunofluorescent	 staining	with	AlexaFluor®488.	A:	 The	expression	of	 globoseries	 glycolipid	antigens	
within	 Vybrant®	DiD-negative	 and	 Vybrant®	 DiD-positive	MDA-MB-231	 cell	 fractions	 is	 displayed	 as	 a	
percentage	of	the	total	cell	population	with	in	the	respective	sub-population.	B:	The	expression	of	high	
molecular	 weight	 keratan	 sulphate	 proteoglycan	 and	 protein	 antigens	 in	 Vybrant®	 DiD-negative	 and	
Vybrant®	 DiD-positive	 MDA-MB-231	 cell	 fractions	 is	 displayed	 as	 a	 percentage	 of	 the	 total	 cell	
population	within	the	respective	sub-population.	Data	are	expressed	as	the	mean	average	±	SEM	for	n	=	
3	 biologically	 independent	 repeat	 experiments.	 Comparison	 of	 marker	 expression	 between	 Vybrant®	
DiD-negative	and	Vybrant®	DiD-positive	populations	was	achieved	using	 two-way	ANOVA	 followed	by	
Sidak’s	Multiple	Comparison	Test	(NS	=	not	statistically	significant	or	P	>	0.05).	
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Figure	5.17.	Expression	of	Post-Differentiation	hES	and	hEC	Markers	
The	percentage	expression	of	post-differentiation	human	embryonal	and	embryocarcinoma	stem	cell-
associated	markers	 in	Vybrant®	DiD-negative	and	Vybrant®	DiD-positive	MDA-MB-231	sub-populations	
after	 five	 consecutive	 passages	 post-staining,	 as	 determined	 cytofluorimetrically	 based	 on	
immunofluorescent	 staining	 with	 AlexaFluor®488.	 A:	 The	 expression	 of	 miscellaneous	 antigens	
commonly	 expressed	 by	 human	 embryonic	 stem	 cells	 following	 differentiation	 within	 Vybrant®	 DiD-
negative	and	Vybrant®	DiD-positive	MDA-MB-231	cell	fractions	is	displayed	as	a	percentage	of	the	total	
cell	population	with	in	the	respective	sub-population.	B:	The	expression	of	neuronal-,	neuroendocrine-	
and	mesenchymal	stem	cell-associated	protein	antigens	CD57	and	CD271	in	Vybrant®	DiD-negative	and	
Vybrant®	 DiD-positive	 MDA-MB-231	 cell	 fractions	 is	 displayed	 as	 a	 percentage	 of	 the	 total	 cell	
population	within	the	respective	sub-population.	Data	are	expressed	as	the	mean	average	±	SEM	for	n	=	
3	 biologically	 independent	 repeat	 experiments.	 Comparison	 of	 marker	 expression	 between	 Vybrant®	
DiD-negative	and	Vybrant®	DiD-positive	populations	was	achieved	using	 two-way	ANOVA	 followed	by	
Sidak’s	Multiple	Comparison	Test	(NS	=	not	statistically	significant	or	P	>	0.05).	
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Figure	5.18.	Expression	of	Markers	Identified	by	Novel	Anti-Stem	Cell	Antibodies	
The	percentage	expression	of	markers	 identified	by	novel	antibodies	 raised	against	human	embryonal	
and	embryocarcinoma	stem	cells	 (hES)	 in	Vybrant®	DiD-negative	and	Vybrant®	DiD-positive	MDA-MB-
231	 sub-populations	 after	 five	 consecutive	 passages	 post-staining,	 as	 determined	 cytofluorimetrically	
based	 on	 immunofluorescent	 staining	 with	 AlexaFluor®488.	 A:	 The	 expression	 of	 glycolipid	 antigens	
identified	by	novel	anti-hES	antibodies	within	Vybrant®	DiD-negative	and	Vybrant®	DiD-positive	MDA-
MB-231	cell	fractions	is	displayed	as	a	percentage	of	the	total	cell	population	with	in	the	respective	sub-
population.	 B:	 The	 expression	 of	 non-glycolipid	 antigens	 identified	 by	 novel	 anti-hES	 antibodies	 in	
Vybrant®	 DiD-negative	 and	 Vybrant®	 DiD-positive	 MDA-MB-231	 cell	 fractions	 is	 displayed	 as	 a	
percentage	of	the	total	cell	population	within	the	respective	sub-population.	Data	are	expressed	as	the	
mean	 average	 ±	 SEM	 for	 n	 =	 3	 biologically	 independent	 repeat	 experiments.	 Comparison	 of	 marker	
expression	between	Vybrant®	DiD-negative	and	Vybrant®	DiD-positive	populations	was	achieved	using	
two-way	ANOVA	followed	by	Sidak’s	Multiple	Comparison	Test	 (NS	=	not	statistically	significant	or	P	>	
0.05,	*	=	P	≤	0.05,	**	=	P	≤	0.01).	
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Table	5.4.	Summary	of	Stem	Cell	Marker	Immunophenotyping	
Marker	 hES/hEC*	 Vybrant®	DiD	-ive	 Vybrant®	DiD	+ive	
SSEA-3	 Intermediate	 Intermediate	 Intermediate	
SSEA-4	 High	 High	 High	
TRA-1-60S	 High	 Low	 Low	
TRA-1-60R	 High	 Low	 Low	
TRA-1-81	 High	 Low	 Low	
TRA-2-49	 Intermediate	 Low	 Low	
TRA-2-54	 High	 Low	 Low	
SSEA-1	 Low	 Low	 Low	
Ganglioside	GD2	 Low	 Low	 Low	
Ganglioside	GD3	 Low	 Low	 Low	
Ganglioside	GT	3	 Low	 Low	 Low	
CD46	 High	 High	 High	
CD56	 Low	 Low	 Low	
CD57	 Low	 Low	 Low	
CD271	 Low	 Low	 Low	
	
*Immunophenotype	 of	 hES	 and	 hEC	 populations	 taken	 from	 Adewumi	 et	 al.	 (2007).	 Expression	 of	 a	
specific	marker	of	0	-	30%	was	defined	as	"low",	while	an	"intermediate"	level	of	expression	was	defined	
as	being	between	30	-	60%	and	a	"high"	level	of	expression	being	in	excess	of	60%.	Rows	shaded	in	red	
(TRA-1-60S	to	TRA-2-54	inclusive)	indicate	markers	at	which	both	Vybrant®	DiD-negative	and	Vybrant®	
DiD-positive	 MDA-MB-231	 fractions	 differed	 from	 the	 signature	 which	 demarks	 hES	 and	 hEC	
populations.	
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5.5.6. Dye-Retaining	and	Negative	Cells	Showed	Equal	Mammosphere	Formation	
	
Dontu	 et	 al.	 (2003)	 first	 reported	 the	 ability	 of	 putative	 breast	 cancer	 stem	 cell	
populations	to	form	tumour-like	spheroidal	structures,	termed	mammospheres	in	the	
context	of	breast	cancer,	under	non-adherent	conditions.	In	the	years	since,	the	ability	
of	 a	 cancer	 cell	 population	 to	 self-renew	 in	 suspension	has	 frequently	 been	used	 to	
assess	intrinsic	stem	cell	or	progenitor	activity	in	vitro	(Ponti	et	al.,	2005;	Farnie	et	al.,	
2007;	Fillmore	and	Kuperwasser,	2008;	Grimshaw	et	al.,	2008;	Croker	et	al.,	2009).	The	
ability	of	Vybrant®	DiD-negative	and	Vybrant®	DiD-positive	MDA-MB-231	populations	
to	form	mammospheres	was	used	to	determine	whether	these	populations	differed	in	
terms	of	stem	cell-like	functional	capacity.	Following	their	isolation	by	FACS	on	day	15	
post-staining,	 the	 mammosphere	 forming	 ability	 of	 Vybrant®	 DiD-negative	 and	
Vybrant®	 DiD-positive	 MDA-MB-231	 fractions	 was	 determined	 according	 to	 the	
methods	 described	 in	 Section	 5.4.8.	 Following	 168	 hours	 of	 growth	 under	 non-
adherent	 conditions,	 no	 statistically	 significant	 difference	 in	 the	 mammosphere	
forming	 ability	 of	 Vybrant®	 DiD-negative	 and	 Vybrant®	 DiD-positive	 MDA-MB-231	
populations	 was	 observed,	 with	 Vybrant®	 DiD-negative	 cells	 forming	 2.44	 ±	 0.10%	
mammospheres	 on	 average	 while	 Vybrant®	 DiD-positive	 cells	 formed	 2.50	 ±	 0.17%	
mammospheres	 on	 average	 (Figure	 5.19.).	 These	 results	 demonstrate	 that	 no	
difference	 in	 the	 intrinsic	 in	 vitro	 mammosphere	 forming	 potential	 of	 the	 rapidly	
dividing	 Vybrant®	DiD-negative	 and	 relatively	 quiescent	 Vybrant®	DiD-positive	MDA-
MB-231	 populations	 exists,	 reflecting	 the	 apparent	 overall	 lack	 of	 difference	 in	
stemness	between	these	two	fractions	previously	identified	during	marker	expression	
analyses.	
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Figure	5.19.	Formation	of	Mammospheres	by	Dye-Retaining	and	Negative	Cells	
A:	The	number	of	non-adherent	mammospheres	 formed	by	Vybrant®	DiD-negative	and	Vybrant®	DiD-
positive	 MDA-MB-231	 cells	 isolated	 at	 five	 passages	 post-staining.	 Data	 are	 expressed	 as	 the	 mean	
average	±	SEM	for	n	=	3	biologically	independent	repeat	experiments	and	were	compared	using	a	two-
tailed	 unpaired	 t-test	 (NS	 =	 not	 statistically	 significant	 or	 P	 >	 0.05).	 B:	 Representative	 images	 of	
mammospheres	formed	by	Vybrant®	DiD-negative	(left)	and	Vybrant®	DiD-positive	(right)	MDA-MB-231	
cells	at	168	hours	post-isolation;	a	single	intensely	fluorescent	Vybrant®	DiD-positive	cell	(red)	remains	
evident	amongst	other	 less	 intensely	 stained	and	 seemingly	dye-negative	cells	having	arisen	 from	 the	
same	parental	cell.	All	images	were	captured	using	a	10x	objective	lens	(scale	bar	=	50μm).	
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5.5.7. Dye	Retaining	Cells	Divide	Asymmetrically	
	
An	 interesting	 observation	 made	 during	 mammosphere	 formation	 assays	 was	 that	
mammospheres	 formed	 by	 cells	 that	 were	 initially	 Vybrant®	 DiD-positive	 upon	
isolation	contained	single	dye-retaining	cells	but	were	otherwise	dye-negative	(Figure	
5.19.).	 This	 observation	 was	 seen	 to	 indicate	 that	 some	 of	 the	 slow-cycling	 cell	
population	were	able	to	divide	asymmetrically,	a	functional	property	that	is	associated	
with	stem	cell	populations.	In	order	to	directly	assess	whether	this	was	the	case,	time-
course	 tracking	 of	 cell	 division	 was	 undertaken	 as	 described	 in	 Section	 5.4.9.	 In	
concurrence	with	 the	 initial	 observation,	 some	 initially	 dye-retaining	 cells	 seeded	 at	
clonogenic	 density	 were	 stimulated	 to	 divide	 following	 isolation	 from	 the	 bulk	 cell	
population	but	did	so	in	an	asymmetric	manner,	with	the	parental	cell	that	was	initially	
seeded	undergoing	mitotic	 division	 to	 give	 rise	 to	 a	 daughter	 cell	which	went	 on	 to	
retaining	 its	dye	 label	and	another	daughter	cell	which	appeared	to	give	rise	to	non-
dye-retaining	cells	(Figure	5.20.).	
	
	
	
Figure	5.20.	Time-Course	of	Dye-Retaining	MDA-MB-231	Cell	Division	
Representative	 images	depicting	 the	dynamics	of	Vybrant®	DiD-positive	MDA-MB-231	 cell	 division	 for	
up	to	120	hours	post-isolation	from	samples	continuously	cultured	for	five	consecutive	passages	post-
staining.	Distribution	of	the	Vybrant®	DiD	dye	between	daughter	cells	formed	appears	to	be	asymmetric	
upon	stimulation	of	cell	division	when	removed	from	a	mixed	population;	a	single	Vybrant®	DiD-positive	
cell	gives	rise	to	dye-negative	progeny	while	seemingly	retaining	the	Vybrant®	DiD	fluorescent	label.	All	
images	were	captured	using	a	20x	objective	lens	(scale	bar	=	100μm).	
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5.6. Discussion	
	
A	 number	 of	 studies	 have	 reported	 a	 significant	 expansion	 of	 the	 supposed	 cancer	
stem	cell	compartment	following	chemotherapy	(Naumov	et	al.,	2003;	Yu	et	al.,	2007;	
Dembinski	and	Krauss,	2009;	Gao	et	al.,	2010;	Liu	et	al.,	2010).	Such	enrichment	would	
require	either	an	enormous	expansion	of	the	cancer	stem	cell	population	or	effective	
reduction	 of	 the	 bulk	 cell	 mass.	 A	 similar	 pattern	 of	 preferential	 proliferation	 or	
cytotoxicity	 would	 also	 be	 required	 to	 account	 for	 the	 significant	 increase	 in	 the	
relative	proportion	of	 slow-cycling,	 fluorescent	dye-retaining	 cells	 surviving	 following	
chemotherapy	 reported	 here.	 Calculation	 of	 the	 absolute	 number	 of	 Vybrant®	 DiD-
positive	 cells	 present	 in	MDA-MB-231	 cultures	 at	 the	 time	 of	 seeding	 and	 following	
exposure	to	a	high	concentration	(IC95)	of	chemotherapeutic	agents	demonstrated	an	
increase	 in	 the	 absolute	 label-retaining	 cell	 number	 from	 ~1600	 to	 ~2800	 across	 all	
treatment	groups.	In	the	MCF-7	cell	line	this	expansion	of	the	dye-retaining	population	
was	 from	 ~1000	 cells	 at	 the	 time	 of	 seeding	 to	 ~3600	 cells	 at	 the	 end	 of	 the	 assay	
period.	These	increases	in	dye-retaining	cell	numbers	almost	certainly	occurred	due	to	
mitotic	division	generating	partially	 labelled	daughter	cells.	However,	such	expansion	
alone	could	not	possibly	account	for	the	significantly	 increased	relative	proportion	of	
label-retaining	 cells	measured	within	 each	of	 the	drug-treated	 cultures	 compared	 to	
untreated	cultures.	These	data	not	only	demonstrate	that	slow-cycling	(label-retaining)	
cells	continued	to	proliferate	when	exposed	to	standard	chemotherapeutic	agents	but	
that	 the	 rapidly	 dividing	 (non-label-retaining)	 population	 were	 significantly	 more	
susceptible	to	drug-induced	cell	death	than	their	slow-cycling	counterparts,	resulting	in	
a	net	enrichment	for	label-retaining	cells.	These	conclusions	mirror	those	drawn	from	
in	vitro	 studies	reported	 in	the	closely-related	work	of	Moore	et	al.	 (2012),	who	also	
demonstrated	 effective	 enrichment	 of	 a	 slow-cycling	 fluorescent	 label-retaining	
population	in	vivo	using	clinically	relevant	doses	of	oxaliplatin	and	fluorouracil	to	treat	
tumours	derived	from	the	HCT116	human	colon	cancer	cell	line.	
	
While	 the	 intrinsic	 ability	 of	 cancer	 cell	 populations	 to	 survive	 anti-neoplastic	
chemotherapy	is	clinically	important,	cells	that	are	able	to	initiate	tumoural	relapse	or	
disease	recurrence	must	also	be	capable	of	subsequent	proliferation.	It	was	therefore	
deemed	 important	 to	establish	 that	 the	Vybrant®	DiD-retaining	population	were	not	
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avoiding	 the	cytotoxic	effects	of	doxorubicin	or	paclitaxel	by	entering	a	permanently	
non-dividing	 state,	 or	 that	 the	 onset	 of	 the	 cytotoxicity	 exerted	 by	 these	 drugs	was	
simply	 delayed	 due	 to	 the	 slow	 cycling	 nature	 of	 the	 label-retaining	 population.	
Through	measuring	incorporation	of	BrdU	into	cellular	DNA,	Moore	et	al.	(2012)	were	
able	 to	 show	 that	 a	 sub-population	 of	 oxaliplatin	 and	 fluorouracil-treated	 label	
retaining	cells	 could	actively	proliferate	both	 in	vitro	 and	 in	vivo	shortly	after	halting	
treatment.	This	capability	was	more	directly	demonstrated	here	through	the	formation	
of	new	clonal	populations	directly	from	a	fraction	of	cells	in	the	surviving	dye-retaining	
sub-population	 post-cessation	 of	 exposure	 to	 chemotherapeutic	 drugs.	When	 taken	
together,	these	results	indicate	that	slow-cycling	cells	are	not	only	able	to	survive,	but	
are	 capable	 of	 becoming	 re-activated	 after	 withdrawal	 of	 chemotherapy	 to	 initiate	
either	local	tumoural	relapse	or	formation	of	a	secondary	metastatic	lesion.	However,	
the	data	described	 in	 this	 chapter	 that	 support	 this	 conclusion	were	 solely	obtained	
from	 in	vitro	models	and	therefore	this	hypothesis	will	require	direct	testing	in	the	 in	
vivo	setting	in	future.	
	
Given	the	slow-cycling	and	therapy-resistant	nature	of	the	Vybrant®	DiD-retaining	cell	
fraction,	an	associated	between	slow-cycling	cells	and	the	purported	cancer	stem	cell	
population	 appears	 entirely	 plausible.	 Indeed,	 a	 number	 of	 studies	 across	 various	
cancer	 types	 have	 transitively	 linked	 quiescence	 to	 the	 cancer	 stem	 cell	 phenotype	
through	 retrospective	 functional	 validation	 of	 putative	 cancer	 stem	 cell	 populations	
isolated	 using	 cell	 surface	markers	 (Gao	 et	 al.,	 2010;	 Roesch	 et	 al.,	 2010).	 In	 breast	
cancer,	the	seminal	study	of	Al-Hajj	et	al.	(2003)	identified	the	CD44+CD24-/low	surface	
marker	 signature	 describing	 the	 putative	 CSC	 population	 that	 was	 associated	 with	
enhanced	tumourigenic	potential	 following	murine	xenotransplantation.	Fillmore	and	
Kuperwasser	 (2008)	 subsequently	 used	 this	 signature	 to	 identify	 stem-like	 cells	 in	
multiple	 established	 breast	 cancer	 cell	 lines	 that	were	 found	 to	 be	 up	 to	 90%	 label	
retaining.	 In	 contrast,	 a	 number	 of	 studies	 in	 which	 prospective	 identification	 of	 a	
quiescent	 cell	 population	 was	 undertaken	 through	 label	 retention	 assays	
demonstrated	only	partial	overlap	with	cell	surface	marker	signatures	associated	with	
the	supposed	cancer-type-specific	stem	cell	population	(Dembinski	and	Krauss,	2009;	
Wang	 et	 al.,	 2015a).	 The	 findings	 reported	here	echo	 the	outcome	of	 these	 studies;	
only	a	modest	increase	in	ALDH	activity	differentiated	the	Vybrant®	DiD-negative	and	
	 223	
Vybrant®	DiD-retaining	populations,	and	the	 latter	did	not	appear	 to	be	enriched	 for	
the	 CD44+CD24-/low	 putative	 breast	 CSC	marker	 signature.	 Interestingly	 however,	 the	
Vybrant®	 DiD-retaining	 population	 in	 both	 MCF-7	 and	 MDA-MB-231	 cell	 lines	 did	
illustrate	a	significant	enrichment	with	cells	expressing	the	CD44+CD24+	phenotype	(2-
fold	and	53-fold,	respectively).	The	functional	implications	of	the	enrichment	for	ALDH	
and	CD44+CD24+	cells	in	the	dye-retaining	population	remain	to	be	established.	
	
As	previously	discussed,	the	utility	and	rigid	employment	of	cell	surface	marker	profiles	
for	 definition	 of	 cancer	 stem	 cell	 populations	 through	 correlative	 association	 with	
tumourigenic	 potential	 is	 not	 without	 considerable	 limitations.	 Indeed,	 the	 concept	
that	 exclusive	 tumour	 cell	 sub-sets	 possess	 increased	 nascent	 capacity	 for	 tumour	
propagation	is	still	evolving.	In	certain	cancer	stem	cell	models,	such	as	those	reported	
in	melanoma,	 the	 vast	majority	 if	 not	 all	malignant	 cells	 are	 tumourigenic,	 while	 in	
other	 cancer	 types,	 such	 as	 colorectal	 cancer,	 purported	 surface	 marker	 signatures	
have	 been	 shown	 to	 lack	 specificity,	 with	marker-positive	 and	 negative	 populations	
exhibiting	tumourigenicity	(Ricci-Vitiani	et	al.,	2007;	Quintana	et	al.,	2008;	Shmelkov	et	
al.,	 2008).	One	very	notable	example	of	 this	 situation	 in	breast	 cancer	 is	 that	of	 the	
MDA-MB-231	cell	line;	in	excess	of	99%	of	the	total	cell	population	has	been	reported	
to	 express	 the	 CD44+CD24-/low	marker	 signature	 that	 is	 supposed	 to	 describe	 breast	
CSC,	yet	only	a	minority	fraction	of	the	cell	population	possesses	the	ability	to	initiate	
population	re-growth	(Li	et	al.,	2017).	The	results	reported	in	this	chapter	reaffirm	this	
lack	of	specificity;	both	dye-negative	(predominantly	CD44+CD24-/low)	and	dye-retaining	
(predominantly	CD44+CD24+)	 sub-populations	of	 the	MDA-MB-231	 lineage	possessed	
comparable	 intrinsic	 potential	 to	 reinitiate	 tumour	 growth	 as	 estimated	 by	 in	 vitro	
mammosphere	 forming	efficiency	assays.	 Indeed,	 an	often	overlooked	 finding	of	 the	
landmark	study	undertaken	by	Al-Hajj	et	al.	(2003)	was	that	CD44+CD24+	breast	cancer	
populations	also	remained	viable	and	exhibited	tumourigenicity	in	xenotransplantation	
studies	 but	 seemingly	 possessed	 reduced	 proliferative	 capacity	 compared	 to	 the	
CD44+CD24-/low	 cells	 that	 were	 taken	 to	 represent	 the	 stem-like	 fraction.	 Based	 on	
these	findings	it	seems	plausible	that	the	CD44+CD24-/low	signature	was	implicitly	linked	
to	 enhanced	 tumourigenicity	 simply	 due	 to	 the	 intrinsic	 rapid	 expansion	 of	 this	
population	 coupled	 with	 an	 insufficient	 follow	 up	 period	 in	 mice	 injected	 with	
CD44+CD24+	 cells,	 leading	 to	 the	 conclusion	 that	 the	 former	 exclusively	 possessed	
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tumourigenic	potential.	In	fact,	a	number	of	other	studies	have	indicated	that	stem	cell	
activity	in	breast	cancer	is	not	exclusively	limited	to	the	CD44+CD24-/low	phenotype	but	
that	 CD44+CD24+	 can	 be	 equally	 tumourigenic	 in	 mouse	 xenograft	 models,	 most	
notably	 illustrated	 by	 Meyer	 et	 al.	 (2010)	 in	 oestrogen	 receptor-negative	 disease.	
Whether	dye-retaining	and	non-retaining	MDA-MB-231	fractions	are	more	dormancy	
competent	but	remain	tumourigenic	in	vivo	remains	to	be	established.	
	
Given	 the	 increasing	 recognition	 that	 purported	 CSC	 markers	 are	 limited	 in	 their	
specificity,	 an	 increasing	 effort	 has	 been	made	 to	 attempt	 to	 identify	 novel	marker	
signatures	 that	more	 accurately	 identify	 tumourigenic,	metastasis-initiating	 or	 stem-
like	sub-populations.	Amongst	these,	a	number	of	cell	surface	antigens	that	have	been	
used	 to	 characterise	 human	 embryonic	 stem	 cells	 have	 been	 investigated	 for	 their	
expression	in	various	cancer	types	(Nohara	et	al.,	1998;	Sivasubramaniyan	et	al.,	2015).	
In	 this	 chapter,	 the	expression	of	 the	 standard	 ISCI	panel	of	human	embryonic	 stem	
cell	markers	by	the	Vybrant®	DiD-negative	and	Vybrant®	DiD-retaining	populations	was	
investigated.	While	the	rapidly-	and	slowly-dividing	MDA-MB-231	sub-populations	did	
not	 differentially	 express	 any	 of	 the	 standard	 ISCI	 markers,	 the	 overall	 pattern	 of	
expression	in	the	MDA-MB-231	cell	line	indicated	an	overall	stem-like	phenotype.	The	
ISCI	have	previously	demonstrated	that	human	embryonic	stem	cells	can	primarily	be	
defined	 by	 their	 expression	 of	 the	 glycosphingolipid	 series	 of	 cell	 surface	 antigens	
synthesised	from	the	common	lactosyl	ceramide	precursor	(Adewumi	et	al.,	2007).	Of	
these	markers,	the	globoseries	antigens	(SSEA-3	and	SSEA-4)	are	typically	found	to	be	
highly	 expressed	 in	 human	 embryonic	 stem	 cells	 pre-differentiation,	 while	 the	
ganglioseries	 (ganglioside-GD2,	 -GD3	and	 -GT3)	and	 lactoseries	 (SSEA-1)	antigens	are	
typically	down-regulated	 (Adewumi	 et	 al.,	 2007;	Wright	 and	Andrews,	2009).	Hence,	
the	 expression	 pattern	 of	 glycosphingolipids	 and	 post-differentiation	 antigens	
observed	in	the	MDA-MB-231	cell	line	that	is	summarised	in	Table	5.4.	would	typically	
be	 considered	 indicative	 of	 the	 undifferentiated	 state.	 This	 conclusion	 is	 further	
supported	 by	 the	 expression	 pattern	 of	 a	 number	 the	 novel	 anti-stem	 cell	 markers	
which	 have	 been	 structurally	 related	 to	 certain	 glycosphingolipid	 antigens;	 AA11	
appears	to	be	structurally	related	to	SSEA-3	while	AG10	and	EF12	appear	analogous	to	
SSEA-4	and	the	expression	pattern	of	these	antigens	observed	in	the	MDA-MB-231	cell	
line	 as	 reported	 here	mirrors	 that	 of	 the	 globoseries	 antigens	 (Wright	 et	 al.,	 2011).	
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Interestingly,	 the	 MDA-MB-231	 cell	 line	 did	 differ	 in	 their	 expression	 of	 the	 high	
molecular	weight	keratan	sulphate	antigens	(TRA-1-60	isoforms	and	TRA-1-81)	and	the	
two	 tissue-non-specific	 alkaline	 phosphatase	 antigens	 (TRA-2-49	 and	 TRA-2-54)	 that	
are	 usually	 expressed	 at	 intermediate	 to	 high	 levels	 in	 undifferentiated	 human	
embryonic	stem	cells.	The	novel	anti-stem	cell	antibody	CC9	that	has	previously	been	
structurally	 related	 to	 TRA-1-60	 and	 TRA-1-81	 by	 Wright	 et	 al.	 (2011)	 was	 also	
expressed	 by	 MDA-MB-231	 cells	 at	 minimal	 levels,	 somewhat	 validating	 these	
observations.	 The	 absence	 of	 these	 antigens	 might	 relate	 to	 the	 well-supported	
hypothesis	 that	 cells	 of	 the	MDA-MB-231	 lineage	 originated	 in	 differentiated	 breast	
tissue	 and	 subsequently	 underwent	 spontaneous	 dedifferentiation,	 thereby	 having	
initially	 lost	 the	 embryonic	 phenotype	 during	 development	 and	 only	 having	 partially	
recapitulated	this	during	acquisition	of	their	malignant	status.	The	lack	of	expression	of	
cell	 surface	 alkaline-phosphatase	 might	 also	 relate	 to	 their	 dysregulation	 and	 loss	
during	 malignancy,	 as	 low	 expression	 levels	 have	 been	 reported	 in	 both	 human	
embyrocarcinoma	cell	lines	and	cell	lines	of	other	cancer	types	previously	(Wright	and	
Andrews,	 2009;	 Wright	 et	 al.,	 2011).	 The	 exact	 basis	 for	 the	 expression	 pattern	 of	
these	markers	does,	however,	remain	to	be	established.	Indeed,	despite	a	number	of	
studies	 having	 investigated	 the	 deployment	 of	 a	 number	 of	 the	 human	 embryonic	
stem	 cell	 markers	 investigated	 here	 in	 various	 cancer	 types,	 their	 exact	 biological	
function	 in	 malignancy	 and	 their	 relationship	 to	 stemness	 in	 cancer	 cell	 sub-
populations	remains	undetermined.	Given	the	overall	lack	of	differential	expression	of	
the	human	embryonic	stem	cell	markers	by	the	Vybrant®	DiD-negative	and	Vybrant®	
DiD-retaining	 MDA-MB-231	 sub-populations,	 a	 different	 approach	 such	 as	 whole-
transcriptomic	sequencing	or	array-based	RT-qPCR	profiling	will	be	required	in	future	
in	 order	 to	 identify	 a	 robust	 quiescence-associated	 marker	 signature	 to	 act	 as	 a	
surrogate	for	dye-retention	capability.	
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5.7. Conclusions	
	
The	slow-cycling	population	within	both	MCF-7	and	MDA-MB-231	cell	 lines	 identified	
by	long-term	fluorescent	dye-retention	were	more	resistant	to	high	concentrations	of	
anti-neoplastic	drugs	routinely	used	to	treat	breast	cancer	 in	the	clinical	setting	than	
their	rapidly-dividing	counterparts.	This	enhanced	drug	resistance	was	associated	with	
up-regulated	 aldehyde	 dehydrogenase	 activity	 within	 dye-retaining	 cells.	 Whether	
other	established	drug-resistance	mechanisms	are	associated	with	mitotic	quiescence	
remains	to	be	explored.	Colonies	formed	by	MDA-MB-231	cells	post-cessation	of	anti-
neoplastic	 drug	 exposure	 were	 exclusively	 formed	 by	 sub-clones	 within	 the	 dye-
retaining	 cell	 population.	 The	 identification	 of	 a	 slow-cycling	 and	 inherently	 therapy	
resistant	cellular	sub-set	capable	of	leading	to	tumour	recurrence	such	as	this	is	both	
biologically	and	clinically	significant.	Breast	cancer	stem	cell	markers	analysis	showed	
an	association	of	dye-retaining	cells	within	MCF-7	and	MDA-MB-231	cell	 lines	with	a	
CD44+CD24+	 phenotype	 and	 not	 the	 CD44+CD24-/low	 profile	 that	 has	 typically	 been	
associated	 with	 enhanced	 tumourigenicity	 in	 putative	 breast	 stem	 cell	 populations	
elsewhere.	 The	 functional	 significance	 of	 these	 findings	 and	 whether	 or	 not	 the	
CD44+CD24+	 signature	 demarks	 a	 transitory	 epithelial-mesenchymal	 stem-like	 state	
remains	to	be	fully	elucidated.	
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6.1. Discussion	
	
Metastatic	 disease	 remains	 the	 major	 cause	 of	 death	 in	 patients	 diagnosed	 with	
advanced	 breast	 cancer.	 Efforts	 to	 effectively	 treat	 metastasis	 have	 been	 severely	
hampered	by	the	entry	of	disseminated	tumour	cells	into	a	reversible	state	of	mitotic	
arrest	 known	 as	 dormancy	 that	 enables	 them	 to	 evade	 chemotherapy.	 Dormant	
tumour	cells	often	persist	within	distal	tissues	for	many	years	or	even	decades	before	
re-emerging	to	form	lethal	overt	lesions.	Targeting	the	dormant	disseminated	tumour	
cell	population,	either	to	maintain	dormancy	or	effect	killing,	is	believed	to	represent	
the	 greatest	 potential	 opportunity	 for	 therapeutic	 intervention	 to	 improve	 patient	
prognosis.	 However,	 the	 development	 of	 effective	 treatments	 has	 been	 severely	
impeded	by	a	poor	understanding	of	the	metastasis-initiating	cell	population	and	the	
biological	processes	that	maintain	their	dormant	phenotype.	
	
An	 emerging	 consensus,	 supported	 by	 a	 growing	 body	 of	 experimental	 evidence,	 is	
that	cancer	stem	cells	(CSCs)	are	the	metastasis-initiating	population	in	breast	cancer	
(Luo	 et	 al.,	 2015).	 However,	 the	 predominant	means	 of	 isolating	 CSCs	 using	 protein	
marker	 signatures	 is	 increasingly	 recognised	 as	 being	 unreliable	 due	 to	 cellular	
plasticity	 and	 the	 poorly	 defined	 functional	 roles	 of	many	 of	 these	marker	 proteins.	
The	 requirement	 exists,	 therefore,	 for	 a	 reliable	 and	 functionally	 informed	 system	
enabling	 the	 isolation	 and	 characterisation	 of	 putative	 metastasis-initiating	 cancer	
stem	 cells.	 Breast	 CSCs,	 like	 their	 non-malignant	 counterparts,	 are	 presumed	 to	 be	
mitotically	quiescent	(Gerdes	et	al.,	2014).	Relatively	recently,	pulse-chase	techniques	
for	assessment	of	stem	cells	based	on	their	inherent	quiescent	nature	has	undergone	
something	 of	 a	 renaissance	 due	 to	 the	 advent	 of	 lipophilic	 tracer	 dyes.	 The	 use	 of	
fluorescent	 dyes	 for	 monitoring	 cellular	 division	 kinetics	 offers	 the	 distinctive	
advantage	over	traditional	label-retention	methods	(e.g.	BrdU	incorporation)	of	being	
able	to	isolate	and	further	characterise	live	cell	populations	(Luo	et	al.,	2015).	While	a	
number	 of	 studies	 in	 other	 cancer	 types	 have	 demonstrated	 the	 prospective	
identification	of	CSCs	or	stem-like	populations	using	this	approach,	its	potential	utility	
in	breast	cancer	has,	until	now,	remained	virtually	unexplored.	The	primary	aim	of	this	
project	was	 to	explore	 the	potential	utility	of	 lipophilic	dye-retention	 for	 isolation	of	
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mitotically	quiescent	breast	cancer	cells	and	determine	whether	these	display	features	
of	the	putative	metastasis-initiating	cancer	stem	cell	population	in	breast	cancer.	
	
The	initial	aim	of	the	work	presented	in	Chapter	3	of	this	thesis	was	to	determine	the	
suitability	 of	 select	 fluorescent	 lipophilic	 tracer	 dyes	 for	 the	 application	 of	 detecting	
mitotically	 quiescent	 breast	 cancer	 cells	 in	 vitro.	 Fluorescent	 dyes	 available	 for	 label	
retention	applications	may	be	sub-divided	into	two	predominant	groups:	cytoplasmic	
dyes	(e.g.	Calcein	derivatives	and	CFSE)	or	membrane-bound	dyes	(e.g.	PKH	dye	series	
or	 Vybrant®	 dye	 series).	 The	 cytoplasmic	 dye	 CFSE	 is	 considered	 a	 gold	 standard	
fluorescent	dye	for	measuring	cell	proliferation	and	has	been	widely	used	for	study	of	
proliferation	kinetics	and	cellular	lineage	tracing	(Parish,	1999;	Moore	et	al.,	2012;	Hu	
et	al.,	2017).	However,	since	their	binding	to	cytoplasmic	proteins	is	able	to	inhibit	the	
function	of	cellular	enzymes,	cytoplasmic	dyes	can	exhibit	high	levels	of	cytotoxicity	to	
cells	and	reduce	cellular	proliferation	and	migration	(Parish,	1999;	Quah	et	al.,	2007;	
Last'ovicka	et	al.,	2009;	Yumoto	et	al.,	2014).	 In	contrast,	membrane-bound	dyes	are	
generally	 found	 to	 be	 less	 toxic	 (Honig	 and	 Hume,	 1986;	 Honig	 and	 Hume,	 1989).	
Indeed,	the	results	described	in	Chapter	3	and	in	the	closely	related	works	of	Yumoto	
et	 al.	 (2014),	 Docherty	 (2014)	 and	 Wang	 et	 al.	 (2015b)	 demonstrate	 that	 even	
relatively	high	concentrations	 (2μM	-	5μM)	of	such	dyes	 (e.g.	Vybrant®	DiD)	have	no	
significant	effect	on	cell	proliferation,	clonogenicity,	migration	or	apoptosis,	and	hence	
would	 be	 well	 suited	 to	 use	 in	 pulse-chase	 applications	 for	 detection	 of	 mitotically	
quiescent	breast	cancer	cells.	Although	PKH26	has	perhaps	been	the	most	widely	used	
membrane-bound	fluorescent	dye	 for	assessment	of	cell	proliferation,	 it	 is	expensive	
and	relatively	complicated	to	use	for	 labelling,	requiring	an	isosmotic	mannitol-based	
loading	medium.	By	comparison,	the	equivalent	Vybrant®	dye,	DiD,	is	inexpensive	and	
can	 be	 added	 directly	 to	 culture	 medium,	 thereby	 making	 handling	 less	 technically	
involved	and	permitting	uniform	labelling	of	cells	either	in	suspension	or	when	growing	
as	adherent	monolayers	 (Honig	and	Hume,	1986;	Honig	and	Hume,	1989;	Yumoto	et	
al.,	2014).	
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Historically,	the	label-retention	technique	has	been	predominantly	used	in	conjunction	
with	 other	 characterisation	 assays	 to	 validate	 putative	 stem	 cell	 phenotypes	 (Luo	 et	
al.,	 2015).	One	of	 the	main	 criticisms	 limiting	 the	 use	 of	 this	 approach	 as	 a	 primary	
means	 of	 identifying	 prospective	 stem	 cell	 populations	 has	 been	 that	 its	 relative	
simplicity	 requires	 further	 validation	 and	 phenotypic	 characterisation	 to	 be	 carried	
out.	However,	one	distinct	advantage	of	this	technique	is	that	the	progressive	dilution	
or	retention	of	dye	is	reliant	on	a	functional	cellular	phenotype	and	is	independent	of	
the	expression	of	protein	markers	with	poorly	understood	 functional	 roles	 in	mitotic	
dynamics	(Moore	et	al.,	2012;	Luo	et	al.,	2015).	Indeed,	fluorescent	label	retention	has	
been	 used	 to	 great	 effect	 in	 identifying	 normal	 mammary	 stem	 cells	 from	 patient-
derived	 tissue	 isolates,	 identifying	 stem	 cell-associated	 gene	 signatures	 that	 predict	
clinical	outcome	in	breast	cancer	and	elucidating	molecular	mechanisms	that	underpin	
stem	cell	function	(Pece	et	al.,	2010;	Tosoni	et	al.,	2012).	The	utility	of	this	technique	is	
not	 limited	 to	 application	 in	 patient	 derived	 tissue.	 In	 fact,	 stem-like	 label-retaining	
populations	 have	 been	 identified	 in	multiple	 established	 cancer	 cell	 lines	 that	 were	
once	 thought	 to	 be	 largely	 homogenous	 and	 devoid	 of	 stem	 cells	 (Fillmore	 and	
Kuperwasser,	 2008;	Moore	 et	 al.,	 2012;	 Akrap	 et	 al.,	 2016).	 These	 findings	 strongly	
suggest	that	label	retention	techniques	can	be	simple	yet	powerful	tools	for	studying	
quiescent	and	stem-like	cell	populations,	even	when	using	commercially	available	cell	
lines,	 as	 long	 as	 the	 findings	 are	 evaluated	 critically,	 data	 interpreted	 within	 the	
context	 of	 the	 experimental	 parameters,	 and	 results	 confirmed	 under	 biologically	
relevant	conditions.	
	
In	the	early	experimental	work	described	in	Chapter	3,	lipophilic	dye-retention	assays	
using	 Vybrant®	DiD	 revealed	 the	 presence	 of	 a	 latent	 label-retaining	 sub-population	
within	human	breast	cancer	cell	 lines	representing	each	of	the	five	distinct	molecular	
sub-types	 originally	 described	 by	 Perou	 et	 al.	 (2000)	 and	 Sorlie	 et	 al.	 (2001).	
Subsequent	cytofluorimetric	analysis	of	the	intensity	of	Vybrant®	dye	staining	in	label-
retaining	cells	compared	with	that	of	the	freshly	stained	parental	culture	indicated	that	
some	dye	 loss	had	occurred	during	retention	assays.	Given	that	dye	retention	assays	
undertaken	 following	 induction	 of	 growth	 arrest	 using	 mitomycin	 C	 had	 previously	
demonstrated	 that	mitotic	 activity	 was	 the	 primary	 determinant	 of	 dye	 loss	 (Figure	
3.17.),	these	findings	suggested	that	label-retaining	cells	were	relatively	slowly	cycling.	
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Cell	 cycle	 distribution	 profiling	 undertaken	 here	 confirmed	 this	 observation	 and	
revealed	that	 label-retaining	cells	tended	to	collect	 in	the	G2/M-phase	relative	to	the	
bulk	 cell	 population.	 Analysis	 of	 immunostaining	 for	 the	 proliferation	 marker	 Ki67	
showed	 that	 the	 label-retaining	population	was	enriched	 for	 cells	 in	 the	G0-phase	of	
the	 cell	 cycle.	 These	 results	 closely	mirror	 those	 reported	 elsewhere.	 Using	 both	 in	
vitro	 and	 in	 vivo	 models,	 Moore	 et	 al.	 (2012)	 showed	 that	 chemoresistant,	 label-
retaining	MDA-MB-231	human	breast	 cancer	 cells	 had	 a	 propensity	 to	 collect	 in	 the	
G2/M-phase	of	 the	cell	cycle.	Similarly,	 the	 findings	reported	by	Docherty	 (2014)	and	
Wang	 et	 al.	 (2015b)	 together	 demonstrated	 that	 label-retaining	 bone-metastatic	
prostate	 cancer	 cells	 identified	 within	 multiple	 prostate	 cancer	 cell	 lines	 were	 also	
chemoresistant,	 collected	 in	 the	 G2/M-phase	 of	 the	 cell	 cycle	 and	 displayed	
significantly	 lower	Ki67	expression	than	their	non-label-retaining	counterparts.	When	
taken	 together	 with	 these	 reports,	 the	 work	 presented	 in	 Chapter	 3	 of	 this	 thesis	
suggests	that	the	label-retaining	cells	 identified	within	human	breast	cancer	cell	 lines	
represent	 a	 population	 composed	 of	 both	 absolutely	 quiescent	 and	 infrequently	
dividing,	relatively	quiescent	cells.	
	
Mitotically	 quiescent	 cell	 sub-populations	 have	 been	 identified	 in	 multiple	 non-
malignant	 human	 epithelial	 tissues,	 including	 the	 skin,	 colon	 and	 breast,	 suggesting	
that	they	serve	an	important	functional	role	in	tissue	longevity	and	that	their	presence	
in	cancer	might	be	a	 residual	 characteristic	of	 the	 tissues	of	origin	 (Lyle	 et	al.,	1998;	
Potten	et	al.,	2003;	Shackleton	et	al.,	2006).	While	absolute	quiescence	or	infrequent	
division	are	not	definitive	for	adult	stem	cell	populations,	published	reports	do	suggest	
that	quiescence	plays	a	 critical	 role	 in	maintenance	of	 stem	cell	pools	by	preventing	
exhaustion	 of	 proliferative	 capacity,	 inhibiting	 differentiation,	 and	 limiting	 the	
accumulation	 of	 mutations	 during	 frequent	 rounds	 of	 DNA	 synthesis	 (Coller	 et	 al.,	
2006;	 Sang	 et	 al.,	 2008;	 Viatour	 et	 al.,	 2008).	 A	 number	 of	 studies	 in	 cancer	 have	
similarly	associated	quiescence	or	a	slow	cycling	nature	with	preservation	of	putative	
cancer	 stem	cell	populations	 through	conferring	a	propensity	 to	 resist	apoptosis	and	
chemotherapy	(Harper	et	al.,	2010;	Chikamatsu	et	al.,	2012;	Moore	et	al.,	2012).	In	line	
with	findings	reported	by	Harper	et	al.	 (2010)	and	Moore	et	al.	 (2012),	 it	 is	plausible	
that	the	growth	arrest	in,	or	extension	of,	the	G2/M-phase	demonstrated	in	Chapter	1	
contributed	 significantly	 to	 the	 enhanced	 survival	 and	 enrichment	 of	 label-retaining	
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cells	 in	 cultures	 treated	 with	 anti-neoplastic	 drugs	 described	 in	 Chapter	 5.	 Growth	
arrest	or	slowed	cell	cycle	transition	would	effectively	increase	the	time	for	drug	efflux,	
drug	metabolism	or	repair	of	drug-induced	cellular	stress	and	thereby	enable	evasion	
of	pro-apoptotic	signals	in	the	relatively	quiescent	Vybrant®	DiD-retaining	cell	fraction.	
Indeed,	while	 reduced	mitotic	 activity	 is	 likely	 to	 contribute	 to	 the	 survival	 of	 label-
retaining	cells	in	response	to	chemotherapy,	it	may	not	be	the	sole	means	by	which	de	
novo	drug	resistance	occurs	and	probably	works	in	synergy	with	other	mechanisms	to	
increase	 their	 survival.	 The	 expression	 of	 anti-apoptotic	 proteins,	 such	 as	 c-FLIP	 and	
Bcl-2	 family	members,	are	 frequently	observed	 in	quiescent	normal	and	cancer	stem	
cell	populations	and	have	been	shown	to	contribute	to	enhanced	cell	survival	following	
chemotherapy	(Turton	et	al.,	2001).	Enhanced	DNA	damage	repair	pathway	activation,	
up-regulation	 of	 xenobiotic	 drug	 pumps,	 and	 increased	 enzymatic	 drug	 metabolism	
(particularly	by	ALDH)	has	also	been	reported	in	quiescent	stem	cell	populations	(Eyler	
and	Rich,	2008;	Cree	and	Charlton,	2017).	Based	on	these	reports,	ALDH	activity	was	
assayed	in	quiescent	and	rapidly-dividing	breast	cancer	cell	populations	here	and	was	
found	to	be	significantly	up-regulated	within	the	quiescent,	label-retaining	fraction	of	
both	 oestrogen	 receptor-positive	 and	 oestrogen	 receptor-negative	 cell	 lines	 (Figure	
5.13.).	 Although	 the	 contribution	 of	 quiescence	 to	 these	 established	 drug-resistance	
mechanisms	remains	to	be	established,	it	is	likely	that	a	reduced	proliferative	rate	only	
augments	their	effectiveness.	It	will	be	important	for	future	experiments	to	determine	
whether	other	drug-resistance	mechanisms	are	enriched	within	label-retaining	breast	
cancer	 cells	 and	whether	 their	 inhibition,	 either	 alone	 or	 in	 combination,	 is	 able	 to	
prevent	the	survival	and	subsequent	outgrowth	of	drug-resistant	sub-clones.	
	
Seminal	 studies	 by	 Ginestier	 et	 al.	 (2007)	 and	 Charafe-Jauffret	 et	 al.	 (2009)	 have	
showed	 that	 increased	 ALDH	 expression	 demarks	 stem	 cells	 in	 both	 normal	 and	
malignant	breast	 tissue.	High	ALDH	expression	has	 since	been	widely	employed	as	a	
marker	 for	 isolation	of	breast	 cancer	 stem	cells	 (Morimoto	 et	 al.,	 2009;	 Tanei	 et	 al.,	
2009;	 Park	 et	 al.,	 2010;	 Charafe-Jauffret	 et	 al.,	 2013).	 Given	 that	 ALDH	 activity	 was	
found	 to	 be	 up-regulated	 in	 dye-retaining	 populations	 (Figure	 5.13.),	 it	 was	
hypothesised	 that	 other	 stemness	markers	might	 also	 be	 differentially	 expressed	 by	
this	population.	In	both	the	MCF-7	and	MDA-MB-231	cell	lines,	quiescence	as	denoted	
by	label	retention	status	was	associated	with	a	significant	enrichment	for	CD44+CD24+	
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cells;	 in	 the	 epithelial-like	 MCF-7	 cell	 line	 this	 was	 associated	 with	 a	 gain	 in	 the	
mesenchymal	 marker	 CD44,	 whereas	 the	 mesenchymal-like	 MDA-MB-231	 cell	
displayed	 dual	 positivity	 due	 to	 a	 gain	 of	 the	 epithelial	 marker	 CD24.	 Although	 the	
functional	 implications	of	 these	 findings	 remain	 to	be	 fully	elucidated,	dual	positivity	
for	 these	markers	 (both	 independent	of	and	 in	conjunction	with	ALDH	positivity)	has	
recently	been	associated	with	 stemness,	 enhanced	 chemotherapeutic	 resistance	and	
worsened	patient	prognosis,	particularly	in	triple-negative	breast	cancer	(Meyer	et	al.,	
2010;	Qiu	et	al.,	2016;	Deng	et	al.,	2017).	
	
A	 study	 by	 Bhat-Nakshatri	 et	 al.	 (2010)	 reported	 that	 the	 generation	 of	 either	 the	
CD44+CD24-/low	 or	 CD44+CD24+	 phenotype	 is	 dependent	 on	 expression	 of	 particular	
EMT-associated	 gene	 signatures.	 Given	 the	 apparent	 re-acquisition	 of	 the	 epithelial	
marker	CD24	in	the	inherently	drug-resistant,	dye-retaining	cells	of	the	mesenchymal-
like	 MDA-MB-231	 lineage,	 and	 the	 emerging	 association	 between	 a	 transitory	
epithelial-mesenchymal	 stem-like	 phenotype	 and	 enhanced	 chemoresistance	
(reviewed	by	Fabregat	 et	al.,	 2016),	 it	was	hypothesised	 that	dye-retention	 status	 in	
MDA-MB-231	cells	would	be	associated	with	increased	epithelial	marker	expression	or,	
conversely,	decreased	expression	of	mesenchymal	markers.	Although	the	preliminary	
assays	of	EMT	marker	expression	status	(Figure	5.14.	and	Figure	5.15)	did	suggest	that	
this	might	be	the	case,	difficulties	in	discerning	and	quantifying	the	relative	degree	of	
marker	expression	between	dye-retaining	and	non-dye-retaining	cells,	and	the	limited	
number	of	markers	assayed	means	that	a	more	robust	experimental	approach	across	
additional	cell	lines	will	be	required	in	future	to	definitively	establish	how	EMT	marker	
expression	 relates	 to	 the	quiescent	phenotype	and	how	 this	 varies	by	 the	molecular	
sub-type	 of	 breast	 cancer	 involved.	 The	 current	 working	 hypothesis	 regarding	 the	
relationship	between	 these	characteristics	 is	outlined	 in	Figure	 6.1.,	which	highlights	
how	 the	 quiescent	 breast	 cancer	 population	 identified	 by	 label-retention	 might	
represent	a	epithelial-mesenchymal	stem	cell	compartment	associated	with	significant	
chemoresistance.	
	
	
	
	
	 234	
	
	
Figure	6.1.	Crossroads	between	EMT,	Stemness,	Quiescence	and	Chemoresistance	
The	combined	evidence	 from	published	experimental	models	and	data	presented	herein	 suggests	 the	
conceptual	model	depicted	above,	 illustrating	the	 interplay	between	EMT,	stemness,	chemoresistance	
and	mitotic	 quiescence.	 The	 induction	 of	 EMT	 in	 epithelial	 cancer	 cells,	 such	 as	 the	MCF-7	 cell	 line,	
results	 in	acquisition	of	a	mesenchymal-like	phenotype	that	has	been	described	by	the	CD44+CD24-/low	
marker	 signature.	This	 signature	 is	widely	 reported	 to	characterise	 the	MDA-MB-231	cell	 line	and	 the	
supposed	cancer	stem	cell	compartment	within	MCF-7	cultures.	Partial	 reversion	of	mesenchymal-like	
cells	to	a	more	epithelial-like	phenotype,	induced	by	factors	such	as	hypoxia	and	TGF-β	signalling,	results	
in	 a	 transitory	 epithelial-mesenchymal	 phenotype	 associated	 with	 enhanced	 chemotherapeutic	
resistance.	Our	current	working	hypothesis	proposes	that	this	state	characterises	the	quiescent,	 label-
retaining	cell	sub-population	identified	in	breast	cancer	cell	lines.	This	transitory	phenotype,	denoted	by	
expression	of	both	epithelial	and	mesenchymal	stemness	markers,	might	give	rise	to	a	sub-set	of	cells	
that	 are	more	 epithelial-like	 and	 competent	 to	 take	 up	 long-term	 residency	 at	 post-metastatic	 sites.	
Image	 adapted	 from	 Fabregat,	 I.,	 Malfettone,	 A.	 &	 Soukupova,	 J.	 (2016).	 New	 Insights	 into	 the	
Crossroads	between	EMT	and	Stemness	 in	the	Context	of	Cancer.	J	Clin	Med,	5.	with	permission	from	
Multidisciplinary	Digital	Publishing	Institute	(MDPI).	
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A	recent	mechanistic	study	by	Deng	et	al.	(2017)	suggests	that	the	acquisition	of	CD24	
within	 the	 label-retaining	 quiescent	 MDA-MB-231	 sub-population	 demonstrated	 in	
Chapter	 5	 could	be	 linked	to	quiescence-associated	signalling	programmes	described	
previously.	 In	their	study,	Deng	et	al.	 (2017)	report	that	expression	of	CD24	in	triple-
negative	 breast	 cancer	 cells	 is	 regulated	 by	 Bcl-2	 and	 TGF-βRI	 signalling	 via	 ATM-
NDRG2	 pathways.	 Interestingly,	 the	 TGF-β	 signalling	 axis	 in	 particular	 has	 previously	
been	 implicated	 in	 acquisition	 of	 a	 chemoresistant,	 partial	 epithelial-mesenchymal	
phenotype	and	 in	 tumour	 cell	 quiescence	at	both	primary	and	post-metastatic	 sites.	
Fernando	et	al.	(2015)	demonstrated	that	mesenchymal-like	hepatocellular	carcinoma	
cells	 (HCCs)	exhibit	autocrine	over-activation	of	 the	TGF-β	pathway	and	that	 treating	
epithelial-like	HCCs	with	exogenous	TGF-β	resulted	in	concomitant	expression	of	both	
epithelial	 and	 mesenchymal	 stem	 genes	 and	 a	 transitory	 epithelial-mesenchymal	
phenotype.	Previous	studies	in	head	and	neck	and	breast	carcinoma	by	Bragado	et	al.	
(2013)	and	Marlow	et	al.	(2013),	respectively,	demonstrated	that	TGF-β2	signalling	via	
TGF-βRIII	and	TGF-βRI	was	able	 to	strongly	activate	p38	and	diminish	ERK	activation.	
Altering	 the	 p38:ERK	 signalling	 ratio	 in	 this	manner	 resulted	 in	 the	 induction	 of	 p27	
and	the	dormancy-associated	transcription	factors	DEC2	and	NR2F1,	ultimately	leading	
to	entry	into	a	state	of	mitotic	quiescence.	Whether	these	pathways	are	related	to	the	
quiescent	 phenotype	 identified	 by	 fluorescent	 dye	 retention	 and	 in	 the	 apparent	
enrichment	 of	 CD24	 in	 the	 quiescent	 MDA-MB-231	 population	 remains	 to	 be	
elucidated	 and	 will	 be	 the	 topic	 of	 future	 studies.	 However,	 this	 hypothesis	 is	
supported	by	the	indication	that	HIF-1α	levels	were	increased	within	the	dye-retaining	
breast	cancer	cells	depicted	in	Figure	4.7.,	comparable	findings	having	previously	been	
reported	in	dye-retaining	prostate	cancer	cells	by	Docherty	(2014),	and	a	recent	study	
by	 Fluegen	 et	 al.	 (2017)	 demonstrating	 that	 HIF	 signalling	 drives	 the	
NR2F1hi/DEC2hi/p27hi/TGF-β2hi	 quiescence-associated	 gene	 signature.	 Further	 work	
will	 first	 be	 required	 to	 confirm	 that	 HIF-1α	 signalling	 is	 differentially	 activated	 in	
association	with	the	quiescent	phenotype	demarked	by	fluorescent	dye	retention,	and	
to	determine	whether	this	varies	according	to	the	molecular	sub-type	of	breast	cancer	
involved.	
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While	 the	 potential	 utility	 of	 lipophilic	 dye-retention	 model	 in	 the	 study	 of	
intratumoural	mitotic	heterogeneity,	quiescence	and	de	novo	drug	resistance	has	been	
demonstrated	in	this	thesis	it	is	not	without	limitations.	As	discussed	in	Chapter	4,	the	
incompatibility	of	 this	assay	system	with	experiments	designed	to	 identify	conditions	
that	generate	quiescent	sub-clones	is	a	by-product	of	its	reliance	on	the	mitotic	activity	
of	the	non-quiescent	bulk	population	and	the	inevitable	slowing	of	culture	growth	that	
occurs	 upon	 application	 of	 metabolic	 stress.	 Similarly,	 the	 stimulation	 of	 overt	
outgrowth	 of	 initially	 quiescent	 sub-clones	 following	 their	 replacement	 into	 culture	
post-isolation	 is	 not	 necessarily	 conducive	 to	 determining	 their	 differential	 ability	 to	
survive	 nutritional	 or	 cytotoxic	 stress	 compared	 to	 non-quiescent	 cells.	 These	
limitations	could	be	subverted	by	employing	a	surrogate	marker	profile	demarking	the	
quiescent	phenotype,	 thereby	removing	the	reliance	of	 identifying	quiescent	cells	on	
fluorescent	dye-based	 lineage	 tracing.	The	markers	 currently	associated	with	cellular	
quiescence,	namely	the	NR2F1hi/DEC2hi/p27hi/TGF-β2hi	signature	recently	described	by	
Linde	et	al.	(2016),	are	intracellular	molecules	and	therefore	cannot	be	used	to	isolate	
live	 cells.	 While	 the	 CD44+CD24+	 signature	 might	 demark	 chemoresistant	 and	
potentially	metastasis-initiating	 initiating	 cells	 in	 breast	 cancer,	 it	 is	 enriched	within,	
but	 not	 exclusive	 to,	 the	 quiescent	 breast	 cancer	 sub-population.	 Identifying	
extracellular	markers	that	more	accurately	distinguish	the	quiescent	phenotype	should	
therefore	be	 the	 focus	of	 future	work	 in	order	 to	 facilitate	experimental	procedures	
that	require	the	isolation	of	live	cells	for	functional	studies,	both	in	vitro	and	in	vivo.	In	
addition,	 pharmacologically	 targetable	 pathways	 for	 the	 removal	 of	 quiescent	
disseminated	 tumour	 cells	 from	 secondary	 tissues	 still	 remain	 to	 be	 identified.	
Extending	 future	work	beyond	 identification	of	a	 robust	 surrogate	marker	profile	 for	
quiescence	 to	 a	 more	 extensive	 identification	 of	 proteins	 or	 signalling	 pathways	
differentially	 expressed	 by	 quiescent	 cells	 might	 distinguish	 pharmacologically	
targetable	nodes	in	the	quiescence	programme.	This	broader	approach	will	ultimately	
result	in	strategies	to	eliminate	the	risk	posed	by	the	cells	responsible	for	de	novo	drug	
resistance	 and	 eventual	 disease	 relapse	 and	 thereby	 improve	 the	 long-term	 clinical	
prognosis	of	patients	diagnosed	with	breast	cancer.	
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6.2. Conclusions	
	
The	 work	 presented	 in	 this	 thesis	 demonstrates	 that	 the	 lipophilic	 fluorescent	 dye-
retention	model	 system	 offers	 the	 potential	 to	 isolate	 and	 further	 characterise	 live	
slow-cycling	 cancer	 cell	 populations	 independent	 of	 cell	 surface	 protein	 signatures	
with	 ambiguous	 or	 poorly	 understood	 functional	 implications	 for	 cell	 dynamics.	 The	
slow	 cycling	 quiescent	 cells	 isolated	 using	 this	 method	 were	 shown	 to	 exhibit	
resistance	 to	 anti-neoplastic	 chemotherapeutic	 agents	 and	 appear	 to	 exclusively	
contain	 a	 sub-set	 capable	 of	 subsequent	 outgrowth	 post-cessation	 of	 treatment.	
Although	 the	 exact	 processes	 that	 lead	 to	 quiescence	 and	 inherent	 drug-resistance	
remain	 to	 be	 established,	 the	 activity	 of	 the	 drug	 resistance	 and	 stemness	 marker	
aldehyde	dehydrogenase	was	significantly	up-regulated	in	the	quiescent	population	of	
both	 oestrogen-receptor	 positive	 and	 negative	 cell	 lines.	 Quiescence	 was	 also	
associated	with	enrichment	for	the	CD44+CD24+	marker	signature	that	has	previously	
been	associated	with	stemness,	enhanced	chemotherapeutic	resistance	and	worsened	
patient	 prognosis,	 particularly	 in	 triple-negative	 breast	 cancer,	 but	 did	 not	 correlate	
with	enhanced	mammosphere	formation	in	the	triple-negative	MDA-MB-231	cell	line.	
Whether	 these	 traits	 are	 associated	 with	 enhanced	 metastatic	 capacity,	
tumourigenicity	or	dormancy-competence	in	vivo	remains	to	be	established.	However,	
given	the	potential	for	a	majority	of	cancer	cells	or	numerous	intrinsic	sub-populations	
to	display	tumourigenicity,	the	 identification	of	a	slow-cycling	and	 inherently	therapy	
resistant	 cellular	 sub-set	 capable	 of	 leading	 to	 tumor	 recurrence	 is	 both	 biologically	
and	clinically	significant,	 independent	of	a	cancer	stem	cell	model.	Whether	this	sub-
population	 is	 capable	 of	 establishing	 colonies	 within	 secondary	 tissues	 and	 hence	
represents	 the	 metastasis-initiating	 population	 is	 the	 subject	 of	 on-going	 studies.	
Further	 characterising	 the	 cell	 population	 identified	 by	 quiescence	 denoted	 by	 long-
term	 dye-retention	 could	 allow	 for	 future	 live	 enrichment	 of	 quiescent	 cells	 and	
potentially	yield	novel	 insight	 into	the	cellular	biology	underpinning	tumoural	relapse	
and	 recurrence	 leading	 to	 the	 development	 of	 new	 therapeutic	 approaches	 to	
preventing	or	treating	metastatic	disease.	
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6.3. Summary	of	Future	Work	
	
The	 following	 list	 details	 future	work	 proposed	 following	 the	work	 presented	 in	 this	
thesis,	some	of	which	will	be	 included	in	a	post-doctoral	project	awarded	by	Weston	
Park	Cancer	Charity.	
	
1. Undertake	whole	 transcriptomic	profiling	 to	 characterise	 the	gene	expression	
profile	of	dye-retaining	quiescent	cells	and	compare	this	to	that	of	the	bulk	cell	
population	 in	 oestrogen-receptor	 positive	 and	 oestrogen-receptor	 positive	
breast	cancer	cell	lines	
	
2. Establish	 differentially	 regulated	 genes	 and	 pathways	 following	 analysis	 of	
transcriptomic	profiling	data	and	confirm	expression	of	a	select	panel	of	target	
genes	and	proteins	in	order	to:	
	
a. Identify	a	surrogacy	marker	signature	for	the	quiescent	phenotype	
	
b. Identify	 prospective	 pathways	which	underpin	 cellular	 quiescence	 and	
which	might	represent	therapeutic	targets	for	terminal	maintenance	of	
dormancy	or	effective	killing	of	quiescent	cells	
	
3. Determine	 whether	 drug	 resistance	 mechanism	 other	 than	 aldehyde	
dehydrogenase	activity	are	enriched	within	dye-retaining	quiescent	cells	across	
oestrogen-receptor	positive	and	oestrogen	receptor	negative	breast	cancer	cell	
lines	and	whether	their	 inhibition	 is	able	to	sensitise	 inherently	drug-resistant	
quiescent	cells	to	the	effects	of	chemotherapeutic	agents	
	
4. Establish	 how	 the	 quiescence-associated	 gene	 signature	 identified	 in	 (2.)	 is	
modulated	in	quiescent	cells	that	survive	chemotherapy	
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5. Determine	whether	hypoxia	signalling	drives	the	quiescent	phenotype	 in	both	
oestrogen	receptor-positive	and	oestrogen	receptor	negative	cells	by:	
	
a. Establishing	whether	hypoxia	 signalling	 is	 hyper-activated	 in	quiescent	
cells	
	
b. Establishing	 whether	 induction	 of	 hypoxia	 in	 a	 novel	 experimental	
model	system	developed	by	our	collaborator	Dr.	Paul	Shore	(University	
of	 Manchester)	 is	 able	 to	 recapitulate	 the	 quiescent	 phenotype	 and	
gene	signature	identified	in	(2.)	
	
6. Determine	 whether	 dye-retaining	 quiescent	 cells	 are	 more	 tumourigenic	 at	
primary	and	metastatic	 sites	or	are	more	prone	 to	 long-term	dormancy	post-
metastasis	 than	 rapidly	 dividing	 cells	 in	 vivo	 using	 limiting	 dilution	
xenotransplantation	
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